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Pharmaceutical maintenance with methadone is the current gold standard for pregnant women 
with opioid-dependence. While there are many benefits of methadone, its use during pregnancy 
is associated with high rates of neonatal abstinence syndrome, and long term developmental and 
behavioural deficits in exposed infants and children. Buprenorphine is increasingly being 
prescribed as pharmaceutical treatment for opioid dependence due to its milder withdrawal 
effects, longer duration of action, and improved safety profile, compared with methadone. 
Although there is a growing body of research supporting the safety and efficacy of buprenorphine 
during pregnancy and the early neonatal period, studies of the longer term development of 
children exposed to buprenorphine are scarce.  
 
This is the first study to provide comprehensive, longitudinal information about the physical 
growth, neurological and psychological development of Australian children prenatally exposed to 
buprenorphine or methadone. Participants were 30 women maintained on buprenorphine, 24 
women maintained on methadone, and 33 women who were not opioid-dependent, and their 
children. Women were enrolled during pregnancy as part of an open-label non-randomised 
flexible-dosing longitudinal study, and children were assessed at four, 12 and 24 months post 
partum. Physical development was monitored in terms of weight, length and head circumference 
(HC) at each follow-up assessment. Neurological development was assessed by measuring latency 
of Visual Evoked Potentials (VEP) at four months of age and the Bayley Scales of Infant 
Development (2
nd ed.) at 12 and 24 months.  Care-giver ratings of child temperament were used 
as a measure of psychological development, and were collected at each follow-up assessment. 
Assessment of social, environmental and family risk factors was also undertaken. 
 vii 
 
Results showed that children prenatally exposed to buprenorphine did not differ from a non-
exposed control group in their physical growth, neurological development, or temperament over 
the first two years of life. However, results indicated that prenatal exposure to methadone may 
have a pervasive influence on weight in early childhood, with children prenatally exposed to 
methadone continuing to have significantly lower weight, compared with non-exposed children, 
until two years of age. Additionally, it appears that prenatal exposure to methadone may result in 
significant delays to visual maturation in infancy. At four months of age, VEP latencies of infants 
prenatally exposed to methadone were found to be prolonged compared with those of both 
infants prenatally exposed to buprenorphine, and those of non-exposed infants. Scores on the 
Bayley Scales at 12 and 24 months of age, and caregiver-rated infant temperament at 4-, 12- and 
24-months, did not differ between children prenatally exposed to methadone, buprenorphine, or 
non-exposed controls. Finally, regardless of substance-exposure, the quality of a child’s care-
giving environment was shown to have a strong influence over infant cognitive, motor and 
behavioural development, while maternal-infant attachment was found to be an important 
predictor of child temperament.  
 
Overall, the findings of this study suggest that maternal use of buprenorphine in pregnancy 
appears to be as safe as methadone in terms of early child developmental outcomes. The benefits 
of buprenorphine, in terms of early neurodevelopment and healthy weight gain, suggest that it 
should be considered as a first line treatment for opioid dependence in pregnant women. 
Moreover, results from this study highlight the importance of a child’s care-giving environment, 
and of early maternal mental health, over and above prenatal substance exposure, in shaping 
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1.1 A brief history of opioid use and misuse 
The term ‘opioid’ is used to describe both natural opiates (such as codeine and morphine) and 
their synthetic derivatives (including heroin and methadone). The word ‘opium’ originates from 
the Greek opos (juice) and opion (poppy juice), in reference to the Opium Poppy Papaver 
somniferum (Borg & Kreek, 1998; Hodgson, 1999). It is thought that the Egyptians used Opium 
Poppy extracts for pain relief and for treating diarrhoea (Simon, 2005), however, the medicinal 
qualities of this plant were first documented by the physician Dioscoride (circa 40-90 AD) in his 
pharmacopoeia De Materia Medica, in which he detailed its usefulness in treating pain and 
chronic cough, as well as the soporific properties that opium is known to possess (Hodgson, 
1999).  
 
Opium was introduced to the West from China in the mid-nineteenth century and its use became 
synonymous with decadence and opulence, particularly in Europe where it was romanticised by 
artists, writers and poets. However, in North America, use of opium was generally associated with 
sailors, prostitutes and other such ‘degenerates’ (Hodgson, 1999). It was common for people to 
eat or smoke raw opium until the development of patent medicines when unregulated 
‘concoctions’, such as Laudanum (a potent mixture of alcohol and opium), became widely 
available (Gold & Johnson, 1998).   
 
The principle active ingredient in opium is the alkaloid morphine, which was first isolated by 
Friedrich Wilhelm Sertürner in 1805 (Hodgson, 1999). However it was the synthesis of 
diacetylmorphine in 1874, by Charles Alder Wright at St Mary’s Hospital Medical School in 
London, which led to the development of one of the most notorious drugs known to humankind  
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(Sneader, 1998). Marketed by German pharmaceutical company F Bayer & Co. in 1898 as Heroin, 
the drug took its name from the German heros, in reference to an ancient Greek demigod 
honoured for his heroic feats (Sneader, 1998). This new ‘wonder-drug’ was originally utilised as a 
cough suppressant and respiration aid for patients with tuberculosis, and, ironically, a possible 
cure for morphine addiction (Gold & Johnson, 1998; Hodgson, 1999; Sneader, 1998). Along with 
cough suppression, opioids exert their effects on pain and mood through the central nervous 
system (CNS). Opioids are powerful analgesics and have the ability to decrease anxiety, elevate 
mood and increase drowsiness (Simon, 2005). Because of these effects, heroin was often the key 
ingredient in popular ‘health tonics’ and ‘cordials’ which were recommended for many conditions 
including earache, haemorrhoids, morning sickness, cholera, and were also marketed as soothing 
syrups for unsettled infants (Hodgson, 1999).  
 
When first introduced to the medicinal market, heroin was usually prescribed in oral doses too 
small to cause habituation or, in the cases of chronic lung disease; patients were continually 
medicated, thus keeping withdrawal symptoms at bay. However, as its sale was unregulated, 
social use of heroin escalated and warnings about the addictive properties of heroin began to 
appear (Sneader, 1998).  
 
With the development of the hypodermic needle in the mid nineteenth century, intra-venous 
delivery of opioids became possible. When opioids are administered directly into the circulation 
there is a rapid increase in opioid levels in the brain which can induce an intense, euphoric sense 
of well-being, known as a ‘rush’ or ‘high’ (Gold & Johnson, 1998; Hodgson, 1999; Jaffe, Knapp, & 
Ciraulo, 1997).The desire to experience this extreme state of pleasure is thought to be the 
motivation behind the repeated self-administration of heroin, as well as the irrationality that 
often accompanies the drug-seeking behaviour of addicted individuals (Gold & Johnson, 1998; 




From the late 1800s to the early 1900s, it was common in the United States for physicians to 
prescribe medications and ‘tonics’ containing opiates to women suffering from ‘female 
complaints’, including gynaecological problems and ‘nervous weakness’. Additionally, patent 
medicines and ‘home remedies’ (many containing heroin) were widely promoted through 
women’s magazines, and were available without prescription via mail-order catalogues. This 
widespread availability and over-prescription of opiates often led to addiction, with early US 
surveys suggesting that between 50-75% of chronic opiates users were women, often of white, 
middle- to upper-class background. Society usually turned a blind eye to the ‘drug habits’ of these 
women as long as they were ‘acceptable’ members of the community (Kandall, 1996). At the 
beginning of the twentieth century, various drug laws and legislations restricted the trafficking of 
substances, and society began to view opiate use as objectionable. Along with tighter controls of 
opioids in Europe and North America, this meant that by the 1920s opium and morphine were no 
longer available without prescription (Hodgson, 1999).  
 
In order to provide treatment for individuals addicted to opioids and reduce crime associated with 
the illicit trade of narcotics, public outpatient clinics were set up in the United States to dispense 
morphine and heroin at low cost to clinic registrants. The largest facility, in New York City, treated 
just over 1, 500 women (23% of its patients) in its seven months of operation in 1919, many of 
whom were white and under the age of 40. Records of similar clinics around the country indicate 
that between 25 and 57% of patients were female (Kandall, 1996).  
 
In contrast to the latter half of the 19
th century, by the 1940s the majority of America’s opioid 
users were men, and the typical ‘profile’ of female opioid users was changing. Women who 
sought treatment for opioid addiction between 1920 and 1940 in the United States were likely to 
be white, Protestant, rural housewives in their early 40s. Most had acquired their long-standing 
addiction (usually to morphine) through prescribed treatment for a psychosomatic or physical 
illness. Over the next forty years opioids were increasingly used for recreational purposes, with up  
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to two thirds of female opioid-users citing ‘curiosity’ or peer influences as the reasons for trying 
drugs. Women began to seek treatment for opioid addiction earlier and heroin was more 
frequently the drug of choice. By the 1970s and 1980s, women comprised 20-30% of opioid users 
in the United States (Kandall, 1996). This figure has remained relatively stable in recent years and 
is similar to rates of opioid use by women cited in Australian and international studies (Anderson, 
2006; Australian Institute of Health and Welfare, 2011)]. While there does not appear to be 
comprehensive information available about the history of women and opioid addiction in 
Australia, it is possible that use of opioids by Australian women has mirrored that of their 
American counterparts. 
 
1.2 Opioid actions 
Opioids produce their pharmacological effects by binding to opioid receptors located on the 
membranes of neurons and other cells in the body.  The three principle classes of opioid receptors 
are mu (μ), delta (δ), and kappa (κ), with various subtypes within each class. Because these opioid 
receptors are found throughout the brain and spinal cord, as well as other organ sites, opioids 
exert their effects on many of the organ systems in the body (Farid, Dunlop, Tait, & Hulse, 2008; 
Jaffe, et al., 1997). When activated, μ-opioid and δ-opioid receptors appear to influence analgesia, 
sedation, blood pressure, reinforcing effects, along with endocrine and gastrointestinal function; 
while activation of κ –opioid receptors can produce analgesia and endocrine changes (Jaffe, et al., 
1997).  
 
Opioid drugs are categorised in terms of their capacity to bind with and activate different classes 
of receptors. It is thought that drugs produce their effects by mimicking the post-synaptic 
stimulation of the endogenous opiate peptides that are neurotransmitters in the brain (Kolb & 
Wishaw, 1996). Drugs that produce a biological effect after binding to and activating a receptor 
are known as agonists, those that bind to a receptor but produce less than full receptor activation  
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are known as partial agonists, while antagonists bind to a receptor but do not activate it and may 
also block the effects of agonists (Jaffe, et al., 1997; Zacny & Walker, 1998).  
 
While medically managed oral doses of opioid drugs are unlikely to result in major toxic effects, 
the protracted use of illicit, and often contaminated opioids, particularly those administered 
intravenously, can be associated with severe and sometimes fatal consequences (Jaffe, et al., 
1997).  
 
1.3 Substance dependence  
Substance dependence is characterised by a combination of physiological, cognitive and 
behavioural symptoms, with an individual persisting in the use of substances despite significant 
problems associated with their use. In a dependent individual, consequences of repeated self-
administration can be tolerance to the substance, withdrawal symptoms with the cessation of 
use, and compulsive drug-taking behaviours (American Psychiatric Association, 2000; Simon, 
2005). 
 
Tolerance refers to the requirement for increasing quantities of a substance in order to achieve a 
desired effect, or to a marked reduction in the effect of a substance with continued use of the 
same dosage. Withdrawal refers to maladaptive behavioural changes, characterised by 
concurrent physical and psychological symptoms that occur with the cessation of, or reduction in, 
substance use after a sustained period of heavy use. Physical symptoms of opioid withdrawal 
include fever, nausea, muscle and bone pain, diarrhoea, pupillary dilation, piloerection, and 
yawning; while psychological withdrawal symptoms can include drug cravings, dysphoric mood, 
anxiety, and irritability. In order to relieve or completely avoid these symptoms an individual 
needs to take the same, or a closely related, substance (American Psychiatric Association, 2000; 




Whilst a diagnosis of substance dependence does not require the presence of tolerance or 
withdrawal, previous occurrence of either is suggestive of a clinical pattern of dependence (i.e., 
early onset, high substance intake, and large number of substance-related problems). Compulsive 
substance use that is characteristic of dependence includes any number of features. Individuals 
may take larger amounts of a substance, or take a substance over a longer period, than they 
initially intended. There may be a persistent desire to control, reduce, or discontinue substance 
use, often with many unsuccessful attempts. Individuals may spend substantial amounts of time 
engaged in activities to obtain and use the substance, or recovering from its effects. In severe 
cases of substance dependence, the majority of a person’s daily activities may be centred on the 
need to procure and use the substance. Individuals may reduce or withdraw from social, 
occupational and recreational activities in order to be able to use the substance. Finally, use of 
the substance may continue despite awareness that physical or psychological problems are likely 
to have been caused or exacerbated by continuing substance use (American Psychiatric 
Association, 2000). 
 
1.4 Opioid dependence in Australia 
Research indicates that, globally 185 million adults (4.5% of the global population aged 15-64 
years) are current consumers of illicit drugs, with 15.3 million (0.4% of the global adult 
population) using illicit opioids, and 15.2 million injecting drug users (Anderson, 2006). While it is 
difficult to estimate the worldwide numbers of women who use illicit opioids, it has been 
suggested that of the 15.3 million adults with substance use disorders, almost 25% (3.6 million) 
are women (Anderson, 2006). In a study of prevalence estimates of lifetime substance use across 
seven international sites, Vega et al. (2002) reported that between 0.1 -4.4% of women reported 
illicit opioid use. Recent epidemiological surveys suggest that between 0.3-0.7% of the Australian 
community use illicit opioids, of whom, approximately one third are women (Australian Institute 
of Health and Welfare, 2008, 2011; Hall, Ross, Lynskey, Law, & Degenhardt, 2000; McBride et al., 
2009; Teesson, Baillie, Lynskey, Manor, & Degenhardt, 2006). McBride et al. (2009) have shown  
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that the prevalence of drug use and dependence, and the conditional prevalence of dependence 
(i.e. prevalence of dependence amongst past year users only) in adults aged 18-54, was 
significantly higher in Australia than in the United States of America (USA). Using data from two 
cross-sectional nationally representative household surveys (the Australian National Survey of 
Mental Health and Well-Being, 1997 and the American National Epidemiologic Survey on Alcohol 
and Related Conditions, 2001-2002) they found that 10.8% of Australians and 5.2% of Americans 
reported using at least one illicit drug (including cannabis, stimulants, sedatives and opioids) in 
the previous 12 months. The rate of self-reported opioid use was higher amongst American 
respondents than for the Australian population, with 1.2% and 0.3% of respondents from the 
respective surveys indicating that they had used opioids in the previous 12 months.  The 
percentage of respondents who met Diagnostic and Statistical Manual of Mental Disorders, 4
th 
Edition (DMS-IV) criteria for dependence on any drug within the previous 12 months was 2.7% in 
the Australian sample and 0.7% in the American sample, with the estimated past year prevalence 
of opioid dependence 0.3% for the Australian sample and 0.2% for their American counterparts.  
The prevalence of conditional dependence on opioids differed substantially between the two 
samples, with Australian opioid users over six times more likely to meet dependence criteria than 
American opioid users. The authors suggested that differing societal and political attitudes 
towards drugs may influence patterns of substance use in each country. However, the Australian 
data was collected more than 10 years earlier than the data in the American study and it is 
possible that patterns of substance use in Australia have changed over this time (McBride, et al., 
2009). 
 
Data from the 2007 AIHW National Drug Strategy Household Survey (NDSHS) (Australian Institute 
of Health and Welfare, 2008) indicated that trends in illicit-opioid use remain similar to that 
reported in the 1997 Australian National Survey of Mental Health and Well-Being.  The 2007 
NDSHS found that almost 350,000 Australians aged 14 years or older (2%) reported using opioids 
(heroin, methadone and/or buprenorphine for non-maintenance purposes, other opioids for non- 
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medical purposes) during their lifetime. Almost twice as many males as females reported use of 
illicit opioids within the 12 months prior to the survey (36,800 versus 20,200; 0.3% of the 
population). While separate data was not provided for the proportion of males and females who 
had recently used other opioids, 14,000 males and 4,900 females (0.1% of the population) 
reported illicit heroin or methadone use within the previous week. The highest proportion of 
respondents reporting illicit opioid use was aged 20-29 years, with 2.7% (79,000) of this group 
reporting lifetime use and 0.6% (19,100) reporting use in the previous 12 months. Sixty percent of 
recent users aged 14 years or older, reported using heroin, methadone and/or other opioids for 
non-medical purposes weekly or more frequently. Recent heroin users averaged 2.6 ‘hits’ of 
heroin on days used, with the majority (90%) using heroin intravenously, and almost 70% using it 
in their own home. The majority of recent methadone users reported one dose of methadone on 
days used, with 74% reporting intravenous use. The mean reported age for first heroin use was 
21.9 years, whilst for methadone it was 23.3 years of age (Australian Institute of Health and 
Welfare, 2008). Whilst age of initiation was not provided separately for use of other opioids, the 
2010 NDSHS found that the mean age for use of any illicit pharmaceutical (including analgesics, 
tranquilisers, steroids along with non-prescribed use of methadone, buprenorphine and other 
opioids) was 23.7 years (Australian Institute of Health and Welfare, 2011). 
 
1.5 Associated harms of substance use and dependence  
In terms of problematic illicit drug use, opioids are the primary contributor to increasing burdens 
on public order and public health worldwide (Anderson, 2006). There is a high cost associated 
with the continued use of illicit substances, with recent data from the Illicit Drug Reporting 
System (IDRS) indicating that the median price of a gram of heroin ranged between $300 to $600, 
and the median price of a ‘cap’ (a typical amount used in a single injection or ‘hit’) was $50 
(O’Brien et al., 2007).  The IDRS also found that 45% of injecting drug users interviewed reported 
they had engaged in some kind of criminal activity (most commonly drug dealing or property 
crime) within the month prior to participating in the survey, and 43% reported having been  
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arrested within the previous 12 months (O’Brien, et al., 2007).  In a recent AIHW report (2007), 
heroin accounted for four percent of all arrests relating to illicit drugs in 2004-05 (including 
dealing, trafficking, possession and use), and 62% of arrests related specifically to use or 
possession of illicit drugs.  In 2005, 10% of sentenced prisoners were incarcerated for a drug-
related offence, whilst amongst adults apprehended by police, approximately 18% tested positive 
to illicit opioids (Australian Institute of Health and Welfare, 2007). 
 
The most recent Burden of Disease and Injury in Australia study (Begg et al., 2007), estimated that 
illicit drugs were responsible for 2.0% of the total burden of disease in Australia, an increase of 
0.2% from 1996 (Begg, et al., 2007; Mathers, Vos, & Stevenson, 1999). Substance use is associated 
with significant risks to physical and mental health attributable to individual substances, poor 
nutrition and hygiene, and health risk behaviours.  The IDRS found that 38% of injecting drug 
users surveyed reported experiencing a mental health problem, other than drug dependence, in 
the six months prior to interview. Twenty seven percent of the sample reported experiencing 
depression, with anxiety the next most commonly reported mental health problem. Of those 
reporting mental health problems, 70% had consulted a health professional within the six months 
prior to participating in the survey (O’Brien, et al., 2007). 
 
Sixty-five percent of the national sample of injecting drug users reported experiencing injecting-
related health problems in the month preceding participating in the survey (O’Brien, et al., 2007). 
These problems included significant bruising, scarring, and difficulty injecting, the latter being an 
indication of poor vascular health. Approximately one third of participants reported sharing 
needles or other injecting equipment in the month prior to interview (O’Brien, et al., 2007). 
Through equipment sharing, injecting drug users are at significant risk of blood-borne viruses, 
such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). 
In 2005, 61% of people attending needle and syringe program sites tested positive to HCV, with 
the prevalence of HCV increasing with longer duration of injecting drug use. This is in comparison  
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to the prevalence of HCV in the general population, which is estimated to be only two percent. In 
2005, 16% of new acquired immune deficiency syndrome (AIDS) diagnoses were amongst people 
with a history of injecting drug use (Australian Institute of Health and Welfare, 2007). 
 
Opioid use is also associated with risk of overdose. Of the injecting drug users surveyed in the 
IDRS who reported heroin use within the previous six months, 59% reported overdosing at least 
once within their lifetime (O’Brien, et al., 2007). In 2004-05 the number, per million persons, of 
opioid-related hospital admissions among 15 to 54 year olds was 415; with the rate of accidental 
opioid-related death (in which opioids were considered the primary cause of death) 32.5 per 
million persons aged 15 to 54 years. 
 
Substance related harm is not directed solely at the user. In 2006, 21% of injecting drug users 
reported that they had become verbally aggressive after using heroin (O’Brien, et al., 2007), whilst 
the 2007 National Drug Strategy Household Survey found that 14.6% of Australians aged 14 years 
or older reported having been abused or ‘placed in fear’ by someone affected by illicit drugs 
(Australian Institute of Health and Welfare, 2008). 
 
1.6 Treatment of opioid dependence 
Opioid dependence is a serious medical condition, with physiological and psychological elements, 
that is often chronic in nature.  Many opioid users find it difficult to control their addiction and 
experience multiple relapses following treatment or attempted abstinence. There are several 
treatment options available for those wishing to cease opioid use. Some methods, such as 
treatment with antagonist therapies, therapeutic communities and supported self-help groups, 
are ‘abstinence-based’ and aim for complete, often rapid, cessation of opioid use; whilst others 
involve medically managed detoxification or pharmaceutical maintenance programs (O'Brien, 
2004; Verster & Buning, 2005). Maintenance pharmacotherapies, in combination with ongoing  
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psychological counselling and support, have been shown to be the most effective of these 
treatments for opioid dependence (Verster & Buning, 2005). 
 
While treatment with antagonist therapies and involvement in residential programs have shown 
to reduce heroin use in the short term, many individuals return to illicit opioid use due to 
unwanted side effects or lack of support. Rates of relapse to illicit opioid use following 
detoxification are also high, if additional treatment or support is not continued (Gold & Johnson, 
1998; O'Brien, 2004; Verster & Buning, 2005). For example, in an American study of 116 adults 
admitted to a short-term (3-day) inpatient detoxification program, only 13% remained abstinent 
from heroin use within the first month post detoxification and 25% reported a return to daily use 
of heroin within six months (Chutuape, Jasinski, Fingerhood, & Stitzer, 2001). Additionally, of 66 
participants who were assessed for latency-to-relapse, 26% reported heroin use on the day they 
were discharged from the program. This study also found significantly lower rates of self-reported 
days of heroin use, incarceration rates, and positive drug screens for participants who engaged 
with other forms of treatment (i.e. methadone programs, drug-free treatment) during the six-
month follow-up, compared with those who did not engage in other treatment (Chutuape, et al., 
2001). 
 
While the long term objective of pharmaceutical maintenance is to assist an individual to 
discontinue illicit opioid use, the short term goals of treatment focus on harm reduction and 
public health. The aims of maintenance medication include: 1) reduction in a person’s use of illicit 
substances, 2) improvement in the person’s health and well being, 3) minimisation of the risks 
associated with injecting drug use, including the spread of blood-borne viruses and the risk of 
overdose, 4) decreasing criminal activity associated with illicit opioid use, and 5) facilitation of 
social rehabilitation through removing the individual from a drug-seeking environment (Henry-




In Australia, individuals with opioid-dependence have had the option of treatment with 
maintenance pharmacotherapies since the late 1960s. In June 2009, there were 43,445 individuals 
in Australia registered as participants in opioid maintenance programs, with 70% registered as 
receiving methadone maintenance treatment (MM), and the remainder receiving buprenorphine 
maintenance treatment (BM).  Currently, the provision of these medications is funded by the 
Australian Government and they are delivered through pharmacies and clinics within a holistic 
treatment framework that includes medical management along with psychological and social 
assistance (Australian Institute of Health and Welfare, 2010). 
 
In South Australia in June 2009, there were 3,151 people registered as receiving pharmacotherapy 
maintenance, 62% of whom were receiving MM and the remainder receiving BM. Sixty four 
percent of South Australian registrants were male, and 53% were aged 20-39 years. These are 
similar to the proportions in national samples (Australian Institute of Health and Welfare, 2010). 
 
1.6.1 Methadone Maintenance Treatment  
Methadone hydrochloride is a synthetic narcotic analgesic which was first synthesised in Germany 
in the 1930s. Patented in 1941, it was further developed after World War II and was studied as an 
analgesic and withdrawal treatment for heroin addiction when it was found to possess similar 
properties to morphine (Borg & Kreek, 1998; Lowinson et al., 2005). Methadone was initially 
trialled as a maintenance treatment for heroin dependence in the United States in 1964-65. When 
administered in adequate oral doses every 24-36 hours it stabilised individuals addicted to heroin 
without inducing euphoria, sedation or analgesia. It was also medically safe, tolerable, relieved 
drug cravings, and ‘blocked’ the narcotic effects of short acting opioids, such as heroin (Dole & 
Nyswander, 1965; Lowinson, et al., 2005).  Methadone was approved for use as a maintenance 
medication for opioid dependence by the United States Food and Drug Administration (FDA) in 
1972. It was introduced to Australia for this purpose in 1969. With adjunct treatment, such as 
counselling and social services, methadone maintenance has become the ‘gold standard’ for  
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treatment of illicit opioid dependence internationally (Farid, et al., 2008; Henry-Edwards, et al., 
2003).  
 
Methadone is a full agonist at μ-opioid receptors and thus produces similar effects to morphine, 
but with a longer duration of action (R. E. Johnson, Strain, & Amass, 2003; Lowinson, et al., 2005).  
Because it has good oral bioavailability and a long elimination half-life, methadone is usually 
administered in a single daily oral dose (Australian Drug Foundation, 2005b; Henry-Edwards, et 
al., 2003; R. E. Johnson, Strain, et al., 2003). Side effects of methadone maintenance, such as 
opioid intoxication, lethargy and pinpoint pupils, are usually observed in the early stage of 
treatment, but abate with dose adjustment. However, withdrawal symptoms may be experienced 
if a dose is missed. Due to methadone’s full agonist properties there is no ‘ceiling’ to the level of 
respiratory depression or sedation that it can induce, and overdose can be fatal (Mattick, Kimber, 
Breen, & Davoli, 2003). Ongoing complaints for people maintained on methadone can include dry 
mouth, constipation, increased sweating, reduced libido, and irregular menstruation or 
amenorrhea in women (Henry-Edwards, et al., 2003; Lowinson, et al., 2005). Additionally, 
individuals with opioid-dependence may view methadone maintenance in an unfavourable light, 
or experience stigma associated with its use (Anstice, Strike, & Brands, 2009; Mattick, et al., 2003; 
Murphy & Irwin, 1992).  
 
1.6.2 Buprenorphine Maintenance Treatment 
Buprenorphine hydrochloride is a semi-synthetic derivative of the morphine alkaloid thebaine 
(Reisinger, 1985). It was initially developed in the 1970s and used as an analgesic for acute pain 
management (Verster & Buning, 2005). Research published in 1978 (Jasinski, Pevnick, & Griffith, 
1978) was the first to propose that buprenorphine could be used for the treatment of opioid-
dependence, and to demonstrate that it had a low physical abuse potential and mild withdrawal 
syndrome (Fudala & O'Brien, 2005; Lintzeris et al., 2006; Mattick, et al., 2003; Reisinger, 1985). 
Buprenorphine was first registered for treatment of opioid dependence in France in 1995, and  
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was registered in Australia by the Therapeutic Goods Association (TGA) for maintenance and 
detoxification purposes in 2000 (Lintzeris, et al., 2006; O’Brien, et al., 2007). 
 
Buprenorphine is a partial agonist at μ-opioid receptors, and an antagonist at κ-opiate receptors. 
It has an analgesic potency up to 50 times that of morphine (Fudala & O'Brien, 2005; Lintzeris, et 
al., 2006; Mattick, et al., 2003; Reisinger, 1985). Because of its partial agonist properties and slow 
dissociation from opioid receptors, buprenorphine blocks the effects of full opioid agonists over a 
prolonged period of time.  Its opiate-like effects are weaker than those of a pure agonist, and do 
not induce strong feelings of euphoria, and there is a lower risk of abuse, addiction and unwanted 
side effects. Unlike methadone, there is a ‘ceiling effect’ of buprenorphine on respiratory 
depression and sedation. Buprenorphine has poor bioavailability and is administered in a 
sublingual tablet. At high doses it has a longer duration of effect than methadone which allows for 
alternate-day or thrice-weekly dosing regimens. Buprenorphine’s long duration of action also 
results in a delayed withdrawal syndrome that appears to be milder than that of heroin, morphine 
or methadone (Davids & Gastpar, 2004; Fudala & O'Brien, 2005; Lintzeris, et al., 2006; Reisinger, 
1985). 
 
1.7 Illicit opioid use in pregnancy 
A large proportion of the drug-using population, both in Australia and overseas, are young adults, 
and many are women of childbearing age (Adams, Gfroerer, & Rouse, 1989; Australian Institute of 
Health and Welfare, 2008, 2010; Berlin et al., 1998; Chang, Carroll, Behr, & Kosten, 1992; Hoare, 
2009; R. E. Johnson, Jones, & Fischer, 2003; Kayemba-Kay's & Laclyde, 2003; Laken, McComish, & 
Ager, 1997; Lejeune, Simmat-Durand, Gourarier, & Aubisson, 2006; McBride, et al., 2009; 
Teesson, et al., 2006). Accurate estimation of the proportion of women using illicit substances 
during pregnancy is difficult, not least because collecting this information frequently relies on 
voluntary disclosure (Oei & Kei, 2007). However, recent data from the United States suggested 
that 4.5% of pregnant women aged 15 to 44 years had used an illicit substance in the previous  
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month (Substance Abuse and Mental Health Services Administration, 2010). While prevalence of 
opioid use was not reported, an earlier survey of birth records in Oregon found that maternal 
substance use was evident in 5.2% of singleton deliveries and that 6% of substance-using women 
reportedly used heroin whilst pregnant (Slutsker, Smith, Higginson, & Fleming, 1993). Other North 
American studies have shown that between 1% and 2.3% of all infants are exposed to opiates 
prenatally (C. R. Bauer et al., 2002; Finch, Vega, & Kolody, 2001; Lester et al., 2001). 
 
The prevalence of illicit substance use by pregnant women appears to be much lower in the 
United Kingdom (UK), with only 0.9% of women attending at a Welsh maternity unit reporting 
substance use during their pregnancy (Goel, Beasley, Rajkumar, & Banerjee, 2010). which is 
similar to that reported in earlier research in the UK (Northern and Yorkshire Public Health 
Observatory, 2002).  Recent Australian research suggests that, in New South Wales and the 
Australian Capital Territory, 1.3% of women report use of illicit substances during pregnancy, and 
that 5% of infants admitted to neonatal intensive care units are prenatally exposed to illicit 
substances (Abdel-Latif, Bajuk, Lui, & Oei, 2007; Oei & Kei, 2007). Kennare, Heard and Chan (2005) 
found that substance use during pregnancy was reported by 0.8% (707/ 89,080) of women who 
delivered in South Australia between 1998 and 2002. An audit of 144 of these cases found that 
almost 40% of women reported use of marijuana whilst pregnant, 30% used methadone 
(including for maintenance reasons), 12.5% reported heroin use and 2.1% reported using other 
opioids during their pregnancy (Kennare, et al., 2005). 
 
Prenatal exposure to illicit opioids has been shown to increase the risk of poorer outcomes for 
both mothers and infants, compared with non-exposed populations (Adams, et al., 1989; Chang, 
et al., 1992; Farid, et al., 2008; Kaltenbach, Berghella, & Finnegan, 1998). Women who use illicit 
opioids in pregnancy experience a high rate of obstetric complications, often because of poor 
attendance or non compliance with antenatal care. Complications for pregnant substance-
dependent women can include poor intra-uterine growth, toxaemia, miscarriage, premature  
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labour, and antepartum haemorrhage (Adams, et al., 1989; Australian Drug Foundation, 2005a; 
Kaltenbach, et al., 1998; Kennare, et al., 2005; Morse, Weiner, & Garrido, 1989; Sobrian et al., 
1989). Fluctuations in maternal drug levels, due to the continued cycling between states of 
intoxication and withdrawal, place increased stress on the developing foetus (Fischer et al., 2000; 
Kaltenbach, et al., 1998). Prenatal exposure to illicit opioids has also been associated with 
increased risk of prematurity, low Apgar scores, low birth weight, being small for gestational age, 
neurobehavioural problems and an increased risk of sudden infant death syndrome (SIDS), 
compared with non-exposed infants (Berlin, et al., 1998; Chang, et al., 1992; Kandall et al., 1976; 
Koren, Matsui, Einarson, Knoppert, & Steiner, 2005; Laken, et al., 1997; Robins & Mills, 1993; 
Sobrian, et al., 1989).  Infants exposed to opioids in pregnancy are also at high risk of developing 
infant withdrawal symptoms, or neonatal abstinence syndrome (NAS) (Finnegan, 1990; Finnegan 
& Kandall, 1997; Kaltenbach, 1994; Kandall et al., 1977). NAS develops when infants who are 
prenatally exposed to opioid agonists become passively dependent and subsequently undergo 
opioid withdrawal upon delivery. NAS is characterised by hyperirritability of the central nervous 
system. Symptoms among infants include high-pitched crying, frantic fist sucking, poor feeding, 
regurgitation, diarrhoea, hyperactive reflexes, tremors, sweating, nasal stuffiness, skin mottling, 
fever, respiratory distress, and convulsions (Finnegan, 1990; Finnegan & Kandall, 1997; 
Kaltenbach & Finnegan, 1986). These symptoms are generally acute and can be managed with 
pharmacological treatment. However, prolonged hospital stays for substance-exposed newborns 
are common as onset of NAS can be delayed. Current clinical guidelines therefore recommend 
that infants are observed by medical staff for up to 10 days post delivery to prevent unsupervised 
withdrawal which may be fatal (New South Wales Department of Health, 2006b).  
 
Given these problematic outcomes, complete abstinence from opioid use during pregnancy is the 
‘ideal’ objective. However, in the majority of cases, total abstinence is an unrealistic goal, 
particularly if the woman’s partner is also substance-dependent. Rates of relapse to illicit opioid 
use after detoxification attempts are high (Dashe, Jackson, Olscher, Zane, & Wendel, 1998; Jones,  
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O'Grady, Malfi, & Tuten, 2008; Luty, Nikolaou, & Bearn, 2003) and illicit opioid use has been 
associated with increased rates of infant morbidity and mortality (Finnegan & Kandall, 1997). In 
order to assist a pregnant opioid-dependent woman to abstain from illicit drug use and the 
associated lifestyle, current best practice is maintenance with a long-acting pharmaceutical 
maintenance opioid (Fischer, et al., 2000; Kakko, Heilig, & Sarman, 2008; Kaltenbach, et al., 1998).  
 
1.8 Treatment of opioid dependence in pregnancy 
1.8.1 Methadone 
In Australia, medical maintenance with methadone hydrochloride is the first line treatment for 
pregnant women with opioid-dependence (Dunlop et al., 2003; Farid, et al., 2008; Lintzeris, et al., 
2006). Benefits for women maintained on methadone during pregnancy include increased 
likelihood of attendance at antenatal care appointments, reduction in obstetric complications, 
stabilisation of plasma drug concentrations across the day, improvement in maternal nutrition, 
and engagement in a more balanced and stable lifestyle (Australian Drug Foundation, 2005b; 
Chang, et al., 1992; Dunlop, et al., 2003; Lejeune, et al., 2006; Lifschitz, Wilson, Smith, & 
Desmond, 1985; Lintzeris, et al., 2006). Infants prenatally exposed to methadone have been 
shown to have better outcomes than heroin-exposed infants in terms of the proportion who are 
born small for gestational age (SGA), have low birth weight, or have problems related to feeding, 
settling and hypertonicity (Kandall, et al., 1976; Lifschitz, Wilson, Smith, & Desmond, 1983; 
Wilson, 1989; Wilson, Desmond, & Wait, 1981; Wilson, McCreary, Kean, & Baxter, 1979).  
 
However, whilst treatment with methadone during pregnancy results in fewer complications for 
both mothers and infants when compared to use of illicit opioids, maternal methadone use has a 
number of detrimental effects (R. E. Johnson, Jones, et al., 2003).  Kandall et al. (1976) found that 
the birth weight of infants exposed to maintenance methadone (n=106), while significantly higher 
than that of infants exposed to heroin (n=153), was significantly lower than that of control infants 
(n=66).  This same study also reported that the gestational age of infants exposed to methadone  
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did not differ significantly from that of infants exposed to heroin, and furthermore, was 
significantly lower than that of infants in the control group (Kandall, et al., 1976).   
 
Prenatal exposure to methadone maintenance (MM) is associated with high rates of NAS (60-90% 
of methadone maintained pregnancies) (Finnegan & Kandall, 1997; Lundgren, Fitzgerald, Young, 
Amodeo, & Schilling, 2007). Greater duration and severity of NAS have been recorded in infants 
undergoing withdrawal from methadone when compared with infants undergoing withdrawal 
from heroin alone (Jarvis & Schnoll, 1995). Lifschitz et al. (1983) reported prolonged symptoms of 
NAS for infants prenatally exposed to methadone (n=21, M±SD =25.3±14.0 days) compared with 
infants prenatally exposed to heroin (n=22, M±SD =13.5±12.9 days, ns). Wilson and colleagues 
(Wilson, 1989; Wilson, et al., 1981) described the prevalence and severity of NAS in infants 
exposed to methadone (n=39) as comparable to that of infants exposed to heroin (n=30).  
However in this study, a greater percentage of methadone-exposed infants experienced NAS 
symptoms (100% vs. 83%) and required a significantly longer course of treatment than infants 
exposed to heroin (M±SD =30±14 days vs. M±SD =20±16 days, t=2.76, p<.01) (Wilson, 1989; 
Wilson, et al., 1981).  
 
In a study examining the early neonatal period of infants exposed to opioids, Kandall and 
colleagues (1977) reported that NAS symptoms were experienced with similar frequency by three 
groups of infants (i) prenatally exposed to heroin (n=61, 79%), (ii) prenatally exposed to 
methadone (n=86, 86%), and (iii) prenatally exposed to both heroin and methadone (n=59, 85%). 
A greater percentage of infants prenatally exposed to methadone (77%) required pharmacological 
treatment for NAS symptoms, compared with the heroin-exposed (43%) and the 
methadone/heroin-exposed (m/h) groups combined (68%, p<.001). Infants prenatally exposed to 
methadone required significantly higher doses of pharmacological treatment (M±SE =0.31±0.01 
cc) than the other two groups combined (heroin: M±SE =0.21±0.01 cc; m/h: M±SE =0.26±0.01 cc, 
p<.001) and required treatment over a greater period of time (methadone: M±SE =29.2±8.8 days)  
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compared with the other two groups combined (heroin: M±SE =10.8±2.6 days; m/h: M±SE 
=20.8±1.6 days, p<.001) (Kandall, et al., 1977). 
 
Methadone is readily transferred from the mother to the developing foetus, via the placenta, and 
it is retained in placental tissue. It is thought that placental disposition of methadone may affect 
the incidence and severity of NAS symptoms (Nekhayeva et al., 2005). It is unclear as to whether 
maternal methadone dose at delivery is positively associated with the severity of infant NAS.  Levy 
and Spino (1993) reported that severity of NAS appeared unrelated to maternal methadone dose; 
however Doberczak, Kandall, and Wilets (1991) reported a positive correlation between maternal 
methadone dosage and the severity of NAS across a wide range of gestational ages.  
 
1.8.2 Buprenorphine 
Buprenorphine hydrochloride is now widely used in the treatment of non-pregnant opioid-
dependent individuals. A number of observational studies have supported its safety and efficacy 
during pregnancy and the early neonatal period [see (R. E. Johnson, Jones, et al., 2003) for a 
review]. However, these studies have been limited by low subject numbers (i.e. N= 1 to 24) and 
lack comparison with existing treatments or non-exposed controls (Fischer, et al., 2000; R. E. 
Johnson et al., 2001; Kayemba-Kay's & Laclyde, 2003; Lejeune, et al., 2006; Marquet, Chevrel, 
Lavignasse, Merle, & Lachatre, 1997).    
 
Results from larger, more recent studies are now available(Czerkes, 2010; Ebner et al., 2007; 
Fischer et al., 2006; Jones et al., 2005; Jones et al., 2010; Kahila, Saisto, Kivitie-Kallio, Haukkamaa, 
& Halmesmaki, 2007; Kakko, et al., 2008; Lejeune, et al., 2006). The following section provides an 
overview of this research. First, studies using retrospective case-note review and less well 
controlled prospective studies are discussed. This is followed by discussion of randomised-




A recent unpublished study retrospectively reviewed the case notes of 68 women maintained on 
buprenorphine and 101 women maintained on methadone during pregnancy in Portland, Maine 
(Czerkes, 2010). Included in the study were all infants delivered beyond 37 weeks gestation at the 
Maine Medical Centre between 2004 and 2008. It was reported that the mean NAS score of 
infants prenatally exposed to buprenorphine was significantly lower than that of infants 
prenatally exposed to methadone (10.7 vs. 12.5, p<.01), and 50% of BM infants required 
treatment for NAS compared with 75% of MM infants (p<.001). This study also found that infants 
prenatally exposed to methadone had a significantly longer length of hospital stay than infants 
prenatally exposed to buprenorphine (MM=15.7 days vs. BM=8.4 days, p<.001) (Czerkes, 2010). 
No statistically significant differences between the groups in terms of in maternal characteristics 
(e.g. comorbidity, maternal age, mode of delivery) were found, and although it was reported that 
data on infant gestational age at delivery, birth weight, and Apgar scores was collected, this 
information was not available (Boughton, 2010; Czerkes, 2010). 
 
In a prospective study of 66 Finnish women maintained on buprenorphine throughout their 
pregnancies, Kahila et al. (2007) reported that the prevalence of premature delivery, caesarean 
section, low Apgar scores and low umbilical artery pH was comparable to national Finnish 
averages. However, infants in the study had significantly lower birth weights and longer hospital 
stays than the national average in Finland. A high rate of NAS (76%) and a higher than expected 
rate of sudden infant deaths (2/67 compared with a national incidence of 0.19/1000) was also 
reported (Kahila, Saisto, et al., 2007). Kakko et al. (2008) prospectively followed a consecutive 
sample of 47 pregnancies in 39 women maintained on buprenorphine in Stockholm between 2001 
and 2006. Pregnancy and neonatal outcomes were compared with a retrospective review of all 35 
pregnancies (26 women) maintained on methadone in the same Swedish county, between 1982 
and 2006. The authors reported no differences in pregnancy outcomes, however a significantly 
higher proportion of methadone-exposed infants had a birth weight <2500 gm (MM=25% vs. 
BM=6.4%; compared with a national Swedish average of 4.3%). Mean birth weight of the  
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methadone-exposed infants (2941±483 gm) was also significantly lower than the buprenorphine-
exposed infants (3250±528 gm; F[1,82] = 7.4, p = .008), however the difference was no longer 
statistically significant when adjusting for gestational age (F[1,81] =3.4, p = .07). Significantly 
higher rates and severity of NAS was seen in the methadone-exposed group (Kakko, et al., 2008).  
 
In a large prospective multicentre study, Lejeune et al. (2006) prospectively followed 260 infants 
born to women maintained on methadone (39%) or buprenorphine (61%) during pregnancy. 
Women were recruited consecutively from 35 French perinatal centres in public hospitals over a 
12 month period. No significant differences in terms of maternal or neonatal outcomes were 
reported. Mean birth weight of the buprenorphine-exposed infants (2843 gm) was comparable to 
that of infants prenatally exposed to methadone (2790 gm) and there was a non-significant 
association between methadone-exposure and preterm delivery (16% of MM vs. 10% of BM). 
Forty six percent of methadone-exposed infants had a birth length <10
thpercentile, compared 
with 34% of infants prenatally exposed to buprenorphine. There was a seven percent increase in 
intrauterine growth retardation (IGR) for infants prenatally exposed to methadone, although this 
difference was not statistically significant. Fifty two percent of buprenorphine-exposed infants 
required treatment for NAS, compared with 49% of methadone-exposed infants, while the mean 
age at maximum NAS score was higher for the methadone-exposed infants (80 hr post-delivery) 
compared with the buprenorphine-exposed infants (66 hr post-delivery, p=.07) (Lejeune, et al., 
2006).  
 
In a well-controlled prospective study, Ebner et al. (2007) compared the neonatal outcomes of 22 
infants prenatally exposed to methadone during pregnancy and 14 infants prenatally exposed to 
buprenorphine in Vienna, Austria. Women with illicit poly-substance abuse (self-reported or 
detected via urinalysis) in the third trimester or at delivery were excluded, as were women with 
alcohol or benzodiazepine co-dependence. The authors reported no significant difference in birth 
growth measurements or Apgar scores between infants prenatally exposed to methadone or  
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buprenorphine. Although infants prenatally exposed to buprenorphine had an earlier mean onset 
of NAS symptoms compared with the methadone-exposed infants (34 hr [SD ±5.3; range 25-52 hr] 
vs. 58 hr [SD ±37.5; range 16-161 hr] post-delivery), this difference was not statistically significant. 
A significantly greater proportion of methadone-exposed infants required pharmacological 
treatment for NAS symptoms (68% vs. 21%) compared with buprenorphine-exposed infants 
(Ebner, et al., 2007). 
 
To date, three randomised, controlled, double-blind, flexible-dosing trials have been conducted to 
examine differences between women maintained on methadone and women maintained on 
buprenorphine during pregnancy, and their infants (Fischer, et al., 2006; Jones, et al., 2005; Jones, 
et al., 2010). The first two studies (Fischer, et al., 2006; Jones, et al., 2005) were limited by small 
subject numbers (N=14 and N=20, respectively) and thus had limited power to detect differences 
between the groups. However, Jones et al. (2005) found that infants prenatally exposed to 
buprenorphine had significantly shorter hospital stays compared with methadone-exposed infants 
(BM=6.8 days vs. MM=8.1 days, p=.02). Additionally, non-significant trends were observed in both 
studies suggesting slightly better outcomes for infants exposed to buprenorphine on a number of 
other measures. Jones and colleagues (2005) reported no differences between the BM (n=9) and 
MM (n=11) groups in terms of infants’ gestation at delivery, Apgar scores, or NAS severity. They 
also reported that head circumference and length at birth were similar between the groups, 
although infants exposed to buprenorphine had a heavier mean weight at birth (3530±16.7 gm) 
than infants exposed to methadone (3001±120.7 gm). In this study, 22% of BM infants required 
treatment for NAS, compared with 46% of MM infants. Although mean peak NAS scores did not 
differ between the groups, the total amount of morphine solution (equivalent to morphine 0.02 
mg/drop) administered to treat NAS was greater in the MM group (93.1±23.5 drops vs. 
BM=23.6±19.3 drops). Additionally, infants prenatally exposed to methadone had a significantly 
longer length of hospital stay than infants prenatally exposed to buprenorphine (MM=8.1±0.8 
days; BM=6.8±0.9 days, p=.02) (Jones, et al., 2005). 
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Consistent with the findings of Jones et al. (2005), Fischer and colleagues (2006) reported no 
differences between the BM (n=8) and MM (n=6) groups in terms of infants’ birth weight, 
gestation, Apgar scores, or NAS severity, however independent values for each group were not 
reported. The authors reported that 50% of the MM infants required treatment for NAS 
symptoms, compared to 63% of the BM infants, however, infants exposed to methadone required 
treatment an average of 12 hours earlier than infants exposed to buprenorphine (Fischer, et al., 
2006).  
 
In the largest randomised, controlled study to date, Jones et al. (2010) compared the neonatal 
outcomes for 131 infants born to women maintained on buprenorphine (n=58) and methadone 
(n=73) during pregnancy. The authors used the Bonferroni principle to set the family-wise alpha 
level (i.e. nominal alpha level, .05 divided by the number of outcome variables) at .0091 for the 
five primary neonatal outcome variables (i.e. proportion of infants treated for NAS, NAS peak 
score, total mg of morphine, duration of hospital stay, and HC at birth), and at .003125 for the 16 
secondary outcome variables (e.g. birth weight, proportion of infants born preterm, gestational 
age at delivery, duration of NAS treatment, and maternal obstetric outcomes) (Jones, et al., 2010; 
Matsunaga, 2006). The groups did not differ significantly on the proportion of infants treated for 
NAS (BM= 47%, MM=57%, p=.26), peak NAS score (BM: M±SE= 11.0±0.6; MM: M±SE= 12.8±0.6, 
p=.04), or birth HC (BM: M±SE= 33.8±0.3 cm; MM: M±SE= 33.0±0.3 cm, p=.03), however 
compared with the BM group, MM infants had significantly poorer outcomes for the total amount 
of morphine required for treatment of NAS (BM: M±SE= 1.1±0.7 mg vs. MM: M±SE= 10.4±2.6, 
p<.0091), duration of NAS treatment (BM: M±SE= 4.1±1.0 days vs. MM: M±SE= 9.9±1.6, 
p<.003125), and duration of hospital stay (BM: M±SE= 10.0±1.2 days vs. MM: M±SE= 17.5±1.5, 
p<.0091). These differences remained after adjusting for length of time that the mother had been 
taking the study medication, maternal use of other substances during pregnancy, number of 
antenatal visits, and gestational age at delivery. Amount of morphine required for treatment of 
NAS and length of hospital stay remained significantly different between the groups (p<.001 and  
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p= .003, respectively) after maternal opioid dependence levels were taken into account. Infants in 
the BM group were also heavier at birth (M±SE= 3093.7±72. 6 gm) compared with the MM group 
(M±SE= 2878.5±66.3 gm, p=.03), and were born at a later gestation age (M±SE= 39.1±0.3 weeks 
vs. M±SE= 37.9±0.3, p=.007), although these differences were not considered statistically 
significant by the authors. The authors reported no differences between the groups in terms of 
maternal obstetric outcomes, although women randomised to receive buprenorphine were more 
likely to discontinue their participation in the study (BM= 28/86, 33%, MM=16/89, 18%, p=.02). It 
was concluded that buprenorphine was superior to methadone in terms of reducing NAS severity, 
in that infants prenatally exposed to buprenorphine required significantly less pharmaceutical 
treatment for NAS, required NAS treatment for a significantly shorter duration, and required a 
hospital stay of shorter duration than methadone exposed infants. The authors asserted that 
buprenorphine should be considered as a first line treatment for opioid dependence in pregnancy, 
but cautioned that patient satisfaction and adherence to treatment was an important 
consideration when prescribing buprenorphine as an alternative to methadone (Jones, et al., 
2010).  
 
Despite these positive outcomes for pregnant women and neonates exposed to buprenorphine in 
utero, buprenorphine has not yet been recommended for use during pregnancy, and methadone 
remains the gold standard of care for the treatment for pregnant women with opioid-dependence 
(Center for Substance Abuse Treatment, 2004; Lintzeris, et al., 2006). This is because the safety, 
efficacy and effectiveness of buprenorphine throughout pregnancy and the neonatal period has 
not yet been definitively established, and there is a paucity of data regarding longer term 
childhood outcomes (Lintzeris, et al., 2006). Research to date indicates that treatment with 
buprenorphine may offer advantages over methadone maintenance during pregnancy and the 
neonatal period in terms of low transplacental transfer, lower incidence and severity of NAS and, 
due to its poor oral bioavailability, less exposure to active medication through breast milk (R. E. 
Johnson, Jones, et al., 2003; Nanovskaya, Deshmukh, Brooks, & Ahmed, 2002).   
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1.9 Physical development after prenatal exposure to opioids 
The opioid system is related to growth and development in utero and opioid receptors are found 
in the brain, spinal cord, as well as in various organ sites of the developing foetus (Farid, et al., 
2008; Jaffe, et al., 1997). Opioid receptor expression is regulated by signals from growth factors 
and neurotransmitters, both of which are affected by prenatal exposure to opioids (Robinson, 
2000, 2002; Tiong & Olley, 1988; Wu, Mo, Yabe, Schwartz, & Robinson, 2001). There is general 
agreement that prenatal exposure to illicit opioids can result in low birth weight, thought to be 
related to intrauterine growth restriction (IGR) (Farid, et al., 2008; Kandall, et al., 1976; Lifschitz, 
et al., 1983; Shankaran et al., 2007). 
 
1.9.1 Physical development after prenatal exposure to methadone and/or heroin 
The following section provides an overview of previous research examining physical development 
after prenatal exposure to methadone and/or heroin. First, animal studies are discussed, followed 
by human studies using retrospective case-note review or cross-sectional designs, then 
prospective longitudinal studies are reviewed. 
 
Animal research has posited that low birth weight in opioid-exposed rat pups may be due to 
withdrawal in utero. Lichtblau and Sparber (1981) suggested that the once daily dosing regimen of 
methadone may result in the foetus undergoing withdrawal symptoms prior to each subsequent 
dose. In an experimental study (Lichtblau & Sparber, 1981) rat pups were prenatally exposed to 1 
or 4 mg/kg of the long-acting derivative of methadone, ι-α-acetylmethadol (LAAM), administered 
once per day to pregnant females. In order to induce withdrawal in the foetus, 1 mg/kg of the 
opioid antagonist naloxone was administered to half of the sample, four and two hours prior to 
LAAM dosing. Results showed that whilst the birth weight and nose-to-tail length of pups 
prenatally exposed to LAAM did not differ significantly from non-exposed control pups, pups who 
were prenatally withdrawn from either dose of LAAM showed significantly reduced body weight 
and nose-to-tail length at birth compared with non-exposed pups. Additionally, pups prenatally  
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exposed to either dose of LAAM failed to gain weight postnatally. The authors suggested that 
restrictions in postnatal weight gain may be related to chronic intoxication, due to persisting 
opioid activity in the brain, which may suppress feeding and other behaviours required for healthy 
development (Lichtblau & Sparber, 1981). 
 
In a more recent study, Hutchings et al. (1992) reported that higher maternal doses of methadone 
administered via constant infusion had a transient effect on postnatal growth of rat pups, with 
pups prenatally exposed to 15 mg/kg/day methadone showing initial deficits in weight gain, 
compared with pups prenatally exposed to 10 mg/kg/day methadone or a non-treated control 
group. The authors reported a catch-up effect by the 50
th postnatal day but it was unclear 
whether delays in growth may have been secondary to NAS symptoms or a direct effect of 
methadone on infant growth (Hutchings, et al., 1992).  
 
In a retrospective study of 266 infants prenatally exposed to heroin (n=61) methadone (n=106), or 
a combination of the two (n=59), Kandall et al. (1976) reported that the average birth weight of 
infants prenatally exposed to methadone alone (M±SEM=2961±52 gm) was significantly higher 
than the combined average birth weight of infants prenatally exposed to heroin 
(M±SEM=2490±87 gm), both heroin and methadone (M±SEM=2535±86 gm) and a group of 33 
infants of drug-free ex-heroin users (M±SEM=2615±74 gm). This difference was not accounted for 
by gestational age. In addition, the authors found that the mean birth weight of 66 infants in a 
non-exposed comparison group had significantly higher birth weights (M±SEM=3176±64 gm) than 
infants in the methadone-only group (M±SE=2961±52 gm). When possible confounding factors 
were examined, it was found that although a lack of prenatal care was associated with poorer 
birth weight in all substance-exposed groups, infants prenatally exposed to methadone alone 
were significantly heavier than infants who had been exposed to heroin or both heroin and 
methadone, independent of the level of prenatal care received (Kandall, et al., 1976). 
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A Dutch cross-sectional study (van Baar, Fleury, Soepatmi, Ultee, & Wesselman, 1989) found that 
infants prenatally exposed to opioids (n=35; predominantly combinations of methadone and 
heroin) had a lower mean birth weight (M±SD=2880.8±415.3 gm) than a non-exposed comparison 
group (n=37; M±SD=3428.8±439.9 gm). These authors noted that there was a high rate of 
maternal cigarette smoking during pregnancy (100%) in the group of opioid-exposed infants, and 
over half of the infants had also been exposed to maternal cocaine use throughout pregnancy 
(van Baar, Fleury, Soepatmi, et al., 1989). The prevalence of maternal smoking was not reported 
for the comparison group in this study, neither was there a measure of prenatal care, and 
analyses of growth measures did not adjust for any of these potentially confounding variables. 
 
An early prospective study compared the growth and development of 22 children prenatally 
exposed to heroin and that of a number of other groups of infants, including those considered to 
be (i) medically ‘high-risk’ (n=15), (ii) children raised in a ‘drug environment’ but with no prenatal 
exposure to any substance (n=20), and (iii) a group of children of similar socioeconomic 
background (n=20) (Wilson, et al., 1979). The children were born between 1968 and 1970 and 
were followed up in 1974. The mean birth weight of the heroin-exposed (M=2750 gm) and the 
medically ‘high-risk’ (M=2722 gm) infants was significantly lower than infants in either the drug 
environment (M=3090 gm) or the socioeconomic comparison (M=3317 gm; pooled SD=24.28, 
p<.05) groups. Mean one-minute Apgar scores of the heroin-exposed (M=7.8) and the medically 
high-risk (M=7.2) infants were significantly lower than infants in either the drug environment 
(M=8.3) or the socioeconomic comparison (M=8.9; pooled SD=1.62, p<.05) groups. Wilson et 
al.(1979) also reported that infants in the heroin-exposed group stayed in hospital for an average 
of 18.0 days post-delivery, while the high-risk group of infants had an average hospital stay of 
11.3 days. This was in comparison to the infants in the drug-environment group who had an 
average hospital stay of 2.8 days, and the socioeconomic comparison group who were discharged, 
on average, 4.0 days after birth (pooled SD=11.48, p<.05). Fifty five percent of heroin-exposed 
infants were treated for NAS; however, no details about NAS severity or duration were reported  
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by the authors. Gestational ages of the four groups of infants were comparable. The authors 
noted that the women who used heroin during pregnancy had significantly fewer prenatal care 
visits; however, data for this variable was not presented and infant analyses were not adjusted for 
this covariate (Wilson, et al., 1979). The children were re-assessed when they were aged 3 years, 
1 month to 6 years, 4 months (M=4 years, 7 months). Although no means or standard deviations 
were provided, the authors reported that, after adjusting for age, sex, race and socioeconomic 
status, children in the heroin-exposed group had lower mean growth percentiles for height, and 
significantly lower mean growth percentiles for weight, and head circumference (HC), than infants 
in the other three groups.  Further, it was reported that at follow-up a greater proportion of 
children in the heroin-exposed group had height and HC measurements below the third percentile 
compared with children in the comparison groups (Height = 32% vs. 12%, HC = 14% vs. 2%) 
(Wilson, et al., 1979). 
 
Lifschitz and colleagues (1983) followed the development of 22 heroin-exposed, 21 methadone-
exposed and 28 non-exposed comparison infants from birth to three years of age. While the small 
sample size of this study limits the power to detect differences between the groups, the authors 
reported that, despite similar gestation periods (38.4 to 39.0 weeks), the birth weight of infants in 
the heroin-exposed (M±SD=2751±521 gm) and the methadone-exposed (M±SD=2882±490 gm) 
groups was significantly lower than infants in the non-exposed comparison group 
(M±SD=3354±471; p<.01). Length and HC at birth were also significantly smaller in the heroin-
exposed (Length: M±SD=47.4±2.8 cm; HC: M±SD=33.0±1.7 cm) and the methadone-exposed 
(Length: M±SD=47.7±2.8 cm; HC: M±SD=33.2±1.7 cm) groups compared to the non-exposed 
comparison group (Length: M±SD=49.8±2.3 cm; HC: M±SD=34.7±1.3 cm). It was also found that 
the proportion of infants who were small-for-gestational age (SGA; birth weight <10
th percentile) 
in the heroin-exposed group (23%) was larger than in the methadone-exposed group (14%), and 
significantly greater compared to the non-exposed group (4%). After adjusting for several 
confounding factors (i.e. gender, race, prenatal care, prenatal risk score, maternal weight gain  
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during pregnancy, maternal education and maternal smoking) birth length no longer differed 
significantly between the three groups of infants (adjusted means not presented). The authors 
reported that the majority of infants who were SGA at birth were of comparable length to the 
other infants at six months of age (Lifschitz, et al., 1983). At three year follow-up the mean 
weight, length and HC of the three groups did not differ significantly (weight: heroin 
M±SD=14.5±2.8 kg, methadone M±SD=14.0±1.9 kg, comparison M±SD=14.3±1.7 kg; length: heroin 
M±SD=93.1±3.2 cm, methadone M±SD =91.8±3.0 cm, comparison M±SD=93.4±3.6 cm; HC: heroin 
M±SD=49.5±1.1 cm, methadone M±SD=49.2±1.5 cm, comparison M±SD=49.8±1.6 cm). However, 
when length at three-years of age was adjusted for birth length, race, parental height and 
maternal smoking, the mean length of the methadone-exposed group (M=91.9 cm) was smaller 
than that of the non-exposed comparison group (M=92.6 cm), and significantly smaller than that 
of the heroin-exposed group (M=94.4 cm; pooled SD=2.8, p<.05) (Lifschitz, et al., 1983).  
 
Further analysis of this cohort (Lifschitz, et al., 1985) showed that there was a deceleration in HC 
in the first year of life for almost one quarter of infants prenatally exposed to methadone 
compared with seven percent of non-exposed comparison children. A similar deceleration of HC 
occurred for a quarter of the heroin-exposed children in the second year. Multiple regression 
analyses found that post natal head growth was significantly associated with birth weight, level of 
maternal intra-partum risk and racial background (Lifschitz, et al., 1985). The authors concluded 
that the postnatal growth of children prenatally exposed to opioids did not differ significantly 
from that of a comparably high-risk group of non-exposed infants when adjusting for confounding 
factors (Lifschitz, et al., 1983, 1985).   
 
Soepatmi (1994) described developmental outcomes for 91 infants prenatally exposed to 
substances of dependence (including opioids and non-opioids), born between 1974 and 1983 in a 
Dutch hospital. Relative to non-exposed infants born at the same hospital, a greater proportion of 
infants prenatally exposed to substances had a birth weight <10
th percentile (non-exposed= 10%  
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vs. exposed= 24%) and were born preterm (non-exposed=15% vs. exposed=24%). Data were not 
presented separately for opioid-exposed and non-opioid exposed infants (Soepatmi, 1994). Long-
term follow-up data were available for 45 opioid-exposed (heroin and methadone) Caucasian-
Dutch infants. At one month post-birth, and at two years of age, children prenatally exposed to 
opioids were significantly smaller, in terms of Dutch growth percentiles for weight, length and HC, 
than children in the general Dutch population. At the final follow-up assessment, in 1986 when 
children were aged between 3.5 and 12 years of age, growth percentiles for weight and HC of the 
opioid-exposed children were similar to the Dutch general population; however growth 
percentiles for length remained significantly lower (Soepatmi, 1994). All growth percentiles were 
expressed in mean growth classes, however, as no explanation of this measurement was given 
and standard deviations were not provided the implications of these findings are difficult to 
interpret. While it was concluded that the developmental outcome of children prenatally exposed 
to opioids was poor in comparison to non-exposed children and children in the general Dutch 
population, the author advised that further prospective studies were needed (Soepatmi, 1994). 
 
Johnson and colleagues (H. L. Johnson, Glassman, Fiks, & Rosen, 1987, 1990; H. L. Johnson & 
Rosen, 1982; Rosen & Johnson, 1982) examined the growth and development of 62 methadone-
exposed infants from birth to 36 months of age. Non-exposed infants from comparably high-risk 
backgrounds (n=32) were matched to the methadone-exposed infants for gender, gestational age 
and birth weight. The authors reported that a significantly greater proportion of methadone-
exposed infants had birth HC below the third percentile when compared with the non-exposed 
infants. However, proportions, means and standard deviations were not reported (Rosen & 
Johnson, 1982). This cohort was followed up at 36 months of age and the authors reported that 
weight and height did not differ significantly between the methadone-exposed group (n=39) and 
the non-exposed comparison group (n=23). The authors reported that there were a significantly 
greater proportion of children in the methadone-exposed group with HC below the third 
percentile (H. L. Johnson, et al., 1987, 1990). However, as proportions, means and standard  
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deviations were not reported for any of the growth parameters, it is difficult to interpret these 
findings.  
 
In an American study Hans (1989) compared the developmental outcome of a group of children 
prenatally exposed to methadone (n=30) to that of a group of non-exposed children (n=44) of 
comparable economic, maternal intellectual and racial background.  He reported that the mean 
birth weight of the methadone-exposed infants (M±SD=2865±605 gm) was significantly lower 
than that of the non-exposed comparison group [M±SD=3236±395 gm; t(72)=3.15, p<.01]. At two 
years of age, children exposed to methadone were significantly shorter (M±SD=85.1±4.3 cm) than 
non-exposed children [M±SD=87.3±2.9 cm; F(1,70)=4.54, p<.05] and had significantly smaller 
mean HC (M±SD=48.5±1.4 cm) compared with the non-exposed children [M±SD=49.5±1.5 cm; 
F(1,70)=6.97, p<.05]. Effect sizes were small  to medium (Pearson eta coefficients = .26 to .28) and 
all mean growth parameters were reportedly within the normal range (Hans, 1989). While it was 
noted that the majority of women in the methadone group had also used other substances 
(including alcohol, marijuana, heroin, cocaine and Valium®) during pregnancy, the author did not 
provide any further details regarding the proportion of women who had used these substances in 
addition to methadone, and pre-natal exposure to other substances was not controlled for in 
analyses. 
 
In a recent Australian paper, Hunt and colleagues (2008) described a case control study following 
the development of 133 methadone-exposed infants and 103 non-exposed infants to three years 
of age. Twenty-four percent of the methadone-exposed infants were born preterm and 25% were 
SGA, the proportions for the non-exposed infants were not reported although, at birth, the mean 
growth measurements of the non-exposed infants (weight=3.3 kg, length=51.6 cm, and HC=34.5 
cm) were significantly greater than those of the methadone-exposed group (weight =2.9 kg, 
length=49.6 cm, and HC=33.6cm). However, these differences were accounted for by the earlier  
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mean gestation of the methadone-exposed infants (M=37.7 weeks) compared with the non-
exposed group (M=40.2 weeks). When the infants were assessed at 18 months and three years of 
age, the methadone-exposed group had caught up to the non-exposed group in terms of mean 
weight and HC.  Hunt and colleagues reported that the methadone-exposed children remained 
significantly shorter (18 months M=81.0 cm, 3 years M=92.8 cm) than the non-exposed children 
(18 months M=82.4 cm, 3 years M=96.7 cm), after adjusting for gestation, maternal height and 
maternal smoking, with the difference in height increasing over time (Hunt, et al., 2008). 
However, the authors did not appear to adjust for any other potentially important covariates, 
including gestational age, maternal use of other substances, treatment for NAS, or other health 
and social factors, and no explanations for the obtained results were provided. 
 
1.9.2 Physical development after prenatal exposure to buprenorphine 
Animal studies have shown differing results in term of postnatal growth after prenatal exposure 
to buprenorphine. In an experimental study (Tiong & Olley, 1988) rat pups were prenatally 
exposed to 4 mg/kg or 8 mg/kg methadone, or 1 mg/kg or 2 mg/kg buprenorphine, administered 
once per day to pregnant dams. When mean litter size was compared, non-treated control dams 
produced significantly larger litters (M±SEM=9.7±0.6 pups), compared with dams receiving 
4mg/kg methadone (M±SEM=7.6±0.8 pups, p<.05) and 2 mg/kg buprenorphine (M±SEM=7.4±1.2 
pups, p<.05). Birth weight of pups was not reported. There was a significantly higher rate of death 
for pups exposed to buprenorphine, with 53% of the 1 mg/kg group and 65% of the 2 mg/kg 
group perishing by postnatal day five, compared with 2% of non-exposed controls, although the 
authors suggested that rejection of pups by foster mothers or pup viability may have contributed 
to this high rate of mortality. When pups were weighed on postnatal day 20, the buprenorphine-
exposed groups weighed less than methadone-exposed and control pups, however this difference 
was not statistically significant (Tiong & Olley, 1988). The authors cautioned that the adverse 
events observed in the neonatal rat pups may have been related to the regimen of a once daily 
injection of buprenorphine to the pregnant females. It was explained that rats metabolise opioids  
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more rapidly than do humans, and the fluctuations in drug levels may have exposed the 
developing foetus to withdrawal, with subsequent harmful effects (Tiong & Olley, 1988). 
 
Research by Hutchings, Zmitrovich, Hamowy and Liu (1995) found no differences in birth weight 
or postnatal growth (to postnatal day 60) between male rat pups prenatally exposed to differing 
amounts of buprenorphine (0.3 mg, 1 mg, or 3 mg/kg/day), sterile water (both administered via 
constant infusion), and those in a non-treated group (Hutchings, et al., 1995). However, female 
pups prenatally exposed to 3 mg/kg/day buprenorphine demonstrated a significant decrease in 
body weight at postnatal day 30, compared to the pups prenatally exposed to sterile water and 1 
mg/kg/day buprenorphine. This difference was not observed at any other time. The authors 
suggested that fewer toxic effects have been found with the administration of medication via 
constant infusion, thus eliminating daily peak drug concentrations (Hutchings, et al., 1995), as 
opposed to the once per day dosing as described in Tiong and Olley’s study (1988).  
 
In terms of studies examining growth outcomes, beyond the neonatal period, for human infants 
prenatally exposed to buprenorphine, Schindler et al. (2003) described the development of four 
infants born to two women maintained on buprenorphine during pregnancy. Both women had 
been inducted onto buprenorphine during the second trimester of their first pregnancy and had 
conceived their second infant whilst receiving buprenorphine maintenance therapy. It was 
reported that all infants were born at term, had high Apgar scores (9 to 10) and birth 
measurements within normal limits (weight=2800 to 3430 gm; length=49 to 51 cm; HC=33 to 35 
cm). While no long term data was presented, according to the authors, the longer term 
development of all four children was comparable to non-exposed children (Schindler, et al., 2003). 
Retrospective case-note review of 13 infants exposed to buprenorphine in pregnancy was 
reported by Kayemba-Kay’s and Laclyde (2003). In this sample the majority of infants (12/13) 
were born at term (one infant was born at 36 weeks gestation, overall M=39 weeks gestation). 
Two infants had a birth weight ≤2500 gm (overall M=3000 gm), four infants were SGA, Apgar  
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scores for all infants were within the normal range (data not provided) and 77% of cases required 
pharmacological treatment for symptoms of NAS. Length of hospital stay ranged from 6 to 48 
days post delivery. Although the authors reported that milestone acquisitions for the majority of 
infants were within normal limits, no long term growth data were presented (Kayemba-Kay's & 
Laclyde, 2003). A recent study by Sandtorv et al. (2009) followed the development of 15 infants 
prenatally exposed to methadone (n=11) or buprenorphine (n=4) born in a Norwegian hospital 
between 1999 and 2005. The authors reported that 10 of the infants were born at term, with two 
sets of twins and one singleton delivered prior to 36 weeks gestation (overall M=39 weeks 
gestation). The mean birth weight was 3102 gm and mean HC at birth was 34.1 cm. Three of the 
four buprenorphine-exposed infants and all of the methadone exposed infants experienced NAS. 
Two buprenorphine-exposed infants and eight methadone-exposed infants were treated 
pharmacologically with morphine. The mean length of hospital stay was 27.4 days post delivery 
(range 6-88 days). While it was reported that infant development was followed up to a mean age 
of 30 months, no growth measurements were provided. Further, outcomes for the methadone 
and buprenorphine exposed infants were not reported separately for many variables (Sandtorv, 
et al., 2009). 
 
1.10 Neurodevelopment after prenatal exposure to opioids 
Early evaluation of neurological sequelae related to prenatal exposure to substances is 
problematic because task-based assessment of neurological development is difficult with pre-
verbal children. Standardised tests are valuable in providing clinical assessments, however 
they often rely on attention, motivation and learning, all three of which can affect results of 
testing in infants (Moskowitz & Sokol, 1983). 
 
Neurophysiologic techniques, such as visual evoked potentials (VEP) record electrographic 
patterns which can be employed to assess brain development and maturation of visual 
functioning (Scher et al., 1998). VEP tests the integrity of the visual pathway and provides  
35 
 
information about neural maturity by measuring the change in electrical potential within the 
primary visual cortex in response to a visual stimulus (Cibis & Fitzgerald, 1993). Many studies 
of visual system maturation have used diffuse flashes of light as the stimulus and it is 
recognised that the latency of the flash VEP (FVEP) decreases with age (Moskowitz & Sokol, 
1983). More recently pattern-reversal stimuli (PVEP) has been used to measure visual 
maturity in infants as it is known to show less inter- and intrapersonal variability in measures 
of latency in normal infants. It is also more sensitive than FVEP to visual pathway lesions (Aso 
et al., 1988). An advantage of assessment using VEP is that from as early as a few weeks of 
age, changes are evident in the development of mechanisms fundamental to the maturation 
of visual functioning (Moskowitz & Sokol, 1983). Abnormal responses (including prolonged 
latencies) may be a sign of neurological immaturity and reflect neurophysiologic dysfunction 
in otherwise asymptomatic infants (Hansen, Struthers, & Gospe, 1993; McCulloch, Orbach, & 
Skarf, 1999; Scher, et al., 1998). A decrease in latency to the first major positive component 
(P1) elicited through VEP is a reliable index of visual maturation, predominantly associated 
with myelination of the optic nerve (Algarin, Peirano, Garrido, Pizarro, & Lozoff, 2003; Aso, et 
al., 1988; Hansen, et al., 1993; Pinto, Onofrj, Pola, Tempesta, & Torrioli, 1986). 
 
1.10.1 Visual Evoked Potentials after prenatal exposure to methadone 
Delays in both P1 and N75 (the first major positive and negative components of the VEP 
waveform) latencies were reported by Bauer (1998) who found that adults maintained on 
methadone (n=22) exhibited significantly slower latencies than non-drug using adults (n=21) and a 
group of adults with past history of heroin dependence, but no current use (n=37). There was a 
significant relationship between the severity of heroin use (i.e. years used) and the N75 latency 
response; however this relationship was not evident for the P1 latency response. Bauer found no 
correlation between latencies and either duration of abstinence from heroin or methadone blood 
levels. It was concluded that delayed latencies were best accounted for by accumulated effects of 
chronic opioid dependence (L. O. Bauer, 1998). Alterations in P1 latencies of rat pups prenatally  
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exposed to high doses of methadone have also been observed at the peak of NAS, however they 
returned to normal by 21 days of age (Pinto, et al., 1986). Abnormal responses to VEP (including 
absent or delayed latencies) in children prenatally exposed to cocaine, cannabis, alcohol and 
nicotine have also been reported (Dixon, Coen, & Crutchfield, 1987; Olegard et al., 1979; Scher, et 
al., 1998; Tansley, Fried, & Mount, 1986).  
 
A very early study compared VEP responses of infants prenatally exposed to methadone and/or 
heroin (n=15) to those of non-exposed control infants (n=10) (Lodge, Marcus, & Ramer, 1975). It 
was reported VEPs of newborn infants prenatally exposed to narcotics were irregular and less 
reliable than those of the non-exposed newborn infants. Exposed infants also showed poorer 
levels of arousal and attentiveness than the non-exposed infants (Lodge, et al., 1975). A recent 
study found that amplitudes of flash VEP were small and of poorer quality in infants prenatally 
exposed to methadone and illicit opioids (n=21) compared to non-exposed infants (n=20) 
(McCulloch et al., 2007; McGlone et al., 2008). When tested at one to four days of age, a greater 
proportion of MM exposed infants (>50%) had abnormal waveforms that were significantly 
smaller in amplitude than those of the non-exposed infants (MM: median 10.6 mV, range 0–30; 
non-exposed: median 24.4 mV, range 8–69). Median amplitude of VEPs remained smaller for 
MM-exposed infants when re-tested after one week. The authors noted that, compared with the 
non-exposed infants, the MM-exposed infants were significantly smaller at birth (2818 gm vs. 
3486 gm; p<.01), had significantly smaller occipito-frontal circumferences (32.9 cm vs. 34.9 cm; 
p<.01), and were born at a significantly earlier gestation (M±SD=38.6±1.4 vs. M±SD=39.8±0.95 
weeks, p<.01). Over half of the MM mothers had used benzodiazepines whilst pregnant; however, 
because of the small sample size it was not possible to adjust for the effects of potential 
confounders (McGlone, et al., 2008). Mulvihill and colleagues (2007) described ophthalmic 
examinations of children prenatally exposed to opiates and/or benzodiazepines (n=14). Children 
were recruited if they had a diagnosis of horizontal nystagmus. Seven children reportedly had 
delays in visual functioning, although details of testing were not provided. Three children were  
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examined using VEP (two were aged four years and one was aged eight years at testing). The 
authors reported that all three children had normal responses to VEP; however neither data nor 
details of the VEP testing were provided (Mulvihill, et al., 2007).  
 
Most recently Hamilton et al. (2010) presented a retrospective case review of children prenatally 
exposed to methadone maintenance (n=20). Responses to flash, pattern-reversal and pattern 
onset VEPs were recorded, with age at assessment ranging from three months to seven years. The 
authors reported delayed responses to flash VEP in 3/11 children, delay or absence of response to 
pattern-reversal VEP was seen in 4/6 children, whilst 1/6 children had a delayed response to a 
pattern onset VEP. One child had a delayed or absent response to all three VEP assessments, 
although no abnormality in MRI was observed for this child. In the majority of cases, delayed or 
absent responses to VEPs were associated with a history of pharmacological treatment for NAS 
and the presence of nystagmus. Whilst the authors noted that over half of the children in the 
study had been exposed to benzodiazepines or heroin in utero, in addition to MM, the sample 
was too small to separate the individual effects of these substances on VEP responses (Hamilton, 
et al., 2010).  
 
1.10.2 Cognitive Development after prenatal exposure to methadone and/or heroin 
It is unclear whether children prenatally exposed to opioids are at greater risk than non-exposed 
children of longer term cognitive problems. Whilst some researchers have reported adverse 
outcomes for children prenatally exposed to either illicit heroin use or prescribed methadone 
maintenance (Davis & Templer, 1988; Hunt, et al., 2008; van Baar & de Graaff, 1994), others have 
reported no longer term developmental problems (Kaltenbach & Finnegan, 1987; Wilson, 1989).  
There is a paucity of research examining children’s cognitive development longitudinally, and 
many studies have not compared outcomes with those of non-exposed infants, have had small 
samples, or poor follow-up rates.  
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In a cross-sectional study, Davis and Templer (1988) compared the neuropsychological status of 
children who were exposed to opioids (heroin and/or methadone, n=28) in pregnancy, with a 
group of reference children (n=28) who were not prenatally exposed to opioids but who resided 
with a father figure with an opioid-addiction.  Children were aged between six and 15 years at 
assessment. Mean age at assessment was significantly lower for the narcotic-exposed children 
than the non-exposed children (M±SD=8.50±2.52 vs. M±SD=11.21±2.96 years, p<.001), and age 
was used as a covariate in analyses. Opioid-exposed children scored significantly lower than non-
exposed children on the Wechsler Intelligence Scale for Children - Revised (WISC-R) Full Scale 
(M±SD =90.36±11.36 vs. M±SD =96.32±8.72, F=5.03, p<.05) and Performance IQ scores 
(M±SD=88.21±17.33 vs. M±SD=100.00±9.82, F=5.95, p<.05). Mean scores for Verbal IQ did not 
differ significantly between the groups. When results were examined at the subtest level, opioid-
exposed children performed more poorly on subtests that examined perception, attention and 
motor skills (Digit Span: M±SD=8.04±2.81 vs. M±SD=9.29±2.79, F=5.37, p<.05; Picture Completion: 
M±SD=8.54±2.08 vs. M±SD=10.21±2.28, F=7.16, p<.01; Object Assembly: M±SD=9.00±2.19 vs. 
M±SD=10.39±1.99, F=6.21, p<.05; Coding: M±SD=8.11±3.07 vs. M±SD=10.42±3.08, F=5.35, p<.05). 
Opioid-exposed children also achieved significantly higher mean scores (indicating poorer 
performance) than the non-exposed children, on the neurological indicators of the Bender-Gestalt 
Test (M±SD=6.95±3.42 vs. M±SD=2.54±2.00, p<.001) (Davis & Templer, 1988). Results were 
examined separately for a group of children who were prenatally exposed to only heroin (n=9), 
and a group who were exposed to only methadone (n=12). The methadone-exposed children 
scored more poorly than the heroin exposed children on the Information subtest of the WISC-R 
(M±SD=5.33±2.15 vs. M±SD=8.11±2.89, F=-2.53, p<.05), and achieved significantly higher scores 
(indicating poorer performance) than the heroin-exposed children on the Handwriting Skill 
subtest of the Quick Neurological Screening Test (M±SD=1.08±1.08 vs. M±SD=0.11±0.33, t=2.58, 
p<.05).  No other significant differences were observed (Davis & Templer, 1988).  
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One of the earliest longitudinal studies followed the development of infants born to women 
participating in methadone maintenance (MM) in San Francisco (n=34), from birth to two years of 
age (Lodge, et al., 1975; Ramer & Lodge, 1975). Infants were assessed on the Bayley Scales of 
Infant Development (BSID) at three monthly intervals in the first year of life, and then at six 
monthly intervals thereafter. Preliminary BSID data were presented for six assessments (with n’s 
at each assessment ranging from 4 to 20). Mean scores for the Mental Developmental Index 
(MDI) ranged from low average (M±SD=89.80±10.94) to high average (M±SD=117.30±16.56); 
whilst mean scores for the Psychomotor Developmental Index (PDI) ranged from average 
(M±SD=105.71±14.65) to high average (M±SD=136.29±19.20). It was noted that MM-exposed 
infants appeared to show strengths in the areas of vocalisation and language development, but 
performed poorly on tasks requiring perceptual motor skills (Ramer & Lodge, 1975). A further 
study by the same research group included data from 88% of this sample (Lodge, et al., 1975). 
When tested on the BSID at one-month of age, MDI scores of 29 infants prenatally exposed to 
heroin and/or methadone were lower (M±SD=90.41±13.06) than scores of 10 non-exposed 
infants (M±SD=96.60±10.11). The authors suggested that the lower scores of the opiate-exposed 
infants were due to poorer orientation and less attentiveness to visual tasks. Mean scores on the 
Psychomotor Developmental Index (PDI) were found to be above average for both the opiate-
exposed (M±SD=121.30±18.89) and the non-exposed (M±SD=126.60±14.14) infants (Lodge, et al., 
1975). 
 
In a prospective study, Wilson and colleagues (1979) compared the developmental outcomes of  
preschool children prenatally exposed to heroin (n=22) to those of (i) non-exposed children raised 
in a ‘drug environment’(n=20), (ii) children deemed to be ‘at risk’ due to medical factors (n=15), 
and (iii) children from a similar socioeconomic background (n=20). The children were born 
between 1968 and 1970 and were followed up in 1974 (mean age at follow-up = 4 years, 7 
months). The groups did not differ in mean age, gender, race, or socioeconomic status (SES). At 
follow-up, the heroin-exposed children were found to perform significantly more poorly on the  
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McCarthy Scales of Children’s Abilities (McCarthy General Cognitive Index:  M=88.71) than infants 
in the drug environment (M=92.87), the medically ‘high-risk’ (M=93.08), and the socioeconomic 
comparison (M=97.42; pooled SD=14.62, p<.05) groups. Mean Columbia Mental Maturity Scale 
Intellectual Quotient (IQ) scores were lower (but not significantly different) for the heroin-
exposed children (M=96.06), when compared with the other three groups (drug environment: 
M=99.15; ‘high-risk’: M=100.51; socioeconomic comparison: M=99.48; pooled SD=13.44). The 
authors noted that whilst mean scores for the heroin-exposed group were consistently lower than 
those of the comparison groups, the majority of scores fell within the average range (Wilson, et 
al., 1979).  
 
A further study by this research group followed the development of 29 heroin-exposed infants, 39 
methadone-exposed infants and 57 non-exposed comparison infants (Wilson, 1989; Wilson, et al., 
1981). The authors reported that groups were matched for maternal age, race, SES, marital status, 
and gestational age at the commencement of prenatal care, however matching criteria were not 
provided. Information on the infants’ medical, neurological, social and behavioural development 
was collected at six weeks of age, at three monthly intervals during the first year of life, at 18 and 
24 months of age, then annually until the children were at preschool.  Mean scores on the BSID 
and McCarthy Scales were within the normal range and did not differ significantly between the 
groups. The exceptions to this were a significant delay in psychomotor development reported for 
nine-month old infants prenatally exposed to methadone (M±SD=89.9±12.6) compared with 
children in the non-exposed comparison group (M±SD=99.0±14.5; p<.01), and significant delays in 
cognitive function reported for 18-month old children prenatally exposed to heroin (MDI: 
M±SD=86.5±10.7) compared with children in the non-exposed comparison group 
(M±SD=97.4±14.4; p<.01) (Wilson, 1989; Wilson, et al., 1981). No significant differences in MDI 
performance were reported for the methadone-exposed group at the 18-month assessment 
(M±SD=92.0±14.5), and cognitive function of all three groups was comparable at 24 months of 
age. The cognitive developmental scores for the heroin-exposed group were noted to fluctuate  
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between assessments, and scores for all three groups of children were noted to decline over time. 
A phenomenon that the authors attributed to the level of disadvantage experienced by this study 
population and particularly the poor home environments of the drug-exposed children (Wilson, 
1989).  
 
This same group of children were assessed using the McCarthy Scales of Children’s Abilities 
between three and five years of age (mean age at testing = three years, five months) (Lifschitz, et 
al., 1985). Mean McCarthy General Cognitive Index (GCI) scores did not differ significantly 
between the three groups of children, although the authors suggested that it was of clinical 
importance that a higher proportion of heroin-exposed infants scored within the ‘mildly retarded’ 
range compared with the non-exposed infants (20% vs. 2%).  Multiple regression analyses showed 
that amount of prenatal care, level of prenatal risk, and quality of the child’s home environment 
were the best predictors of GCI score (Lifschitz, et al., 1985; Wilson, 1989). 
 
In another American study, Johnson et al. (H. L. Johnson, et al., 1987, 1990; H. L. Johnson & Rosen, 
1982; Rosen & Johnson, 1982) compared the development of children prenatally exposed to 
methadone (n=62 ) with non-exposed infants from comparably high-risk backgrounds (n=32). At 
six months of age mean scores on the MDI and PDI of the BSID were lower for infants prenatally 
exposed to methadone (MDI: M±SD=95.8±16.1; PDI: M±SD=101.0±18.2) than for the comparison 
group (MDI: M±SD=100.7±20.1; PDI: M±SD=105.1±14.2), however the authors commented that 
the differences did not reach statistical significance due to large within-group variance (H. L. 
Johnson & Rosen, 1982). Additionally, lower BSID scores were significantly associated with 
abnormal neurological signs for the methadone-exposed infants. A greater frequency of low 
scores (< 85, or 1 SD below the mean) was observed in the methadone-exposed group, with 20% 
of methadone-exposed infants scoring <85 on the MDI, compared with 17% of the non-exposed 
infants. A significantly greater proportion of methadone-exposed infants (15%) scored <85 on the 
PDI, compared with infants in the non-exposed group (8%, p<.01). When the distribution of low  
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scores across the two groups was examined for males and females separately, no significant 
differences were found for females infants, however male methadone-exposed infants were 
significantly more likely to score <85 on both the MDI (25%) and PDI (20%), compared with their 
non-exposed male peers (0%, p<.05 for both MDI and PDI) (H. L. Johnson & Rosen, 1982).   
 
A subset of these children was followed up until 36 months of age (H. L. Johnson, et al., 1987, 
1990; Rosen & Johnson, 1982). All mean scores fell within normal limits, however, at 12 months of 
age infants prenatally exposed to methadone (n =41) achieved significantly lower mean scores 
than comparison infants (n =22) on both the MDI (M±SD=98.37±2.68 vs. M±SD=107.00±2.81, 
p<.05) and the PDI (M±SD=94.93±2.53 vs. M±SD=102.78±2.30, p<.05). The authors noted that the 
gap in BSID scores between the two groups of infants widened over the course of the study, and 
at 18 months of age infants prenatally exposed to methadone (n =38) achieved significantly lower 
mean scores than comparison infants (n =23) on both the MDI (M±SD=96.00±2.31 vs. 
M±SD=106.38±3.56, p<.05) and the PDI (M±SD=92.62±2.38 vs. M±SD=105.29±2.21, p<.05) (Rosen 
& Johnson, 1982). At 36 months of age the two groups of infants did not differ significantly on 
scores or percentiles of the Merrill-Palmer Scale of Mental Tests (H. L. Johnson, et al., 1987, 
1990). 
 
Chasnoff and colleagues (Chasnoff, Hatcher, & Burns, 1982; Chasnoff, Schnoll, Burns, & Burns, 
1984) compared the development of infants prenatally exposed to methadone (n=39), to that of 
poly-drug exposed infants (i.e. combinations of benzodiazepines, marijuana and other illicit 
substances, n=19) and non-exposed infants (n=27). When assessed with the BSID at 3, 6, 12 and 
24 months of age, mean MDI and PDI scores for all three groups of children were within the 
normal range. There was a decline in mean scores between the 12 and 24 month assessments for 
all groups of children, which was attributed to low levels of SES and maternal education. The 
authors suggested that infants’ long term development appeared to be related to these 
environmental factors rather than prenatal substance exposure. A limitation of this study was that  
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there was a high rate of attrition with nearly two thirds of the sample lost to follow-up over the 
study period (Chasnoff, et al., 1984). 
 
A further study by this research group (Chasnoff, 1985; Chasnoff, Burns, Burns, & Schnoll, 1986) 
reported that, at six months of age, infants prenatally exposed to opioids (heroin, methadone and 
other illicitly used opioids, n =26) had significantly lower mean scores than non-exposed 
comparison infants (n =29) on the MDI (M±SD=103.6±13.5 vs. M±SD=111.0±12.3, p<.05). Twelve-
month mean MDI scores were significantly lower for opioid-exposed infants (n =20, 
M±SD=99.6±10.6) than for non-exposed controls (n =27, M±SD=105.8±8.1, p<.05).  Assessment at 
24 months of age showed no significant differences in MDI or PDI scores, however, a slight decline 
in scores was observed for all groups of infants over time. As in their earlier research, there was a 
high rate of participant attrition over the course of assessments with over 50% of the sample lost 
to follow-up (Chasnoff, 1985; Chasnoff, et al., 1986). 
 
Hans and colleagues (Bernstein & Hans, 1994; Hans, 1989; Huntington, Hans, & Zesking, 1990) 
followed 30 methadone-exposed infants from birth to 24 months of age and compared their 
development to that of 44 non-drug exposed infants.  Groups were comparable in terms of 
maternal IQ, years of education, single parent status, race and SES. At two years of age, infants 
exposed to methadone had significantly lower PDI scores on the BSID than the non-exposed 
infants (M±SD=100.8±12.6 vs. M±SD=108.5±14.6, F(1,70)=5.19, p<.05, eta=.26). Methadone-
exposed infants also scored significantly higher (indicating poorer functioning) on several of the 
BSID Infant Behaviour Record (IBR) items than their non-exposed peers. These were IBR tension 
(M±SD=4.3±0.8 vs. M±SD=4.0±0.6, F(1,70)=5.54, p<.05, eta=.26), IBR gross motor coordination 
(M±SD=26.±0.8 vs. M±SD=2.2±0.7, F(1,70)=6.08, p<.05, eta=.28), and IBR fine motor coordination 
(M±SD=2.8±0.6 vs. M±SD=2.5±0.7, F(1,70)=4.29, p<.05, eta=.24). It was noted that mean scores 
for these outcomes were well within the average range (Hans, 1989). Mean scores on the MDI 
were in the average range and did not differ significantly between methadone-exposed and  
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comparison children. However, when the children from very low SES families were examined 
separately (n not provided), the methadone-exposed infants scored more poorly than the non-
exposed infants on the MDI (M=86 vs. M=97, eta=.41). While methadone-exposed infants also 
performed more poorly on the PDI than the non-exposed children (M=98 vs. M=104), the effect of 
substance-exposure was not as large (eta=.21). Additionally, methadone-exposed infants from 
low SES backgrounds scored more poorly on the IBR items than non-exposed infants. It was 
concluded that prenatal exposure to methadone may increase susceptibility to the effects of a 
disadvantaged environment (Hans, 1989).  
 
In further research, these authors explored the relative contribution of social-environmental risks 
to the developmental outcomes of the same group of children and found that substance-
exposure alone did not predict poorer developmental outcome. Further, the authors discovered 
that individual and cumulative risk factors (e.g. maternal IQ, level of maternal psychosocial stress, 
parent-child interaction), independent of prenatal exposure to methadone, predicted 
developmental outcome for methadone-exposed children at only the extremes of the risk 
continuum (Bernstein & Hans, 1994).   
 
In a Dutch longitudinal study, van Baar et al. described the cognitive development of 35 children 
prenatally exposed to methadone maintenance as well as other substances (including heroin and 
cocaine), to that of a group of 37 children who were not exposed to substances in pregnancy (van 
Baar, 1990; van Baar & de Graaff, 1994; van Baar, Fleury, & Ultee, 1989; van Baar, Soepatmi, 
Gunning, & Akkerhuis, 1994). Children were assessed at six monthly intervals from six to 30 
months of age on a Dutch version of the BSID, and then yearly to five and a half years of age on 
Dutch intelligence tests. Mean scores on the PDI of the BSID were all within the average range and 
did not differ significantly between the groups at any of the assessments. There were no 
significant differences between the groups for mean MDI scores at 6, 12 and 18 months of age, 
and all mean scores were within the average range. However, at 24 and 30 months of age, the  
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substance-exposed children scored significantly more poorly than the non-exposed children on 
the MDI [24 months: M±SD=86±15 vs. M±SD=98±16, t(58)=2.98, p<.01; 30 months: M±SD=87±18 
vs. M±SD=101±20, t(57)=2.68, p<.01]. At the 24 month assessment, a greater proportion of 
substance-exposed children scored <84 (1 SD below the mean), on the MDI (n=12/26, 46%), 
compared with the non-exposed children (n=8/34, 24%). This was also the case with the 30 month 
assessment where 36% (n=9/25) of the substance-exposed children scored 1 SD below the mean, 
compared with 15% (n=5/34) of the non-exposed group (van Baar, 1990; van Baar, Fleury, & 
Ultee, 1989; van Baar, et al., 1994).  
 
Testing at later ages showed that the substance-exposed children continued to perform 
significantly more poorly on measures of general intelligence and language development, in 
comparison to their non-exposed peers. When assessed at three and a half years of age, children 
prenatally exposed to substances had significantly lower mean scores on the Snijders-Oomen 
Nonverbal (SON) intelligence test IQ scale than their non-exposed peers (M±SD=99±9 vs. 
M±SD=109±11, t(53)=3.75, p<.01). Similarly, mean scores on the Revision of the Amsterdam 
Children’s Intelligence Test (RAKIT) IQ scale were significantly lower for substance-exposed 
children, compared with the non-exposed group, when assessed at four and a half, and five and a 
half years of age (4 ½ years: M±SD=85±11 vs. M±SD=103±15, t(52)=4.98, p<.01; 5 ½ years: 
M±SD=90±12 vs. M±SD=102±17, t(50)=2.61, p<.05). For the latter two of these assessments, a 
greater proportion of substance-exposed children scored <84 (1 SD below the mean), on the 
RAKIT (4 ½ years: n=14/23, 61%; 5 ½ years: n=9/22, 41%), compared with the non-exposed 
children (4 ½ years: n=5/31, 16%; 5 ½ years: n=4/30, 13%) (van Baar & de Graaff, 1994). 
Substance-exposed children were also found to have significant difficulties with language 
development when tested at four years of age on the Dutch version of the Reynell Developmental 
Language Scales, with the substance-exposed children performing significantly more poorly than 
the non-exposed children on both the Language Comprehension (M±SD=46±6 vs. M±SD=52±6, 
t(56)=4.32, p<.01), and the Language Expression (M±SD=46±9 vs. M±SD=50±6, t(55)=2.00, p<.05)  
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Scales (van Baar & de Graaff, 1994). A limitation of this longitudinal study was that 63% of the 
substance-exposed group were prenatally exposed to other substances (i.e. cocaine, tranquillisers 
and amphetamines) along with opioids.  Two children (6%) were exposed to methadone only, 
whilst 31% were exposed to both heroin and methadone. It is therefore possible that the 
significant developmental deficits observed in the substance-exposed group may have been 
related to their exposure to substances other than opioids. 
 
In a large American prospective, longitudinal, multi-site study, Messinger and colleagues (2004) 
administered the Bayley Scales of Infant Development- Second Edition (BSID-II) to a large number 
of infants (n=1227) at one, two and three years of age. The infants were divided into four groups 
(i) infants prenatally exposed to cocaine only (n=474), (ii) infants who were prenatally exposed to 
opioids only (n=50), (iii) infants who were exposed to both cocaine and opioids (n=48), and (iv) 
infants who were not exposed to either substance (n=655). Mean BSID-II scores of infants who 
were exposed to opioids (n=98) were compared to those of infants who were not opioid-exposed 
(n=1129). At one year of age opioid-exposed children (n=79) scored significantly more poorly than 
the non opioid-exposed children (n=960) on the MDI at (M±SD=88.5±1.2 vs. M±SD=91.6±0.4, 
p<.05). Mean MDI scores at two and three years of age did not differ significantly between the 
two groups. Overall performance on the MDI (measured using an intercept term in a hierarchical 
linear model) was not associated with prenatal exposure to opioids (Messinger, et al., 2004). 
Opioid exposure was associated with significantly poorer PDI mean scores at two and three years 
of age (2 years: M±SD=89.0±1.7, n =79 vs. M±SD=95.2±0.5 n=859, p<.01; 3 years: M±SD=89.2±1.6, 
n=75 vs. M±SD=93.4±0.5, n=859, p<.05), and significantly poorer BRS mean scores at two years of 
age (M±SD=34.4±3.1, n=80 vs. M±SD=41.9±1.0, n=925, p<.05). Overall performance on the PDI 
was significantly associated with opioid exposure, with opioid-exposed children scoring 3.9 PDI 
points below non-opioid exposed children (p<.01). However, when analyses were adjusted for 
data collection site, infant age, ethnicity, birth weight, infants’ home environment, and maternal 
care, no significant effect of opioid exposure remained. Overall performance on the BRS was not  
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associated with prenatal exposure to opioids (Messinger, et al., 2004). While it must be noted that 
the authors pooled these groups of infants for the purposes of the analyses (i.e. the non-opioid 
exposed group consisted of the 655 non-exposed infants as well as the 474 infants prenatally 
exposed to cocaine only), the opioid-cocaine exposure interaction effect was not statistically 
significant for any of the BSID-II analyses (Messinger, et al., 2004). 
 
Hunt and colleagues (2008) followed the development of a group of methadone-exposed infants 
and a non-exposed group of infants in Sydney, Australia between 1979 and 1984. When assessed 
on the BSID at 18 months of age, scores for both groups of infants were in the normal range of 
development, although the methadone-exposed infants (n=79) were found to score significantly 
more poorly on the MDI (M±SD=88.2±16.4) than non-exposed infants (n=61, M±SD=105.0±23.0, 
p<.001). At three years of age methadone-exposed infants (n=67) were found to score 
significantly more poorly than the non-exposed infants (n=44) on the Stanford-Binet Intelligence 
Scale (M±SD=99.9±15.1 vs. M±SD=107.5±13.4, p<.01), the McCarthy Motor Scale (M±SD=49.5±8.7 
vs. M±SD=53.9±8.3, p<.05), and the Reynell Expressive Language (M±SD=35.5±7.9 vs. 
M±SD=42.8±12.6, p<.05) and Verbal Comprehension scales (M±SD=42.4±11.6 vs. 
M±SD=49.2±11.4, p<.05). Mean scores of both groups were within the average range for all scales 
(Hunt, et al., 2008). Although this research mentioned significant differences between the two 
groups of infants in terms of infant growth and stability of primary carer, these covariates were 
not included in analyses. Neither was there any inclusion of other potentially important covariates 
such as gestational age, maternal use of other substances, treatment for NAS, or other health and 
social factors.  
 
1.10.3 Neurodevelopment after prenatal exposure to buprenorphine 
Only five studies have described the neurodevelopmental outcome of human infants prenatally 
exposed to buprenorphine (Kahila, Kivitie-Kallio, Halmesmaki, Valanne, & Autti, 2007; Kayemba-
Kay's & Laclyde, 2003; Salo et al., 2009; Sandtorv, et al., 2009; Schindler, et al., 2003). Schindler et  
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al. (2003) described the pregnancy and early neonatal development of two infants conceived 
whilst their mothers were maintained on buprenorphine. It was reported that both infants had 
normal neurodevelopmental outcomes on clinical examination at six and 12 months of age 
(Schindler, et al., 2003). However, the details of the examinations were not included in the 
publication.  
 
Retrospective case-note review of 13 infants exposed to buprenorphine in pregnancy was 
reported by Kayemba-Kay’s et al. (2003). No anomalies were found in the reviewed 
electroencephalogram (EEG) recordings or cranial ultrasounds; however 54% of infants presented 
with transient hypertonia on clinical examination. In the majority of cases this resolved and 
developmental outcome at six and nine months, assessed using the Denver Developmental 
Screening Test, was considered within normal limits for 11 of the 13 infants (Kayemba-Kay's & 
Laclyde, 2003). However, no details of the test scores were provided in the publication. The 
authors suggested that future studies examining the longer term neurodevelopment of infants 
prenatally exposed to buprenorphine were needed (Kayemba-Kay's & Laclyde, 2003). 
 
Kahila et al. (2007) undertook magnetic resonance imaging (MRI) scans of seven infants prenatally 
exposed to buprenorphine. All infants were assessed before two months of age. Visual 
examination of brain scans found no structural anomalies and no evidence of irregular MRI signal 
intensity. The authors concluded that buprenorphine maintenance therapy did not cause hypoxic-
ischemic brain changes to exposed infants. The need for further studies examining the brain 
development of children exposed to buprenorphine was acknowledged by the authors (Kahila, 
Kivitie-Kallio, et al., 2007). 
 
Sandtorv et al. (2009) described the development of 15 infants prenatally exposed to methadone 
(n=11) or buprenorphine (n=4) in Norway. It was reported that half of the infants experienced 
delays in language or psychomotor development, three children had strabismus and two were  
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followed up at age four because of hyperkinetic conduct symptoms (Sandtorv, et al., 2009). 
However no details about the specific assessments were included in the publication and data for 
individual outcomes were not reported for the methadone and buprenorphine exposed infants 
separately. 
 
In a Finnish study, Salo et al. (2009) compared the development of 21 children prenatally-exposed 
to non-maintenance buprenorphine (used for recreational purposes) and 13 non-exposed 
children.  Fourteen of the buprenorphine-exposed children were in foster care, and seven were 
residing with their biological mother, although nearly all of these latter children had been placed 
in alternative care at least once. At three years of age, children prenatally exposed to 
buprenorphine achieved significantly poorer standardised scores on the Cognitive (maternal care: 
M±SD=8.14±0.38; foster care: M±SD=9.29±0.91) and Language Scales (maternal care: 
M±SD=18.00±2.00; foster care: M±SD=19.21±2.80) of the BSID-III, compared with the non-
exposed children (Cognitive Scale: M±SD=10.54±1.26, F = 8.33, p < .01; Language Scale: 
M±SD=23.69±2.13, F = 9.91, p < .001). After adjusting for covariates (including birth weight and 
height, gestational age, maternal age, SES and number of foster placements), only the Language 
Scale scores remained associated with substance-exposure. The authors noted that the majority 
of buprenorphine-exposed children were also prenatally exposed to other substances along with 
illicit buprenorphine use (Salo, et al., 2009). 
 
1.11 Temperament after prenatal exposure to opioids 
Few studies have examined the construct of temperament in substance-exposed infants and 
children. However many researchers have used observations of behaviour and measures such as 
the Brazelton Neonatal Behavioural Assessment Scale (NBAS) to examine self-regulatory 
behaviour, such as responsiveness, activity, irritability, and consolability, in infants prenatally 
exposed to opioids (Chasnoff, et al., 1982; Chasnoff, et al., 1984; Jeremy & Bernstein, 1984; 
Jeremy & Hans, 1985; Lodge, et al., 1975; Ramer & Lodge, 1975; van Baar, Fleury, Soepatmi, et al.,  
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1989). The Brazelton NBAS appears to assess similar constructs to those examined in 
temperament testing (e.g. irritability, response to stimuli, activity levels and state lability) and 
scores on the NBAS of non-exposed infants have been shown to be correlated (r =.33 to .65) with 
analogous infant temperament scale scores, as rated by caregivers (Sostek & Anders, 1977).  
 
In the first few weeks or months of life, infants exposed to opioids in utero are susceptible to high 
rates of neurobehavioural difficulties associated with Neonatal Abstinence Syndrome (NAS) 
(Finnegan, 1990). The constellation of symptoms displayed by infants with NAS has been likened 
to the ‘difficult’ temperament profile described by Thomas and Chess (Jeremy & Bernstein, 1984; 
1977). Problems with self confidence, poor self discipline and inattention, as rated by parents and 
school teachers, have been reported more frequently for opioid exposed children than for non-
exposed controls (Davis & Templer, 1988; Wilson, et al., 1979).  
 
1.11.1 Temperament after prenatal exposure to methadone and/or heroin 
Wilson et al. (1973) documented the development of infants prenatally exposed to heroin (n=30) 
from birth to between 3 and 34 months of age. Twenty-four infants showed signs of NAS in the 
first few days of life, and 82% continued to experience symptoms (including restlessness, 
irritability, and tremors) for up to six months. Fourteen infants (47%) attended follow-up 
appointments for 12 months or more and it was reported that seven of them continued to 
demonstrate ‘behavioural disturbances’, including poor attention span, hyperactivity, sleep 
problems, temper tantrums, and low frustration tolerance, as assessed by maternity and infant 
care clinic staff. The authors reported that the frequency of behavioural problems in this sample 
was high (50%) compared with a group of ‘high-risk’ non-exposed infants (6/271, 2%), however 
further details of the non-exposed sample were not published. The authors speculated that 
children residing in a chaotic home environment might display behavioural problems such as 
those observed in the study. However, as all of the heroin-exposed children with reported 
behavioural difficulties were residing with foster families at the time of assessment, influence of  
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home environment was thought not to be associated with child behavioural outcome (Wilson, et 
al., 1973). Limitations of this study were low rates of participant follow-up and lack of information 
regarding important covariates, such as length of time a child had been in foster care and 
measurement of the quality of the home environment.  
 
A further study by this research group (Wilson, et al., 1979) reported that preschool aged 
children, prenatally exposed to heroin (n=22), were rated by their parents or caregivers as 
significantly more aggressive, impulsive, and as having more social difficulties than children 
considered to be (i) medically ‘high-risk’ (n=15), (ii) children raised in a ‘drug environment’ but 
with no prenatal exposure to any substance (n=20), and (iii) a group of children of similar 
socioeconomic background (n=20). Specifically, children prenatally exposed to heroin were 
reported to have significantly more parent-rated problems than their non-exposed peers in terms 
of temper control, aggression, impulsive behaviour, self-confidence and maintaining friendships, 
as measured on the Child Behaviour Rating Scales (Wilson, et al., 1979). However, as no mean 
scores or SDs were published, it is difficult to interpret these findings. The authors reported that 
the groups were comparable in terms of parental educational level, single parent status and home 
environment, and analyses were adjusted for children’s age, gender, ethnicity, SES, and school 
readiness. The authors commented that the only difference between the groups was that a 
significantly greater proportion of the heroin-exposed children (50%) did not reside with their 
biological mother (Wilson, et al., 1979). However, the proportion of non-exposed children in 
alternative care was not provided.  
 
This same group of researchers (Wilson, 1989; Wilson, et al., 1981) examined the development of 
a group of infants prenatally exposed to heroin (n=29) with that of infants prenatally exposed to 
methadone (n=39) and a non-exposed control group (n=57). Following discharge from hospital, 
caregivers rated the prevalence of excessive crying to be significantly greater for the methadone-
exposed group of infants (49%) than for the non-exposed group of infants (15%, χ
2 =10.8, p<.01).  
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Disturbances of sleep were reported significantly more frequently for infants prenatally exposed 
methadone (80%) compared with the non-exposed control group (50%, χ
2 =6.04, p<.05). While the 
prevalence of both problems was greatest for the heroin-exposed infants (excessive crying: 58%; 
sleep problems: 96%), prevalence did not differ significantly from the methadone-exposed group 
and statistical data were not presented for these comparisons. Parent-rated prevalence of 
hypertonia was significantly greater for infants born to untreated heroin users (52%) when 
compared with infants prenatally exposed to methadone (22%, χ
2 =4.54, p<.05). The prevalence of 
hypertonia was comparable for the methadone-exposed group and the non-exposed group of 
infants (20%) (Wilson, 1989; Wilson, et al., 1981). 
 
Ramer and Lodge (1975) reported that of 34 infants prenatally exposed to methadone, 76% 
experienced withdrawal symptoms in the neonatal period (with 41% showing moderate to severe 
symptoms).  Fifty nine percent of infants required pharmacological treatment for NAS, although 
length of treatment was not reported. Further, symptoms of irritability, excessive crying and 
tremulousness persisted up until six weeks of age for 38% of the infants (Ramer & Lodge, 1975). 
The authors reported that approximately 50% of the sample was also exposed to heroin in utero, 
however data were not provided separately for the two groups of infants. The majority of the 
infants (88%) were included in a longitudinal follow up study, described below (Lodge, et al., 
1975). 
 
Lodge and colleagues (1975) found that infants prenatally exposed to methadone and/or heroin 
(n=27) were significantly less alert than a group of non-exposed infants (n=10) (M±SD=3.84±1.70 
vs. M±SD=5.40±1.84, t =2.40, p<.05) and had significantly poorer visual orientation and following 
response (M±SD=3.80±1.85 vs. M±SD=5.30±1.30, t =3.30, p<.01) when assessed on the Brazelton 
NBAS within the first week of life. Opioid-exposed infants also showed significantly increased 
levels of hypertonicity (M±SD=6.80±1.35 vs. M±SD=5.10±0.88, t =3.66, p<.001), activity 
(M±SD=5.80±1.35 vs. M±SD=4.80±1.23, t =2.02, p<.05), state lability (M±SD=5.32±1.31 vs.  
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M±SD=3.90±1.20, t =2.96, p<.01) and irritability (M±SD=5.54±2.02 vs. M±SD=3.80±1.14, t =2.55, 
p<.05) when compared with the non-exposed group (Lodge, et al., 1975). When the opioid-
exposed subgroups were examined separately, infants prenatally exposed to heroin only (n=9) 
were rated more similarly to the non-exposed control group (n=10) on many of these items. The 
performance of infants prenatally exposed methadone only (n=12) was generally poorer, whereas 
infants prenatally exposed to a combination of heroin and methadone (n=6) performed the most 
poorly. That is, infants in the heroin/methadone subgroup had the lowest levels of alertness and 
visual orientation, and the highest levels of hypertonia, activity, state lability and irritability. This 
was particularly evident for activity levels, where infants prenatally exposed to heroin/ 
methadone had significantly greater activity levels (M±SD=7.00±0.00) than both the heroin-only 
sub group (M±SD=5.12±1.64, t =2.77, p<.05) and the non-exposed control group 
(M±SD=4.80±1.23, t =4.32, p<.001). Mean activity levels of the methadone-only sub group 
(M±SD=5.36ﾱ1.12) did not differ significantly from the other groups’ mean scores (Lodge, et al., 
1975). The authors reported that infants in the heroin/ methadone-subgroup experienced 
significantly greater severity of NAS symptoms (M=2.29, p<.01), as scored on a four point scale 
(0=no symptoms to 3=severe symptoms), and a greater proportion of this subgroup required 
pharmacological treatment for NAS (71%); compared to the methadone-only subgroup (NAS 
severity score: M=0.92; proportion requiring treatment: 54%) and the heroin-only subgroup (NAS 
severity score: M=1.22; proportion requiring treatment: 33%). While the authors cautioned that 
these results should be tentatively interpreted due to the small group numbers, it is also difficult 
to interpret the information about NAS severity, as no details about the scoring criteria were 
provided (Lodge, et al., 1975).  
 
Research by Chasnoff et al. (1982; 1984) compared the development of infants prenatally 
exposed to methadone (n=39), to that of poly-drug exposed infants (i.e. combinations of 
benzodiazepines, marijuana and other illicit substances, n=19) and a non-exposed comparison 
group (n=27). When tested on the Brazelton NBAS at two days of age, infants prenatally exposed  
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to methadone performed significantly more poorly on tasks of orientation (e.g. visual inanimate 
orientation: M±SD=3.25±2.17) and motor maturity (M±SD=3.26±1.35) than the poly-drug exposed 
infants (visual inanimate orientation: M±SD=5.67±2.12; motor maturity: M±SD=4.50±1.43) and 
the non-exposed infants (visual inanimate orientation: M±SD=5.48±1.94, p<.001; motor maturity: 
M±SD=4.67±1.73, p<.01). This study also found that non-exposed infants scored significantly 
better on measures of state control (e.g. consolability: M±SD=6.50±1.56) than both the 
methadone-exposed infants (M±SD=4.52±2.42) and the poly-drug exposed group 
(M±SD=3.67±2.24, p<.001) (Chasnoff, et al., 1982; Chasnoff, et al., 1984). 
 
Van Baar et al. (1989) found no significant differences in an early neonatal (40 weeks post-
conception) Brazelton NBAS assessment between a group of infants prenatally exposed to 
combinations of methadone, heroin and cocaine (n=28) and a non-exposed control group of 
infants (n=37). Infants’ performances were recorded as number of deviations from the optimum 
category (van Baar, Fleury, Soepatmi, et al., 1989). Scores for motor responses for the substance-
exposed infants were poorer (median deviation: 2.33; range=0.33-3.83) compared with the non-
exposed group (median deviation: 2.00; range=0.33-3.83). At a later assessment (44 weeks post-
conception) motor performance of the substance-exposed group continued to be worse (median 
deviation: 2.17; range=0.67-3.17) compared with the non-exposed group (median deviation: 1.83; 
range=0.33-4.50, p=.10). Interactive responses were poorer for the methadone-exposed group 
(median deviation: 2.19; range=0.71-5.25 vs. median deviation: 2.13; range=0.25-4.75, p=.06), 
indicating that the substance-exposed infants were not as responsive to their environment as the 
non-exposed infants. Additionally, substance-exposed infants were more active than the non-
exposed infants (median deviation: 3.20; range=1.60-5.00 vs. median deviation: 3.00; range=2.00-
5.00), although this difference was not significant (van Baar, Fleury, Soepatmi, et al., 1989). When 
this group of infants was assessed at three months of age, substance-exposed infants were 
considered more active compared with the non-exposed infants (median: 3.67; range=2.20-4.75 
vs. median: 3.32; range=1.75-5.25, p=.05). The authors suggested that this greater level of activity  
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could be related to sub-acute symptoms of NAS (van Baar, Fleury, & Ultee, 1989). At nine months 
of age, caregiver-rated temperament scores, including those pertaining to activity level, positive 
response, reactions to stimuli, and soothability, did not differ significantly between the two 
groups, although results suggested that the substance-exposed infants had a longer duration of 
orientation toward a single object (median: 4.00; range=2.00-5.64) when compared with the non-
exposed infants (median: 3.44; range=2.18-5.27, p=.08) (van Baar, Fleury, & Ultee, 1989). A 
difficulty with interpreting these results is that scoring information was not provided for the 
temperament questionnaire used in the study. 
 
Jeremy and Hans assessed 29 infants prenatally exposed to methadone on the Brazelton NBAS 
during the first week of life (approximately 2 days of age) and at one month of age, and compared 
the results to those of 37 non-exposed comparison infants (Jeremy & Hans, 1985). Groups were 
comparable in terms of maternal age, race, SES, education, prenatal care and parity, and infants 
were excluded if they were premature or small for gestational age (SGA). The authors reported 
that during the first week of life, after adjusting for possible confounding factors (birth weight, 
perinatal problems and delivery medication), infants prenatally exposed to methadone had 
significantly higher levels of irritability [M=5.00 vs.3.83, F(1,60)=5.54, p<.05], were significantly 
more active[M=4.62 vs. 3.86, F(1,60)=7.24, p<.01], more tremulous [M=7.35 vs.5.94, 
F(1,60)=10.76, p<.01], more hypertonic [M=6.79 vs.5.64, F(1,60)=13.81, p<.001], and had 
significantly lower levels of motor maturity [M=3.41 vs.5.28, F(1,60)=36.58, p<.001]. Additionally, 
methadone exposed infants were less cuddly, had higher levels of arousal, were more labile, less 
able to self sooth, and displayed more hand-sucking than the non-exposed infants.  By one month 
of age the majority of these behaviours did not differ between the two groups, although the 
methadone-exposed group continued to have significantly increased muscle tone [M=6.59 
vs.6.08, F(1,61)=3.89, p<.05] compared with the non-exposed infants. Methadone-exposed 
infants continued to show a tendency toward higher levels of arousal and poorer motor 
functioning when compared with the comparison group (Jeremy & Hans, 1985). The authors  
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suggest that the difficult behaviours displayed by the methadone-exposed infants in the first 
week of life, particularly those related to poor state control, irritability and responsiveness, may 
place them at risk of poor attachment relationships and poor interaction with caregivers (Jeremy 
& Hans, 1985). In another study by this group, the authors found that maternal-infant interaction 
was not predicted by maternal substance-use. Rather, maternal levels of psychological and 
psychosocial resources were associated with quality of interaction with infants. However, it was 
noted by the authors that the women in the methadone group generally had poorer levels of 
resources compared with the comparison group (Jeremy & Bernstein, 1984). 
 
Davis and Templer (1988) compared the behaviour of children who were exposed to opioids 
(heroin and/or methadone, n=28) in pregnancy, with a group of reference children (n=28) who 
were not prenatally exposed to opioids but who resided with a father figure with an opioid-
addiction.  As described above, children were aged between six and 15 years at assessment. 
It was reported that children exposed to opioids in pregnancy had significantly more behaviour 
problems on most subscales of the Burks Behavioral Rating Scales, as rated by their school 
teachers, than non-exposed children. The exception to this was the Resistance subscale, although 
opioid-exposed children still scored more poorly than the non-exposed group. When the opioid-
exposed group were examined independently, children exposed to methadone (n=12) were rated 
by teachers as having significantly more problems than heroin-exposed children (n=9) in terms of 
impulsiveness (M±SD=16.75±6.27 vs. M±SD=9.22±5.14, t =2.93, p<.01), anger control 
(M±SD=13.42±4.23 vs. M±SD=8.44±2.13, t =3.22, p<.01) and participating with peers in physical 
interactions (M±SD=10.33±3.42 vs. M±SD=7.44±1.94, t =2.27, p<.05). They were also rated as 
being significantly more withdrawn (M±SD=18.83±6.06 vs. M±SD=11.22±7.16, t =2.64, p<.05) than 
the heroin-exposed children. The authors suggested that the constellation of deficits displayed by 
the children exposed to opioids in pregnancy were consistent with the symptoms of attention 
deficit type disorders, including impulsive, under socialised and inattentive behaviours.  Further, 
they indicated that the findings of poorer neurobehavioural functioning displayed by the  
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methadone-exposed children, compared to the heroin-exposed children, correlate with other 
research showing that methadone-exposed infants experience greater severity of NAS symptoms 
(Davis & Templer, 1988).  
 
Weiss, Jonn-Seed, and Harris-Muchell  (2007) found that six month old infants prenatally exposed 
to cocaine or opiates (n=30) were rated more negatively, by their mothers, on all dimensions of 
the Revised Infant Temperament Questionnaire, than infants not exposed to any substance in 
pregnancy (n=90). Although the study found that infants prenatally exposed to substances were 
significantly more distractible (M±SD = 4.24±0.60 vs. M±SD = 3.87±0.67, t(118)=2.55, p=.01) and 
more intense in their expression of emotions (M±SD=4.36±0.86  vs. M±SD=4.00±0.65, t(118)=2.55, 
p<.05) than their non-exposed peers, after adjusting for infant factors (i.e. gender, gestational 
age, neonatal morbidity and ethnicity) and maternal factors (i.e. stress, quality of caregiving, child 
maltreatment and perceived adequacy of income), only distractibility remained significantly 
associated with substance exposure and accounted for 12% of the variance in distractibility 
(p<.001). The authors suggested that the higher levels of distractibility observed in infants and 
children prenatally exposed to substances may be associated with poor regulation of the arousal 
and excitatory response (Weiss, et al., 2007). This supposition is supported by neurobiological 
research which indicates that the area of the brain involved in the regulation of attention and 
inhibitory control is the striatum (Herrero, Barcia, & Navarro, 2002; Roberts et al., 2004). It is 
known that prenatal exposure to opioids can disrupt the normal development of the striatal 
system, including alteration of opioid peptide levels and reduction in striatal nerve growth factor 
content (Tempel, Yang, & Basheer, 1995; Tiong & Olley, 1988; Wu, et al., 2001), which may 
account for high rates of distractibility and poor inhibition in opioid-exposed infants and children. 
A limitation of this research is that all substance-exposed infants were prenatally exposed to more 
than one substance (e.g. opioids, cocaine, marijuana, amphetamines) and analyses were not 
conducted to investigate the separate effect of each substance on infant temperament. However 
the authors noted that problems with distractibility and attention are not limited to prenatal  
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exposure to one specific substance, but have been found to correlate with prenatal exposure to 
alcohol, opioids, marijuana or cocaine (Weiss, et al., 2007). 
 
1.11.2 Temperament after prenatal exposure to buprenorphine 
Only one study has described the self-regulatory behaviour of infants prenatally exposed to 
buprenorphine. This study, which examined three month old infants in Norway, found no 
differences in sleep patterns, amount of day or night time wakefulness, or the number of 
episodes of day-time distress, between 35 infants prenatally exposed to opioid maintenance 
medication (methadone n=24, buprenorphine n=11) and a group of 36 comparison infants (Sarfi, 
Martinsen, Bakstad, Røislien, & Waal, 2009). The authors found that infants prenatally exposed to 
methadone or buprenorphine had fewer parent-rated episodes of night-time distress 
(M±SD=1.4±1.2) than non-exposed infants (M±SD=2.0±1.5), although this difference did not reach 
statistical significance (p=.07). These similarities in self-regulation were evident despite worse 
neonatal outcomes for the infants prenatally exposed to maintenance medication. These were 
significantly lower birth weight (M±SD=3148±608 gm vs. M±SD=3618±343 gm, p<.001), lower 
gestational age (M±SD=38.7±2.5 weeks vs. M±SD=39.5±0.9 weeks, p<.08), and a high rate of NAS 
(60%). Values were not provided separately for infants prenatally exposed to buprenorphine or 
methadone, thus it is difficult to draw strong conclusions about buprenorphine-exposure from 
this research. The authors noted that intensive pre- and post-natal support (including the 
provision of adequate housing or residential parenting assistance services) is available in Norway 
for women in maintenance treatment programs, and was utilised by women in their study. They 
suggested that this psychosocial support, along with the lack of other illicit drug use may have 
contributed to the positive outcomes observed for the opioid-exposed infants (Sarfi, et al., 2009).  
 
1.12 The contribution of maternal and environmental factors to child developmental outcome 
Problems with behaviour, temperament and developmental delay in infants prenatally-exposed 
to narcotics are very often attributed to substance-exposure; however it is important to examine  
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the contribution of other influences on a child’s development (Bernstein & Hans, 1994; Black, 
Schuler, & Nair, 1993).   
 
Research with non-drug using populations has shown that maternal depression and poverty is 
associated with poorer developmental outcomes in both infants and children (Beckwith, Howard, 
Espinosa, & Tyler, 1999; Grace, Evindar, & Stewart, 2003; Petterson & Albers, 2001; Whiffen & 
Gotlib, 1989). Infants of women experiencing postpartum depression perform less well on 
cognitive measures and exhibit fewer positive emotions than infants of non-depressed mothers.  
Depressed women are also more likely to perceive their infants as more bothersome and more 
difficult to care for, and are less likely to engage with them in active, playful and responsive 
interactions than are non-depressed women (Whiffen & Gotlib, 1989). Postpartum depression 
may continue to have an effect on a child’s cognitive performance and behavioural disturbance, 
particularly in boys, until school age, even when maternal symptoms have remitted (Beckwith, et 
al., 1999; Grace, et al., 2003).   
 
Ongoing maternal depression has also been studied in relation to infant mental health and early 
childhood development (Seifer, Dickstein, Sameroff, Magee, & Hayden, 2001). Correlations 
between kindergarten-aged children’s social and emotional competence have been found with 
maternal depression scores; while increased incidence of teacher- and parent-rated behaviour 
problems have been associated with exposure to maternal depression (Essex, Klein, Miech, & 
Smider, 2001). A study of over 7,500 mother-child dyads found that maternal depression was 
associated with poorer cognitive and motor development in two to four year olds. Additionally, 
chronic maternal depression had a greater detrimental effect on children’s development than 
transitory maternal depression (Petterson & Albers, 2001).This study also found that poverty 
(defined as living below the U.S. Census poverty line) was negatively associated with toddlers’ 
performance on cognitive items of the Denver Developmental Screening Test (DDST) (Petterson & 
Albers, 2001). Poverty was inversely related to children’s motor performance, with toddlers from  
60 
 
poorer families significantly more likely to be toilet trained, and to be able to perform every-day 
motor tasks such as dressing themselves, and pedalling a tricycle, than children from higher 
income households.  
 
A study examining the relationship between birth weight and cognitive functioning among 
children in Port Pirie, South Australia, followed children through early and middle childhood 
(Tong, Baghurst, & McMichael, 2006). Children’s cognitive functioning at two years of age was 
significantly related to birth weight; however the magnitude of the association between cognitive 
functioning and birth weight attenuated over time and became non-significant later in childhood.  
The authors found that at the later assessments, socio-environmental factors, including 
socioeconomic status, maternal IQ, quality of the home environment and children’s lead 
exposure, substantially contributed to children’s cognitive functioning (Tong, et al., 2006).   
 
There is increasing interest in examining the developmental outcome of children exposed to 
multiple environmental risk factors, including maternal depression, poverty, domestic violence, 
single parent families, home environment, and parenting stress.  Each of these variables has been 
found to exert an influence over child outcomes including cognitive functioning, social 
development, health and growth (Petterson & Albers, 2001; Ram & Hou, 2003; Thernlund & 
Samuelsson, 1993). A study exploring the effect of cumulative risks on children’s intellectual 
functioning identified a set of risk variables that predicted verbal IQ scores and social-emotional 
outcome at four years of age. These ten risk factors were: maternal mental health, maternal 
anxiety, maternal attitude toward parenting, maternal-child interaction, maternal education, 
parental occupation, minority status, maternal social support, stressful life events, and family size. 
The authors established that no single risk factor contributed exclusively to intellectual 
functioning, however as the number of risks increased, children’s intellectual performance 




Relationships between maternal mental-health, mother-infant attachment, child temperament, 
home environment, and other risk factors have been shown to play an important role in 
determining the developmental outcome of substance-exposed infants and children (Bernstein & 
Hans, 1994; Black, et al., 1993; Jeremy & Bernstein, 1984). Bernstein and Hans (1994) noted that 
while research has found differences in development between drug-exposed children and non-
exposed controls, effect sizes have generally been small.  Further, the authors noted that prenatal 
drug exposure is rarely the sole element of developmental risk experienced by children of drug 
users (Bernstein & Hans, 1994).   
 
The prevalence of psychopathology, including depression, anxiety and antisocial behaviours, in 
persons taking illicit drugs is very high. For example, the prevalence of depressive disorders 
amongst populations seeking treatment for opioid dependence has been reported to range from 
35% to over 50% (Beckwith, et al., 1999; Hans, Bernstein, & Henson, 1999; Kessler et al., 1996; 
Kosten, Morgan, & Kosten, 1990). Female substance abusers have been reported to be at greater 
risk of experiencing clinically significant levels of anxiety and depression than their male 
counterparts (Chander & McCaul, 2003; Hans, et al., 1999; Teesson et al., 2005). These findings, 
together with strong evidence that depression in non drug-abusing women has a negative effect 
on a number of areas of child development, increases the importance of examining the 
developmental outcome of children born to women who use illicit drugs during pregnancy 
(Beckwith, et al., 1999; Essex, et al., 2001; Hipwell, Goossens, Melhuish, & Kumar, 2000; Murray, 
Fiori-Cowley, Hooper, & Cooper, 1996; Patel, DeSouza, & Rodrigues, 2003; Seifer, et al., 2001).   
 
Difficulties with mother-infant bonding have been observed for opioid-using women even prior to 
delivery. Mikhail and colleagues found that methadone-maintained pregnant women had 
significantly lower maternal-foetal attachment scores than women with no drug abuse history 
(Mikhail, Youchah, DeVore, Ho, & Anyaegbunam, 1995).  One of the earlier studies evaluating 
parenting and depression in methadone maintained mothers found strong negative correlations  
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between higher depression scores and attendance for antenatal care (Finnegan, Oehlberg, Regan, 
& Rudrauff, 1981). This study concluded that that whilst drug-dependence is not necessarily an 
indicator of inadequate parenting skills, the environment in which many drug-exposed children 
are raised may contribute to increased risk of child abuse and neglect (Finnegan, et al., 1981).  A 
study by Hans, Bernstein and Henson (1999) found that opioid-dependent mothers were more 
likely than non-dependent mothers to meet criteria for a variety of mental health problems, and 
that poorer mental health was related to difficult interactions with infants, including insensitive, 
harsh and unresponsive parenting in this population (Hans, et al., 1999). Problems with poor 
attachment and depression in substance using mothers may thus have dire implications for their 
infants’ already poorer expected outcomes.   
 
Black, Schuler and Nair (1993) studied the relationships between the home environment, 
parenting stress and neurological performance on the Brazelton NBAS amongst 20 infants 
prenatally exposed to cocaine and other substances, including heroin and marijuana, and a 
control group of non-exposed infants (n=20). They found that at six weeks of age, infants exposed 
to substances in utero showed greater autonomic instability than non-exposed infants (Black, et 
al., 1993). No significant group differences were evident in terms of parental nurturance, child-
centred home environment or parenting stress, however there was a trend for mothers in the 
control group to provide a more child-centred and nurturing care-giving environment than the 
mothers in the substance-using group. The authors also found that infants who were raised in a 
child-centred environment (regardless of drug-exposure status) performed better on infant 
neurodevelopmental assessments,  were less depressed, and demonstrated lower levels of 
excitability (Black, et al., 1993).  
 
A more recent study by this research group examined the relationship between cumulative 
environmental and psychosocial risk factors, parenting attitudes and child development in a group 
of substance-using women and their infants (n=161) (Nair, Schuler, Black, Kettinger, & Harrington,  
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2003).  Over 70% of participating women reported depressive symptoms and negative life events, 
including incarceration, homelessness and domestic violence. Results indicated that as the 
number of risks increased, women reported greater levels of parenting stress and child abuse 
potential. However, no relationship was found between levels of risk and children’s development 
on the BSID at six or 18 months of age (Nair, et al., 2003). The authors suggested that there may 
have been no relationship between cumulative risk and infant development in their study due to 
the age of the children. They postulated that psychosocial risk factors may exert greater influence 
on development in preschool and school aged children (Nair, et al., 2003). 
 
A study by Carta and colleagues (2001) examined the effects of prenatal substance exposure and 
environmental risk on children’s developmental trajectories from three to 57 months of age, in a 
sample of substance exposed (n=137) and non-exposed children (n=141). The authors found that 
individually, prenatal substance exposure and environmental risk negatively influenced children’s 
development. Further, children with higher levels of risk developed more slowly over time than 
children with lower risk levels, and that the gap between the two groups widened as the children 
aged. When substance exposure and environmental risk were entered into the same statistical 
model, only environmental risk remained significantly related to developmental outcome (Carta, 
et al., 2001).  
 
Modest correlations (r=.28=.38) have been observed between home environment scores on the 
Home Screening Questionnaire (HSQ) and mean IQ scores on the WPPSI-R, WISC-III and Stanford-
Binet Intelligence Scale (Azuma & Chasnoff, 1993; Chasnoff et al., 1998). Chasnoff and colleagues 
examined the cognitive development of children prenatally exposed to cocaine (n=95) and a non-
exposed comparison group (n=75) between the ages of four and six years (Chasnoff, et al., 1998). 
This study found that lower HSQ scores, indicating poorer home environment, were strongly 
correlated with increased levels of maternal substance use. Although IQ scores on the WPPSI-R 
and WISC-III did not differ significantly between the two groups of children in univariable  
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analyses, in path analyses there was an indirect effect of prenatal substance-exposure on IQ 
scores that was mediated by the quality of the home environment. That is, children prenatally 
exposed to substances experienced a poor quality home environment, which was subsequently 
related to lower performance on tests of cognitive development. However, this study also found 
that quality of the home environment was not associated with behavioural problems, as assessed 
on the Child Behaviour Checklist (CBCL). Rather prenatal substance exposure was associated with 
worse behavioural outcomes. The exception to this was child self-regulation (encompassing 
children’s’ scores on the Aggressive Behaviour, Delinquent Behaviour, Attention Problems and 
Social Problems scales), in which better home environment was associated with better capacity 
for self-control, regardless of group status (Chasnoff, et al., 1998).  
 
As described above, Wilson (1989) found that children’s cognitive performance fluctuated over 
time, when assessed on the MDI of the BSID at 9, 18 and 24 months of age, and on the McCarthy 
Scales between the ages of three and five years. She reported that uneven performances were 
most obvious amongst the heroin-exposed children compared with those exposed to methadone 
or a non-exposed group. Additionally, fluctuations in developmental performance occurred most 
frequently in children who resided in an unstable or disadvantaged home environment. It was 
suggested by the author that environmental changes may have a considerable effect on a child’s 
cognitive functioning, and for this reason it was posited that longitudinal, rather than cross-
sectional studies, were more useful in examining the development of this population of children 
(Wilson, 1989). This view is supported by other research which has indicated that the relationship 
between early scores on the HOME scale (i.e. those obtained at ≤ 12 months of age) are generally 
only moderately correlated with tests of cognitive development; and that the association 
between HOME scores and cognitive development appears to gain strength over the second year 




In a study examining the influence of environmental risks on children’s development, Ornoy and 
colleagues (2001) compared the development of children with prenatal exposure to heroin raised 
by their biological mothers (n=31), with that of children who were not prenatally exposed to 
heroin, but who resided with a father who was heroin-dependent (n=33), a group of children 
prenatally exposed to heroin but living in foster homes (n=34), and two groups of non-exposed 
children who were from low SES (n=32) and average SES (n=30) homes. This study found that 
when assessed at an average age of eight years, children residing with substance-dependent 
parents, and those in the low SES group, had significantly poorer home-environments, assessed 
on the Caldwell HOME scale, than both the average SES group and the heroin-exposed children 
who were residing in foster homes. This study also found that while mean Verbal and 
Performance IQ scores on the WISC-R of all children were within the average range, children 
prenatally exposed to heroin and living with a heroin using mother achieved significantly lower 
mean scores (Verbal: M±SD=102.0±8.8; Performance: M±SD=101.0±24.0) than children prenatally 
exposed to heroin but living in foster homes (Verbal: M±SD=108.3±17.6; Performance: 
M±SD=106.2±24.9, p<.05).  Scores of children residing in low SES households were also 
significantly lower than those of the adopted children (Ornoy, et al., 2001). This study did not 
examine the respective contributions of substance-exposure and home environment to child 
development scores, neither were correlations between the WISC-R and HOME scores discussed. 
 
1.13 Thesis rationale and study aims 
Prenatal exposure to illicit substances increases the risk of poorer pregnancy outcomes, growth 
deficits, neurodevelopmental problems and behavioural difficulties in exposed infants and 
children, compared with their non-exposed peers (Adams, et al., 1989; Berlin, et al., 1998; Chang, 
et al., 1992; Kandall, et al., 1976; Laken, et al., 1997; Robins & Mills, 1993). In many countries, 
including Australia, pharmaceutical maintenance with methadone is the first line treatment for 
pregnant opioid-dependent women (Dunlop, et al., 2003; Lintzeris, et al., 2006). Benefits for 
women maintained on methadone during pregnancy include reduction in obstetric complications,  
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stabilisation of plasma drug concentrations, and engagement in a more stable lifestyle. Infants 
prenatally exposed to methadone are less likely to be small for gestational age (SGA), have low 
birth weight, or have problems related to feeding, settling and hypertonicity, than infants 
prenatally exposed to illicit opioids (Australian Drug Foundation, 2005b; Chang, et al., 1992; 
Dunlop, et al., 2003; Lintzeris, et al., 2006; Lejeune, 2006 #111). Whilst treatment with 
methadone during pregnancy results in fewer complications for both mother and infant when 
compared with the use of illicit opioids, its use in pregnancy is associated with high rates of 
neonatal abstinence syndrome (NAS), and has been independently associated with long term 
developmental and behavioural deficits for exposed infants and children (Bernstein, Jeremy, 
Hans, & Marcus, 1984; Davis & Templer, 1988; Finnegan & Kandall, 1997; R. E. Johnson, Jones, et 
al., 2003; Marcus, Hans, & Jeremy, 1984; van Baar, Fleury, Soepatmi, et al., 1989; van Baar, et al., 
1994). In particular, smaller growth percentiles (Hans, 1989; Hunt, et al., 2008; Lifschitz, et al., 
1983, 1985; Soepatmi, 1994), delayed or absent responses to VEP (Hamilton, et al., 2010), and 
poorer cognitive and motor development outcomes (Davis & Templer, 1988; Hunt, et al., 2008; H. 
L. Johnson, et al., 1987, 1990; H. L. Johnson & Rosen, 1982; Rosen & Johnson, 1982; van Baar & de 
Graaff, 1994).    
 
Buprenorphine hydrochloride is now widely used in the treatment of non-pregnant opioid-
dependent individuals, and there is a growing body of research to support its safety and efficacy 
during pregnancy and the early neonatal period (Gordon, 2006; R. E. Johnson, Jones, et al., 2003; 
Jones, et al., 2005; Jones, et al., 2010; Kayemba-Kay's & Laclyde, 2003; Lacroix et al., 2004; 
Lejeune, et al., 2006). However, buprenorphine has not yet been recommended for use during 
pregnancy, because its safety, efficacy and effectiveness have not yet been firmly established for 
pregnant women and their infants (Lintzeris, et al., 2006). Further, information regarding longer 
term developmental outcomes for children prenatally exposed to buprenorphine is scarce. 
Studies describing the development beyond the neonatal period, for infants prenatally exposed to 
buprenorphine, have had very small sample sizes (N = 2 to 13), and the majority have not included  
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a comparison to methadone exposure (Kahila, Kivitie-Kallio, et al., 2007; Kayemba-Kay's & 
Laclyde, 2003; Schindler, et al., 2003). Two Norwegian studies have described longer term 
outcomes for infants prenatally exposed to methadone or buprenorphine (Sandtorv, et al., 2009; 
Sarfi, et al., 2009). The first study compared sleep–wakefulness–distress patterns of three month 
old infants prenatally exposed to methadone or buprenorphine (n=35) with those of a group of 
non-exposed comparison infants (n=36) (Sarfi, et al., 2009). The other study provided an overview 
of the development of infants prenatally exposed to methadone or buprenorphine (n = 15) to an 
average of 30 months of age. However, no details about the measures were included in the 
second publication, and neither study reported results separately for the buprenorphine and 
methadone exposed infants. 
 
While methadone maintenance appears to be effective and widely acceptable in the treatment of 
opioid-dependence in pregnancy, there are some concerns regarding the long term outcomes for 
prenatally exposed children. Additionally, negative associations with methadone maintenance 
may discourage some women from seeking treatment for opioid addiction (Anstice, et al., 2009; 
Mattick, et al., 2003; Murphy & Irwin, 1992). Therefore, research into alternative 
pharmacotherapies that are safe and effective in pregnant populations is needed (Davids & 
Gastpar, 2004; Lintzeris, et al., 2006; Mattick, et al., 2003). Use of buprenorphine for treatment of 
opioid-dependence has increased due to its partial agonist properties, which produce milder 
withdrawal effects and may be safer in overdose. In addition, its extended duration of action can 
allow for longer periods between doses. Further, it appears that buprenorphine is comparable to 
methadone in terms of safety and efficacy in pregnancy, and may result in a reduction in the 
duration and severity of NAS in exposed infants. Benefits of buprenorphine maintenance during 
pregnancy may also extend to reduced hospital stays for exposed neonates. This may reduce the 




Much of the research on the developmental outcome of substance-exposed infants has targeted 
direct drug effects. As substance use seldom occurs in isolation from other bio-psychosocial 
problems, maternal substance use is unlikely to be the only risk factor for a child prenatally 
exposed to opioids. Risk factors such as poverty, poor household environment, low parental 
academic achievement, parental unemployment and parental mental illness may all contribute to 
poorer child developmental outcome. While some studies have examined the contribution of 
environmental risk factors to the development of substance-exposed children, many have not and 
it is therefore difficult to draw firm conclusions about the developmental effect of prenatal 
substance exposure (Carta, et al., 2001; Jones, Kaltenbach, & O'Grady, 2009; Nair, et al., 2003). 
 
To date, no studies have comprehensively described the longer term outcomes of infants 
prenatally exposed to buprenorphine. The aim of the research described in this thesis was to 
compare the physical growth, neurological development, and temperament of infants 
prenatally exposed to buprenorphine, methadone, and a non-exposed control group. An 
additional aim was to explore the relationships between potential covariates and the 
developmental outcomes of children exposed to opioid maintenance medications in 
pregnancy. Overall, it was expected that the developmental outcomes of infants prenatally 
exposed to buprenorphine would not differ substantially from those of non-exposed infants. 
Additionally, it was anticipated that infants prenatally exposed to methadone would do more 
poorly on the measures examined, than both infants prenatally exposed to buprenorphine 
and a non-exposed control group of infants. Finally, it was expected that these differences in 
developmental outcome would remain stable over time. These expectations were applied to 
all outcome variables. Accordingly the following individual hypotheses were proposed:  
69 
 
Physical Growth  
Hypothesis 1: The weight, length and HC of infants prenatally exposed to buprenorphine will not 
differ significantly from those of a non-exposed control group when assessed at four, 12 and 24 
months of age.  
 
Hypothesis 2: The weight, length and HC of infants prenatally exposed to methadone will be 
significantly smaller than those of infants prenatally exposed to buprenorphine and a non-
exposed control group of infants when assessed at four, 12 and 24 months of age.  
 
Hypothesis 3: Change in weight, length and HC over time will not vary significantly between 
children prenatally exposed to buprenorphine, methadone, or in a non-exposed control group. 
 
Neurological Development 
a) Visual Evoked Potentials 
Hypothesis 4: P1 latencies of infants prenatally exposed to buprenorphine will not differ 
significantly from those of a non-exposed control group, when measured at four months of age.  
 
Hypothesis 5:  Infants prenatally exposed to buprenorphine will have significantly shorter P1 
latencies at four months of age, suggesting greater visual maturation, than children prenatally 
exposed to methadone. 
 
b) Bayley Scales of Infant Development 
Hypothesis 6: The mental, motor and behavioural scores of infants prenatally exposed to 
buprenorphine will not differ significantly from a non-exposed control group when assessed at 12 




Hypothesis 7: The mental, motor and behavioural scores of infants prenatally exposed to 
methadone will be significantly lower than those of infants prenatally exposed to buprenorphine 
and a non-exposed control group of infants when assessed at 12 and 24 months of age.  
 
Hypothesis 8: Change in mental, motor and behavioural scores over time will not vary significantly 
between children prenatally exposed to buprenorphine, methadone, or in a non-exposed control  
 
Temperament 
Hypothesis 9: Temperament scores of infants prenatally exposed to buprenorphine will not differ 
significantly from a non-exposed control group when assessed at four, 12 and 24 months of age.  
 
Hypothesis 10: The temperament scores of infants prenatally exposed to methadone will be 
significantly lower, indicating easier temperament, than those of infants prenatally exposed to 
buprenorphine and a non-exposed control group of infants when assessed at four, 12 and 24 
months of age.  
 
Hypothesis 11: Change in temperament scores over time will not vary significantly between 






Study Design and Methodology  
The first section of this chapter describes the overall design of the research study, the recruitment 
of participants, ethics approval, consent processes, and the response and retention of 
participants. The second section describes the assessment and statistical methods employed. 
 
2.1 Study Overview 
The study which forms the basis of this thesis is the second phase of a prospective longitudinal 
research project. The overarching longitudinal research project was designed to examine the 
safety and efficacy of the opioid maintenance drug buprenorphine, during pregnancy, the 
neonatal period, and early childhood. Research presented in this thesis comprises the early 
childhood period. 
 
To distinguish the research presented in this thesis from the first phase in the longitudinal 
research project, the first phase will be referred to as ‘the pregnancy and neonatal phase’, while 
the second phase (the research presented in this thesis) will be referred to as ‘the early childhood 
phase’. 
 
The pregnancy and neonatal phase of the prospective longitudinal research project commenced 
in early 2002. During this phase, pregnant women who were opioid-dependent were enrolled in 
an open-label, non-randomised, flexible-dosing trial examining the safety and efficacy of 
buprenorphine, compared with methadone, throughout pregnancy and the neonatal period. 
Pregnant, non opioid-dependent women were recruited as controls. At each ante-natal visit and 
weekly after delivery, until their infant was four weeks old, women were assessed on measures of 
physical symptoms related to pregnancy, opioid withdrawal, and recent use of both licit and illicit  
72 
 
substances. Women with opioid dependence were also asked about side effects relating to their 
maintenance medication. Random urine samples were collected from all women (including 
controls) during the antenatal period to screen for illicit drug use. All infants born into the study 
were observed for signs of neonatal abstinence syndrome (NAS, opioid withdrawal) until 
discharge from hospital and then weekly until four weeks of age. Details about the results from 
the pregnancy and neonatal phase of the project are reported elsewhere (Gordon, 2006). 
 
The early childhood phase of the longitudinal research project commenced in April 2003 and is 
the focus of this thesis. The aim of this phase was to examine prospectively the effects of prenatal 
exposure to maternal maintenance with buprenorphine or methadone on the neurological, 
psychological and physical development of the children at four, 12 and 24 months post-partum. 
The 87 families who completed at least one of these follow-up assessments between April 2003 
and May 2009 are the focus of this thesis.  At each follow-up assessment, mothers (or children’s 
primary caregiver) completed a questionnaire assessing child health, feeding and sleeping, child 
temperament, child’s care-giving environment, parent’s mental health, parent-child interaction, 
parental social support, recent caregiver substance use and demographic characteristics. 
Neurological development was assessed using Visual Evoked Potentials (VEP) at four months of 
age, and the Bayley Scales of Infant Development, Second Edition (BSID-II) (Bayley, 1993) at 12 
and 24 months. Physical development was monitored in terms of weight, length and head 
circumference (HC) at each assessment. A detailed description of the data collected is provided 
later in this chapter. 
 
2.2 Recruitment  
The following section describes the recruitment procedures for the longitudinal research project. 
Recruitment was initially undertaken during the pregnancy and neonatal phase of the study; 
however as a greater number of participants was required for the early childhood phase, I 
completed the recruitment of participants. While results from the pregnancy and neonatal phase  
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are not reported in this thesis [see (Gordon, 2006)], recruitment of participants is described as it is 
pertinent to the early childhood phase of the study. 
 
Pregnant women with opioid dependence were recruited from outpatient clinics at two Drug and 
Alcohol Services South Australia (DASSA) drug treatment centres, a specialist drug and alcohol 
antenatal clinic at the Women’s and Children’s Hospital (WCH), and the high-risk pregnancy clinic 
at Flinders Medical Centre (FMC), in Adelaide, South Australia. Potential participants with opioid 
dependence were provided with information about the study by DASSA medical staff at each 
clinic when they first attended for an appointment. A research assistant then described the study 
in more detail, and administered the screening questionnaire (Appendix A).  
 
Women were eligible to participate if at enrolment they were ≤28 weeks gestation, and were 
aged between 16 and 40 years. Women were excluded from the study if they were taking any 
medication that interacted with the maintenance drugs or was known to affect pregnancy 
outcome (e.g., medications for HIV, epilepsy, schizophrenia or other major psychiatric illness), had 
a self-reported level of alcohol use greater than seven standard drinks per week [i.e., higher than 
levels recommended by 2001 NHMRC guidelines for alcohol use in pregnancy (National Health 
and Medical Research Council, 2001)], were pregnant with more than one foetus, or were 
participating in another clinical research project that interfered with the present study.   
 
Eligible women were provided with an information sheet (Appendix B), and consent was obtained 
either at that time or at the woman’s next antenatal appointment (Appendix C). Separate consent 
for the enrolment of the woman’s infant was also obtained (Appendix D). Women with opioid 
dependence were self-assigned to either buprenorphine-maintenance (BM) or methadone-
maintenance (MM) treatment. It was not possible to randomly assign women to a treatment 
group for the purposes of the study because firstly, at the time of the longitudinal research 
project’s implementation, research on the effects of prenatal exposure to buprenorphine was  
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only just beginning to emerge. While results generally appeared to be encouraging and there had 
been no reports of teratogenic effects (R. E. Johnson, Jones, et al., 2003), longer term effects of 
buprenorphine exposure were undocumented, and random assignation to BM or MM was 
considered unethical. Secondly, the prevalence of opioid-dependent pregnancies in the Adelaide 
metropolitan area was not sufficient to support an adequately powered randomised controlled 
trial without a protracted period of recruitment. In the majority of cases (74%), women in the two 
maintenance groups were already participating in a prescribed opioid program when they became 
pregnant. A small number of opioid-dependent women who were not enrolled in a maintenance 
program had requested treatment with BM or MM after discovering that they were pregnant. 
 
Hospital records of non opioid-dependent women attending antenatal clinics at the WCH were 
examined to identify potential control subjects. This group of participants was included in order to 
provide an opioid-free comparison to the opioid-dependent pregnancies. A research assistant 
approached potential control participants in the waiting area of the clinics either immediately 
before or after their antenatal appointment to provide information about the study. As with the 
two maintenance group participants, women in the control group were screened to make sure 
they met the eligibility criteria (as described above), provided with an information sheet 
(Appendix E), and signed consent for themselves (Appendix F) and their infants’ participation in 
the study (Appendix D). Women in the control group self-reported not using illicit opioids. 
 
Demographic and lifestyle variables were collected from each participant during a face-to-face 
interview at enrolment (Appendix G). Due to the restricted sample pool, strict matching criteria 
were not applied; however groups were similar on a number of measures known to have an effect 
on pregnancy outcomes. These were maternal age, gravida (first pregnancy versus second or 
more), parity (first born infant versus second or more), self-reported alcohol use within the past 
month (Yes/No) and self-reported tobacco use within the past month (Yes/No) (see Table 3.1).  
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2.3 Ethical Approval 
Ethics approval for the pregnancy and neonatal phase of the study was obtained from the 
University of Adelaide, Flinders Medical Centre Research Ethics and Clinical Drug Trials 
committees (Protocol number 130/045) and the Women’s and Children’s Hospital Human 
Research Ethics Committee (Project number REC1330/6/2005). The early childhood phase of the 
study was approved by the University of Adelaide Committee on the Ethics of Human 
Experimentation Psychology Department subcommittee, the Women’s and Children’s Hospital 
Human Research Ethics Committee (Project number REC1348/7/2005), and the Flinders Clinical 
Research Ethics and Clinical Drug Trials Committees, Flinders Medical Centre (Protocol number 
130/045).   
 
Participants received three payments of $A50 during the pregnancy and neonatal phase of the 
study as compensation for their time and any inconvenience experienced due to their 
participation. They were also provided with a payment of $A50 and a small age-appropriate gift 
for their child at each of the three follow-up assessments in the early childhood phase of the 
study. Payment of study participants has been viewed by some as coercive or inappropriate, 
particularly when the sample involves a marginalised population, such as economically 
disadvantaged individuals or those with substance dependence (Dickert & Grady, 1999; Festinger 
et al., 2005; Sears, 2001). Recent research examining the views of adults with substance 
dependence in the United States has indicated that monetary reimbursement for study 
participation was seen by participants as necessary and appropriate for attracting potential study 
recruits. Reimbursement for participation in research was viewed as an honest source of income 
and participants rejected the idea that payment would increase their risk of relapse (Slomka, 
McCurdy, Ratliff, Timpson, & Williams, 2007). Other research has found that monetary incentives 
to participate in research studies were not linked to increases in substance use or perceptions of 
coercion among participants (Dempsey, Back, Waldrop, Jenkins, & Brady, 2008; Festinger, et al., 
2005; Festinger, Marlowe, Dugosh, Croft, & Arabia, 2008). Further to this, larger payment  
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amounts (i.e. ≥US$40 vs. $10 or ≥US$100 vs. $70) have been shown to increase the likelihood of 
attendance at follow-up appointments, thus reducing researcher time and costs related to tracing 
participants (Festinger, et al., 2005; Festinger, et al., 2008). Festinger et al. (2005; 2008) also 
found that participants who received cash payments were more likely to spend the money on 
everyday essential items such as household expenses compared with those who received gift 
certificates. We therefore considered that a mid-range cash payment of $A50 and a small age-
appropriate toy or book for the child was reasonable reimbursement for participation in a study 
which required a long term commitment. 
  
2.4 Participants 
Response and retention for each phase of the study 
The study design and flow of participants through each stage of the study is summarised in Figure 
2.1.  
 
The Pregnancy and Neonatal Phase  
One hundred and forty eight women were approached to participate in the longitudinal research 
project. Nineteen women (group unknown) were either unwilling to participate (n=9, reasons 
unknown) or did not meet inclusion criteria (n=10). One woman was enrolled into the BM group 
at 31 weeks gestation as she wished to remain on buprenorphine maintenance throughout the 
remainder of her pregnancy and one woman was enrolled into the BM group the day following 
delivery because she had not attended any of her ante-natal visits at the delivery hospital. 
Because these women were maintained on buprenorphine during their pregnancies, hospital 
policy required that the infants were monitored for Neonatal Abstinence Syndrome (NAS) and 
both women agreed to enrolment in the follow-up study. One woman was initially enrolled into 
the BM group at 16 weeks gestational age. This woman subsequently requested a change in 
maintenance treatment before her next antenatal appointment (at 21 weeks gestation), and her 
data were therefore included in the MM group. Two women in the MM group agreed to  
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participate in the study prior to 28 weeks gestation but data were not collected from them until 
later gestational ages. One control participant was enrolled one month prior to turning 16 years 
of age. Thus 129 women (87% of 148 women approached) were enrolled in the longitudinal 
research project (52 BM, 39 MM and 38 controls). In an effort to minimise participant attrition, 
and to provide a link between the two phases of the study, I organised to meet participants 
during at least one antenatal appointment during the pregnancy and neonatal phase of the study. 
Twenty three women were not eligible for inclusion in the subsequent early childhood phase of 
the study on which this thesis is based. Reasons for discontinuation varied between groups. 
Details are presented for each group separately below.  
 
Nine women and four infants in the BM group were not able to be included in the early childhood 
phase  of  the  study:  three  women  were  withdrawn  after  miscarriage  (considered  by  their 
obstetrician to be unrelated to buprenorphine) prior to 20 weeks gestation, two women were 
withdrawn after seeking termination of pregnancy, two women withdrew one week post-delivery 
after stating that the study was too onerous, one was withdrawn from the study because her 
infant was diagnosed with an autosomal defect at 32 weeks gestation, and one woman was lost to 
follow-up after she moved interstate. Four women in the BM group, who had already completed 
the early childhood phase of the study with their first child, became pregnant with their second 
child whilst data collection for the pregnancy and neonatal phase of the study was still underway. 
Hospital  policy  required  that  these  four  mother-infant  dyads  were  monitored  throughout 
pregnancy and the infants monitored for NAS. However, follow-up data were not collected for 
these infants. 
 
Seven women in the MM group were not available for inclusion in the early childhood phase of 
the study: two women were lost to follow-up, one woman was withdrawn from the study after 
seeking termination of her pregnancy, one woman was withdrawn from the study because she 
was prescribed olanzapine and sodium valproate for a previously diagnosed mood disorder (bi- 
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polar and schizoaffective disorder), one woman withdrew at a gestational age of 28 weeks, and 
one woman withdrew one week post-delivery, both stating that the study was too onerous. After 
completion of the pregnancy and neonatal phase of the study it was discovered that one woman 
in the MM group had a psychiatric diagnosis and was on medication that should have precluded 
her from enrolment. Although follow-up information was collected for this family, their data are 
not included in the analyses.  
 
Three women in the control group were not available for inclusion in the early childhood phase of 
the  study:  one  woman  was  withdrawn  at  16  weeks  gestation  as  she  was  receiving  isoniazid 
treatment  for  tuberculosis  exposure,  one  woman  was  withdrawn  after  miscarriage  at  a 
gestational age of 24 weeks, and one woman who initially attended the general antenatal clinic 
changed her antenatal care to midwifery group practice (MGP). Because the care provided by 
MGP differs from that provided by the general antenatal clinics (in that women are visited at 
home by a midwife rather than attending a hospital-based clinic) this woman was not eligible to 
continue in the study.  
 
The Early Childhood Phase 
Four month assessment 
Of the 106 mother-infant dyads eligible to participate in the early childhood follow-up, 87 (82%) 
attended an appointment at the WCH ± 1 week of their infant reaching four months of age. 
Amongst those who did not participate, 12 families (seven in the BM group, four in the MM 
group, and one in the control group) could not be contacted despite exhaustive efforts. Six 
families (two BM, three MM and one control) did not wish to continue their involvement in the 
study, and one child in the MM group died of meningococcal disease. The final sample for the 
four month follow-up assessment consisted of 30 women maintained on buprenorphine, 24 
women maintained on methadone and 33 women who were not opioid-dependent, and their 
infants. Two infants in the MM group did not undergo VEP assessment or have growth  
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measurements taken at this assessment because their families had moved too away from the 
study area for them to be brought into the Women’s and Children’s Hospital (WCH) for 
assessment; however questionnaires for each of these families were returned by post. 
 
Twelve month assessment 
Eighty three children and their mothers (or primary caregivers) completed the 12 month 
assessment (28 BM, 22 MM and 33 controls), which was 78% of the 106 eligible; and 95% of those 
assessed at four months. At the 12 month assessment, three children were not in the care of their 
natural mothers and questionnaires were completed by their primary caregivers. This was the 
maternal grandmother in the case of two children (one BM, one control) and the natural father in 
the case of the third (BM group). Three families (two BM, one MM) were lost to follow-up and 
one woman in the MM group withdrew her child from the study when a notification of suspected 
child abuse was made to Families SA (the state child protection agency) after the four month 
assessment. One child in the BM group did not complete a BSID-II assessment as he was too tired 
to participate at the scheduled time and the family could not be contacted to make another 
appointment, and one child in the MM group did not undergo assessment on the BSID-II as the 
family had moved away from the study area. All other questionnaires were completed for each of 
these children.  
 
Twenty four month assessment 
Seventy three children and their mothers (or primary caregivers) completed the 24 month 
assessment (24 BM, 19 MM and 30 controls), which was 69% of the 106 eligible; and 88% of those 
assessed at 12 months. At this assessment, three children were not in the care of their natural 
mothers and questionnaires were completed for them by their primary caregiver. This was the 
natural father in the case of one child in the BM group. In the control group one child was in the 
care of her maternal grandmother, whilst one was in state care. Ten families (4 BM, 3 MM, 3 
controls) were lost to follow-up. Questionnaires were not returned by two families (one in each of  
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the BM and MM groups) and only their children’s growth measurements and BSID-II scores were 
collected.  
 
The number of participants and retention for each of the stages in the early childhood phase of 
the study are presented in Table 2.1. 
 
2.5 Procedure  
The Early childhood phase  
Four month assessment 
Families were telephoned approximately 14 weeks post delivery. The infant’s mother or primary 
caregiver was asked whether they wished to continue participating in the study, and the parent 
was provided with a verbal description of the planned assessments. In the majority of cases, a 
child’s primary caregiver was the natural mother, but for brevity, the term ‘parent’ will be used to 
describe a child’s primary caregiver. 
 
Parents were invited to attend an appointment at the Women’s and Children’s Hospital at ± 1 
week of their infant reaching four months of age(chronological). Infants were assessed at a 
specific chronological age, rather than a corrected age, to ensure that parents had spent the same 
amount of time with their infants before completing the measures which incorporated questions 
about parenting, parent-infant attachment and infant temperament. Differences in gestational 
age were adjusted for in analyses. At the four month assessment parents completed the 
questionnaire (Appendix J), with assistance if requested, infants’ neurological development was 
assessed using Visual Evoked Potentials (VEP) and infants’ weight, length and head circumference 
were measured. At the end of this appointment the family’s contact details were confirmed, and 
details of a family member or friend were collected in the event that the participant could not be 
contacted for the next assessment. The family was provided with a parking or taxi voucher and 
the $A50 reimbursement for their time; and an age-appropriate toy was given to the infant.  
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Twelve and twenty-four month assessments 
The protocol for the assessments at 12 and 24 months was the same. Families were contacted by 
telephone prior to the children’s first and second birthdays and invited to participate in the next 
stage of the study. A description of the questionnaire and developmental assessment was 
provided and an appropriate time to visit the family at their home or at another suitable location 
was arranged. I attempted to schedule visits within two weeks of a child’s birthday as the BSID-II 
specifies sets of items to administer dependent on a child’s chronological age (Bayley, 1993). 
Parents were informed that the visit would last from one and a half to two hours. The 
questionnaire was posted to the parent for completion prior to the home visit. Two contact 
telephone numbers were provided to parents in the event that a home visit needed to be 
rescheduled. If the parent was unable to be contacted by telephone, I attempted to obtain new 
contact details from nominated family or friends, the telephone book or online White Pages or, in 
the case of the MM and BM groups, via the central methadone register. If this was unsuccessful, a 
letter reminding the parent about the study and asking them to contact me (Appendix K) was 
posted to the last known address. 
 
During the home visit the completed questionnaire booklet was collected and children’s 
neurological development was assessed using the BSID-II item-set appropriate for their age 
(Bayley, 1993). For children born prematurely, the child’s corrected age (chronological age minus 
the number of days born premature) was calculated and the BSID-II item-set appropriate for their 
corrected age was administered. The test is described in more detail below. Children’s weight, 
length and head circumference were also measured at the home visit. The procedure followed is 
described in more detail in section 2.6. 
 
The BSID-II was generally completed during one session. However if the child became too tired or 
distressed, a second appointment was arranged. At the completion of the assessment the 
children were praised and presented with a picture book as a token reward for their participation.  
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Parents were also thanked for their participation and received the $A50 as reimbursement for 
their time.  
 
At the home visit I completed the Home Observation for Measurement of the Environment 
(HOME) Scale (Caldwell & Bradley, 1984) and recorded a general summary of the assessment. The 
summaries were unstructured qualitative records of the visit to the participant’s home and 
provided contextual information about the assessments. While content of the summaries varied 
between visits, they provided a general comment on the child’s behaviour, attention and 
concentration during the assessment.  
 
After the assessment a brief report of the child’s overall development was mailed to the family 
(Appendix L). An invitation was also provided to parents to discuss the assessment if they so 
wished. If a parent raised concerns about their child’s development, they were provided with 
generic information regarding suitable services to which they could be referred (i.e. GP, Child and 
Youth Health, Paediatrician). Direct referral to more comprehensive assessment services was 
beyond my professional capabilities, and may have biased the results of future study assessments. 
 
2.6 Measures  
Table 2.2 provides a summary of data collected and measures used during each stage of the 
study. 
The Pregnancy and Neonatal Phase  
Sample Characteristics 
Background information about mothers was collected at recruitment using a structured face-to-
face interview. This included maternal age at recruitment, gestational age at recruitment, parity, 
gravida, marital/partner status, drug use history (including alcohol and tobacco use); and for 
opioid-dependent participants, maintenance treatment history and maintenance dose. Whilst 
information was obtained from mothers’ medical records about pregnancy complications,  
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adverse events, and labour and delivery statistics, these results are presented elsewhere (Gordon, 
2006). 
 
Information obtained from infants’ medical records included gestational age at delivery, APGAR 
scores at 1 minute and 5 minutes, birth growth parameters, and severity, duration and treatment 
of neonatal abstinence syndrome (NAS, opioid withdrawal). All infants were monitored for 
symptoms of NAS four-hourly until discharge using a modified Finnegan Scale (New South Wales 
Department of Health, 2006b) (Appendix H). This is an 18-item scale assessing the presence and 
severity of NAS symptoms, including central nervous system disturbances (such as tremors, poor 
sleeping and high pitched crying), metabolic vasomotor and respiratory disturbances (such as 
fever, sneezing respiratory rate) and gastrointestinal disturbances (such as poor feeding, 
excessive sucking and vomiting). Infants in the control group were included in this scoring because 
some of the items on the scale may be due to normal neonatal behaviour (e.g. yawning, sleep 
difficulties) or other infant health problems (fever, seizures). This modified scale is used 
extensively throughout Australian hospitals (New South Wales Department of Health, 2006b). It 
differs slightly from the original scale developed by Finnegan et al. (Finnegan, Connaughton, Kron, 
& Emich, 1975) in that two items regarding the Moro reflex have been omitted, as have items 
evaluating sweating and mottling.  
 
The modified scale has a minimum score of 0, indicating absence of NAS, and a maximum score of 
41, indicating severe NAS. Pharmacological treatment was initiated with morphine (with a starting 
dose of 0.5 mg/kg per day) if an infant scored ≥8 on three consecutive occasions. Dose was 
increased in increments of 0.2mg/kg per day, based on the infant’s score (see Appendix I for 
treatment and weaning protocol). One infant in the BM group was treated with phenobarbitone 
at the mother’s request and two others in the BM group were treated concurrently with 
morphine and phenobarbitone. Approximately half of the infants in each maintenance group  
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were pharmacologically treated for NAS (see Table 3.5). No infant in the control group was 
treated pharmacologically for NAS symptoms. 
 
The Early Childhood Phase  
Neurological Development 
Children’s neurological development was assessed at each assessment. At four months, infants’ 
neural maturity was assessed at the Women’s and Children’s Hospital using Visual Evoked 
Potentials (VEP). At 12 and 24 months, children were assessed in their homes using the Bayley 
Scales of Infant Development- Second Edition (BSID-II).  
 
Visual Evoked Potentials (VEP) 
VEP elicit electrographic patterns which reflect brain development in terms of axon and dendrite 
growth, synapse formation and extent of myelination (Pryds, Trojaborg, Carlsen, & Jensen, 1989; 
Scher, et al., 1998).  VEP latency provides a measure of the speed of processing from the visual 
stimulus to the peak of neuronal depolarisation in the primary visual cortex, and provides a 
sensitive and impartial indication of the maturation of the visual pathway (Madrid & Crognale, 
2000; Skarf, 1989). 
 
Binocular pattern-reversal visual evoked potentials (VEP) were recorded in a darkened room 
under transient conditions (during which polyphasic responses are evoked by low frequency 
stimuli). Infants were tested at 15-17 chronological weeks of age and were seated on the lap of a 
parent or caregiver. Pacifiers were used to settle infants and attention to the screen was 
maintained with a small toy or auditory stimulus (a bell, jingled out of view, behind the screen).   
 
Latencies for the first 69 infants were recorded using the Enfant 4010 system (Neuroscientific 
Corp, Farmingdale, NY). Infants were seated in front of a 48 cm (19 inch) monitor (Neuroscientific 
Corp) on which high-contrast, black and white, checkerboard pattern reversal (2 Hz) stimuli were  
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presented for 30 second periods (Figure 2.2). The mean luminance of the stimulus display was 50 
cd/m
2 (contrast 80%). Three 5 mm Grass gold cup electrodes were attached to the infants’ scalp 
with Grass EC2 conducting paste. The active electrode was placed 1 cm above the inion (external 
occipital protuberance), the reference electrode at the vertex, and the inactive electrode on the 
forehead. Checkerboard patterns subtending two different check sizes (48 and 69 minutes of the 
retinal arc
1) were presented. The viewing distance for each pattern was 50 cm, with a viewing 
field of 25 degrees.  
 
Frequencies between 1-100 Hz were collected and amplified 10K using Grass PC model 511 AC 
amplifiers. A minimum of two recordings were performed for each check size and the latencies 
(measured in milliseconds) of the first positive wave (P1) for each recording were averaged for 
analysis. Recording was paused if the infant looked away from the screen and breaks were given if 
the child was tired or hungry. 
 
The Enfant equipment was not available for assessment of the final 16 infants. As a result, 
latencies for these children were recorded using the Nicolet Bravo Evoked Potential system 
(Nicolet Biomedical, Viasys Neurocare Madison, WI). Stimuli (mean luminance 32 cd/m
2, contrast 
91.9%) were presented on a 38 cm (15 inch) monitor (Nicolet) until a stable response was 
obtained and replicated. Infants were seated 50 cm and 75 cm in front of the stimulus screen to 
obtain the respective check sizes of 48 minutes and 69 minutes of arc. Electrode placement (10 
mm Grass gold cup) was the same as for the Enfant equipment except for the reference electrode 
which was placed mid-frontal. Nicolet 16 channel EC amplifiers were used to amplify collected 
frequencies. Two experienced operators (one per machine), blind to participants’ group status, 
conducted the VEP assessments.  
 
                                                           
1 A minute (‘) of arc is a unit of angular distance, with one minute equal to one sixtieth of a degree.  
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Equivalence testing of the VEP equipment was carried out on a test subject prior to conducting 
the infant VEP tests on the Nicolet Bravo system. Although the luminance and contrast differed 
slightly between the two pieces of equipment, recorded values were judged by two experienced 
technicians to be of appropriate equivalence (latencies in response to both check sizes averaged 
between 96.0 and 100.0 ms on each system). 
   
Bayley Scales of Infant Development – Second Edition (BSID-II) 
The BSID-II is a widely used standardised assessment which measures a child’s current 
developmental functioning (Bayley, 1993). Designed for use with children aged between 1 month 
and 42 months, it is a revised version of the first edition of the scales which were based on early 
work by Nancy Bayley. Aspects of development such as memory, simple problem solving, 
language abilities, body control, coordination, and fine motor movement are tested via 
observations and a series of simple tasks for children. A child’s performance on these tasks, 
together with parents’ observations, yield estimates of the child’s current functioning, compared 
to other children of their age. The BSID-II consists of three scales: the Mental Scale, Motor Scale, 
and Behaviour Rating Scale (BRS). For the Mental and Motor Scales, age related item-sets are 
administered in a flexible format and raw scores (in appropriate age categories of one-month 
increments), representing the total number of items successfully completed, are converted to the 
Mental Developmental Index (MDI) and Psychomotor Developmental Index (PDI) scores. The MDI 
and the PDI were constructed to have a normalised standard score with a mean of 100 and a 
standard deviation (SD) of 15. The BRS is a 30-item investigator completed questionnaire 
assessing the child’s behaviour (including attention, initiative and temperament) during the 
testing session. Behaviours are rated on a 5-point Likert scale; scores are summed to generate 
four subscale scores and a Total Behaviour Score. Scores from the BRS are primarily used to 





The BSID-II test manual reports good internal consistency for the MDI, PDI and total BRS scores 
for a sample of 100 children at 12 months (MDI, α=.88; PDI, α=.84; BRS, α=.90) and 24 months 
(MDI, α=.92; PDI, α=.83; BRS, α=.91); and good test-retest stability (MDI, r=.87; PDI, r=.78) over 
intervals ranging from 1 to 16 days (median 4 days). Content and construct validity for the MDI 
and PDI is reportedly good (Bayley, 1993) and concurrent validity has been demonstrated for the 
BSID-II with strong correlations between the MDI and scales scores on the Weschler Preschool 
and Primary Scales of Intelligence – Revised (WPPSI-R) and McCarthy Scales of Children’s Abilities; 
and moderate correlations between the PDI and the McCarthy Scales of Children’s Abilities 
(Bayley, 1993).  
 
In 2006, the BSID-II was developed and re-standardised as the Bayley Scales of Infant and Toddler 
Development – Third edition (BSID-III) (Bayley, 2006). Because the current longitudinal study was 
commenced prior to the availability of the BSID-III, the BSID-II was used for all assessments in 
order to maintain consistency of score interpretation. 
 
Children’s Temperament 
At four months, temperament was assessed using  the Short Temperament Scale for Infants (STSI) 
(Sanson, Prior, Garino, Oberklaid, & Sewell, 1987) completed by the child’s primary caregiver. 
Temperament at 12 and 24 months was assessed using the Short Temperament Scale for Toddlers 
(STST) (Prior, Sanson, Smart, & Oberklaid, 1989). These 30-item questionnaires have Australian 
norms and were developed as part of the Australian Temperament Project (Prior, et al., 1989; 
Prior, Sanson, Smart, & Oberklaid, 2000). Parents respond by rating their child’s recent behaviour 
in response to everyday activities and events on a 6-point scale (ranging from ‘almost never’ to 
‘almost always’). Higher scores reflect more difficult temperament (e.g. greater distractibility, 
lower persistence). Both measures are based on the model of temperament proposed by Thomas 
and Chess (Thomas & Chess, 1977) and used in the New York Longitudinal Study (NYLS) which 
conceptualises temperament as a child’s disposition on nine characteristics: activity level,  
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rhythmicity (or regularity) of body functions, approach or withdrawal (response to new stimuli), 
adaptability (adjustment to new experiences), intensity of reactions (energy level of a child’s 
response), quality of mood, persistence (or attention span), distractibility, and sensory threshold. 
The questionnaires are described in more detail below. 
 
Short Temperament Scale for Infants 
This scale was developed from a factor analysis of the Revised Infant Temperament Questionnaire 
(Carey & McDevitt, 1978). It contains five subscales, each assessing different dimensions of 
temperament: Approach measures a child’s sociability and adaptability to new situations and 
experiences (e.g. “The baby’s first reaction, at home, to approach by strangers is acceptance”); 
Rhythmicity measures the regularity and predictability of the child’s usual biological functions 
(e.g. “The baby gets sleepy at about the same time each evening, within ½ hour”) ; 
Cooperation/Manageability measures the ease with which the child adapts to everyday events 
(e.g. “The baby continues to fret during nappy change in spite of efforts to distract him/her with 
game, toy or singing, etc”); Activity/Reactivity refers to the amount of body movement the child 
usually makes, and the intensity of the child’s reactions to stimuli (e.g. “The baby moves a lot, 
squirms, bounces, kicks, while lying awake in cot”); and Irritability measures the amount of the 
child’s crying and fussing (e.g. “The baby amuses self for ½ hour or more in cot or playpen, looking 
at mobile, playing with toy, etc”). Acceptable internal consistency (α=.57 to .76) and test-retest 
reliability over a two to nine week period (r=.77 to .90) have been demonstrated for the infant 
subscales. A composite ‘Easy/Difficult’ Temperament Score (EDS) is calculated by averaging the 
Approach, Cooperation/Manageability, and Irritability scale scores. Infants scoring ≥ one standard 
deviation above the standardised Infant EDS mean are classified as ‘difficult’, while those scoring 
≤ 1 SD below the standardised EDS mean are classified as having an ‘easy’ temperament 
(Oberklaid, Sanson, & Prior, 1986; Sanson, Prior, & Oberklaid, 1985). 
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Short Temperament Scale for Toddlers  
The toddler version was developed from a factor analysis of the Toddler Temperament Scale 
(Fullard, McDevitt, & Carey, 1984). It also contains the Approach/Adaptability, 
Cooperation/Manageability, Rhythmicity, and Reactivity subscales (using items developmentally 
appropriate for toddlers aged 12 to 42 months), and includes two extra subscales measuring 
Persistence: the child’s ability to focus on activities and tasks (e.g. “The child plays continuously 
for more than 10 minutes at a time with a favourite toy”) and Distractibility: the ease with which a 
child can be distracted or comforted when required (e.g. “The child stops eating and looks when 
he/she hears a sudden noise, such as telephone, doorbell”). Satisfactory internal consistency 
(α=.56 to .85) have been reported for the toddler subscales. The STST questionnaire also yields a 
composite EDS, which is the mean of the Approach/Adaptability, Cooperation/Manageability, and 
Reactivity subscales (Prior, et al., 1989). Toddlers scoring one standard deviation above the 
standardised Toddler EDS mean are classified as ‘difficult’, while those scoring one standard 
deviation below the EDS mean are classified as having an ‘easy’ temperament (Prior, et al., 1989). 
 
Children’s Physical Development 




At each assessment, infants’ weight, length and head circumference (HC) were measured. At the 
4-month assessment infants were weighed without clothes on a calibrated Seca Baby
 Balance 
(model 727; Seca, Hamburg, Germany). Length was measured
 in the supine position to the 
nearest 0.5 cm by two individuals
 using an infant measuring mat. Head circumference was 
measured
 at the largest occipitofrontal circumference to the nearest




At the 12-month assessment, infants were weighed without clothes on a calibrated Seca Infant 
and Toddler Digital Scale (model 734; Seca, Hamburg, Germany). Length and HC were measured 
as per the 4-month assessment. At the 24-month assessment, toddlers were weighed on Soehnle 
bathroom scales (Soehnle Professional, Backnang, Germany). Height was measured, without 
shoes, on a stadiometer and HC measured as per the previous assessments. 
 
Sample Characteristics for the Early Childhood Phase 
At each assessment, information was obtained about the children’s general health, sleep 
behaviours, current breastfeeding status, and demographic characteristics of participating 
families. Additionally, information was collected about psychosocial characteristics including the 
quality of parent-child interaction, parental psychopathology, perceived social support, the 
quality of the child’s care-giving environment, and recent parental substance use. 
 
Children’s General Health  
At each follow-up assessment parents were asked to report whether their child had experienced 
any medical problems since the last assessment. If they answered ‘yes’ they were then asked to 
list the medical problems. Parents were also asked whether their child had experienced any 
seizures since the previous assessment and whether they were febrile or afebrile.  
 
Children’s Sleep Behaviours   
Information about the sleeping patterns of infants and children was collected using a 
questionnaire based on the Brief Infant Sleep Questionnaire (BISQ) (Sadeh, 2004). The BISQ was 
designed as a screening instrument for use in paediatric settings. It has been validated in a sample 
of 100 infants and showed significant correlations with actigraphic sleep measures (which record 
activity levels) and daily sleep logs. The BISQ has been shown to discriminate between children 
with and without sleep difficulties, and good test-retest reliability (r>.82) has been demonstrated 
over an interval of three weeks (Sadeh, 2004). The questionnaire used in the early childhood  
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phase of the study obtained information about nocturnal and daytime sleep duration, number 
and duration of night wakings, child’s usual bed-time, time spent settling the child at night, and 
whether parents thought their child’s sleep was a problem. It differed from the BISQ in that the 
questions about infants’ sleeping location, sleeping position and method of falling asleep were 
omitted. Sadeh’s cut-off scores (which do not incorporate these omitted questions) were used to 
identify children who were poor sleepers. The criterion for poor sleeping was defined as one or 
more of the following: a) waking >3 times per night; b) nocturnal wakefulness of >1 hour; or c) 
total sleep time (including day and night sleeps) <9 hours (Sadeh, 2004). 
 
Breastfeeding Status 
At the 4-month assessment, questions based on the World Health Organisation (WHO) definitions 
of breastfeeding (Webb, Marks, Lund-Adams, Rutishauser, & Abraham, 2001) were used to assess 
feeding status of infants. Parents were also asked whether they had introduced solid food to their 
child’s diet. At the 12- and 24-month assessments parents reported if their child was still 
breastfed, or at what age breastfeeding had ceased. 
 
Research suggests that breastfeeding has a protective effect on infant health, particularly in terms 
of infectious childhood illnesses, such as otitis media, respiratory tract infections and 
gastrointestinal infections. It has been shown that breastfeeding a child for longer confers greater 
protective effect against these illnesses, while exclusive breastfeeding (i.e. infant receives only 
breast milk) appears to have the most beneficial health effects (House of Representatives 
Standing Committee on Health and Ageing, 2007). Breast feeding has also been found to be 
associated with better developmental outcomes in full-term and premature infants. Khedr and 
colleagues (Khedr, Farghaly, Amry, & Osman, 2004) found that full term infants exclusively fed 
breast milk (n=30) had significantly shorter P1 latencies in response to flash VEPS at 12 months of 
age, compared with formula fed infants (n=23, M±SD=96.4±9.0 ms, p<.05)(Khedr, et al., 2004). 
Feldman and Eidelman (2003) found that in a group of 86 premature infants, infants receiving a  
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greater amount of breast milk (>75% nutrition, n=34) had better neurological development scores 
on the Brazelton Neonatal Behaviour Assessment Scale (NBAS) at 37 weeks gestational age (GA), 
and higher MDI and PDI scores on the BSID-II at six months corrected age (CA), than infants 
receiving ≤75% breast milk. Breast feeding was also associated with increased levels of positive 
maternal-infant interaction and decreased levels of maternal depression (Feldman & Eidelman, 
2003). 
 
Demographic Characteristics  
Information about the demographic characteristics of participants was collected at each 
assessment using a questionnaire developed by the Research and Evaluation Unit, Children Youth 
and Women’s Health Service, South Australia. This questionnaire obtains information about the 
child’s age, gender, the respondent’s relationship to the child, the number of dependent children 
in the household, the number of household moves, family structure, accommodation and annual 
income, as well as maternal age, and information about the educational attainment, employment 
status and usual occupation of the mother (or maternal figure) and father (or paternal figure) in 
the child’s household. 
 
Maternal Psychosocial Characteristics 
Parent-Child Interaction 
Parents completed two measures of parent-child interaction: The Maternal Postnatal Attachment 
Scale (Condon & Corkindale, 1998) at the 4-month assessment and the Parenting Stress Index 
(Abindin, 1995) at the 12- and 24-month assessments.  
 
Maternal Postnatal Attachment Scale 
This 19-item questionnaire, developed by Condon and Corkindale (Condon & Corkindale, 1998), 
was designed to assess the quality of a mother’s emotional response to her infant. Mothers 
report on the intensity and frequency of subjective experiences regarding their infant during the  
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first year postpartum. It was administered to parents at the 4-month assessment. For the majority 
of items parents choose from four or five responses (e.g., for the item ‘When I interact with the 
baby I feel…’ the response options are ‘very incompetent and lacking in confidence‘, ‘moderately 
incompetent and lacking in confidence‘, ‘moderately competent and confident‘, and ‘very 
competent and confident‘). For two items, parents choose from two responses (e.g., for the item 
‘I try to spend as much time as I possibly can playing with the baby’, for which the response 
options are ‘this is true’ and ‘this is untrue’). Each response is recoded to a score on a 5-point 
scale with higher scores indicating higher levels of attachment. The scale yields three construct 
scores: Quality of Attachment, Absence of Hostility, and Pleasure in Interaction, as well as a 
Global Attachment score which is calculated by summing responses to all items (range 19-95). 
Internal consistency of the Global Attachment score was demonstrated in a sample of 210 
mothers of 4-month old infants with α=.79. Good test-retest reliability over a 2-week test interval 
was reported on a subsample of 56 women, with a significant Pearson correlation coefficient of 
.86 and an intraclass correlation coefficient of .70 (Condon & Corkindale, 1998). Construct validity 
of the Global Attachment score was evaluated with the same sample of mothers. Global 
Attachment scores were found to be significantly related to infant temperament, levels of 
maternal social support, and maternal psychopathology (Condon & Corkindale, 1998).  
 
Parenting Stress Index  
The Parent Domain subscale of the Parenting Stress Index (PSI) (Abindin, 1995) was administered 
to parents at the 12- and 24-month assessments. This self-report measure is designed to identify 
stressful parent-child systems which may relate to dysfunctional parenting and later child 
emotional and/or behavioural problems (Abindin, 1995). The 120-item PSI has been standardised 
for parents of children aged one month to 12 years. It yields total scores and a number of 
subscale scores within separate Child and Parent Domains, as well as a Total Stress score and a 
Life Stress score. Only the Parent Domain scores were used in the present study as the other 
scales were not considered pertinent.   
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The PSI Parent Domain is comprised of 54 items relating to parental functioning, from which 
seven subscales can be calculated: Competence measures a parent’s feelings of capability in 
fulfilling the parenting role (e.g. ‘I feel capable and on top of things when caring for my child’), 
Isolation measures the extent to which the parent feels socially isolated, Attachment measures 
the parent’s feelings of emotional closeness to the child (e.g. ‘ My child knows I am his or her 
parent and wants me more than other people’), Health assesses the parent’s physical health (e.g. 
Physically, I feel good most of the time’), Role Restriction measures the extent to which the parent 
views their parenting role as restricting them in terms of maintaining their own identity (e.g. ‘I 
feel trapped in my responsibilities as a parent’), Depression assesses feelings of unhappiness or 
guilt (e.g. ’I feel every time my child does something wrong, it is really my fault’) and Spouse 
measures feelings of emotional and practical support from the other parent (e.g. ‘Having a child 
has caused more problems than I expected in my relationship with my spouse (or male/female 
friend)’). For the majority of questions, parents rate their level of agreement on a 5-point scale 
(ranging from ‘strongly agree’ to ‘strongly disagree’), with statements about child and parent 
characteristics and family context. A Parent Domain Total score is calculated by summing the 
seven subscale scores. Higher scores indicate greater levels of dysfunction. The Parent Domain 
subscales of the PSI have a demonstrated satisfactory degree of internal consistency (α=.70 to 
.84), and good test-retest reliability across time intervals between 1- and 12-months (r=.69 to 
.91). Adequate levels of construct validity have been reported, with Parental Domain scores 
significantly correlated with BSID scores, quality of parent-child attachment and maternal 
psychological distress (Abindin, 1995). 
 
Parental Psychopathology 
Parents completed two measures of parental psychopathology: the Edinburgh Postnatal 
Depression Scale (EPDS) (Cox, Holden, & Sagovsky, 1987) at the 4-month assessment, and the 28-




Edinburgh Postnatal Depression Scale 
The Edinburgh Postnatal Depression Scale (EPDS; (Cox, et al., 1987) is a 10-item self-report 
screening tool widely used for the identification of postnatal depression (PND)(Boyce, Stubbs, & 
Todd, 1993; Eberhard-Gran, Eskild, Tambs, Opjordsmoen, & Samuelsen, 2001; B. Edwards, 
Galletly, Semmler-Booth, & Dekker, 2008; Matthey, Henshaw, Elliott, & Barnett, 2006; McMahon, 
Barnett, Kowalenko, Tennant, & Don, 2001; Murray & Carothers, 1990; Patel, et al., 2003). The 
EPDS is comprised of items assessing common symptoms of postnatal depression (including 
anhedonia, anxiety, panic, insomnia due to unhappiness, sadness, tearfulness and self-harm) 
experienced within the previous 7 days. Participants respond to statements on a 4-point scale (0-
3). For example, for the first item, ‘I have been able to laugh and see the funny side of things’, 
participants choose from one of the following four responses, a)’As much as I always could’, b) 
‘Not quite so much now’, c) ‘Definitely not so much now’, d)’Not at all’. A total EPDS score ranging 
from 0 to 30 is calculated, with higher scores indicating greater severity of symptoms.  
 
The EPDS has been validated in a sample of 103 Australian women using a cut-off score of 12.5 
which yielded 100% sensitivity, a specificity of 95.7% and positive predictive value of 50% (Boyce, 
et al., 1993). A recent Australian study (Matthey, et al., 2006) has highlighted the increasing use of 
unvalidated cut-off scores in published studies using the EPDS and the use of potentially confusing 
wording to describe scores indicating ‘caseness’. On the recommendation of these authors, the 
current study uses the validated score of ’10 or more’ for reporting at least probable minor 
depression and ‘13 or more’ for reporting on probable major depression (Matthey, et al., 2006).  
 
General Health Questionnaire  
The General Health Questionnaire (GHQ; (Goldberg & Hillier, 1979) is a widely used self-report 
screening tool for the detection of psychological distress in community populations (Donath, 
2001). Participants rate themselves, on a 4-point scale, according to the degree to which they  
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have experienced symptoms over the past few weeks. The GHQ asks about changes in normal 
functioning rather than assessing the presence of chronic disorders.  
 
The 28-item version of the questionnaire (GHQ-28) was completed by parents at each follow-up 
assessment. Four subscales are calculated for this version of the questionnaire: Somatic 
Symptoms (e.g. ‘Have you recently been feeling perfectly well and in good health?’), Anxiety and 
Insomnia (e.g. ‘Have you recently lost much sleep over worry?’), Social Dysfunction (e.g. ‘Have 
you recently been managing to keep yourself busy and occupied?’), and Severe Depression (e.g. 
‘Have you recently been thinking of yourself as a worthless person?’); along with a Total score 
which is calculated by summing all 28 items. The standard binary ‘GHQ scoring method’ (0-0-1-1), 
as advocated by Goldberg (Goldberg et al., 1997; Goldberg & Hillier, 1979), was employed for this 
study. Item responses indicating the presence of psychopathology were scored as 1. Total scores 
for the GHQ-28 range from 0 to 28 and higher scores indicate higher levels of psychological 
distress. Concurrent validity for the GHQ-28 has been demonstrated with the Total score 
correlating with independent clinical assessment (α=.32-.76) (Goldberg & Hillier, 1979). The GHQ-
28 has shown acceptable levels of sensitivity (79.7%), specificity (79.2%) and positive predictive 
value (54.7%) across a sample of over 5000 participants in 15 general health care centres 
(Goldberg, et al., 1997).  
 
The scale’s author recommends using a total threshold score of 4/5 to indicate the likelihood of 
significant levels of psychological distress (Goldberg & Hillier, 1979). However, in the WHO study 
of psychological disorders in general medical settings, Goldberg and colleagues (1997) found that 
the average threshold score across all 15 centres (and 10 different languages), was 5/6, with a 
threshold of 6/7 for a Manchester, UK sample (Goldberg, et al., 1997). Studies using the GHQ with 
postpartum women recommend using a raised threshold score due to sleep disturbances and 
physical symptoms that may be related to the post-natal period (Boyce, et al., 1993; Nott & Cutts,  
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1982; Skari et al., 2002; Watson & Evans, 1986). A threshold score of ≥6 (Skari, et al., 2002) was 
used to indicate a significant level of psychological distress for the purpose of this thesis. 
 
Social Support 
Parental social support was measured at each assessment using the Interview Schedule for Social 
Interaction -Short Form (ISSI-SF) (Unden & Orth-Gomer, 1989).  
 
Interview Schedule for Social Interaction-Short Form 
This 30-item self-report instrument is an adaptation of the Interview Schedule for Social 
Interaction developed by Henderson, Duncan-Jones, Byrne and Scott (1980). It assesses subjective 
perceptions of one’s social support network (including close relationships, friends, colleagues and 
acquaintances), in particular, the availability and perceived adequacy of social integration and 
attachment (Persson & Ørbæk, 2003; Thernlund & Samuelsson, 1993). The ISSI-SF yields four 
subscales: availability of attachment (AVAT; with a maximum obtainable score of 6), adequacy of 
attachment (ADAT; with a maximum obtainable score of 10), availability of social interaction 
(AVSI; with a maximum obtainable score of 6) and adequacy of social interaction (ADSI; with a 
maximum obtainable score of 8). A Total social support score is derived by summing all of the 
items (Eklund, Bengtsson-Tops, & Lindstedt, 2007; Thernlund & Samuelsson, 1993). Higher scores 
indicate better perceived social support. 
 
High internal consistency of the ISSI-SF (α=.84-.91) has been demonstrated in a sample of 297 
Swedish mental health patients (Eklund, et al., 2007) and it has been shown to distinguish 
between respondents with high and low trait anxiety, and social desirability scores (Persson & 
Ørbæk, 2003). Good test-retest reliability (over a six week interval) was reported for the Total 
score in a sample of staff members from a Swedish child psychiatric clinic (α=.87); however 
stability of scores was lower (α=.45) in a community group of parents over the same interval 
(Thernlund & Samuelsson, 1993). Adequate levels of construct validity have been reported in an  
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Australian sample, with the Total ISSI-SF scores significantly correlated with greater parental 
psychological distress (α=-.51); however correlations were lower (α=-.22 to -.35) with parent-
rated child temperament scores in the same sample (Miller-Lewis et al., 2006).  
 
Care-giving Environment 
Evaluation of the child’s care-giving environment was undertaken at the home visits, during the 
12- and 24-month assessments, using the Infant version of the Home Observation for 
Measurement of the Environment (HOME) Inventory (Caldwell & Bradley, 1984).  
 
The Infant HOME Inventory  
This is a 45-item instrument designed to evaluate the quantity and quality of social, emotional 
and cognitive experiences available to infants in their own home. Each item is scored 
dichotomously (yes/no) with the inventory yielding six subscales: Parental Responsivity (e.g. 
‘Parent spontaneously praises child at least twice’), Acceptance of Child’s Behaviour (e.g. ‘Parent 
does not scold or criticise child during visit’), Organisation of the Environment (e.g. ‘Child has a 
special place for toys and treasures’), Provision of Appropriate Learning Materials (child has a 
range of learning materials e.g. ‘Cuddly toy or role-playing toys’, ‘ Toys for literature and music’), 
Parental Involvement with Child (e.g. ‘Parent keeps child in visual range, looks at often’) and 
Variety in Experience (‘Child eats meals with parent and/or other children’). A Total HOME score is 
calculated by summing the scores of the six subscales. Total scores range from 0 to 45 with higher 
scores indicating a more optimal home environment (Caldwell & Bradley, 1984). Information 
needed to score items on the scale is obtained via a combination of observation and interview 
questions.  
 
The HOME Inventory has been used extensively in developmental research (Bradley, 1994). Total 
HOME scores have been shown to be significantly associated with birth weight and cognitive 
function in children aged 2 to 13 years (Tong, et al., 2006) and moderately correlated with  
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perceived level of social support in new mothers (r =.43 to .50) (Bradley, 1994). HOME scores have 
also been correlated with cognitive outcomes at 5 and 6 years of age of children whose mother’s 
smoked during pregnancy (Fried, O’Connell, & Watkinson, 1992). Internal consistency Kuder-
Richardson coefficients for the scale scores have been reported to range from r=.44 to .89 with a 
coefficient of r=.89 for the Total HOME score in a sample of middle-class North American children 
aged 4 to 36 months (Caldwell & Bradley, 1984). Slightly lower coefficients for the subscale scores 
(r=.31 to .66) and the Total HOME score (r=.84) were reported for a sample of lower-middle class 
Costa Rican children aged 13 to 24 months (Lozoff, Park, Radan, & Wolf, 1995). Concurrent and 
predictive validity has been demonstrated with the Total HOME score being low to moderately 
correlated (r=.06 to .30) with the MDI of the BSID in infancy, and moderately associated with 
WPPSI scores at 5 years of age (r=.28 to .53) in these two samples (Lozoff, et al., 1995). 
 
Parental Substance Use  
Information about parental substance use was collected using a questionnaire developed for this 
purpose by Drug and Alcohol Services South Australia (DASSA). This questionnaire asks about licit 
and illicit use of substances in the month prior to the assessment, as well as the parents’ use of 
substances since the previous assessment. Information collected included type of maintenance 
drug (if applicable), dose, and timing of doses over the past three days. Respondents were also 
asked whether they had used any of the following classes of drugs: tobacco, alcohol, heroin, other 
opioids, marijuana, amphetamines, inhalants, benzodiazepines. For each substance that a parent 
indicated they had used, they were asked to report the specific substance (e.g. for 
‘amphetamines’, this could have been cocaine, ecstasy, methamphetamine etc), how it was taken 
(e.g. orally, inhaled, intravenously etc), the number of days on which they had used it, and the 
number of times used per day on the days they had used it. For tobacco, alcohol and marijuana 
parents were asked about the respective number of cigarettes, drinks or cones/bongs they had 
used on the days they reported using each substance. Parents were also asked to indicate if they  
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had used any other over-the-counter or prescribed medication (including vitamins, supplements 
and pain relief).  
 
2.7 Statistical Analyses  
Analyses were conducted using Stata/IC 10.0 (StataCorp LP, College Station Texas) and a Type 1 
Error of .05 was used for significance testing in analyses, except when stated otherwise. An 
overview of the statistical analyses employed in the thesis is described in this section with further 
details provided in individual results chapters. 
 
Mean scores and standard deviations (SD), or median scores and observed ranges, were 
calculated for continuous variables and frequencies were calculated for categorical variables. 
One-way between groups analyses of variance (ANOVA) were conducted to test for statistically 
significant differences in mean scores between the three groups on normally distributed 
continuous outcome measures. Post hoc tests using the Bonferroni adjustment procedure were 
employed to examine the locus of any differences between the groups. Non-normally distributed 
variables were transformed when appropriate. For variables where a suitable transformation 
could not be found, Kruskal-Wallis equality-of-populations rank tests were used to examine 
statistically significant differences in median scores between the three groups. Mann-Whitney U 
tests were conducted to evaluate pair-wise differences between the three groups of infants. 
 
A series of simple linear regression analyses (for continuous measures) and ANOVAs (for 
categorical measures) were conducted to examine the contribution of individual potentially 
confounding variables to each of the dependent outcome variables. Each bivariable model was 
examined for normality and constant variance, and data transformations were applied if these 
assumptions were not met. Non-parametric techniques were employed when a suitable 




The 21 variables which were examined for their potential to confound comparisons between the 
three groups were chosen from a number of theoretically appropriate maternal and infant 
characteristics that were collected at enrolment, throughout pregnancy, post-natally and at the 4-
month follow-up assessment. Variables from Tables 3.9 to 3.9 were used as covariates when they 
differed significantly between groups, were associated with a given outcome at P ≤ .05, and were 
not highly correlated (r > .70) with other covariates. Variables were excluded if there were too 
few responses in a category for analysis to be meaningful (i.e. ethnicity) or if they were defined by 
group status (i.e. heroin use). In the case of scale scores, only total scores were examined. 
Independent variables examined were maternal age at enrolment, self-reported use of tobacco, 
alcohol, other opioids, marijuana, benzodiazepines and antidepressant medication during 
pregnancy, infant gender, gestational age at delivery, length, weight and HC at birth, method of 
feeding at four month follow-up (receiving some breast milk versus no breast milk), number of 
parental figures in the infant’s household, number of children living in the household (≤3 versus 4 
or more), education level of primary caregiver, family income category, family accommodation, 
maternal postnatal attachment total score at four month follow-up, GHQ total score at four 
month follow-up and ISSI total score at four month follow-up.  On the basis of theoretical criteria 
(described in Chapter 1), in addition to those variables listed above, infants’ mean Finnegan score, 
infants’ corrected age, and Sadeh’s sleep category (poor sleeper = yes/no) at four month follow-
up were examined in relation to the four month dependent variables. The PSI Parent Domain total 
score and Total HOME Inventory score were examined in relation to the 12- and 24- month 
dependent variables. It has been suggested that child cognitive function may be influenced by 
environmental changes (Wilson, 1989), therefore analyses utilised the PSI and HOME scores 
collected at the relevant assessment. Only results for the variables that were significantly 
associated with individual dependent variables at p <.05 are presented in this thesis.  
 
Standard multiple regression analyses were then conducted to examine the contribution of each 
potentially confounding variable to the individual dependent variables, whilst adjusting for the  
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effect of the other variables in the model. Variables were chosen for inclusion in the multivariable 
models if they were theoretically appropriate and had a significant bivariable relationship with the 
dependent variable at p <.05. Each model was examined for multicollinearity, normality of 
residuals and equality of variance. Data were transformed using suitable techniques if these 
assumptions were not met.  
 
Finally, a series of split-plot analyses of variance (also known as mixed between-within subjects 
ANOVAs) were undertaken to examine whether there was a change in each of the dependent 
measures over time and whether changes over time varied between infants in each of the three 
groups. Split-plot designs can be “…used to test for differences between two or more 
independent groups while subjecting participants to repeated measures. The dependent variable 
is continuous and is measured for each group across each level of the repeated factor” (Vicky, 
2009). A split-plot ANOVA design was chosen over mixed-effects models, as the latter usually 
require large sample sizes in order to verify assumptions about the variance-covariance structure 
of repeated measures. 
 
Power analyses  
The dependent outcome variables of principle interest in this study were: 
  P1 latencies in response to the 48 min arc visual stimulus, measured at four months 
  P1 latencies in response to the 69 min arc visual stimulus, measured at four months 
  Bayley Scale Mental Developmental Index Score, measured at 12 and 24 months 
  Bayley Scale Psychomotor Developmental Index Score, measured at 12 and 24 months 
  Bayley Scale Behavior Rating Scale Score, measured at 12 and 24 months  
  ‘Easy/Difficult’ Temperament Score, measured at four, 12 and 24 months 




Given the extended data collection period (2002-2006) due to difficulty recruiting a large enough 
sample, post hoc power analyses, using nQuery Advisor (Statistical Solutions, Boston, MA), were 
calculated for the two drug-exposed groups of infants. Table 2.3 shows the observed n for the BM 
and MM groups for each of the dependent outcome variables. Presented for each dependent 
variable is: (1) the mean score for the BM and MM groups, (2) the observed difference in mean 
scores, (3) the effect size of the observed analysis and (3) a calculation of the n required for each 
group in order to detect the observed difference with 80% power. Table 2.3 indicates that the 
majority of analyses were under powered, given the restricted sample size; although some 
differences were so small that they may well have become insignificant with any sample size. It is 
therefore recommended that results of the current thesis should be viewed with caution and 
treated as preliminary. Whilst this is the first study to describe development past the neonatal 
period in detail for infants prenatally exposed to buprenorphine, any clinically relevant trends in 






This chapter describes the characteristics of families participating in the follow-up assessments of 
the longitudinal study. First, maternal characteristics at enrolment are described followed by 
information on maternal drug use reported during pregnancy. Infant characteristics at birth, 
Finnegan scores and treatment of neonatal abstinence syndrome are then presented. 
Characteristics of participating infants and families at the four month follow-up assessment are 
described, including socio-demographic information, infant sleep and maternal psychosocial 
factors. 
 
Statistical analyses  
Prior to analyses, the distributions of the variables were examined for normality and homogeneity 
of variance. Transformations were employed if an appropriate technique could be found. For 
normally distributed continuous data, one-way analyses of variance (ANOVA) were conducted to 
test the statistical significance of differences between means across the three groups. Post hoc 
tests using the Bonferroni procedure were employed to determine the statistical significance of 
differences between pairs of groups. Kruskal-Wallis tests were used to examine differences 
between groups if data did not meet the assumptions for parametric analyses. Chi square 
analyses and Fisher’s exact tests (for variables of low frequency) were used to examine the 
differences between groups for categorical variables. 
 
3.1 Maternal characteristics at enrolment 
The three groups of participants were statistically comparable in terms of maternal age, gravida 
(first pregnancy versus second or more), parity (first born infant versus second or more), and use  
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of tobacco and alcohol (yes/ no) within the month prior to enrolment. Table 3.1 shows the 
maternal characteristics of the sample at enrolment.  
 
Participating women were aged between 15 and 40 years (M±SD=27.45±5.94) at the time of 
enrolment, with the control group being on average almost two years younger than women in the 
other two groups. Seventy six percent of women had had a previous pregnancy (M±SD=3.15±2.05, 
range=1-9 pregnancies). Women in the two maintenance groups were more likely to be 
multigravid compared with women in the control group. The number of children a woman had 
delivered, prior to the current pregnancy, ranged from 0 to 5 (M±SD=0.90±1.15). Women in the 
control group were slightly more likely to be primparous than women in the other two groups. 
Eighty nine percent of participants reported smoking tobacco in the month prior to enrolment, 
with 84% (64/76) reporting that they smoked daily. Women in the control group were less likely 
than women in the other two groups to have smoked tobacco in the month prior to enrolment. 
Forty two percent of the sample reported consuming alcohol on at least one day in the month 
prior to enrolling in the study. Women in the MM group were the least likely to report consuming 
alcohol, with only one third reporting alcohol use in the month prior to enrolment. Half of women 
in the BM group reported drinking alcohol on at least one day in the month prior to enrolling in 
the study. 
 
Gestational age at enrolment ranged from 4 to 35 weeks (M±SD=18.79±6.68), with the control 
group enrolled significantly later in their pregnancies than women in either of the two 
maintenance groups. This difference in gestational age at enrolment arose because potential 
controls were recruited from a large pool of women attending the general antenatal clinics at the 
WCH. They were approached to participate only after their case notes had been reviewed for 
eligibility by a research assistant. Potential BM and MM participants were identified by medical 
staff from DASSA services or the specialist antenatal clinics when they first attended for an 
appointment, usually early in their pregnancy. 
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The majority of women enrolled in the study were Caucasian, with one woman in each group 
reporting Asian ethnicity, and one in each of the BM and MM groups identifying as being of 
Aboriginal or Torres Strait Islander (ATSI) origin (Table 3.1).  
 
The characteristics of the participating sample (n=87) were also compared, using independent 
samples t-tests and Fisher’s exact tests, with those of the women who did not participate in the 
early childhood phase of the study (n=19, Table 3.2). There were no significant differences in 
terms of maternal characteristics at enrolment between participants and non-participants; 
however, participating women were on average two years older than non-participants 
[F(1,103)=1.46, p=.23], were more likely to be primigravid (23% versus 17%, Fisher’s exact test 
p=.76) and to have had no previous children (49% versus 33%, Fisher’s exact test p=.30). Women 
who continued their participation in the early childhood phase of the study were also more likely 
to report drinking alcohol in the month prior to enrolment in the study (45% versus 28%, Fisher’s 
exact test p=.20). 
 
In terms of other maternal characteristics, gestational age at enrolment did not differ between 
participants and non-participants. There were a significantly higher proportion of Caucasian 
participants than non-participants, with 28% of non-participants identifying as being of ATSI or 
‘other’ origin, compared to 6% of participants who identified as Asian or ATSI. 
 
3.2 Maternal substance use reported at enrolment and during pregnancy 
Reported heroin use and maintenance therapy history  
Table 3.3 summarises the heroin use and maintenance therapy history of the women participating 
in the study. The data for age at first heroin use was positively skewed and was normalised with a 
square root transformation. Although there was no significant difference between the ages at 
which women in the maintenance groups had first used heroin, women in the MM group were 
approximately 18 months younger than women in the BM group when they used heroin for the  
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first time (Table 3.3). The overall mean reported age at first heroin use for women in the two 
maintenance groups (M±SD=18.68±3.29 years, range=13-28 years) is considerably younger than 
that reported by the 2007 National Drug Strategy Household Survey which found that for 
Australians aged ≥14 years the average reported age at first heroin use was 21.9 years (Australian 
Institute of Health and Welfare, 2008). The majority of women in the maintenance groups (94%) 
had used heroin on a daily basis, and reported beginning daily use approximately 12 months after 
first using heroin. Two
 women in the control group reported using heroin approximately 10 years 
prior to enrolment in the study; but neither had used it on a daily basis or had ever sought 
treatment for heroin use. Data for the length of consistent heroin use and for average daily heroin 
use prior to commencing maintenance therapy were both positively skewed. For comparative 
purposes, length of heroin use was transformed using a power 0.4 transformation (i.e. the score 
multiplied by itself 0.4 times); while a square root transformation was employed for average daily 
heroin use. Women in the MM group reported a greater average length of consistent heroin use 
and slightly higher daily heroin use prior to commencing maintenance therapy than women in the 
BM group, although neither difference reached statistical significance. The length of time women 
had been on their current episode of opioid maintenance therapy was examined using a Kruskal-
Wallis test. Length of maintenance therapy did not differ significantly between the two groups. 
The overall mean length of treatment was 12.90 months (SD=17.85 months); with women in the 
MM group reporting beginning maintenance therapy approximately six months earlier than 
women in the BM group.  
 
The majority of women in the BM and MM groups (40/54, 74%) were already participating in 
maintenance therapy when they became pregnant. All women taking buprenorphine were taking 
it in the form of the sublingual tablet, Subutex®. A small number were not participating in a 
treatment program at the time of conception and started treatment with BM or MM at enrolment 
into the study. No physical anomalies, attributable to MM or BM were noted in any of the infants  
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(Gordon, 2006). Gestational ages at commencement of maintenance treatment in these women 
ranged from 6 to 28 weeks for the eight BM women and 3 to 18 weeks for the six MM women. 
When examined with Fisher’s exact test, there was no significant difference between the MM and 
BM groups in the number of women who commenced maintenance treatment on enrolment into 
the study (and thus after conception) compared with those who commenced treatment prior to 
conception (Fisher’s exact test, p= 1.00). Neither was there a significant difference between the 
two groups in terms of the mean number of weeks that infants were exposed to a maintenance 
therapy in utero (BM=34.4±9.7, MM=36.8±4.0, [F(1,50)=1.17, p=.28]). The mean maintenance 
medication dose reported during pregnancy was 7.3 mg (SD=4.3, range= 0.4-20.0 mg) for the BM 
group and 44.3 mg (SD=20.1, range= 15.0-100.0 mg) for the MM group, both of which are 
relatively low by current clinical standards. It has been suggested that 8 mg of buprenorphine is 
approximately equivalent to 60 mg methadone. On this basis, the mean doses reported in the 
present study are of a similar magnitude (Ling & Wesson, 2003). 
 
Eighty three percent of women in the maintenance groups had undertaken at least one previous 
episode of opioid-maintenance therapy with methadone or buprenorphine prior to their current 
treatment episode. There was no difference between the number of women in the BM or MM 
groups who had previously tried maintenance therapy with methadone [F(1,27)=0.18, p=0.68] 
(range=1-5 previous treatment episodes) or buprenorphine [F(1,19)=0.17, p=0.69] (range=1-6 
previous treatment episodes). 
 
Self reported substance use during pregnancy 
Table 3.4 provides a précis of mothers’ self-reported substance use during pregnancy. A summary 
of the antenatal random urine drug screen results is also shown. Ninety percent (78/87) of 
participating women reported smoking tobacco during their pregnancy. This is considerably 
higher than the 18% of women who smoked during pregnancy as reported in the South Australian 
pregnancy outcome report for 2006 (Chan, Scott, Nguyen, & Sage, 2007), but comparable to the  
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85% of opioid-dependent women in New South Wales who reported smoking during pregnancy 
(Burns, Mattick, & Cooke, 2006). The proportion of women in this study who smoked tobacco 
daily (74%, 64/87) is also higher than the overall national average of 15.2% for all Australian 
females aged ≥14 years (Australian Institute of Health and Welfare, 2008). In the present study, a 
significantly greater percentage of smokers in the MM group (100%) reported smoking tobacco 
daily compared with smokers in both the BM (82%) and control groups (74%, Fisher’s exact test 
p=.02). For women in this study, the average number of cigarettes smoked per day was 12 
(SD=7.5, range 0.5-30 cigarettes) with the control group reporting smoking fewer cigarettes per 
day than women in both the BM and MM groups. While the proportion of women reporting use 
of tobacco in the current study is substantially higher than would be expected in a community 
sample (i.e. 90% vs. 18% in the 2006 South Australian pregnancy statistics sample) the high rates 
of smoking observed for the substance dependent groups is consistent with other research 
(Burns, et al., 2006; Choo, Huestis, Schroeder, Shin, & Jones, 2004; Jones et al., 2009; Kahila, 
Saisto, et al., 2007; Kakko, et al., 2008; Ross et al., 2005), and, in an attempt to obtain a relatively 
homogeneous sample, pregnant non opioid-dependent women who were smokers were 
specifically targeted for the control group. 
 
Sixty percent (52/87) of women reported drinking alcohol on at least one occasion during 
pregnancy. The mean number of days that women reported drinking alcohol during pregnancy 
was 2.24 (SD=2.37, range= 1-16 days), with a mean of 1.40 drinks (SD=1.02, range=0.5-10 drinks) 
consumed on those days. The pattern of alcohol consumption was similar across the three groups 
of participants. 
 
Women were also asked about recreational use of other substances during the antenatal period. 
Forty six percent of women in the maintenance groups (25/54) reported using heroin during their 
pregnancies (15 BM, 10 MM). The mean number of days that women reported heroin use did not 
differ significantly between the BM and MM groups [overall M±SD=5.80±7.78, range= 1-30 days,  
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F(1,91)=1.19, p=.27]. There were no statistically significant differences between the three groups 
in terms of maternal self-reported use of tobacco, alcohol, other opioids, amphetamines, 
hallucinogens or prescribed antidepressant medication during pregnancy, although it must be 
noted that the power to detect significant differences with the numbers in the current sample is 
limited (Table 3.4).  
 
Seven controls reported use of other opioids, and four reported use of benzodiazepines during 
the antenatal period. Codeine and Kapanol® were the most commonly reported other opioids 
used by control subjects and temazepam was the most commonly reported benzodiazepine. 
While it was not reported whether these substances were used licitly or illicitly, most control 
subjects reported using other opioids or benzodiazepines on only one or two days during the 
antenatal period, suggesting that they may have been used for legitimate medical reasons rather 
than recreationally. Nine women in each of the MM and BM groups reported use of other opioids 
during pregnancy. Opioids reportedly used were codeine, Kapanol®, morphine, and ‘other’. Most 
of these women reported taking the substance orally and on fewer than five occasions. One 
woman in the MM group reported injecting both morphine and Kapanol® on more than one 
occasion during her pregnancy, while another in the MM group reported use of an opioid on 10 
days within the month prior to enrolment (substance and route of administration was not 
reported). One woman in the BM group reported injecting an opioid twice a day on a daily basis 
within the month prior to enrolling in the study. Twelve women in each of the BM and MM 
groups reported use of benzodiazepines during pregnancy. Diazepam was the most commonly 
used benzodiazepine reported by MM and BM women, with use of temazepam and alprazolam 
also being reported. All women reported taking the substances orally. The majority of women in 
the BM and MM groups reported using a benzodiazepine on fewer than 10 days during their 
pregnancy, with frequency of use on days used averaging between one to four times per day. The 
mean number of days during pregnancy on which benzodiazepines were reportedly used by  
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women in the maintenance groups was 18.81 (SD=34.14, range= 1-143 days). Again, it was not 
reported whether benzodiazepines were used licitly or illicitly, however some women reported 
that they had previously been diagnosed with anxiety or depression and may have been 
legitimately prescribed these medications.   
 
Overall, 55% (48/87) of women reported use of cannabis during pregnancy (Table 3.4), over half 
of whom (n=25) reported using it daily. Women in the BM group were the most likely to report 
daily use of cannabis (45%) compared with women in either the MM (33%) or the control groups 
(14%, Fisher’s exact test, p=.04). The 2007 National Drug Strategy Household Survey (Australian 
Institute of Health and Welfare, 2008) showed that 30% of Australian females aged ≥14 years 
reported using cannabis in their lifetime while 12.3% reported using cannabis on a daily basis. 
While the overall level of cannabis use observed in this sample is substantially higher than the 
reported national average (Australian Institute of Health and Welfare, 2008), the proportion of 
women in the control group who reported cannabis use is relatively representative of the national 
average. The high rate of cannabis use in the two maintenance groups is consistent with the 
report from the 2007 National Drug Strategy Household Survey that between 30% and 66% of 
recent users of illicit opioids (including heroin, non-prescription methadone and other opioids) 
had used cannabis concurrently (Australian Institute of Health and Welfare, 2008). 
 
Urine drug screen results during pregnancy 
Table 3.4 also shows the percentage of women in each group with a positive drug screen during 
pregnancy for opioids, benzodiazepines or cannabinoids. Urine samples were routinely screened 
for opioids, cannabinoids, benzodiazepines, sympathomimetic amines, barbiturates and cocaine. 
No woman had a positive screen for barbiturates or cocaine during pregnancy. Results of the 
sympathomimetic amine screens are not included in the analyses because women across all 
groups were taking medication for reflux, some preparations of which contain ranitidine which is 
known to produce a positive sympathomimetic amine drug screen result (personal  
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communication, B Davies, March 27, 2009). Because further detailed analysis of positive urine 
screens was beyond the resources of the current study it was not possible to distinguish between 
licit and illicit forms of sympathomimetic amines. Thus, the urine drug screen results presented 
are for opioids, benzodiazepines and cannabinoids only.  
 
There was no significant difference between the number of women in the BM and MM groups 
with a positive drug screen during pregnancy (Fisher’s exact test p=.77). Eight women in the 
control group had a positive screen for cannabinoids during pregnancy which is consistent with 
self-reported cannabis use amongst this group. Three controls had a positive screen for opioids 
during pregnancy, and two had a positive screen for benzodiazepines. While it was not possible to 
determine whether these substances were used licitly or illicitly, the positive screens for women 
in the control group were consistent with self-reported use of these substances. 
 
3.3 Infant characteristics at birth 
Table 3.5 displays the neonatal characteristics of infants in the study. Half (43/87) of the infants in 
the study were male. Gestational age at delivery ranged from 33 to 41 weeks (M=38.6, SD=1.9). 
The distribution of the gestational age data was negatively skewed; therefore a power 4 
transformation (i.e. the score multiplied by itself four times) was used to test differences in 
analyses. The majority of infants (89%) were born at term (≥ 37 weeks gestation). The mean 
weight at birth was 3041 g (SD = 543, range = 1800 g - 4360 g) with 16 infants being of low birth 
weight [<2500 g, (Chan, et al., 2007; Laws & Hilder, 2008)]. There was a significant difference 
between the MM and control groups in terms of infant birth measurements, with MM infants 
significantly more likely to be lighter at birth, to be shorter, and to have smaller head 
circumferences. Birth measurements did not differ significantly between the BM and MM groups 
or between the BM and control groups (Table 3.5). Simple linear regressions revealed that, after 
adjusting for gestational age, a significant main effect of prenatal exposure to methadone  
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remained for all three birth growth measurements (see Appendix M). Apgar scores at 1 minute 
post delivery ranged from 4 to 10, while 5 minute Apgar scores ranged from 6 to 10.  
 
3.4 Finnegan scores and Treatment of Neonatal Abstinence Syndrome 
All infants were scored on a modified Finnegan scale for signs of neonatal abstinence syndrome 
(NAS). Control infants were included in this scoring because some of the items on the scale may 
be attributable to normal neonatal behaviour (e.g. yawning, sleep difficulties) or other infant 
health problems (e.g. fever, seizures). The overall mean Finnegan score was 2.90 (SD=1.83, range= 
0-21) suggesting that infants in the study experienced only very low levels of NAS symptoms. As 
expected, one-way ANOVA using the transformed (square root) mean Finnegan scores showed 
that control infants were scored significantly lower on the Finnegan scale than infants in either of 
the BM or MM groups (see Table 3.5). Mean Finnegan scores did not differ significantly between 
the two maintenance-exposed groups of infants, indicating that infants in these two groups 
experienced similar levels of NAS. However, the average maximum and range of Finnegan scores 
obtained by infants was greatest in the MM group, suggesting that individual infants in the MM 
group experienced greater severity of NAS symptoms than individual infants in the BM group. As 
expected, the maximum and range of Finnegan scores obtained by infants in the control group 
was lower than that of infants in either of the maintenance groups. 
 
Forty eight percent of infants in the maintenance groups (26/54) were pharmacologically treated 
for NAS. There was no significant difference between the two maintenance groups in terms of 
proportion of infants pharmacologically treated for NAS (see Table 3.5). Thirteen infants in the 
BM group and 12 in the MM group were treated with morphine. One infant in the BM group was 
treated, at the mother’s request, with phenobarbitone only, and 2 others in the BM group were 




3.5 Characteristics of participating infants and families at four month follow-up assessment 
Information about the demographic characteristics of participating infants and families was 
collected at the four month follow-up assessment (Table 3.6). At four months of age over half of 
the infants in the study were no longer breastfed. Almost half of all infants had experienced at 
least one medical problem since birth. The most frequently reported medical problem was an 
upper respiratory tract infection (including otitis media and fever, n=15), followed by skin rash 
(including thrush and eczema, n=7). At four months of age no infant in the study had experienced 
a seizure.  
 
In terms of infant sleeping behaviours, 21% of the total sample was classified as having poor sleep 
according to Sadeh’s criteria. Poor sleeping was defined as one or more of the following: a) 
waking >3 times per night; b) nocturnal wakefulness of >1 hour; or c) total sleep time (including 
day and night sleeps) <9 hours (Sadeh, 2004). The proportion of infants in each group who were 
classified as poor sleepers did not differ between the groups, and the majority of parents (80/87, 
92%) reported that they did not consider their child’s sleep a problem.  
 
Just over half of the infants in the study were the only child living in their household (53%). 
Previous research has indicated that large family size is a risk factor for poorer child cognitive 
development and mental health (Nair, et al., 2003; Sameroff, 1998; Sameroff, et al., 1987), and 
that substance using mothers are more likely to be mulitgravid and multiparous compared with 
non-using women (Ostrea, Ostrea, & Simpson, 1997). This was not the case in the present study 
where four families in the control group and only two families in each of the BM and MM groups 
had four or more children (including the child in the study) living in the household.  
 
The majority of infants (75%) lived in two-parent families and all, but one, were in the care of 
their natural mothers (this infant in the BM group was in the care of his natural father). Infants in 
the BM and MM groups were more than twice as likely to be living in a single parent family as  
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infants in the control group. Although not reaching statistical significance at the p<.05 level in the 
current study, the observed differences in family structure may be statistically significant if re-
examined in a larger population.  
 
More than half of all infants had at least one parent who had not completed secondary schooling. 
The MM group had a higher proportion of parents who had not completed secondary school 
compared with the other two groups. Thirty four percent of infants lived with a father who was 
not in paid employment, with fathers of infants in the control group significantly more likely to be 
in paid employment than fathers of infants in the MM group.  
 
Sixty three percent of families reported an annual household income of ≤$31,200 and almost one 
third of the sample (27%) lived in government subsidised housing. A significantly higher 
proportion of families in the MM group reported receiving a low annual income and living in 
government subsidised housing compared with families in the control group. While differences 
between the MM and BM groups on these measures did not reach statistical significance, a 
greater proportion of families in the MM group reported lower household income and living in 
government assisted housing. The majority of families (82%) had not moved house in the four 
months since the birth of the infant enrolled in the study. However 11% (5 controls, 4 BM, 1 MM) 
had moved house once and six families (7%, 2 BM, 4 MM) had moved house at least twice 
(range=2-5 times) in the previous four months. 
 
3.6 Maternal psychosocial characteristics at four month follow-up assessment 
Information about maternal-infant attachment, postnatal depression, maternal psychological 
distress, perceived social support and continuing parental substance use was collected at the four 




Maternal postnatal attachment  
There were no significant differences between the three groups of women on any of the postnatal 
attachment subscale scores (Table 3.7). As these scales did not meet the assumptions for 
parametric statistics and suitable transformations could not be found, differences between 
groups on each subscale were assessed using Kruskal-Wallis tests.  
 
Median scores for the Quality of Attachment scale (which examines the quality of a mother’s 
emotional response toward her infant) were very similar across the three groups. With a 
maximum possible score of 45, the majority of women reported a high quality of attachment with 
their infant (overall median=43.6, range= 31.5-45). With a maximum possible score of 25, median 
scores for the Absence of Hostility scale were relatively high (overall median= 22, range 12.6-25) 
indicating that women in the study generally reported high levels of tolerance when interacting 
with their infant. Median scores for the Pleasure in Interaction scale were very similar across the 
three groups of women. With a maximum score of 25, the overall median score was high 
(median=23, range=16-25), indicating that overall women in the study had strong feelings of pride 
toward their baby, preoccupation with thoughts of the baby during separations, and feelings of 
joy at reunion with them.  
 
The Global Postnatal Attachment score was significantly negatively skewed and was therefore 
normalised with a power 5 transformation (i.e. the score multiplied by itself five times) for 
hypothesis testing. Overall, participants in the study scored relatively highly on the Global 
Postnatal Attachment score [untransformed M±SD=86.8±5.7, F(2,83)=1.60, p=0.21, range=66.8-
95], suggesting that they had strong positive emotions and feelings of attachment toward their 
infants. The mean global attachment scores observed in this study are slightly higher than those 
reported by Condon and Corkindale (M±SD=84.6±7.0, range=59-95) for a community sample of 
210 women who completed the Maternal Postnatal Attachment Scale when their infant was four 
months of age (Condon & Corkindale, 1998). In the current study, women in the MM group had  
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the highest mean global attachment scores, compared to women in the control and BM groups, 
although this difference was not statistically significant.  
 
Maternal postnatal depression  
The mean Total Score for the Edinburgh Postnatal Depression Scale (EPDS) was moderately 
positively skewed and was normalised using a square root plus one transformation. The overall 
mean score for the EPDS in the current study was 7.1 [SD=5.1, F(2,84)=0.87, p=0.42, range= 0-
21.1], with women in the MM group reporting slightly higher levels of postnatal depressive 
symptoms than women in either of the other two groups (Table 3.8). While the overall mean is 
slightly higher than that reported for a sample of over 3000 South Australian women who 
participated in the beyondblue National Postnatal Depression Program (M±SD=6.2±4.7), the mean 
EPDS score for the control group in the current study (M±SD =6.16±4.6) more closely reflects the 
South Australian average (Buist & Bilszta, 2005).  
 
The overall incidence of probable minor depression, as defined by an EPDS cut-off score ≥10 
(Matthey, et al., 2006), was 26.4%; which is considerably higher than the national Australian 
average of 15.7% (Buist & Bilszta, 2005). The proportion of women in the current study meeting 
criteria for probable minor depression is similar to that reported by Edwards et al. (2008) who 
found that in a sample of 154 South Australian women tested 6 weeks postnatally, 22.6% had a 
mean EPDS score ≥10. The rate of probable major depression, as defined by an EPDS cut-off score 
≥13 (Matthey, et al., 2006), was 17.2%, which is more than twice the national average [7.6%, 
(Buist & Bilszta, 2005)]. Table 3.8 shows that this observation is driven by the higher levels of 
symptoms reported by women in the MM group.  
 
Maternal psychological distress 
Because the General Health Questionnaire-28 (GHQ-28) total score was significantly positively 
skewed and a suitable transformation could not be found, Kruskal-Wallis tests were used to  
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compare the mean ranks of scores between the three groups. There were no significant 
differences between the three groups of women on the GHQ-28 total score. Neither was there a 
significant difference in the proportion of women from each group who met criterion for the 
likelihood of experiencing significant levels psychological distress (score ≥6, Table 3.8). The overall 
median score of 3 was lower than the recommended criterion score (Goldberg, et al., 1997), with 
women in the control group reporting the lowest levels of psychological distress and women in 
the MM group reporting the highest.  
 
Due to the skewness of the data, the statistical significance testing of differences between the 
groups’ mean GHQ-28 scores is problematic. However, in order to provide some comparison with 
previous research, mean scores will be briefly discussed. Women in the MM group had the 
highest mean score, which at 6.1 is just above the recommended threshold score of ≥6 (Goldberg, 
et al., 1997). Women in the BM and control groups had lower mean scores (4.5 and 3.8 
respectively) which did not meet the cut-off criterion. The mean scores observed in this study 
were between three to five times lower than those reported for 127 Norwegian women in a 
population-based study of post partum depression (Skari, et al., 2002). While the overall mean 
GHQ-28 total score observed in the current study was 4.7, the mean GHQ-28 total scores in Skari 
et al.’s study, collected at three time points over the first 6 months post partum, ranged from 22.0 
at 0-4 days post partum to 16.7 at 6-months post partum, suggesting that the Norwegian sample 
had high levels of psychological distress that persisted over time (Skari, et al., 2002). Despite the 
high mean scores observed in the Norwegian study, the proportion of women who scored above 
the threshold of ≥6 was lower than in the present sample *21% & 19% (measured at 6 weeks and 
6 months post partum) compared with 32% of the current sample]. 
 
Perceived social support 
In general, the majority of women in the present study reported that they were satisfied with 
their level of social support. Sixty four percent indicated that the number of people in their day- 
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to-day life was ‘about right’. Generally women in the control group reported greater satisfaction 
with their level of social support than women in the other two groups. For example, a greater 
proportion of women in the control group (76%) reported that the number of people in their life 
was ‘about right’, compared with women in the BM group (53%) and women in the MM group 
(58%). Similarly, only 6% of women in the control group indicated that they had no-one to ‘lean 
on’, compared with 14% of women in the BM group and 13% of women in the MM group. 
 
Overall, women in the control group scored more highly than women in the other two groups on 
all four subscales of the Interview Schedule for Social Interaction -Short Form (ISSI-SF), as well as 
the ISSI-SF Total score (Table 3.9); suggesting they had better perceived availability and adequacy 
of social integration and attachment. Women in the MM group obtained significantly lower 
median scores on the Availability of Attachment subscale than women in the control group. 
Questions in this subscale include ’Do you feel there is one particular person who feels very close 
to you?’ and ‘When you are happy is there any particular person you can share it with – someone 
whom you feel sure will feel happy simply because you are?’. The lower scores obtained by 
women in the MM group on this subscale indicate a lack of opportunity for developing close 
relationships.  
 
There was a statistically significant difference in mean ISSI-SF Total scores between women in the 
MM and control groups with the control group scoring, on average, five points higher than the 
MM group (Table 3.9). Although the BM group also scored more highly than the MM group, this 
difference in scores was not significant. 
 
Continuing maternal substance use 
At the four month follow-up assessment participating women were asked about their use of 
substances in the previous month (Table 3.10). Eighty six percent of women in the current study 
(75/87) reported smoking tobacco in the month prior to the four month follow-up assessment. All  
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of these women reported smoking daily, with the number of cigarettes smoked per day ranging 
from 1 to 40. A lower proportion of women in the control group (76%) reported smoking tobacco 
in the month prior to the follow-up assessment, compared with women in the BM and MM 
groups (90% & 96% respectively), although this difference was not statistically significant (Fisher’s 
exact test p=.08). 
 
Overall, forty women (46%) reported drinking alcohol on at least one occasion in the month prior 
to the assessment, with a significantly higher proportion of women in the control group reporting 
alcohol consumption in the past month than women in the other two groups (Table 3.10). The 
mean number of days that women reportedly consumed alcohol within the month prior to 
assessment did not differ significantly between groups (4.4±5.7, F(2,37)=0.83, p=.44, range 1-29 
days). Twelve percent of women in the study (10/87) reported use of prescribed psychotropic 
medication in the month prior to assessment, with a slightly higher proportion of women in the 
BM and MM groups prescribed a psychotropic medication compared to women in the control 
group. 
 
Forty eight percent (42/87) of women in the study reported use of an illicit substance in the 
month prior to the follow-up assessment. A significantly smaller proportion of women in the 
control group reported use of an illicit substance (21%) compared with both the BM (57%) and 
MM (75%) groups (Fisher’s exact test p<.001). All seven women in the control group who 
reported use of an illicit substance during this time reported use of marijuana only.  Five women 
in the BM group and seven women in the MM reported use of heroin in the previous month, with 
the majority reporting use on between 1-3 days. One woman in the MM group reported use of 
heroin on eight days in the previous month while another (also in the MM group) reporting using 
it on 27 days within the month prior to assessment. Five women in the BM group and four women 
in the MM group reported use of amphetamines on between 1-12 days in the month prior to the 
four month follow-up assessment. All of these women reported use of intravenous  
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methamphetamine or speed. Six women in the BM group and five in the MM group reported use 
of a benzodiazepine in the month prior to the follow-up assessment. Women reported use of 
Valium®, temazepam or alprazolam on between 1-28 days in last month. All reported taking the 
benzodiazepines orally once a day on the days used. It was not reported whether these 
substances were prescribed or used recreationally. 
 
3.7 Additional psychosocial factors at 12 and 24 month follow-up assessments 
Information about parenting stress and the child’s care-giving environment was collected at the 
12- and 24-month follow-up visits.   
 
Parenting Stress 
At 12 months of age, the overall mean Parent Domain Total Score on the Parenting Stress Index 
(PSI) in the current study was 122.98 [SD=25.88, F(2,74)=2.57, p=.08, range= 65-195], with parents 
in the BM group reporting slightly higher levels of parenting stress than those in either of the 
other two groups (Table 3.11). At 24 months of age, the overall mean Parent Domain Total Score 
for the PSI was 124.90 [SD=26.34, F(2,54)=2.38, p=.10, range= 62-205]. Parents in the BM group 
again reported higher levels of parenting stress than parents in either of the other two groups 
(Table 3.11).The overall mean Parent Domain Total scores at each assessment are lower than that 
reported for a sample of 161 women who used opioids and/or cocaine during pregnancy 
(M±SD=135.3±17.8), who were assessed when their infant was 18 months of age (Nair, et al., 
2003). However, the mean 24-month PSI Parent Domain score for the BM group in the current 
study (M±SD=136.12±30.20) is similar to that reported by Nair et al. (2003). 
 
Home Environment 
The Total Score for the 12-month HOME Inventory was moderately negatively skewed and was 
normalised using a square transformation. At 12 months of age, the overall mean Total HOME  
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Score in the current study was 37.00 [SD=3.70, F(2,78)=0.22, p=80, range= 23.52-42], with all 
three groups achieving relatively similar scores (Table 3.11). At 24 months of age, the overall 
mean Total HOME Score was 38.01 [SD=3.75, F(2,64)=4.07, p=.02, range= 28.26-45]. Post-hoc 
analyses indicated that the mean Total HOME score of the BM group was significantly lower than 
that of the MM group (p<.05). Mean scores did not differ significantly between the control group 
and either of the substance-exposed groups (Table 3.11). Mean HOME scores observed in the 
present study were similar to that reported for 180 children randomly selected from the HOME 
normative sample (M±SD=35.60±6.87) (Boffman, Clark, & Helsel, 1997; Williams et al., 2003). 
Total HOME scores were higher than those reported in an American study of infants prenatally 
exposed to heroin (M±SD=34.0±8.2, n=25), methadone (M±SD=34.8±6.6, n=26), and a non-





Infant Physical Development  
This chapter describes the anthropometric data collected at four, 12 and 24 months of age. First, 
growth measurements (weight, length and HC) were compared across the three groups of infants. 
Relationships between potential confounding variables and the three growth measures were 
examined. Differences in growth measurements between groups were then analysed adjusting for 
significant confounding variables. Finally, changes in growth measurements over time were 
examined across the three groups of infants. 
 
This chapter addresses the following hypotheses:  
Hypothesis 1:  
The weight, length and HC of infants prenatally exposed to buprenorphine will not differ 
significantly from a non-exposed control group when assessed at four, 12 and 24 months of age.  
Hypothesis 2:  
The weight, length and HC of infants prenatally exposed to methadone will be significantly smaller 
than those of infants prenatally exposed to buprenorphine and a non-exposed control group of 
infants when assessed at four, 12 and 24 months of age.  
Hypothesis 3:  
Change over time in weight, length and HC will not vary significantly between children prenatally 
exposed to buprenorphine, methadone, or in a non-exposed control group. 
 
Statistical analyses 
Prior to analysis the distributions of the dependent variables were assessed for normality and 
homogeneity of variance between the three groups of infants. A series of simple linear regression 
analyses (for continuous measures) and ANOVAs (for categorical measures) were conducted to  
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examine the contribution of potential confounding variables to individual growth measurements 
at each time point. Each bivariable model was examined for normality and equality of variance 
and data transformation techniques were employed if these assumptions were not met. Non 
parametric techniques were used when a suitable transformation was not found. Please refer to 
the methods section of this thesis (Chapter 2, section 2.7) for a description of the variables chosen 
for the bivariable analyses. 
 
Standard multiple regression analyses were then conducted to examine the contribution of each 
independent variable to infant weight, length and HC at each time point, whilst adjusting for the 
effect of the other variables in the model. Variables were chosen for inclusion in the multivariable 
models if they were theoretically appropriate and had a significant bivariable relationship with the 
dependent variable at p <.05. Each model was examined for multicollinearity, normality of 
residuals and equality of variance. Data were transformed using suitable techniques if these 
assumptions were not met.  
 
A series of split-plot analyses of variance (ANOVAs) were undertaken to examine whether change 
over time for growth (on each of the three anthropometric measurements) varied between 
infants in each of the three groups. The between-subjects factors were group (control, BM and 
MM) and gender (boys and girls). The within-subjects factor was assessment time (four, 12 and 24 
months). 
 
4.1 Growth of infants at four months of age 
Growth data were collected from 85/87 (98%) infants at four months of age. No growth data were 
available for two infants in the MM group because their families lived too far away from Adelaide 
to travel to the WCH for assessment. The 4-month growth data were all positively skewed and did 
not meet assumptions of constant variance when compared across the groups. Weight at four  
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months was normalised using an inverse square transformation and a one-way ANOVA was 
conducted to compare differences in mean weight across the three groups of infants. 
Kruskal-Wallis tests were used to examine group differences in length and head circumference at 
four months.  
 
At four months of age, the weight of infants in the control group ranged from 5.17 kg to 9.17 kg, 
from 5.10 kg to 8.34 kg in the BM group, and from 4.99 kg to 6.89 kg in the MM group. One-way 
ANOVA showed that, at four months of age, there was a statistically significant difference in the 
mean weight of infants (Table 4.1) [F(2,82) = 5.81, p<.01, inverse square transformation]. 
Bonferroni post hoc analyses showed that infants in the MM group weighed significantly less than 
infants in both the control and BM groups, while there was no significant difference in weight 




Infants’ length at four months of age ranged from 57.4 cm to 68.7 cm for the control group, 57.5 
cm to 68.5 cm for the BM group, and 56.3 cm to 63.3 cm for the MM group. A Kruskal-Wallis test, 
corrected for tied ranks, showed that at four months of age there was a significant difference in 
length across the three groups of infants *χ
2 (2) =8.67, n=85, p = .01]. The proportion of variability 
in the ranked dependent variable accounted for by group was η
2 = .10, indicating a medium effect 
of group membership on length at four months of age. Post-hoc Mann-Whitney U tests were 
conducted to evaluate differences between the three groups. Table 4.1 shows that, at four 
months of age, the median length of infants in the MM group was significantly shorter than 
infants in both the control (z = 2.61, p < .01) and BM groups (z = 2.60, p < .01). There was no 
difference in median length at four months of age between infants in the control and BM group  




Head circumference (HC) at four months of age ranged from 38.5 cm to 44.5 cm for the control 
group, from 38.0 cm to 44.1 cm for the BM group, and from 39.2 cm to 42.2 cm for the MM 
group. A Kruskal-Wallis test, corrected for tied ranks, showed that at four months of age there 
were significant differences between the three groups [χ
2 (2) = 7.83, n =  85, p = .02]. The 
proportion of variability in the ranked dependent variable accounted for by group was η
2 = .09, 
indicating a medium effect of group membership on HC at four months of age. Post-hoc Mann-
Whitney U tests were conducted to evaluate differences between the three groups. Table 4.1 
shows that, at four months of age, the median HC of infants in the MM group was significantly 
smaller than infants in the control group (z = 2.65, p < .01).The median HC of infants in the MM 
group was slightly smaller than infants in the BM group and this difference had a statistical 
significance of p =.06. There was no difference in median HC at four months of age between 
infants in the control and BM group (z = 1.26, p =.21). 
 
4.1.1 Relationship between four month growth measurements and potential confounding 
variables 
Weight at four months of age was significantly associated with birth weight *β = -.55, t(82) = -6.03, 
p < .001, inverse square root transformation], gestational age at delivery [β = -.32, t(83) = -3.08,  
p < .01, inverse square transformation], and male gender [Kruskal-Wallis: χ
2 (1) = 15.60, n = 85, 
p<.001].  
 
Length at four months of age was significantly associated with birth length *β = -.62, t(83) = -7.15, 
p < .001, inverse cube transformation], gestational age at delivery [β = .51, t(83) = 5.34, p < .001, 
square root transformation], and male gender [F(1,83) = 9.69, p < .01, inverse transformation].  
 
HC at four months was significantly associated with birth HC *Spearman’s rho = .61, n = 85, p 
<.0001+, gestational age at delivery *β = .24, t(83) = 2.21, p = .03+, and male gender *F(1,83) = 
16.41, p < .001, inverse cube transformation].   
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4.1.2 Four month growth measurements adjusting for potential confounding variables 
Variables entered into the first model were 4-month infant weight as the dependent variable 
(inverse square transformation), with birth weight, gestational age at delivery, infant gender (with 
girls as the reference), and group (with the control group as the reference) as the predictor 
variables. The model explained 44% of the variance in weight at four months of age and was 
significant at p<.0001 (Table 4.2). After adjustment for other covariates, birth weight remained a 
significant predictor of weight at four months of age (p<.01) and provided the largest unique 
contribution to the variance in the model. Male gender also remained a significant predictor of 
weight at four months of age (p<.001) and provided the next largest contribution to the variance 
in the model. Gestational age at delivery did not provide a significant contribution to the model. 
Group status was weakly associated with infant weight at four months of age [F(2,78) = 2.37, p = 
.10, η
2 = .03], this was largely due to the difference between the MM group and the BM group [β = 
.20, t(78) = 2.04, p = .045]. At four months of age, weight of infants in the control group did not 
differ significantly from that of infants in the BM group [β = -.01, t(78) = -0.14, p = .89] or the MM 
group [β = .19, t(78) = 1.86, p = .07]. 
 
Variables entered into the second model were 4-month infant length as the dependent variable, 
with birth length, gestational age at delivery, infant gender, and group as the predictor variables. 
The model explained 50% of the variance in length at four months of age and was significant at 
p<.0001 (Table 4.3). After adjusting for covariates, length at birth remained a significant predictor 
of length at four months of age (p<.01) and provided the largest unique contribution to the 
variance in the model. Male gender provided the next largest unique contribution to the variance 
in the model (p<.001), while gestational age also continued to be significantly associated with 
length at four months (p = .048). Group status retained a weak association with length at four 
months of age [F(2,79) = 2.35, p = .10, η
2 = .03], largely driven by the difference between the MM 
group and the BM group [β = -.20, t(79) = -2.16, p = .03], with prenatal exposure to methadone 
remaining a significant predictor of shorter length at four months of age. Four-month length of  
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infants in the control group did not differ significantly from that of infants in the BM group [β = 
.07, t(79) = 0.74, p = .46] or the MM group [β = -.14, t(79) = -1.42, p = .16]. 
 
Variables entered into the third model were 4-month HC as the dependent variable, with birth 
HC, gestational age at delivery, gender, and group as the predictor variables. The model explained 
47% of the variance in HC at four months of age and was significant at p<.0001 (Table 4.4). After 
adjusting for covariates, HC at birth provided the largest unique contribution to the variance in 
the model and remained a significant predictor of HC at four months of age (p<.001). Male gender 
provided the next largest unique contribution to the variance in the model and remained 
significantly associated with HC at four months of age (p<.01). Neither gestational age nor group 
status [F(2,79) = 1.56, p =.22, η
2 = .02] provided significant contributions to the model.  
 
4.1.3 Summary of infant growth at four months of age 
 Weight 
After adjusting for birth weight, gestational age at delivery, and infant gender, weight at four 
months of age was significantly lower in the MM group compared with the BM group. There was 
no significant difference in weight at four months of age between the control group and infants in 
the two substance exposed groups after adjusting for the same covariates, although the 
difference in weight between the control group infants in the MM group approached statistical 
significance (p=.07). Birth weight was the strongest predictor of weight at four months of age, and 
gender remained significantly associated with weight, with boys significantly heavier than girls. 





After adjusting for birth length, gestational age at delivery, and gender, length at four months of 
age was significantly lower in the MM group compared with the BM group. There was no 
difference in infant length at four months of age between the control group and infants in either 
of the other two groups, after adjusting for the same covariates. Length at birth remained the 
strongest predictor of length at four months of age, while male gender and older gestational age 
continued to be significantly associated with greater infant length at four months of age. 
 
Head Circumference 
After adjusting for birth HC, gestational age at delivery, and gender, there was no significant 
difference in HC at four months of age between the three groups of infants. Larger HC at birth and 
male gender remained significantly associated with larger HC at four months of age. After 
adjusting for the covariates, gestational age at delivery was no longer a predictor of HC at four 
months of age. 
 
4.2 Growth of infants at 12 months of age 
Growth data were collected from 82/83 (99%) infants at 12 months of age. No growth data were 
available for one infant in the BM group because he fell asleep before it could be collected. 
Subsequent attempts to collect this information were unsuccessful. Twelve month length data 
were unable to be collected from two infants in the BM group because they were unsettled at the 
time of assessment.  
 
At 12 months of age, the weight of infants in the control group ranged from 8.12 kg to 12.90 kg, 
from 7.60 kg to 11.85 kg in the BM group, and 6.95 kg to 11.65 kg in the MM group. At 12 months 
of age, the mean weight of infants in the MM group was almost one kilogram less than infants in 
the other two groups (Table 4.1). With a moderate effect size of η
2= .09, this difference was 
statistically significant [F(2,79) = 4.01, p =.02]. Bonferroni post hoc analyses showed that at 12  
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months of age infants in the control group were significantly heavier than infants in the MM 
group. Although infants in the BM group weighed slightly more than MM infants at 12 months, 
this difference was not significant. 
 
Infants’ length at 12 months of age ranged from 70.0 cm to 84.0 cm for the control group, 69.5 cm 
to 82.0 cm for the BM group, and 71.0 cm to 80.0 cm for the MM group. The mean length of 
infants in the MM group was approximately two centimetres less than infants in the other two 
groups (Table 4.1). With a moderate effect size of η
2 = .09, this difference was statistically 
significant [F(2,77) = 3.61, p = .03]. Bonferroni post hoc analyses showed that infants in the 
control group were significantly longer than infants in the MM group. Length at 12 months of age 
did not differ significantly between the BM and MM groups.  
 
Head circumference at 12 months of age ranged from 43.5 cm to 50.3 cm for the control group, 
from 44.0 cm to 49.0 cm for the BM group, and from 44.2 cm to 48.2 cm for the MM group. The 
overall mean HC at 12 months was 46.5 cm (SD=1.41) and none of the group means deviated 
substantially from this (Table 4.1). Differences in HC between the three groups of infants were not 
statistically significant [F(2,97) = 1.25, p=.29]and the effect size was small (η
2= .03). 
 
4.2.1 Relationship between 12-month growth measures and potential confounding variables 
Weight at 12 months of age was significantly associated with birth weight *Spearman’s rho=.37, 
n=81, p<.001] and male gender [F(1,80) =  11.19, p <.01 ]. Length at 12 months of age was 
significantly associated with birth length *β = .48, t(78) = 4.82, p < .001, power .7 transformation], 
gestational age at delivery [β = .31, t(78) = 2.90, p < .01], and male gender [F(1,78) = 7.51, p <.01]. 
HC at 12 months was significantly associated with birth HC *β = .46, t(80) = 4.63, p < .001, power 
.6 transformation], maternal self-reported use of alcohol in pregnancy [F(1,77) = 4.20, p <.05], and 




4.2.2 Twelve month growth measurements adjusting for potential confounding variables 
Variables entered into the first model were 12-month infant weight as the dependent variable, 
with birth weight, gender (with girls as the reference), and group (with the control group as the 
reference) as the independent variables. The model explained 27% of the variance in weight at 12 
months of age and was significant at p<.001 (Table 4.5). After adjusting for group status, gender 
remained a significant predictor of weight at 12 months of age (p<.01) and provided the largest 
unique contribution to the variance in the model. Birth weight provided the next largest 
contribution to the variance in the model and was statistically significant at p<.05. Group status 
was not significantly associated with weight at 12 months of age [F(2,76) = 1.92, p =.15, η
2 = .04], 
however it is important to note that the difference between the MM group and the control group 
approached the conventional level of statistical significance *β = -.22, t(76) = -1.89, p = .06). At 12 
months of age, weight of infants in the BM group did not differ significantly from that of infants in 
the MM group [β = -.18, t(76) = -1.55, p = .13], or the control group [β = .04, t(76) = 0.36, p = .72].  
 
Variables entered into the second model were 12-month infant length as the dependent variable, 
with birth length, gestational age at delivery, gender, and group as the predictor variables. The 
model explained 32% of the variance in length at 12 months of age (Table 4.6) and was significant 
at p <.0001. After adjusting for covariates, infants’ length at birth provided the largest unique 
contribution to the model and remained significantly associated with 12-month length (p <.05).  
Gender provided the next largest contribution to the model and remained significantly associated 
with 12-month length at birth (p<.01). Gestational age was not significantly associated with length 
at 12 months, and neither did group status provide a statistically significant contribution to the 
model [F(2,74) = 1.11, p = .33, η
2 = .02].  
 
Variables entered into the third model were 12-month infant HC as the dependent variable 
(square transformation), with birth HC, maternal self-reported use of alcohol in pregnancy (with 
negative self-report as the reference), gender, and group as the predictor variables. The model  
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explained 36% of the variance in 12-month HC and was significant at p<.0001 (Table 4.7). After 
adjusting for covariates, birth HC and gender remained significantly associated with 12-month HC, 
with birth HC providing the largest unique contribution to the model. After adjustment for 
covariates, maternal self-reported use of alcohol in pregnancy was no longer significantly 
associated with 12-month HC. As in the univariable analyses, group status was no significantly 
associated with HC at 12 months of age [F(2,73) = 0.24, p = .79, η
2 = .004].  
 
4.2.3 Summary of infant growth at 12 months of age 
 Weight 
After adjusting for birth weight and infant gender, weight at 12 months of age did not differ 
significantly between the control group and the BM or MM groups, although the difference in 12-
month weight between the MM group and the control group did approach statistical significance 
(p=.06). After adjusting for the same covariates, gender was the strongest predictor of weight at 
12 months of age, with boys significantly heavier than girls. Birth weight also remained 
significantly associated with weight at 12 months of age. 
 
Length 
After adjusting for birth length, gestational age at delivery, and gender, infant length at 12 
months of age did not differ significantly between the three groups of infants. Birth length was 
the strongest predictor of length at 12 months of age after adjusting for the same covariates, and 
gender remained significantly associated with infant length, with boys significantly taller than 




After adjusting for birth HC, maternal self-reported use of alcohol in pregnancy, and gender, HC at 
12 months of age did not differ significantly between the three groups of infants. HC at birth was 
the strongest predictor of HC at 12 months of age, while gender also remained significantly 
associated with 12-month HC. After adjusting for covariates maternal self-reported use of alcohol 
in pregnancy was no longer significantly associated with HC at 12 months of age. 
 
4.3 Growth of infants at 24 months of age 
Growth data were collected from 73/73 (100%) infants at 24 months of age. Twenty four month 
length data were not collected from two infants in the MM group who were unsettled at the time 
of assessment. Twenty four month HC data were not available for seven infants (1 control, 1 BM, 
5 MM), six of whom were unsettled and one because of a data measurement error (this infant’s 
HC was recorded as 18 cm which was clearly a measurement error). Length at 24 months of age 
was positively skewed and was normalised using an inverse cube transformation. Head 
circumference at 24 months of age did not meet the assumption of homogeneity of variance and 
a suitable transformation could not be found. Kruskal-Wallis tests were therefore used to describe 
differences between the three groups on this measure.  
 
At 24 months of age, the weight of infants in the control group ranged from 10.90 kg to 16.60 kg, 
from 10.20 kg to 15.30 kg in the BM group, and 9.80 kg to 14.20 kg in the MM group. One-way 
ANOVA showed that, at 24 months of age, there was a statistically significant difference in the 
mean weight of infants (Table 4.1) [F(2,70) = 4.10, p <.05]. The effect size was moderate at η
2 = 
.10. Bonferroni post hoc analyses revealed that infants in the MM group weighed significantly less 
than infants in the control group (p = .02), but the difference between the BM and MM groups did 
not reach statistical significance. Neither was there a significant difference in weight between the 




Infants’ length at 24 months of age ranged from 81.3 cm to 97.5 cm for the control group, 80.5 cm 
to 95.0 cm for the BM group, and 78.5 cm to 88.7 cm for the MM group. One-way ANOVA showed 
that there was no significant difference between the three groups of infants in terms of length at 
24 months of age (Table 4.1) [F(2,68) = 1.96, p = .15, inverse cube transformation].  
 
Head circumference (HC) at 24 months of age ranged from 45.00 cm to 52.00 cm for the control 
group, from 46.5 cm to 50.5 cm for the BM group, and from 46.90 cm to 49.30 cm for the MM 
group. A Kruskal-Wallis test, corrected for tied ranks, showed that at 24 months of age there was 
a significant difference in median HC across the three groups *χ
2 (2) = 7.49, n= 66, p = .02]. The 
proportion of variability in the ranked dependent variable accounted for by group was η
2 = .12, 
indicating a medium effect of group membership on HC at 24 months of age. Post-hoc Mann-
Whitney U tests were conducted to evaluate differences between the three groups. Table 4.1 
shows that, at 24 months of age, the median HC of infants in the MM group was significantly 
smaller than infants in the control group (z = 2.45, p = .014). There was no significant difference in 
median HC at 24 months of age between infants in the BM and MM groups (z = 1.27, p = .20). The 
median HC of infants in the BM group was slightly smaller than infants in the control group 
although this difference did not reach statistical significance (z = 1.91, p = .06). 
 
4.3.1 Relationship between 24-month growth measures and potential confounding variables 
Weight at 24 months of age was significantly associated with birth weight *Spearman’s rho= .36, 
n=72, p<.01], and male gender [F(1,71) = 17.03, p < .001]. Length at 24 months of age was 
significantly associated with birth length *β = .42, t(69) = 3.84, p < .001] and male gender [Kruskal-
Wallis: χ
2 (1) = 10.03, n= 71, p<.01]. HC at 24 months was significantly associated with birth HC *β 




4.3.2 Twenty four month growth measurements adjusting for potential confounding variables 
Variables entered into the first model were 24-month weight as the dependent variable (power 5 
transformation), with birth weight, gender (with girls as the reference), and group (with the 
control group as the reference) as the predictor variables. The model explained 35% of the 
variance in weight at 24 months of age and was significant at p<.0001 (Table 4.8). After adjusting 
for group status, gender remained a significant predictor of weight at 24 months of age (p<.001) 
and provided the largest unique contribution to the variance in the model. Birth weight provided 
the next largest contribution to the variance in the model and was statistically significant at p<.05. 
Group status was weakly associated with 24-month weight [F(2,67) = 2.27, p = .11, η
2 = .04], 
largely due to the difference between the MM group and the control group [β =  
-.24, t(67) = -2.10, p = .04]. At 24 months of age, the weight of infants in the BM group did not 
differ significantly to that of infants in the MM group [β = -.18, t(67) = -1.52, p = .13], or the 
control group [β = .07, t(67) = 0.62, p = .54]. 
 
Variables entered into the second model were 24-month length as the dependent variable, with 
birth length, infant gender (with girls as the reference) and group (with the control group as the 
reference) as the predictor variables. The model explained 33% of the variance in length at 24 
months of age (Table 4.9) and was significant at p <.0001. After adjusting for covariates, male 
gender provided the largest unique contribution to the model and remained significantly 
associated with 24-month length (p <.001). Length at birth provided the next largest contribution 
to the model and remained significantly associated with 24-month length at birth (p<.01). Group 




Variables entered into the third model were 24-month HC as the dependent variable, with birth 
HC, infant gender (with girls as the reference), and group (with the control group as the 
reference), as the predictor variables. The model explained 43% of the variance in 24-month HC  
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and was significant at p <.0001 (Table 4.10). After adjusting for covariates, male gender and HC at 
birth remained significantly associated with 24-month HC, with gender providing the largest 
unique contribution to the model. After adjustment for covariates, group status was not 
significantly associated with HC at 24 months of age [F(2,61) =  2.04, p = .14, η
2 = .04], however 
the difference between the MM group and the control group approached statistical significance 
*β = -.20, t(61) = -1.85, p = .07]. At 24 months of age, HC of infants in the BM group did not differ 
significantly from that of infants in the MM group [β = -.07, t(61) = -0.61, p=.54], or the control 
group [β = .16, t(61) = 1.48, p = .14].  
 
4.3.3 Summary of infant growth at 24 months of age 
 Weight 
After adjusting for birth weight and gender, weight at 24 months of age was significantly lower in 
the MM group when compared with infants in the control group. Weight at 24-months did not 
differ significantly between infants in the control group and the BM group, or between the two 
maintenance exposed groups of infants. Gender was the strongest predictor of weight at 24 
months of age, with boys significantly heavier than girls. Birth weight also remained significantly 
associated with weight at 24 months of age. 
 
Length 
After adjusting for birth length and gender, length at 24 months of age did not differ significantly 
between the three groups of infants. Gender was the strongest predictor of length at 24 months 
of age, with boys significantly longer than girls, and length at birth continued to be significantly 
associated with 24-month length.   
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Head Circumference  
After adjustments for birth HC and gender, HC at 24 months of age did not differ significantly 
between the three groups of infants, although the difference between the MM and the control 
group did approach statistical significance (p=.07). After adjusting for covariates, gender was the 
strongest predictor of HC at 24 months of age, with boys having significantly larger HC than girls.  
HC at birth also remained significantly associated with 24-month HC.  
 
4.4 Longitudinal analyses of growth measurements 
Figures 4.1 to 4.3 show the mean growth measurements of each group over the three follow-up 
assessments. A series of split-plot analyses of variance (ANOVA) were undertaken to examine 
whether change in growth (means for each of the three anthropomorphic measures) over time 
varied between each of the three groups. The between-subjects factors were group (control, BM 
and MM) and gender (boys and girls). The within-subjects factor was time (4-, 12- and 24-
months). The corresponding birth measurement, treated as a within-subjects factor, was entered 
as a covariate for each model. Preliminary checks were conducted to ensure that there was no 
violation of the assumptions of normality, linearity, homogeneity of variances, and homogeneity 
of regression slopes. 
 
Weight 
As expected, after adjusting for birth weight, the ANOVA showed that there was a statistically 
significant main effect for time [F(2,145) = 1649.88, p <.0001, η
2 = .70]. There was no significant 
main effect of gender [F(1,81) = 1.57,  p= .21, η
2 = .002]. Neither was there a significant main 
effect of group [F(2,81) = 1.80, p = .17, η
2 = .004] or birth weight [F(1,81) = 2.82, p = .10, η
2 = .003]. 
The time × group interaction did not reach statistical significance [F(4,145) = 1.38, p = .25, η
2 = 
.001], suggesting that change in mean weight over time did not vary significantly between the 
three groups of infants. The weak association between group status and weight noted in the 




After adjusting for length at birth, the ANOVA showed that there was a significant main effect for 
time [F(2,143) = 3336.20, p <.0001] with a large effect size (η
2 = .78), indicating that, as expected, 
overall mean length significantly increased over the follow-up assessments. There was also a 
significant main effect of birth length [F(1,82) = 4.96, p = .03], although this effect was very small 
(η
2 = .002). There was no significant main effect of gender [F(1,82) = 1.07, p = .30, η
2 = .0005] or 
group [F(2,82) = 1.01, p = .37, η
2 = .001]. The time × group interaction was not significant [F(4,143) 
= 0.12, p = .97, η
2 = .00006], indicating that change in mean length over time did not vary 
significantly between the three groups of infants. 
 
Head Circumference 
After adjusting for HC at birth, the ANOVA showed that there was a strong main effect for time 
[F(2,140) = 2505.69, p <.0001, η
2 = .70], indicating that, as expected, overall HC increased 
significantly over the three follow-up assessments. There was no significant main effect of birth 
HC [F(1,82) =  1.09, p = .30, η
2 = .001], gender [F(1,82) = 0.75, p = .39, η
2 = .0007] or group [F(2,82) 
= 0.34, p = .71, η
2 = .0006]. The time × group interaction was not significant [F(4,140) = 0.65, p = 
.63, η
2 = .0004], showing that change in mean HC over time did not vary significantly between the 
three groups of infants. 
 
4.4.1 Summary of growth longitudinal analyses  
 Results of the three split-plot ANOVAs showed that change in anthropometric mean data over 
the three follow-up assessments did not differ significantly between infants prenatally exposed to 
buprenorphine, methadone or the non-exposed control group of infants. None of the interactions 
between group status and time were significant, indicating that change in growth measurements 






This chapter compared the physical development of infants exposed to buprenorphine or 
methadone in pregnancy with that of a group of non-exposed infants. The key finding was that 
the physical development of infants prenatally exposed to buprenorphine did not differ 
significantly from that of a group of non-exposed infants in terms of their weight, length or HC at 
four, 12 or 24 months of age. There was no change in this relationship after adjustment for 
covariates, including birth measurements and gender. This is an important finding in terms of 
providing support for the ongoing use of buprenorphine in pregnancy. At four months of age, 
weight of infants prenatally exposed to methadone remained significantly lower than 
buprenorphine-exposed infants, after adjusting for covariates. Weight did not differ between the 
three groups at 12 months in multivariable analyses, although the cross-sectional analyses at 24 
months of age found that infants prenatally exposed to methadone were significantly lighter than 
non-exposed control infants, after adjusting for birth weight and gender. At four months of age, 
length remained significantly lower in the MM group compared with the BM group, after 
adjusting for birth length, gestational age at delivery, and gender. After adjusting for covariates, 
no differences were observed for infant length at 12 or 24 months of age. Head circumference did 
not differ significantly between the three groups of infants at any of the three assessments after 
adjusting for covariates. This is a reassuring finding in regards to use of both buprenorphine and 
methadone during pregnancy, as HC is an important indicator of brain growth and subsequent 
cognitive development (García-Alix, Sáenz-de Pipaón, Martínez, Salas-Hernández, & Quero, 2004; 
Noyola et al., 2001). Weight, length and HC at birth, and male gender remained the strongest 
predictors of having larger anthropometric measurements at four, 12 and 24 months of age. 
Whilst some of these cross-sectional findings are not entirely consistent with the longitudinal 
findings, it is important to bear in mind that there were fewer subjects with complete data for all 
three assessments than for the individual cross-sectional analyses, and subject numbers available 
at each assessment may be critical in a study of limited power. As hypothesised, change in 
anthropometric measures over time did not vary significantly between the three groups of  
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infants. This was expected as only one study has reported a change in infant length over time for 
methadone-exposed infants compared with non-exposed controls (Hunt, et al., 2008). Whilst the 
authors of this study reportedly adjusted analyses for maternal height, maternal smoking and 
gestation, no other covariates were discussed and no explanations for the obtained results were 
provided.  
 
The opioid system plays an important role in growth and development, and opioid receptors are 
found in the brain, spinal cord, and other organ sites in the developing foetus (Farid, et al., 2008; 
Jaffe, et al., 1997). Opioid receptor expression is regulated by signals from growth factors and 
neurotransmitters, both of which are affected by prenatal exposure to opioids (Robinson, 2000, 
2002; Tiong & Olley, 1988; Wu, et al., 2001). An example of this is the zeta (ζ) opioid growth factor 
receptor which is found throughout the developing rat brain, but is not present in the brains of 
adult rats. The ζ-receptor, which is involved with the mediation of foetal cell proliferation, is 
regulated by the endogenous ligand [Met5]-enkephalin, also known as opioid growth factor. It is 
thought that prenatal exposure to opioid agonists, such as methadone or heroin, may affect 
foetal developmental processes by interacting with the ζ-receptor to impede normal growth. 
Conversely, prenatal exposure to opioid antagonists (BM has some antagonist effects) may 
prevent [Met5]-enkephalin from binding with the ζ-receptor, thus blocking the growth-inhibitory 
response (Farid, et al., 2008). Early research has shown that rat pups prenatally exposed to high-
dose (8 mg/kg/day) methadone showed significant decreases in Met- and Leu-enkephalin levels in 
the striatum, compared with pups prenatally exposed to low-dose (4 mg/kg/day) methadone, or 
high- and low-dose (1 or 2 mg/kg/day) buprenorphine (Tiong & Olley, 1988). [Met5]-enkephalin is 
expressed in both neural (i.e. cerebrum and cerebellum) and somatic (i.e. bone and muscle) areas 
of the developing foetus.  Suppression of cell viability in these regions is thought to be associated 
with smaller size and weight in opioid-exposed newborns (Farid, et al., 2008; Herlenius & 




Studies have also shown that prenatal exposure to opioids may affect the production of the 
hormones in the endocrine system responsible for foetal growth and development. The 
hypothalamic-pituitary-adrenal (HPA) axis is a feedback loop encompassing the release of 
corticotrophin-releasing hormone (CRH) from the hypothalamus, which stimulates the release of 
adrenocorticotropin (ACTH) from the pituitary gland, and in turn the release of the adrenal 
cortical hormones, corticosterone and cortisol (the primary glucocorticoid involved in the stress 
response in humans). The release of adrenal cortical hormones completes the feedback loop as it 
has a negative feedback effect on the hypothalamus and pituitary gland (Konijnenberg & 
Melinder, 2011). Prenatal exposure to opioids may disrupt normal foetal endocrine function 
either via direct exposure of the foetus to opioids, or indirectly through changes in maternal 
endocrine functioning. During pregnancy there is a positive feedback loop between CRH in the 
placenta and maternal adrenal cortisol. While levels of CRH and cortisol increase as the pregnancy 
progresses, only 10 to 20% of maternal cortisol reaches the developing foetus as it is converted to 
the inactive form cortisone by an enzyme in the placenta. In the developing foetus, CRH has a 
pivotal role in foetal growth and maturation, as well as influencing the onset of parturition 
(Ellman et al., 2008; Konijnenberg & Melinder, 2011). Exposure to cortisol during the final 
trimester of pregnancy is vital for the development of numerous physiological systems and for 
overall foetal growth. However, it has been shown that prenatal exposure to synthetic 
corticosterioids may be associated with intrauterine growth restriction and low birth weight, and 
that maternal and placental levels of CRH may also influence foetal growth and gestational length 
(Ellman, et al., 2008). Ellman and colleagues (2008) found that foetal exposure to elevated levels 
of maternal plasma cortisol early in pregnancy, and placental CRH in late pregnancy was 
significantly associated with decreased newborn physical and neuromuscular maturation, 
independent of gestation.  
 
Opioid agonists, such as morphine and methadone, are known to inhibit the HPA-axis in adult 
humans by decreasing levels of plasma cortisol, and antagonists, such as naloxone, are known to  
142 
 
stimulate the HPA-axis, subsequently increasing plasma levels of both ACTH and cortisol. The 
opposite effect is seen in animal models whereby opioid agonists stimulate, and opioid 
antagonists inhibit, the HPA-axis (Pechnick, 1993). Animal studies have indicated that acute 
administration of morphine stimulates the release of adrenal cortical hormones and ACTH, whilst 
buprenorphine (also administered acutely) does not have a stimulatory effect on the HPA-axis 
(Gomez-Flores & Weber, 2000; Konijnenberg & Melinder, 2011; Pechnick, 1993). Buprenorphine’s 
partial agonist properties have been hypothesised to be responsible for its differing effect on 
endocrine functioning compared with full agonists such as morphine (Gomez-Flores & Weber, 
2000). Additionally, it has been suggested that exposure to opioids could alter the hypothalamic 
CRH content and influence the release of CRH from the hypothalamus (Pechnick, 1993). Thus 
maternal use of opioids during pregnancy may negatively affect infant growth and development 
via alterations in hormone levels within the maternal endocrine system. 
 
The findings of the present study suggest that prenatal exposure to methadone may have a 
pervasive influence on physical development, particularly in terms of infant weight, over and 
above environmental factors. Whilst gender and birth measurements were the strongest 
predictors of physical development for each of the three measures at all follow-up assessments, 
prenatal exposure to methadone continued to have an association with lower weight, particularly 
in comparison to the non-exposed group of infants. When the effect of covariates (including birth 
weight) was included in analyses, differences in weight between the MM and control groups did 
not reach conventional levels of statistical significance at four or 12 months of age. However, 
these differences may have been significant, by conventional criteria, if the sample size had been 
larger. 
 
Specifically considering buprenorphine, it is pertinent to note that weight and length at four 
months of age continued to be significantly higher in the buprenorphine-exposed group,  
143 
 
compared with the methadone-exposed infants, after adjusting for covariates. This finding may 
contribute support to the use of buprenorphine as an opioid-maintenance option in pregnancy. 
 
The finding in the present study that infants in the MM group continued to have lower weight 
than a non-exposed group of infants, until at least two years of age, is consistent with research by 
van Baar et al. (1994), who reported that growth restrictions were apparent until early childhood 
for a group of children prenatally exposed to opioids, when compared with a non-exposed control 
group. Similarly, Soepatmi (1994) found that infants prenatally exposed to opioids (methadone 
and heroin) had significantly smaller growth percentiles for weight, length and HC at two years of 
age, than children in the general Dutch population. Consistent with the theory that opiate-
induced growth restrictions often decrease over time (Farid, et al., 2008), Soepatmi reported that 
at follow-up, when the children were aged between 3.5 and 12 years of age, growth percentiles 
for weight and HC had caught up to the Dutch norms, although growth percentiles for length 
remained significantly lower (Soepatmi, 1994).  
 
The results of the present study differ from previous research which has shown that infants 
prenatally exposed to methadone experience a ‘catch up’ effect, over time in weight, but a 
tendency for continued shorter length or smaller HC, compared with non-exposed infants (Hans, 
1989; Hunt, et al., 2008; H. L. Johnson, et al., 1987, 1990; Rosen & Johnson, 1982). Hunt et al. 
(2008) reported no differences in unadjusted weight or HC at 18 months and three years of age 
between infants prenatally exposed to methadone and a non-exposed control group. However, 
after adjusting for gestational age at delivery, maternal height and maternal smoking, infants in 
the MM group remained significantly shorter than the non-exposed infants at both of these 
assessments (Hunt, et al., 2008). Johnson and colleagues reported that weight and height did not 
differ at 36 months of age between methadone-exposed and non-exposed infants; however it 
was reported that a significantly greater proportion of children exposed to methadone had HC 
measurements below the third percentile at this assessment, when compared with the non- 
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exposed group (H. L. Johnson, et al., 1987, 1990). Hans reported smaller HC and shorter length, 
for methadone-exposed infants at two years of age, compared with non-exposed infants (Hans, 
1989).  
 
It is difficult to ascertain what may be the cause of the weight ‘catch up’ effect observed in the 
above mentioned studies, as most of the publications did not provide sufficient information with 
which to make sound conclusions. However, research has indicated that higher doses of maternal 
methadone maintenance in humans (i.e. >40mg/day) may be associated with greater suppressant 
effect on infant growth (Farid, et al., 2008). The mean methadone dose in Hans’ (1989) study was 
reportedly less than 20 mg/ day, while the mean maternal dose of methadone in pregnancy for 
the current study was 45.41±20.21 mg/ day (range 15-100 mg). It is feasible that maternal dose 
may have contributed to the continued lower weight for methadone-exposed infants in the 
current study. Although, if this is the case, it would perhaps be expected that length and HC would 
have also continued to be smaller in this group, which was not evident in the present study. Mean 
maternal methadone dose in the Rosen/Johnson cohort (H. L. Johnson, et al., 1987, 1990; Rosen 
& Johnson, 1982) was similar to the present study at 42.9±2.6 mg/ day, suggesting that maternal 
dose may not be responsible for the catch up effect, or that unmeasured sample characteristics 
may have influenced infant growth. Rosen and Johnson (1982) suggested that deficits in the CNS 
may be associated with small HC, and smaller HC has been observed in poly-substance exposed 
children compared with non-exposed controls at three years of age (Azuma & Chasnoff, 1993). 
Infants in the Rosen/Johnson (H. L. Johnson, et al., 1987, 1990; Rosen & Johnson, 1982) research 
were prenatally exposed to substances other than methadone which may have independently 
negatively affected brain growth and development. Similarly, Hans’ (1989) sample were exposed 





Research comparing the neonatal growth of infants prenatally exposed buprenorphine and 
methadone has found only modest differences in birth measurements. Jones and colleagues 
(2005) found that infants prenatally exposed to buprenorphine were an average of 528 gm 
heavier at birth than infants prenatally exposed to methadone, although this difference did not 
reach conventional levels of statistical significance (p=.09), the study sample being very small 
(N=20). Other studies have reported no differences in birth measurements (Ebner, et al., 2007; 
Fischer, et al., 2006; Jones, et al., 2010; Kakko, et al., 2008; Lejeune, et al., 2006).  
 
There is limited published research on the development of infants prenatally exposed to 
buprenorphine beyond the neonatal period, and the current study appears to be the most 
comprehensive documentation of the physical growth of these infants. Previous studies 
describing development of infants exposed to buprenorphine in utero have reported growth 
outcomes within normal limits (Kayemba-Kay's & Laclyde, 2003; Sandtorv, et al., 2009; Schindler, 
et al., 2003). Two of the publications (Kayemba-Kay's & Laclyde, 2003; Schindler, et al., 2003) 
were case-note review studies and follow-up growth data were not reported. The only study to 
include both methadone- and buprenorphine-exposed infants did not provide long term growth 
data and did not report growth outcomes separately for the two groups of infants (Sandtorv, et 
al., 2009).  All studies were limited by low subject numbers (N = 4 to 15). 
 
Animal studies have also shown mixed results, with Tiong et al. (1988) reporting that rat pups 
prenatally exposed to 1 mg or 2 mg /kg /day buprenorphine, weighed less than pups exposed to 4 
mg or 8 mg/kg/day methadone and non-exposed control pups, on postnatal day 20. The authors 
reported that pup mortality (by postnatal day 5) was significantly greater in the buprenorphine-
exposed groups. This was attributed to either rejection by non-treated foster mothers or pup 
viability, with the authors suggesting that the causes be further investigated (Tiong & Olley, 1988). 
Lichtblau and Sparber (1981) have suggested that pup-mortality may be associated with neonatal 
withdrawal. However this was not measured in Tiong and Olley’s publication (1988). Additionally,  
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it has been suggested that persistent opioid-agonist activity in the developing brain may suppress 
feeding and other behaviours required for normal growth and survival (Lichtblau & Sparber, 
1981). 
 
Hutchings et al. (1992) found that higher maternal doses of methadone had a transient effect on 
the postnatal growth of rat pups, with pups prenatally exposed to higher doses of methadone 
showing initial deficits in weight gain, compared with pups prenatally exposed to lower-dose 
methadone and a non-treated control group. The authors reported a catch-up in weight by the 
50
th postnatal day for the pups exposed to high-dose methadone, but suggested that the delay in 
growth could have been secondary to NAS symptoms (Hutchings, et al., 1992).  Further research 
by this group found no differences in birth weight or postnatal growth (to postnatal day 60) 
between rat pups prenatally exposed to differing amounts of buprenorphine, and pups in a non-
exposed control group (Hutchings, et al., 1995).  
 
In summary, and to put the results of the current study in the context of previous research, there 
are four key explanations for the differences in growth observed. As described above, the lower 
weight and smaller stature of the MM-exposed infants may be due to the interaction of 
methadone with the endogenous ligand [Met5]-enkephalin in the developing foetus. This may 
have the effect of inhibiting cell proliferation in the brain, along with somatic structures including 
muscle and bone. Conversely, the antagonist effects of buprenorphine may be responsible for 
blocking this growth-inhibitory response, thus resulting in growth acceleration in buprenorphine-
exposed infants (Farid, et al., 2008). 
 
A second explanation for the observed differences in growth outcomes for methadone- and 
buprenorphine-exposed infants may be the differing effects of the two drugs on maternal or 
infant endocrine functioning. As described above, it is possible that methadone may negatively 
influence the HPA-axis to increase maternal and placental CRH and ACTH levels, which in turn may  
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inhibit foetal growth. Due to its partial agonist properties, buprenorphine may not have the same 
influence over endocrine functioning (Gomez-Flores & Weber, 2000; Konijnenberg & Melinder, 
2011; Pechnick, 1993). 
 
A third reason for the differences in growth for BM and MM exposed infants in the present study 
may be higher maternal doses of methadone during pregnancy contributing to suppression of 
foetal growth (Farid, et al., 2008; Hutchings, et al., 1992). The mean maternal dose for women in 
the present study (45.41±20.21 mg/day) may, in part, explain why infants in the MM group 
experienced delays in growth, particularly in relation to weight gain. The mean buprenorphine 
dose in the current study was 7.33±4.29 mg (range 0.4-20 mg), and while it has been 
demonstrated that 8 mg BM is comparable to 60 mg MM (Farid, et al., 2008; Ling & Wesson, 
2003) in terms of effectively treating heroin use and dependence, the finding that infants in the 
BM group did not differ in their postnatal growth from a group of non-exposed infants is 
analogous to that of Hutchings et al. (1995), as outlined above. 
 
Finally, the observed differences in growth outcomes observed in the present study may be 
associated with the differing placental transfer of the two drugs. In vitro models have shown that 
whilst both substances are sequestered in human placental tissue, the concentration ratio of 
buprenorphine in the tissue/foetal circuits (27.4 ± 0.4) is higher than that of methadone (9.9 ± 
1.2), indicating that a greater proportion of buprenorphine is retained in maternal tissue, 
comparative to methadone (Nanovskaya, et al., 2002; Nekhayeva, et al., 2005). Additionally, 
whilst both substances cross the placenta from mother to foetus, the maternal to foetal transfer 
is greater for methadone (29.4±4.6%) than for buprenorphine (11.6±2.5%) (Nekhayeva, et al., 
2005). The lower concentration of buprenorphine in the foetal circulation, which has been 
associated with reduced incidence and severity of NAS, compared with methadone, may also 
influence differences in physical growth in BM and MM exposed infants (Nanovskaya, et al., 
2002). In addition, infants with severe NAS symptoms may experience difficulty with feeding and  
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show increased energy expenditure, both of which may contribute to deficits in growth in MM-
exposed infants (Hutchings, et al., 1992).  
 
It is unlikely that postnatal factors contributed to the continued lower weight of the MM group in 
the current study. Groups were comparable on a range of factors which may influence infant 
growth (see Chapter 3), and analyses were adjusted for socio-demographic factors that differed 
between groups. The MM infants may have had more difficult temperaments, compared with the 
BM and control groups, and could have been fussier eaters. However, as shown in Chapter 7, 
parent-rated Temperament did not differ between the three groups of infants. Thus, it is unlikely 







Infant Visual Evoked Potentials  
This chapter describes the visual evoked potential (VEP) latencies of infants at four months of age. 
First, mean latencies to the first major positive peak (P1) of the neuronal response to two 
different sized stimuli (48’ and 69’ of retinal arc – see footnote in Chapter 2, for a definition) were 
evaluated for each of the three groups of infants. Second, relationships between potential 
confounding variables and VEP latencies were examined, and differences in latencies between 
groups were then adjusted for confounding variables.  
 
This chapter has previously been published in a peer-reviewed journal (see Statement of 
Authorship). As the sample size in the manuscript differs from the thesis sample, the demographic 
detail described in this chapter differs from that presented in Chapter 3 (see section 5.1 below). 
VEP data from a subset of the current study sample was analysed for my Master of Clinical 
Psychology thesis, however the analyses utilised and the content of this chapter are substantially 
different from the Master’s thesis (see Appendix O for note regarding the content of this chapter). 
 
The present chapter addresses the following hypotheses:  
Hypothesis 4: Infants prenatally exposed to buprenorphine will have significantly shorter P1 
latencies at four months of age, suggesting greater visual maturation, than children prenatally 
exposed to methadone.  
Hypothesis 5:  The P1 latencies of infants prenatally exposed to buprenorphine will not differ 






One-way ANOVA were conducted to test the statistical significance of differences between the 
mean latencies of the P1 response to each check size across the three groups. Post hoc tests using 
the Bonferroni procedure were employed to identify the statistical significance of differences 
between pairs of groups. Because a number of factors may contribute to differences in VEP 
outcome (Khedr, et al., 2004; Makrides, Neumann, Jeffrey, Lien, & Gibson, 2000), one-way ANOVA 
with Bonferroni adjustments were also conducted to test for differences between the mean 
scores of each group for continuous covariates (one and five minute APGAR scores, gestational 
age, weight, length and HC at birth, child’s age at testing, child’s corrected age at testing, 
mother’s age). Chi square analyses and Fisher’s exact tests were used to examine the differences 
among the three groups for categorical variables (prenatal exposure to other substances, child’s 
gender, breastfeeding status, whether the child received pharmacological treatment for NAS, 
parents’ educational level, fathers’ employment status, family structure, household income, 
accommodation). Pearson product-moment correlation coefficients revealed no significant 
relationship between average antenatal maternal maintenance dose and P1 latency for either of 
the drug-exposed groups (BM: 48’ r= -.27, n=29, p=.15; 69’ r= -.10, n=29, p=.59; MM: 48’ r= -.03, 
n=20, p=.90; 69’ r= .33, n=22, p=.13). Subsequently, standard multiple regression analyses were 
conducted to adjust for the effects of potentially confounding variables on the relationship 
between group status and P1 latency. Variables were chosen for inclusion in the multivariable 
analyses if they were significantly different between groups (Table 5.1). 
 
5.1 Latency of Visual Evoked Potentials at four months of age 
VEP latency data were collected from 98% (85/87) of participating infants.  Two infants in the MM 
group (both male) lived too far away for the families to travel to the Women’s and Children’s 
Hospital (WCH) for VEP testing and their demographic data are not included in analyses for this 




infants (98%). One infant was too tired and distressed to complete the assessment for the smaller 
stimulus, while the P1 latency response for the second infant to this stimulus was not detectable. 
Both of these infants were female and in the MM group. Responses to the larger (69 min arc) 
stimulus were available from all 85 infants and were used in analyses.   
 
Sensitivity analyses 
Because measureable responses to smaller stimuli may not be evident in very young infants, and 
as VEP outcome may be influenced by environmental factors, latencies were collected at four 
months chronological age (Khedr, et al., 2004; Makrides, Neumann, & Gibson, 2001; Moskowitz & 
Sokol, 1983). Parents were invited to attend an appointment at the Women’s and Children’s 
Hospital at ± 1 week of their infant reaching four months (chronological) age. However, because 
not all families were available at this time, infants’ chronological age at testing ranged from 13.00 
to 31.40 weeks (M=17.24, SD=2.45). To adjust for delays in neuronal development attributable to 
either testing age or gestational age, a corrected age variable (corrected age = chronological 
weeks of age at VEP testing + gestational age at birth - 40 weeks) was calculated. Corrected age 
did not differ significantly between the three groups of infants [overall M=15.85 weeks, SD=3.11, 
F(2,82)=2.35, p=0.10]. 
 
One-way ANOVA were conducted to test whether mean latencies of the P1 response to each VEP 
check size differed between the groups tested on the two different VEP systems. There was no 
significant difference in P1 latencies for checks of 48’ *F(1,81)=0.11, p=0.74] for children assessed 
using the different VEP equipment; however there was a significant difference for checks of 69’ 
[F(1,83)=4.48, p=.04]. There was no significant difference between the three groups in terms of 
the percentage of infants assessed on the two VEP systems (Fisher’s exact test p=.17). In order to 
retain statistical power, subsequent analyses combined data from both VEP systems but 




Exposure to phenobarbitone has been shown to produce changes in the neonatal brain (Holmes, 
Harden, Liporace, & Gordon, 2007; Stefovska et al., 2008) and to have an effect on later visual 
development (Brinciotti, 1994) and long-term cognition (Meador, Baker, Cohen, Gaily, & 
Westerveld, 2007). Sensitivity analyses were conducted to test whether inclusion of the three 
infants treated with phenobarbitone contributed to differences in VEP latencies between infants 
treated pharmacologically for neonatal abstinence syndrome (NAS) versus those not treated. 
One-way between-groups ANOVA excluding the three infants treated with phenobarbitone 
showed no significant difference in mean latencies between infants treated with morphine versus 
infants not pharmacologically treated for NAS (48’: *F(1,45)=0.00, p=0.95+; 69’: *F(1,47)=0.55, 
p=0.46]). When the infants treated with phenobarbitone were included in the analyses, results 
remained non significant (48’: *F(1,48)=0.22, p=0.64+; 69’: *F(1,50)=0.29, p=0.59]). Thus data from 
all infants were included in the final analyses.  
 
Two infants in the MM group had considerably longer P1 latencies than the other infants in 
response to one or both check sizes. Because the unadjusted VEP data were not normally 
distributed, the analyses were conducted in three ways: 1) without adjusting the data, 2) after 
first removing the data from the two outlying MM infants, and 3) using an inverse square 
transformation including data for all participating infants. Sensitivity analysis revealed significant 
differences in P1 latency for both check sizes when all participants were included in the 
unadjusted analyses. When the data from the two MM outliers was removed the significance of 
the differences between the groups was reduced, however the MM group continued to have 
longer latencies in response to both check sizes. The effect sizes (calculated using eta squared) 
were .07 and .04 for 48’ and 69’ checks respectively. When data from all participants were 
adjusted using an inverse square transformation, significant differences in P1 latency remained. 




because there were already smaller numbers in the MM group, the transformed data with all 
participants included were used in the final analyses.  
 
VEP latencies 
Table 5.2 shows that there was a statistically significant difference in P1 latencies in response to 
checks of 48’ between the three groups of infants *F(2,80)=5.05, p<.01, inverse square 
transformation+. The effect size was moderate at η
2=.10 (Cohen, 1988). Post hoc comparisons 
indicated that P1 latencies in response to checks of 48’ for infants exposed to methadone were 
significantly longer than those of both control infants (p<.05) and infants exposed to 
buprenorphine (p<.05). There was no significant difference in P1 latencies in response to checks 
of 48’ between buprenorphine-exposed infants and control infants (p=1.0). In addition, there was 
a statistically significant difference between P1 latencies in response to checks of 69’ across the 
three groups [F(2,82)=3.93, p<.05, inverse square transformation], with a moderate effect size of 
η
2=.09. Post hoc comparisons showed that P1 latencies in response to checks of 69’ for infants 
exposed to methadone were significantly longer than those of both control infants (p<.05) and 
buprenorphine-exposed infants (p=.052). The size of the P1 latencies in response to checks of 69’ 
for buprenorphine-exposed infants did not significantly differ from that of control infants (p=1.0). 
There was more variation in 69’ latencies for infants in the MM group than for infants in the other 
two groups due to two outliers. However, for reasons mentioned above, after sensitivity analyses 
were conducted it was decided that the latencies for these two infants would be included in 
analyses. Overall, there was a significant decrease in latencies observed as the size of the stimulus 





5.2 Four month VEP latencies adjusting for potential confounding variables 
Multiple regression analyses were conducted to examine which variables were the best predictors 
of P1 latency, and to examine whether prenatal exposure to methadone made a significant 
contribution to VEP response, whilst adjusting for the effect of potentially confounding variables.  
 
Corrected age was included in the analyses because it correlated significantly with P1 latency (48’: 
r= .40, n=83, p<.001; 69’: r=.44, n=85, p<.0001, inverse square transformation). Birth weight, 
length and HC were not included as covariates because they were all significantly correlated with 
corrected age. Household income was included as a covariate because it is a strong marker of 
socioeconomic status. Low socioeconomic status has been associated with poorer developmental 
outcomes in children (Bor et al., 1997; Petterson & Albers, 2001), while parental social scores 
have been shown to influence VEP outcome (Makrides, et al., 2000). Fathers’ employment status 
was not included in the multivariable analyses because there was a large amount of missing data 
for this variable. Neither was accommodation included as a covariate because it was significantly 
associated with lower family income (Fisher’s exact test p<.01).  
 
To examine whether prenatal exposure to other substances made a significant contribution to 
VEP latency, the multivariable analyses were then conducted with the inclusion of the antenatal 
self-reported substance and drug screen results that differed significantly between groups (Table 
5.3). Neither self-reported use of benzodiazepines during pregnancy nor a positive drug screen 
during pregnancy made any significant contribution to VEP latency to either check size (results not 
shown). However, self-reported marijuana use during pregnancy made a significant contribution 
to VEP response to both check sizes and was thus included as a covariate in the final multivariable 





VEP latency for checks of 48’ arc  
Variables entered into the model were P1 latency for checks of 48’ as the dependent variable, 
group (with the control group as the reference), corrected age, family income (<$A31, 200 vs 
>$A31, 200), VEP equipment (1 vs 2), and maternal self-reported marijuana use in pregnancy (yes 
vs no) as the predictor variables. The model explained 33% of the variance in P1 latency for checks 
of 48’ and was significant at p<.001 (Table 5.4). After adjusting for corrected age, family income, 
VEP equipment and maternal self-reported marijuana use, group status remained a significant 
predictor of P1 latency for checks of 48’ [F(2,69) = 4.58, p=.01]. After adjusting for covariates, 
latencies of infants in the MM group remained significantly longer than those of infants in the BM 
group [β = -.33, t(69)= -2.79, p=.01] and infants in the Control group [β = -.30, t(69)= -2.54, p =.01]. 
P1 latencies of infants in the BM group did not differ significantly from those of infants in the 
Control group [β = .04, t(69)= 0.29, p=.78]. After adjusting for the same covariates, corrected age 
remained significantly associated with P1 latency for checks of 48’ and provided the largest 
unique contribution to the variance in the model. Family income and maternal self-reported use 
of marijuana in pregnancy also remained significant predictors of P1 latency in response to the 48’ 
arc stimulus. VEP equipment did not provide a significant contribution to the model. 
 
VEP latency for checks of 69’ arc 
Variables entered into the model were P1 latency for checks of 69’ as the dependent variable, 
group (with the control group as the reference), corrected age, family income (<$A31, 200 vs 
>$A31, 200), VEP equipment (1 vs 2), and maternal self-reported marijuana use in pregnancy (yes 
vs no) as the predictor variables. The model explained 34% of the variance in P1 latency for checks 
of 69’ and was significant at p<.001 (Table 5.5). After adjusting for group status, family income, 
VEP equipment and maternal self-reported marijuana use, corrected age remained the 
significantly associated with P1 latency for checks of 69’ arc and provided the largest unique 




pregnancy also remained a significant predictor of P1 latency in response to the 69’ arc stimulus 
(p<.05). After adjusting for covariates, family income and VEP equipment did not contribute 
significantly to the model, neither was group status significantly associated with P1 latency for 
checks of 69’ arc [F(2,70) = 1.45, p =.24]. 
 
5.3 Summary of VEP latencies at four months of age  
48 minute checks 
P1 latency in response to checks of 48’ for infants in the MM group were significantly longer than 
for those of infants in the BM and Control groups, after adjusting for corrected age, family 
income, VEP equipment and maternal self-reported marijuana use in pregnancy. There was no 
difference in latencies between infants in the control and BM groups after adjusting for the same 
covariates. Older corrected age and lower family income were significantly associated with 
shorter latencies, whilst maternal self-reported use of marijuana in pregnancy remained a 
significant predictor of longer P1 latencies in response to the 48’ arc stimulus. 
 
69 minute checks 
P1 latency in response to checks of 69’ did not differ significantly between the three groups of 
infants after adjusting for corrected age, family income, VEP equipment and maternal self-
reported marijuana use in pregnancy. Older corrected age was significantly associated with 
shorter latencies, whilst maternal self-reported use of marijuana in pregnancy remained a 
significant predictor of longer P1 latencies in response to the 69’ arc stimulus. 
 
5.4 Discussion   
This is the first study to compare the neurological development, beyond the neonatal period, of 
infants exposed to methadone or buprenorphine in pregnancy with a control group of non-




buprenorphine did not differ significantly from non-exposed control infants in terms of their 
responses to VEP at 4 months of age. In contrast, infants prenatally exposed to methadone had 
significantly prolonged P1 latencies when compared with both control infants and infants exposed 
to buprenorphine. These relationships were evident for P1 latencies in response to checks of 48 
and 69 minutes of retinal arc. However, after controlling for covariates, the effect of prenatal 
exposure to methadone was no longer a significant predictor of VEP response to checks of 69’. 
Latency of the P1 component varies as a function of age and stimulus size. While measurable 
responses to large checks are present in very young infants, the P1 response to smaller checks is 
often not evident until a few months of age (Moskowitz & Sokol, 1983). These results suggest that 
responses to smaller stimuli (which require greater maturation of the visual system) may be more 
readily influenced by prenatal exposure to methadone. 
 
Older age (corrected for gestation) was associated with significantly shorter P1 latencies for both 
check sizes, which is consistent with previous evidence that optic neural maturity continues to 
develop with increasing age (McCulloch, et al., 1999). Also consistent with previous literature 
(Scher, et al., 1998; Tansley, et al., 1986) was the finding that self-reported maternal use of 
marijuana during pregnancy was significantly associated with VEP latencies in response to both 
check sizes. However, P1 latencies were not influenced by maternal self-reported benzodiazepine 
use or by a positive maternal drug screen in pregnancy. Pharmacological treatment for NAS was 
not related to VEP outcome in this sample of infants. Infants who lived in a family with an annual 
income less than $A31,200 had significantly shorter latencies for checks of 48’ than infants from 
higher income families. The direction of this result is counter intuitive and the mechanism 
underlying this relationship is unclear. The association between family income and shorter P1 





Whilst corrected age appears to be the strongest predictor of VEP outcome, prenatal exposure to 
methadone remained a significant predictor of P1 latency in response to checks of 48’, and 
prenatal exposure to marijuana also appears to be a significant predictor of P1 latencies. These 
finding suggest that infants exposed to methadone in pregnancy may experience delays in visual 
maturation, as expressed through prolonged VEP P1 latencies, when compared with infants 
exposed to buprenorphine and non-exposed control infants. Infants prenatally exposed to 
marijuana in pregnancy may also experience delays in visual development compared to non-
marijuana exposed infants. 
 
These findings are consistent with those of previous studies which have found prolonged P1 
latencies in infants and young children prenatally exposed to a range of substances (Hansen, et 
al., 1993; Olegard, et al., 1979; Scher, et al., 1998; Tansley, et al., 1986). Hansen et al. (1993) 
compared the visual maturity of eight infants exposed to cocaine and amphetamines (n=8) to a 
group of eight non-exposed control infants (mean age 4.5 months). P1 latencies in response to 
pattern reversal stimuli, subtending 15’ arc, were prolonged for the substance-exposed infants, 
but not significantly different from controls (Hansen, et al., 1993). Scher et al. (1998) assessed the 
visual maturation of 74 infants prenatally exposed to alcohol, marijuana, tobacco and other 
unspecified illicit drugs. Prolonged P1 latencies in response to pattern reversal stimuli subtending 
50’ arc, were evident at four and 18 months of age (Scher, et al., 1998). In a study of 101 children 
(mean age 48.75 months), Fried and colleagues (1989; 1986) assessed VEPs in response to pattern 
reversal stimuli subtending 30’ arc. The authors reported that prolonged P1 latencies were 
evident for children exposed to combinations of marijuana, nicotine and alcohol in pregnancy 
when compared with aged-matched controls (Tansley, et al., 1986). 
 
The results of the present study differ from the animal studies of Pinto et al. (1986) who found no 




exposed to methadone. One explanation for this difference could be that myelination occurs at 
differing rates in the brains of developing rats and humans. It is recognised that the early 
postnatal period in the rat is equivalent to the third trimester in human gestation, with the period 
of brain myelination in rats ending at around postnatal day (PND) 26; it is possible that the age at 
which the rats in the Pinto et al. study were tested was not equivalent to that of 4-month old 
human infants (Rice & Barone, 2000; Sanchez, Bigbee, Fobbs, Robinson, & Sato-Bigbee, 2008). It is 
also possible that the doses of methadone tested in the Pinto et al. study were too low to produce 
any deleterious effects. Another explanation for this difference is that Pinto et al. used flash 
stimuli (FVEP) to evoke the potential response whereas the current study used pattern-reversal 
stimuli (PVEP). PVEP are known to show less inter- and intrapersonal variability in measures of 
peak latency in normal controls and are also known to be more sensitive than FVEP to lesions of 
the visual pathways (Aso, et al., 1988; Odom et al., 2004).   
 
The finding in the present study that the P1 latencies of infants exposed to buprenorphine were 
significantly faster than those of infants exposed to methadone may, in part, be explained by 
differences in the pharmacology of the two drugs. The PVEP response appears to be generated by 
neurons in the striate area and, in particular, the generation of the P1 latency is localised in the 
lateral extrastriate cortex (Algarin, et al., 2003; Aso, et al., 1988; Di Russo, Martínez, Sereno, 
Pitzalis, & Hillyard, 2002; Ossenblok, Reits, & Spekreijse, 1992). Studies have shown that exposure 
to opioids during pregnancy can result in a disturbance to the development of selected 
neurotransmitter systems and, more specifically, that prenatal exposure to methadone decreases 
Met- and Leu-enkephalin levels in the striatum (Tiong & Olley, 1988).   
 
Another explanation for the differences in the VEP outcome observed between the two groups of 
drug-exposed infants in the present study may be related to placental transfer of the individual 




due to increased placental transfer as pregnancy progresses (Kandall, Doberczak, Jantunen, & 
Stein, 1999); whereas the low placental transfer of buprenorphine and the comparatively low 
concentration of buprenorphine in the foetal circulation may account for a reduced incidence of 
NAS (Nanovskaya, et al., 2002). A decrease in neuronal firing rates has been demonstrated with 
exposure to opioids in vitro (Pepper & Henderson, 1980), and it is possible that the greater 
placental transfer of methadone may have the effect of inhibiting neuronal firing in the striate 
cortex where the VEP response is generated. As mentioned, prenatal exposure to methadone, but 
not to buprenorphine, decreases levels of the opioid peptide enkephalin in the striatum (Tiong & 
Olley, 1988), where the generation of the P1 latency is localised (Algarin, et al., 2003; Aso, et al., 
1988).  It has also been demonstrated that perinatal exposure to buprenorphine affects 
myelination and axonal growth in the developing rat brain (Sanchez, et al., 2008).  
 
The predictive value of the delayed P1 response observed in the methadone (and marijuana) 
exposed infants in this sample is unclear in terms of its clinical relevance. Kato and Watanabe 
(2006) conducted a review of studies on the predictive value of FVEPs in newborn infants. They 
concluded that FVEPs were a good predictor of neurological development at 18-24 months in full-
term infants with birth asphyxia, but that their predictive value in preterm infants was unclear 
(Kato & Watanabe, 2006). Iinuma, Lombroso and Matsumiya (1997) found that FVEP waveforms 
were predictive of later visual development in 56 infants with early visual inattentiveness (Iinuma, 
et al., 1997). To my knowledge there has been no previous literature evaluating the prognostic 
value of VEP in drug-exposed children. Changes in visual maturation appear to continue to 
develop well into childhood (Hansen, et al., 1993; Moskowitz & Sokol, 1983) and myelination of 
the optic nerve may continue until at least 5 years of age (Moskowitz & Sokol, 1983; Taylor & 
McCulloch, 1992). Previous research has found that early differences in FVEP P1 latencies of 




Topcu, Erdem, & Karacan, 1993); while Scher et al. (1998) found transient delays in visual 
maturation in infants with prenatal substance exposure.  
 
This suggests that the apparent delays observed in the present study for infants prenatally 
exposed to methadone and/or marijuana may be only temporary. Infants’ responses to VEP will 
be re-assessed at 36 months of age as part of the longitudinal study protocol. Results from this 
assessment may assist in determining whether the difference in visual maturation, observed 
between the drug-exposed groups at four months of age, remains in later childhood.   
 
Although research to date supports the short-term safety and efficacy of buprenorphine during 
pregnancy and the early neonatal period (Fischer, et al., 2006; Jones, et al., 2005; Kakko, et al., 
2008), studies where the longer term outcome of children exposed to buprenorphine has been 
systematically documented have yet to be published. Overall, this research provides new 
information regarding the neurological outcome of four month old infants prenatally exposed to 
buprenorphine or methadone. Results suggest that maternal maintenance with buprenorphine 
appears to offer an advantage over methadone in terms of infant neural development at four 
months of age. Further research, incorporating larger sample sizes and more rigorous study 
designs, should be undertaken to compare the neurological development of infants exposed to 






Bayley Scales of Infant Development 
This chapter describes the cognitive, psychomotor and behavioural development of infants, 
assessed at 12 months, and 24 months of age, as measured on the Bayley Scales of Infant 
Development – Second Edition (BSID-II). First, development of each of the three groups of infants, 
in terms of their scores on the Mental Developmental Index (MDI), Psychomotor Developmental 
Index (PDI) and Behavior Rating Scale (BRS), were compared. Next, relationships between 
potential confounding variables and the three BSID-II scores were examined, and differences in 
scores between groups were then analysed adjusting for significant confounding variables. Finally, 
change in BSID-II over time was examined across the three groups of infants. 
 
The present chapter addresses the following hypotheses:  
Hypothesis 6:  
The mean cognitive, psychomotor and behavioural development scores of infants prenatally 
exposed to buprenorphine will not differ significantly from those of a non-exposed control group, 
when assessed at 12 and 24 months of age.  
Hypothesis 7:  
The cognitive, psychomotor and behavioural development scores of infants prenatally exposed to 
methadone will be significantly lower than those of infants prenatally exposed to buprenorphine 
and a non-exposed control group of infants, when assessed at 12 and 24 months of age.  
Hypothesis 8:  
Change in cognitive, psychomotor and behavioural development scores over time will not vary 
significantly between children prenatally exposed to buprenorphine, methadone, or in a non-





Analyses were conducted according to the methods described in Chapter 2, section 2.7, and 
previously outlined in the statistical analyses section of Chapter 4.  
 
A series of simple linear regression analyses and ANOVAs were conducted to examine the 
contribution of independent variables to MDI, PDI and BRS scores at 12 and 24 months of age. 
Standard multiple regression analyses were then conducted to examine the contribution of each 
independent variable to the individual BSID outcomes, whilst adjusting for the effect of the other 
variables in the model. A series of split-plot ANOVAs were undertaken to examine whether mean 
BSID scores changed over time and whether change in mean scores varied between infants in 
each of the three groups. The between-subjects factor was group (control, BM and MM) and the 
within-subjects factor was assessment time (12 and 24 months). Total HOME score was entered 
as a covariate. 
 
6.1 Bayley Scales of Infant Development at 12 months of age 
Mental Developmental Index (MDI) and Psychomotor Developmental Index (PDI) scores of the 
Bayley Scales of Infant Development – Second Edition (BSID-II) were available for all participating 
infants except two (both male) at the 12-month follow-up assessment. One infant in the BM 
group was too tired to participate in the assessment at the scheduled time and the family could 
not be contacted to make another appointment, and one in the MM group did not undergo 
assessment on the BSID-II as the family had moved away from the study area. Thus data for 
mental and motor development at 12 months of age were available for 81/83 children (98%). 
Behavior Rating Scale (BRS) scores were available for ninety percent (75/83) of participating 
infants at the twelve month follow-up assessment. BRS data were not collected for eight infants 
(three in each of the control and BM groups, and two in the MM group) at the 12-month 




possible to go back and re-assess the infants’ behaviour. The 12-month MDI variable was 
negatively skewed when compared across the three groups of infants and was squared for use in 
parametric analyses. 
 
Mental Developmental Index (MDI) 
The MM group had the highest mean MDI score at 12 months of age and the BM group had the 
lowest mean score (Table 6.1). However, with a small effect size of η
2= .04, the actual difference 
in mean scores was quite small, and the difference was not statistically significant [F(2,78)=1.43, 
p=.25, square transformation+. Overall, the majority of infants (88%) obtained a score ‘Within 
Normal Limits’ (Index score of 85-114). Five infants (three controls and one in each of the BM and 
MM groups) obtained MDI scores in the ‘Accelerated Performance’ range (Index score ≥115, ≥1 
SD above the standardised mean of 100), while five (two control and three BM) obtained scores in 
the ‘Mildly Delayed’ range, < 1 SD below the standardised mean (Index score ≤85). These infants 
presented with high activity levels, poor concentration, or were difficult to engage, and parental 
reports of their behaviour on the day of testing were noted to be ‘typical’ or ‘very typical’ of their 
usual behaviour. Four of the infants scored ‘Within Normal Limits’ on the MDI at 24-months of 
age, whilst one male infant in the BM group continued to score in the Mildly Delayed range. 
 
Psychomotor Developmental Index (PDI) 
Table 6.1 shows that 12-month PDI scores for infants in the MM group were approximately four 
points lower than infants in either of the other two groups. The effect size was small to medium 
(η
2= .03) and the difference in scores was not statistically significant [F(2,78)=1.31, p=.28]. The 
majority of infants in the study (80%) obtained a PDI score ‘Within Normal Limits’, however 15% 
(six controls, two BM and four MM) obtained a score in the ‘Mildly Delayed Performance’ range. 
The overall mean score of 91.64 (SD=10.03), while still well within normal limits, is almost two 




there is a 95% chance that the true mean PDI score for this sample of infants would fall within the 
range 89.4-93.9. The BSID-II manual suggests that individual scales of the BSID-II are not 
necessarily predictive of later cognitive functioning, particularly when assessed prior to the age of 
two years (Bayley, 1993).  
 
Behavior Rating Scale (BRS) 
Infants in the BM group scored slightly higher on the BRS at 12 months of age than infants in the 
other two groups (Table 6.1). Again, the effect size was small to medium (η
2= .04) and the 
difference in scores was not statistically significant [F(2,72)=1.55, p=.22]. Overall 83% of infants 
scored ‘Within Normal Limits’ (≥26
th percentile) for their age group. However 15% of the sample 
(five controls, three BM, three MM) scored within the ‘Questionable’ range and two infants in the 
MM group scored in the ‘Non-Optimal’ range (≤10
th percentile) for their age. Males were more 
likely to obtain a behaviour score below the 25
th percentile for their age group, compared with 
females (26% vs. 8%, Fisher’s exact test p =.07). 
 
6.1.1 Relationship between 12-month Bayley Scale scores and potential confounding variables 
Cognitive development at 12 months of age was significantly associated with maternal social 
support at four months of age, [β = .26, t(79) = 2.38, p <.05, cubic transformation], with higher 
MDI scores associated with higher levels of perceived support (ISSI-SF Total scores). Higher infant 
MDI scores at 12 months of age were also significantly associated with a more optimal home 
environment (higher Total HOME score) at 12 months of age *β = .30, t(78) = 2.74, p <.01, cubic 
transformation]. While higher MDI scores were associated with lower levels of parenting stress 
(lower Parenting Stress Index scores) at 12 months of age, this relationship did not reach 





Psychomotor development at 12 months of age was significantly associated with birth HC *β = .27, 
t(79) = 2.36, p <.05, power 0.9 transformation], with higher PDI scores associated with larger HC 
at birth. The relationship between 12-month PDI scores and the following independent variables 
did not reach traditional levels of statistical significance: maternal self-reported use of alcohol in 
pregnancy [Kruskal-Wallis: χ
2 (1) = 3.21, n= 78, p=.07], and birth weight *β = .21, t(78) = 1.90, p 
=.06, power 0.4 transformation].  
 
Behaviour scores at 12 months of age were significantly associated with infant gender, with girls 
scoring significantly more highly than boys on the BRS at 12 months of age [Kruskal-Wallis: χ
2 (1) = 
8.03, n= 75, p<.01].  Higher home environment scores at 12 months of age *β = .31, t(72) = 2.78, p 
<.01, log transformation] and better perceived maternal social support at four months of age 
*Spearman’s rho=.26, n=66, p<.05] were also significantly associated with higher BRS scores at 12 
months of age. The median BRS12 score of infants whose mothers had completed high school was 
higher than that of infants whose mothers had not completed high school, although this 
difference did not reach a traditional level of statistical significance [Kruskal-Wallis: χ
2 (1) = 3.46, 
n= 75, p=.06]. 
 
6.1.2 Twelve month Bayley Scale scores adjusting for potential confounding variables 
Twelve month Mental Developmental Index Scores 
Variables entered into the model were 12-month MDI as the dependent variable (power 2.5 
transformation), with maternal social support (ISSI-SF Total score) at four months of age, Total 
HOME score at 12 months of age, and group (with the control group as the reference) as the 
predictor variables. The model explained 18% of the variance in MDI scores at 12 months of age 
and was significant at p<.01 (Table 6.2). Total HOME Score at 12 months of age remained 
significantly associated with 12-month MDI scores and provided the largest unique contribution 




social support at four months of age and MDI at 12 months of age did not quite reach traditional 
statistical significance (p=.06).  Group status was weakly associated with 12-month MDI [F(2,75) = 
2.42, p =.10, η
2 = .05], and this was largely due to the difference between the MM group and the 
BM group [β = .26, t(75) =2.20, p =.03]. Scores of infants in the control group did not differ 
significantly from those of infants in the BM group [β =-.12, t(75) = -0.99, p = .33], or the MM 
group [β =.16, t(75) = 1.34, p = .18]. 
 
Twelve month Psychomotor Developmental Index Scores 
Variables entered into the model were 12-month PDI as the dependent variable (square 
transformation), with birth HC and group (with the control group as the reference) as the 
predictor variables. The model explained nine percent of the variance in PDI scores at 12 months 
of age (Table 6.3), but did not reach traditional levels of statistical significance (p=.06). Infants’ HC 
at birth remained significantly associated with 12-month PDI score and provided the largest 
unique contribution to the variance in the model. After adjusting for birth HC, group status was 
not significantly associated with 12-month PDI [F(2,77) = 0.67, p =.52]. 
 
Twelve month Behavior Rating Scale Scores 
Variables entered into the model were 12-month BRS as the dependent variable (square root 
transformation), with gender (with girls as the reference), ISSI-SF Total score at four months of 
age, Total HOME score at 12 months of age, and group (with the control group as the reference) 
as the predictor variables. The model explained 22% of the variance in BRS scores at 12 months of 
age and was significant at p<.01 (Table 6.4).  After adjusting for covariates, gender remained a 
significant predictor of BRS at 12 months of age (p<.01) and provided the largest unique 
contribution to the variance in the model. Total HOME score at 12 months of age provided the 
next largest unique contribution to the variance in the model and remained significantly 




social support at four months of age, nor group status [F(2,68)= 1.26, p =.29] was significantly 
associated with BRS at 12 months of age.  
 
6.1.3 Summary of Bayley Scale scores at 12 months of age 
 Mental Developmental Index  
MDI scores at 12 months of age were significantly higher in the MM group compared with the BM 
group, after adjusting for perceived maternal social support at four months of age and home 
environment at 12 months of age. There was no difference in 12-month MDI scores between the 
control group and infants in either of the other two groups after adjusting for the same 
covariates. Higher HOME scores (indicating a more optimal home environment) remained 
significantly associated with higher MDI scores at 12 months of age. 
 
Psychomotor Developmental Index  
PDI scores at 12 months of age did not differ significantly between the three groups of infants, 
after adjusting for HC at birth. Larger birth HC remained significantly associated with higher PDI 
scores at 12 months of age. 
 
 Behavior Rating Scale  
BRS scores at 12 months of age did not differ significantly between the three groups of infants, 
after adjusting for gender, perceived maternal social support at four months of age and home 
environment at 12 months of age. Gender remained a significant predictor of BRS scores at 12 
months of age (p<.01), with girls achieving significantly higher BRS scores than boys. Higher HOME 
scores (indicating a more optimal home environment) remained significantly associated with 





6.2 Bayley Scales of Infant Development at 24 months of age  
Mental Developmental Index (MDI) and Psychomotor Developmental Index (PDI) scores of the 
Bayley Scales of Infant Development – Second Edition (BSID-II) were available from all 73 
participating infants at the 24-month follow-up assessment. Behavior Rating Scale (BRS) scores 
were available for ninety percent (66/73) of infants at this assessment. BRS data for seven infants 
(one in the control group, four in the BM group, and two in the MM group) were not collected at 
the 24-month assessment, as it was inadvertently omitted. The 24-month MDI variable was 
skewed and a suitable transformation could not be found, thus Kruskal-Wallis tests were used to 
examine differences between group medians.  
 
Mental Developmental Index (MDI) 
MDI scores at 24 months of age ranged from 61 to 118. A Kruskal-Wallis test, corrected for tied 
ranks, showed that at 24 months of age the rankings of MDI scores across the three groups were 
not significantly different *χ
2 (2) = 2.75, n= 73, p=.25]. The proportion of variability in the ranked 
dependent variable accounted for by group was η
2=.04, indicating a small effect of group 
membership on MDI at 24 months of age. Mann-Whitney U tests were conducted to evaluate 
pair-wise differences between the three groups. Table 6.1 shows that, at 24 months of age, there 
was no significant difference in median MDI scores between infants in the MM group and the 
control group (z = 0.21, p =.84). Neither was there a significant difference in median MDI at 24 
months of age between infants in the BM and MM groups (z = -1.22, p =.22). The median MDI of 
infants in the BM group was lower than infants in the control group although this difference did 
not reach statistical significance (z = 1.57, p =.12). Nearly two thirds of infants in the study (65%) 
obtained a score ‘Within Normal Limits’ (Index score of 85-114) on the MDI at 24 months of age. 
Four infants (two males and two females, all in the control group) obtained scores in the 
‘Accelerated Performance’ range on the MDI at 24 months of age. Nineteen infants (eight 




female infants (two BM and one MM) scored <2 SD below the standardised mean, in the 
‘Significantly Delayed’ range. Both children in the BM group with scores within the ‘Significantly 
Delayed’ range presented with high activity levels, poor concentration, and were difficult to 
engage on the day of assessment. Parental reports of these infants’ behaviour on the day of 
testing were noted to be ‘typical’ or ‘very typical’ of their usual behaviour. One child obtained 
scores ‘Within Normal Limits’ when retested at 36 months of age, but later test scores were not 
available for the second child. The child in the MM groups was also very difficult to engage when 
tested at 24 months of age. She showed little interest in the test items and appeared to have 
difficulty understanding verbal instructions. Her mother reported that this behaviour was ‘very 
typical’ of the child in question, and that results from a speech and language assessment, 
unrelated to the present study, were pending. 
 
Psychomotor Developmental Index (PDI) 
Infants in the control group achieved slightly higher scores than infants in either of the other two 
groups on the PDI at 24 months of age (Table 6.1). The effect size was small (η
2= .02) and the 
difference in mean scores was not statistically significant [F(2,70)=0.54, p=.59]. Forty eight infants 
(66%) obtained a PDI score ‘Within Normal Limits’ and six percent (two controls and one each in 
the BM and MM groups) scored within the ‘Accelerated Performance’ range. Thirty percent of 
infants scored below average for their age range, with 23 percent (seven controls, seven BM and 
three MM) scoring in the ‘Mildly Delayed Performance’ range and six percent (one control, one 
BM and two MM) scoring in the ‘Significantly Delayed’ range.  
 
Behaviour Rating Scale (BRS) 
There was no significant difference in BRS scores between the three groups of infants at 24 
months of age (Table 6.1). The effect size was very small (η
2= .005) and the difference in scores 





th percentile) for their age group, 17 percent of the sample (eight controls, one 
BM, two MM) scored within the ‘Questionable’ range, and 11 percent (4 BM and 3 MM) scored in 
the ‘Non-Optimal’ range (≤10
th percentile) for their age. Female infants were slightly more likely 
to obtain a score below the 25
th percentile for their age group than males (32% compared with 
23%), although this difference was not significant *χ
2 (1) =0.73, n= 66, p=.39]. 
 
6.2.1 Relationship between 24-month Bayley Scale scores and potential confounding variables 
Cognitive development at 24 months of age was significantly associated with maternal self-
reported use of benzodiazepines in pregnancy [Kruskal-Wallis: χ
2 (1) = 7.54, n= 73, p<.01], with 
infants whose mothers reported use of benzodiazepines achieving significantly lower MDI scores 
than infants whose mothers reported no use of benzodiazepines. Higher MDI scores at 24 months 
of age were significantly associated with (1) higher perceived levels of maternal social support at 
four months of age (higher ISSI-SF Total scores) [Spearman’s rho = 0.33, n= 73, p<.01], (2) higher 
HOME scores (indicating more optimal home environment) at 24 months of age [Spearman’s rho 
= 0.44, n= 67, p<.001], and (3) lower scores on the PSI Parent Domain (indicating lower levels of 
parenting stress) at 24 months of age [Spearman’s rho = -0.36, n= 61, p<.01]. 
 
Psychomotor development at 24 months of age was significantly associated with maternal self 
reported use of marijuana in pregnancy [Kruskal-Wallis: χ
2 (1) = 4.39, n= 72, p<.05] and maternal 
self-reported use of benzodiazepines in pregnancy [F(1,71)=11.57, p<.01, log transformation], 
with infants whose mothers reported use of marijuana or benzodiazepines achieving significantly  
lower PDI scores than infants whose mothers reported no use of marijuana or benzodiazepines. 
Higher 24-month PDI scores were significantly associated with (1) higher ISSI-SF Total scores at 
four months of age *β = .36, t(71) = 3.22, p <.01, power 0.7 transformation], (2) higher HOME 




scores on the PSI Parent Domain at 24 months of age *β = .33, t(59) = 2.67, p <.01, power -0.3 
transformation] .  
 
Higher BRS scores at 24 months of age were significantly associated with (1) higher ISSI-SF Total 
scores at four months of age [Spearman’s rho = 0.26, n= 66, p <.05], (2) higher HOME scores at 24 
months of age *β = .31, t(59) = 2.49, p <.05, power 0.9 transformation],  and (3) lower scores on 
the PSI Parent Domain at 24 months of age *β = -.34, t(53) = -2.66, p <.05, power 0.9 
transformation] .  
 
6.2.2 Twenty four month Bayley Scale scores adjusting for potential confounding variables 
Twenty four month Mental Developmental Index Scores 
Variables entered into the model were 24-month MDI as the dependent variable (square 
transformation), with maternal self-reported use of benzodiazepines in pregnancy,  ISSI-SF Total 
score at four months of age, Total HOME score at 24 months of age, and group (with the control 
group as the reference) as the predictor variables. The model explained 30% of the variance in 
Mental Developmental Index Scores at 24 months of age and was significant at p <.001 (Table 
6.5). After adjusting for covariates, Total HOME score at 24 months remained significantly 
associated with cognitive development at 24 months of age (p <.01) and provided the largest 
unique contribution to the variance in the model. Maternal use of benzodiazepines in pregnancy 
provided the next largest unique contribution to the variance in the model and remained 
significantly associated with MDI score at 24 months of age (p <.05). After adjusting for covariates, 
maternal social support at four months of age was no longer significantly associated with 
cognitive development at 24 months of age, neither was group status significantly associated with 





PSI Parent Domain Total score at 24 months of age was not included in the multivariable analysis 
because it was significantly correlated with ISSI-SF Total score at four months of age [r = -.67, n= 
61, p <.0001]. There was also a large amount of missing data for this variable and its inclusion in 
the multiple regression analysis considerably reduced the available sample size. When PSI Parent 
Domain Total score at 24 months of age replaced ISSI-SF Total score in the model, the overall 
results remained similar and it did not make a significant contribution to the model (results not 
shown), and therefore was not included in the final analyses.  
 
Twenty four month Psychomotor Developmental Index Scores 
Predictors included in the model were maternal self-reported use of benzodiazepines in 
pregnancy, ISSI-SF Total score at four months of age, Total HOME score at 24 months of age, and 
group (with the control group as the reference). As with the previous regression, the PSI Parent 
Domain Total score at 24 months of age was not included in the 24-month PDI multivariable 
analyses. The model explained 31% of the variance in Psychomotor Developmental Index Scores 
at 24 months of age and was significant at p <.001 (Table 6.6).  After adjusting for covariates, 
HOME score at 24 months of age remained significantly associated with psychomotor 
development at 24 months of age (p <.01) and provided the largest unique contribution to the 
variance in the model. Maternal self-reported use of benzodiazepines in pregnancy provided the 
next largest unique contribution to the variance in the model and remained significantly 
associated with psychomotor development at 24 months of age (p <.01). After adjusting for 
covariates, maternal social support at four months of age did not retain a significant association 
with PDI score at 24 months of age. Neither did group status provide a significant contribution to 
the model [F(2,61) = 0.28, p =.76]. 
  
Maternal self-reported use of marijuana in pregnancy was not included in the same multivariable 




significantly associated with one another [χ
2(1)=4.10, p=.04]. When maternal self-reported use of 
marijuana during pregnancy replaced maternal self-reported use of benzodiazepines in the 
model, the overall results remained similar and it did not make a significant contribution to the 
model (results not shown). Additionally, when PSI Parent Domain Total score at 24 months of age 
replaced ISSI-SF Total score in the model, the overall results remained similar and it did not make 
a significant contribution to the model (results not shown).These variables were therefore not 
included in the final analyses.  
 
Twenty four month Behavior Rating Scale Scores 
Twenty four month BRS was normalised using a power 2.5 transformation. ISSI-SF Total score at 
four months of age, Total HOME score at 24 months of age, and group (with the control group as 
the reference) were examined as independent predictor variables. As previously, PSI Parent 
Domain Total score at 24 months of age was not included in the multivariable analyses. The 
model explained 15% of the variance in BRS scores at 24 months of age and was significant at 
p<.05 (Table 6.7). After adjusting for covariates, Total HOME score at 24 months remained 
significantly associated with behaviour at 24 months of age (p<.05) and provided the largest 
unique contribution to the variance in the model. After adjusting for covariates, maternal social 
support at four months of age did not provide a significant contribution to BRS scores at 24 
months of age. Neither was group status significantly associated with 24-month behaviour F(2,56) 
= 0.99, p =.38]. When PSI Parent Domain Total score at 24 months of age replaced ISSI-SF Total 
score in the model, the overall results remained similar and it did not make a significant 






6.2.3 Summary of Bayley Scale scores at 24 months of age 
 Mental Developmental Index  
MDI scores did not differ significantly between the three groups of infants at 24 months of age, 
after adjusting for maternal self-reported use of benzodiazepines in pregnancy, perceived 
maternal social support (ISSI-SF Total Scores) at four months of age, and home environment 
scores at 24 months of age. Maternal self-reported use of benzodiazepines in pregnancy was 
significantly associated with lower infant MDI scores at 24 months of age, while higher HOME 
scores (indicating a more optimal home environment) at 24 months of age remained significantly 
associated with higher MDI scores at 24 months of age.  
 
Psychomotor Developmental Index  
PDI scores did not differ significantly between the three groups of infants at 24 months of age, 
after adjusting for maternal self-reported use of benzodiazepines in pregnancy, perceived 
maternal social support at four months of age, and HOME scores at 24 months of age. Maternal 
self-reported use of benzodiazepines was significantly associated with lower PDI scores at 24 
months of age, as were higher HOME scores at 24 months of age.  
 
 Behavior Rating Scale  
BRS scores did not differ significantly between the three groups of infants at 24 months of age, 
after adjusting for perceived maternal social support at four months of age, and HOME scores at 
24 months of age. Higher HOME scores at 24 months of age remained significantly associated 
with higher BRS scores at 24 months of age, although maternal social support at four months of 





6.3 Longitudinal analyses of Bayley Scale Index Scores 
Figures 6.1-6.3 show the mean BSID-II scores of each group over the two follow-up assessments. 
A series of split-plot analyses of variance (ANOVA) were undertaken to examine whether change 
in mean BSID-II scores (MDI, PDI and BRS) over time varied between the three groups of infants. 
For each split-plot ANOVA, the between-subjects factor was group (control, BM and MM) and the 
within-subjects factor was time (12 and 24 month follow-up assessments). Total HOME score was 
entered as a covariate in each model. Preliminary checks were conducted to ensure that there 
was no violation of the assumptions of normality, linearity, homogeneity of variances, and 
homogeneity of regression slopes. 
 
Mental Developmental Index Scores 
After adjusting for total HOME score, the ANOVA showed that there was a statistically significant 
main effect for time [F(1,62)=16.68, p<.0001], with a moderate effect size (η
2=.09). MDI scores of 
infants in the study significantly decreased over the 12 and 24 month follow-up assessments and 
the ANOVA indicated that time accounted for nine percent of the variance in MDI scores. The 
ANOVA showed no significant main effect for group [F(2,78)=0.14, p=.87, η
2 =.002], and total 
HOME score was of marginal statistical significance [F(1,78)=3.74, p=.06, η
2 =.02]. Additionally, the 
time × group interaction did not reach statistical significance [F(2,62)=1.24, p=.30, η
2=.01], 
suggesting that changes in mean MDI score over the 12 and 24 month follow-up assessments did 
not vary significantly between the three groups of infants. The model was repeated with the 
inclusion of maternal self-reported use of benzodiazepines in pregnancy as a covariate. However 
this did not change the overall outcome and the main effect of maternal self-reported 
benzodiazepine use was not statistically significant [F(1,77)=0.94, p=.34, η





Psychomotor Developmental Index Scores 
After adjusting for total HOME score, there was no significant main effect for time [F(1,62)=0.01, 
p<.91, η
2<.0001] or group [F(2,78)=0.94, p=.39, η
2 =.01]. The ANOVA showed that there was a 
statistically significant main effect for total HOME score [F(1,78)=5.26, p<.05], although the effect 
size was small (η
2 =.04,) indicating that total HOME score accounted for only four percent of the 
variance in PDI scores. In addition, the time × group interaction did not reach statistical 
significance: F(2,62)=0.19, p=.82, η
2<.01], indicating that changes in mean PDI scores over the 12 
and 24 month follow-up assessments did not vary significantly between the three groups of 
infants.  
 
Behavior Rating Scale Scores 
After adjusting for total HOME score, there was a significant main effect for time [F(1,51)=105.58, 
p<.0001+ , with a large effect size (η
2=.33). Overall, mean BRS scores decreased significantly over 
the 12 and 24 month follow-up assessments, and time accounted for 33% of the variance in BRS 
scores. There was no significant main effect for group [F(2,77)=0.99, p=.38,  η
2=.01], and the main 
effect for total HOME score was of marginal significance [F(1,77)=3.24, p=.08, η
2 =.02]. The time × 
group interaction did not reach statistical significance [F(2,51)=0.45, p=.64, η
2 =.003], suggesting 
that change in BRS over time did not vary significantly between the three groups of infants. The 
model was repeated with the inclusion of infant gender as a covariate, however this did not 
change the overall outcome and the main effect of gender was not statistically significant 
[F(1,76)=0.11, p=.74, η





6.3.1 Summary of Bayley Scale longitudinal analyses  
Results of the three split-plot ANOVAs supported the hypothesis that change in each of the Bayley 
Scale scores over time would not vary significantly between infants prenatally exposed to 
buprenorphine, methadone or the non-exposed control group of infants. There was a significant 
main effect of time for the Mental Developmental Index and Behavior Rating Scale scores, 
illustrating that mean scores on both of these measures decreased significantly between the 12 
and 24 month assessments. There was a statistically significant main effect of total HOME score 
for the Psychomotor Developmental Index, demonstrating that higher total HOME scores 
(indicating a better quality of Home Environment) were associated with better psychomotor 
development. However, none of the interactions between group status and time were significant, 
indicating that change in Bayley Scale scores over the three follow-up assessments did not differ 
significantly between the three groups of infants. 
 
6.4 Discussion 
This chapter compared the cognitive, psychomotor and behavioural development of infants 
prenatally exposed to methadone or buprenorphine, with that of a group of non-exposed infants. 
Overall, scores on the Mental Developmental Index (MDI), Psychomotor Developmental Index 
(PDI) and the Behaviour Rating Scales (BRS) of the Bayley Scales of Infant Development did not 
differ significantly between infants prenatally exposed to buprenorphine, methadone, or a non-
exposed control group. A small difference found between the MM and BM groups on the 12-
month MDI in multivariable analysis will be discussed below. As hypothesised, change in Bayley 
Scale scores over time did not vary significantly between the three groups of infants. This was 
expected, as while previous research has reported significant changes in BSID-II scores during 
infancy and toddlerhood, substance exposure was not found to be significantly associated with 





As described in Chapter 4, the opioid system is involved in growth and development, and animal 
studies have shown that exposure to opioids during pregnancy can result in a disturbance to the 
development of selected neurotransmitters in the CNS. In terms of how this may affect the 
cognitive and motor development of infants, research examining the role of neurotransmitters in 
brain development has shown that dopamine regulates the growth and branching of neuronal 
axons and dendrites. Dopamine is therefore important in terms of executive functioning, such as 
planning and problem solving, along with motor performance (Herlenius & Lagercrantz, 2004).  
Perinatal exposure to methadone can result in disruption to the dopaminergic system in the 
frontal cortex, and reduced dopamine concentrations in both the forebrain and the striatum 
(Konijnenberg & Melinder, 2011; Robinson, Maher, Wallace, & Kunko, 1997). Prenatal exposure 
to methadone has also been shown to increase levels of serotonin in the parietal cortex, and 
reduce norepinephrine levels in the hippocampus. Serotonin is involved in the coordination of 
sensory and motor responses, whilst norepinephrine is responsible for regulating neuronal 
growth and may be involved in attention and memory functions (Herlenius & Lagercrantz, 2004; 
Konijnenberg & Melinder, 2011; Robinson, et al., 1997). Additionally, previous research has 
suggested that opioids may act indirectly upon the cholinergic system, which in the CNS is 
responsible for regulation of spatial working memory, visual discrimination learning, and visual 
attention (Everitt & Robbins, 1997; Robinson, 2000, 2002; Wu, et al., 2001). Thus, prenatal 
exposure to opioids may affect a number of systems in the developing brain with subsequent 
deleterious effects on cognitive and psychomotor development and behaviour. 
 
Mental Developmental Index  
In the current study, infants prenatally exposed to methadone achieved the highest mean score 
on the MDI at 12 months of age, approximately two points higher than the non-exposed control 
group, and five points higher than the mean score of infants prenatally exposed to 




12-month home environment, MDI at 12 months of age was significantly higher in the MM group 
compared with the BM group. However, this difference was not evident in univariable analyses, 
neither was it found at 24-months of age. Given the small effect size and lack of consistency with 
other results, this may have well reached statistical significance through multicollinearity and may 
be of little clinical significance.  As described in detail below, all other studies have found either 
no significant differences in MDI scores, between methadone-exposed and non-exposed infants, 
or have reported significantly lower MDI scores for infants prenatally exposed to methadone.  In 
the current study, MDI did not differ significantly between the control group and the two 
substance-exposed groups after adjusting for covariates.  Higher MDI at 12 months of age 
remained significantly associated with a more enriched home environment.  
 
Infants in the MM group had higher median scores on the 24-month MDI than infants in the BM 
group, although this difference was not statistically significant. Median MDI scores of infants in 
the MM group were similar to those for infants in the control group. Although the median 24-
month MDI score of infants in the BM group was almost 10 points below that of infants in the 
MM and control groups, the range of scores for each of the three groups was similar. When 
prenatal exposure to benzodiazepines, perceived maternal social support at four months of age 
and current home environment were included in the analyses, prenatal exposure to 
benzodiazepines remained significantly associated with lower MDI scores, and a more enriched 
home environment remained significantly associated with higher MDI scores at 24 months of age.  
 
The finding that infants prenatally exposed to methadone achieved the highest scores on the MDI 
was unexpected. Whilst there are no previous studies comparing cognitive outcomes on the MDI 
between buprenorphine- and methadone-exposed infants, five research groups have reported no 
statistically significant differences in MDI scores between infants prenatally exposed to 




to methadone have generally been lower than their non-exposed peers (see Chapter 1) (Bernstein 
& Hans, 1994; Chasnoff, et al., 1984; Hans, 1989; Messinger, et al., 2004; Wilson, 1989; Wilson, et 
al., 1981). Chasnoff et al. found no differences in mean BSID scores between 39 infants prenatally 
exposed to methadone, 19 poly-drug exposed infants and 27 non-exposed infants at 3, 6, 12 and 
24 months of age (Chasnoff, et al., 1984). Similarly, Wilson and colleagues reported no significant 
differences in MDI performance at nine, 18 or 24 months of age, between 39 methadone-exposed 
infants and 57 non-exposed comparison infants (Wilson, 1989; Wilson, et al., 1981). Bernstein and 
Hans reported that 24-month MDI scores for 30 methadone-exposed infants and 44 non-drug 
exposed infants did not differ significantly (Bernstein & Hans, 1994; Hans, 1989), whilst van Baar 
and colleagues (van Baar, 1990; van Baar, Fleury, & Ultee, 1989; van Baar, et al., 1994) also found 
no significant differences between MDI scores, at 6, 12 and 18 months of age, for 35 infants 
prenatally exposed to methadone and 37 non-exposed infants (van Baar, 1990; van Baar, Fleury, 
& Ultee, 1989; van Baar, et al., 1994). Messinger et al. (2004) found that, in univariable analyses, 
the mean 12-month MDI of infants prenatally exposed to opioids (n =79) was significantly lower 
than non-opioid exposed infants (n=960); however mean MDI scores at two and three years of 
age did not differ significantly between the two groups. After adjusting for covariates, no 
significant effect of opioid exposure remained on overall MDI performance (Messinger, et al., 
2004). 
 
On the other hand, five research groups have reported significantly lower scores on the MDI for 
infants exposed to methadone, compared with non-exposed infants at varying ages (Chasnoff, 
1985; Chasnoff, et al., 1986; Hunt, et al., 2008; H. L. Johnson, et al., 1987, 1990; H. L. Johnson & 
Rosen, 1982; Lodge, et al., 1975; Rosen & Johnson, 1982; van Baar, 1990; van Baar, Fleury, & 
Ultee, 1989). Some of the reasons for this contrast in results may be inadequate control for 
confounding factors, conception whilst on heroin, or exposure to poly-substance abuse. It is 




Chasnoff and colleagues (1985; 1986) found that MDI scores of 26 opioid-exposed infants were 
significantly lower than those of 29 non-exposed controls at six and 12 months of age. The 
authors noted that the majority of the opioid-exposed infants were conceived whilst their 
mothers were using heroin, but were also exposed to maternal methadone maintenance during 
pregnancy. A smaller number of opioid-exposed infants were prenatally exposed to a combination 
of pentazocine (a synthetic mixed agonist/antagonist narcotic) and tripelennamine (an 
antihistamine) which, when taken together, are known as “T’s and blues”. The lower scores of 
these infants may have been due to exposure to high doses of opioids, or the combination of 
substances may have contributed to the infants’ poorer performance on the MDI assessment. 
 
Lodge et al. (1975) found that infants prenatally exposed to heroin and/or methadone (n=29) 
achieved lower MDI scores than non-exposed infants (n=10) when tested at approximately one-
month of age. They suggested that this was due to poorer orientation and lower visual 
attentiveness in the opioid-exposed group. The lower scores of the opioid-exposed infants were 
possibly due to the very low MDI scores of the infants prenatally exposed to a combination of 
methadone and heroin (n=6, M±SD=83.33±9.21). The authors suggested that these infants may 
have been exposed to a higher overall dose of narcotics, however, due to the small study 
numbers it was suggested that the results be interpreted with caution (Lodge, et al., 1975). 
Another possibility for the lower MDI scores for the opioid-exposed infants may have been due to 
the timing of assessment. When tested, the opioid-exposed infants in Lodge et al.’s study may still 
have been recovering from NAS symptoms which could have affected the infants’ performance on 
developmental assessments. Additionally, over half of the opioid-exposed sample was treated for 
NAS with combinations of benzodiazepines and phenobarbital, both of which are known to 
adversely affect brain development and cognitive performance (Brinciotti, 1994; Holmes, et al., 




Aronsson, 1993). Thus, it is possible that the lower scores were attributable to the NAS 
medication, rather than the opioid-exposure per se.  
 
Johnson and colleagues (H. L. Johnson, et al., 1987, 1990; H. L. Johnson & Rosen, 1982; Rosen & 
Johnson, 1982, 1985) found that methadone-exposed infants (n=62 ) scored more poorly on the 
MDI than their non-exposed peers (n=32), when assessed at six months of age. While the 
differences did not reach statistical significance, this was reportedly due to large within-group 
variance. It was also reported that lower BSID scores were significantly associated with abnormal 
neurological signs for the methadone-exposed infants (H. L. Johnson & Rosen, 1982). Repeat 
testing at 12 and 18 months showed that, although mean scores were within the average range, 
methadone-exposed infants achieved significantly lower scores on the MDI compared with the 
non-exposed infants. Additionally, there was a higher rate of recurring otitis media in the 
methadone-exposed infants, which may have been associated with lower MDI scores through 
deficits in auditory processing and subsequent learning and communication difficulties (Rosen & 
Johnson, 1982, 1985).  
 
Van Baar et al. found that MDI scores of 24 and 30 month olds were significantly lower for infants 
prenatally exposed to heroin, methadone and cocaine (n=35), when compared with a group of 
non-exposed children (n=37). The authors suggested that the opioid-exposed children may have 
had difficulty with language comprehension and expression at these assessments, and indicated 
that home environment and social factors may have contributed to language difficulties, although 
these variables were not adjusted for in analyses.  Additionally, as mentioned, 60% of opioid-
exposed infants were also prenatally exposed to cocaine, which may have contributed to their 





Hunt and colleagues (2008) reported that MDI scores of infants prenatally exposed to methadone 
(n=79) were significantly lower than non-exposed infants (n=61) at 18 months of age. However, 
mean scores for both groups of infants were in the normal range of development, and potentially 
important covariates such as gestational age, maternal use of other substances, treatment for 
NAS, or other health and social factors were not included in analyses.  
 
The only previous study to assess the effect of prenatal-exposure to buprenorphine on MDI scores 
was that of Salo et al. (2009) who reported that, at three years of age, children prenatally exposed 
to buprenorphine (n=21) achieved significantly poorer scores on the Cognitive, Language and 
Social-Emotional Scales of the BSID-III, compared with non-exposed children (n=13). However, 
after adjusting for covariates (including gestational age, maternal age, SES and number of foster 
placements), only the Language Scale scores remained significantly associated with 
buprenorphine exposure (Salo, et al., 2009). The authors noted that over 40% of the 
buprenorphine-exposed infants were also exposed to other illicit substances, including 
benzodiazepines and amphetamines. As mentioned above, benzodiazepines are known to 
adversely affect cognitive performance (Viggedal, et al., 1993), thus exposure to other substances 
may have contributed to the infants’ poorer cognitive outcome. 
 
In the present study, overall there was a significant 6.7 point decrease in mean MDI scores over 
the course of the two assessments [12-month MDI: M±SD = 100.46±1.14, 24-month MDI: M±SD = 
93.79±1.70; t(71)=3.80, p<.001]. When examining the mean scores of individual groups of infants, 
the mean MDI score of the control group fell by approximately four points, while the mean MDI 
score for the MM and BM groups fell by approximately eight points each. Similar to the present 
study, research by Chasnoff et al. (1982; 1984) showed a decline in mean MDI scores, between 12 
and 24 months of age, for both methadone-exposed and non-exposed children, a finding which 




declined with age is consistent with the results of Wilson (1989), who reported that MDI scores of 
infants prenatally exposed to heroin, methadone and a non-exposed comparison group declined 
across 9, 18 and 24 months. According to the authors, the level of disadvantage experienced by 
the study population, particularly the poor home environments of the drug-exposed children, may 
have contributed to the decline in scores (Wilson, 1989). The decline in MDI scores observed in 
the present study cannot be attributed to poor home environment. Whilst home environment 
appears to be a strong predictor of infant cognitive development (see Tables 6.2 and 6.5), mean 
scores on the Total HOME scale for infants in the current study were generally high (see Table 
3.11). The present study used HOME scores that were collected concurrently with the BSID-II 
scores to predict cognitive developmental outcome, whilst Lifchitz, Wilson and colleagues 
collected HOME scores at 36 months of age, not at the time of assessment with the MDI (Lifschitz, 
et al., 1985; Wilson, 1989). Further, whilst this research group found that HOME scores were a 
strong predictor of McCarthy General Cognitive Index scores at a mean age of three years and five 
months (Lifschitz, et al., 1985), HOME scores were not examined in relation to the earlier tests of 
cognitive development using the BSID; thus it is difficult to draw any firm conclusions about the 
relationship between home environment and the MDI scores in Wilson’s study (Wilson, 1989). 
 
A study of infants prenatally exposed to cocaine (n=265), alcohol, tobacco and/or marijuana 
(n=66), and a non-exposed control group (n=129), found that the infants prenatally exposed to 
cocaine scored significantly lower than the other two groups on the MDI at 3, 6, and 12-months of 
age (Mayes, Cicchetti, Acharyya, & Zhang, 2003). However, while the infants prenatally exposed 
to cocaine continued to obtain the lowest scores at subsequent follow-up assessments, MDI at 24 
to 36 months, did not differ significantly between the three groups. Results of this study also 
showed that the mean scores of all infants declined between three and 36 months of age, with 
the cocaine-exposed infants showing a greater decrease in scores over time compared with 




common in high-risk samples and indicated that their study population was generally subject to 
poor environmental stability, high levels of parenting stress and extreme poverty. The authors 
suggested that the emphasis on language skills in the latter assessments may have contributed to 
the decline in scores for a high-risk population of children (Mayes, et al., 2003). However, again, 
the quality of the home environment was neither specifically measured, nor adjusted for in 
analyses, and parenting stress did not contribute significantly to any of the models.  
 
Similarly, a study examining the development of cocaine-exposed infants (n=113) and non-
exposed infants (n=90), found that scores on the BSID declined between six and 24 months of age 
for both groups of children (Frank et al., 2002). This research found that decline in MDI scores was 
greater for children residing with their biological mother or in the care of relatives than for 
children in non-relative foster care (Frank, et al., 2002). Only four infants in the present study (two 
in each of the BM and control groups) were cared for by relatives or were in non-relative foster 
care (see Chapter 2), thus subgroup analyses were not possible.  
 
The significant decline in MDI scores observed in the present study may be attributable to 
prenatal benzodiazepine exposure. Examination of scores for infants whose mothers self-reported 
use of benzodiazepines in pregnancy (n=28; 4 controls, 12 each for MM and BM) showed a 
significant 14.5 drop in mean MDI scores across the two assessments [12-month MDI: M±SD = 
101.13±1.70, 24-month MDI: M±SD = 86.61±2.83; t(22)=5.30, p <.0001]. In a sample of Swedish 
infants, Viggedal et al. (1993) found that infants prenatally exposed to therapeutic doses of 
benzodiazepines (n=17) achieved consistently lower scores on the General Developmental 
Quotient of the Griffiths’ Mental Developmental Scale than a non-exposed group of infants (n=29) 
when tested at five, 10 and 18 months of age. Mean scores of infants prenatally-exposed to 
benzodiazepines were significantly lower than the non-exposed infants at 10 and 18 months of 




coordination and performance, along with deviations from normal activity and attention levels 
(Viggedal, et al., 1993).  
 
A high proportion of children in the current study scored below the average range for the 24-
month MDI. Table 6.1 shows that a greater proportion of infants in the BM group scored below 
the average range, compared with infants in the MM and control groups.  The proportion of 
infants in the current study with scores below average (30% of the total sample) is twice that 
observed in the BSID-II normative sample (12.6%), and is also greater than that expected in a 
normal distribution, where approximately 16% of children would be expected to score below the 
average range (Bayley, 1993). The norms for the BSID-II were developed using a sample of 1700 
infants from the United States, and did not include infants who were premature, those with a 
disability, or from other at-risk populations. Subsequently the norms reflect a North American 
non-clinical population in terms of race, ethnicity, gender and parental education levels (Bayley, 
1993). In the present study, the non-exposed control group was selected based on socioeconomic 
status, therefore these differences from the norming sample are not unexpected, and cultural and 
social factors may also have contributed to the proportion of infants in the current study scoring 
below ‘normal limits’ on the MDI. Additionally, there are a large number of items in the 24-month 
MDI assessment related to expressive and receptive language acquisition, language 
comprehension, and vocabulary (e.g. naming and recognising pictures and objects, attending to a 
story). Maternal language and literacy levels are predictive of vocabulary production in infants 
from low-income families (Pan, Rowe, Singer, & Snow, 2005). While this study did not formally 
assess maternal literacy or language capabilities, many infants were from low-income families 
with low parental educational achievement (see Table 3.6). In the current study, a small number 
of women had difficulty with reading and writing to such an extent that they required help 





Psychomotor Developmental Index  
In the current study, infants prenatally exposed to methadone achieved the lowest mean score on 
the 12-month PDI, approximately four points lower than that of infants prenatally exposed to 
buprenorphine and the non-exposed control group (see Table 6.1). When head circumference 
(HC) at birth was included in the analyses, larger HC at birth remained significantly associated with 
higher PDI scores at 12 months of age, but PDI scores remained unrelated to group status.  At 24 
months of age, mean scores on the PDI did not differ significantly between infants in the BM and 
MM groups. The mean score of the control group was approximately three points higher than 
those of the opiate exposed groups, although this difference in scores was not significant, and the 
effect size of the difference was small. When prenatal exposure to benzodiazepines, perceived 
maternal social support at four months of age, and current home environment were included in 
the analyses, prenatal exposure to benzodiazepines remained significantly associated with lower 
PDI scores, and better home environment remained significantly associated with better 
psychomotor development at 24-months of age.  
 
Results of the current study are consistent with much of the previous research which has found 
that while infants prenatally exposed to methadone often experience delays in psychomotor 
development compared with non-exposed infants, mean scores tend to fall within the average 
range (Hans, 1989; H. L. Johnson & Rosen, 1982; Messinger, et al., 2004; Rosen & Johnson, 1982; 
Wilson, et al., 1981). Johnson and Rosen (H. L. Johnson & Rosen, 1982; Rosen & Johnson, 1982, 
1985) reported that infants prenatally exposed to methadone (n=62) achieved lower scores on 
the PDI at six months of age compared with their non-exposed peers (n=32). As reported above, 
the differences did not reach statistical significance, reportedly due to large within-group 
variance. For the methadone-exposed infants only, low BSID scores were significantly associated 
with abnormal neurological signs (H. L. Johnson & Rosen, 1982). This cohort of children was re-




significantly lower on the PDI than the non-exposed infants. Again, all mean scores were within 
the average range (Rosen & Johnson, 1982). 
 
Wilson and colleagues reported a significant delay in psychomotor development for 39 infants 
prenatally exposed to methadone, compared with 57 non-exposed infants, when assessed at 
nine-months of age. Specifically, the authors reported that infants prenatally-exposed to 
methadone demonstrated poorer fine-motor control (Wilson, et al., 1981). While no explanation 
for this was provided by the authors, it is possible that other social or genetic differences between 
the groups, such as maternal-infant interaction or race, may have influenced these results. Sleep 
disturbances and bouts of excessive crying were reported to be significantly more frequent in the 
methadone-exposed group than for the non-exposed infants (Wilson, et al., 1981). In the current 
study there was no difference in sleeping problems noted between groups (see Table 3.6). As 
mentioned above, serotonin assists in regulating the sleep/wake cycle and is important for 
coordination of sensory and motor responses. Animal studies have shown that prenatal exposure 
to methadone has been associated with increased levels of serotonin in the brain, thus the 
difficulties with fine motor control observed in the methadone-exposed infants in Wilson et al.’s 
study may be associated with increased serotonin levels in the brains of these infants 
(Konijnenberg & Melinder, 2011; Robinson, et al., 1997).  
 
Similarly, Hans examined the psychomotor development of two-year-old children prenatally 
exposed to methadone (n=30) and compared it with the development of a group of non-exposed 
children (n=44). Groups were similar in terms of maternal IQ, years of education, single parent 
status, race and SES. Whilst mean scores fell within the average range, infants exposed to 
methadone had significantly lower PDI scores than non-exposed children, equating to a 





More recently, Messinger et al.  (2004) have described the psychomotor development of a large 
sample of toddlers (n=1227). They reported that opioid exposure was associated with significantly 
lower PDI mean scores at two and three years of age. Opioid-exposed children (n=98) also scored 
approximately four PDI points below non-opioid exposed children (n=1129). However, when 
analyses were adjusted for data collection site, infant age at testing, ethnicity, birth weight, 
infants’ home environment, and maternal care, no significant effect of opioid exposure on 
psychomotor development remained. Similar to results of the present study, the research by 
Messinger et al. showed that higher HOME scores (indicating a more optimal home environment) 
were significantly associated with higher scores on the PDI (Messinger, et al., 2004).  
 
Some research has found above average scores on the PDI for opioid-exposed infants. Very early 
research by Ramer and colleagues noted that while infants prenatally exposed to heroin and/or 
methadone (n =29) appeared to perform poorly on tasks requiring perceptual motor skills, mean 
PDI scores did not differ significantly from a non-exposed group of infants (n =10). All mean PDI 
scores were above average when assessed at one month of age (Lodge, et al., 1975; Ramer & 
Lodge, 1975). Similarly, van Baar et al. (1990; van Baar, Fleury, & Ultee, 1989) assessed the 
psychomotor development of 35 infants prenatally exposed to methadone and other substances 
(including heroin and cocaine) at six monthly intervals from six to 30 months of age. This study 
found that mean PDI scores were generally within the average to high-average range and did not 
differ significantly from a group of 37 non-exposed infants. Whilst the authors acknowledged that 
these results were inconsistent with previous research, no explanations were provided for the 
high psychomotor developmental scores obtained in their study (van Baar, Fleury, & Ultee, 1989). 
It may be that van Baar et al.’s sample differed from other research samples in terms of 






In the current study, benzodiazepine exposure remained significantly associated with lower PDI 
scores at 24 months of age. As discussed above, benzodiazepine exposure in utero has been 
linked to poorer developmental outcome in exposed infants. As well as deficits in cognitive 
development, distinctive hand and arm movements, not observed in non-exposed infants, have 
also been reported for infants prenatally exposed to benzodiazepines (Viggedal, et al., 1993).  
 
Contrary to changes in mean MDI scores observed in the current study, mean PDI scores 
remained relatively stable across the 12- and 24-month assessments [t(71)= -0.50, p= .62]. 
Consistent with the pattern of results seen in relation to the 24-month MDI, a high proportion of 
children in the current study (29% of the total sample) scored below the average range for the 24-
month PDI. Table 6.1 shows that, as with the MDI, a greater proportion of infants in the BM group 
scored below the average range, compared with infants in the MM and control groups.  The 
proportion of infants in the current study with 24-month PDI scores below average was twice that 
observed in the BSID-II normative sample (14.8%) (Bayley, 1993). Additionally, whilst mean scores 
for all three groups of infants on the 12-month PDI were in the average range, scores were 
approximately half of one SD below the standardised mean of 100. At 24 months of age, all mean 
PDI scores were within the average range, however, mean scores of the BM and MM groups were 
again approximately half of one SD below the standardised mean. These results are similar to 
those of Johnson and Rosen (1982; Rosen & Johnson, 1985) who found that mean scores on the 
PDI were lower for infants prenatally exposed to methadone compared with a non-exposed 
group, when assessed at six, and 12 months of age. Additionally, a significantly greater proportion 
of methadone-exposed infants scored below the average range on the PDI, compared with infants 
in the non-exposed group (H. L. Johnson & Rosen, 1982; Rosen & Johnson, 1985). 
 
To better understand the proportion of low PDI scores observed in the present study, it is useful 




similar rates of low PDI scores. For example, Gibson et al. (1998) found that the mean 12-month 
PDI scores of infants conceived via in-vitro fertilisation [(IVF), n=65, M±SD=90.4±14.8] and a group 
of comparison infants (n=63, M±SD=89.5±15.5) were at the lower end of the average range, and 
fell approximately two-thirds of one SD below the standardised mean (Gibson, et al., 1998). As 
mentioned above, the BSID-II was standardised on a population of children in the United States, 
whilst the participants in both the current study and in Gibson et al.’s study were drawn from 
Australian populations. Gibson et al. posited that cultural factors may have accounted for the 
lower PDI scores observed in their study, and it is possible that this may also be the reason for the 
large proportion of infants in the current study scoring below ‘normal limits’ on the PDI. 
Additionally, it was suggested that the lower scores observed in Gibson et al.’s study may have 
been related to the re-standardised norms of the BSID-II, which the authors reported were not 
used in earlier studies (Gibson, et al., 1998). The authors appear to be referring to a phenomenon 
known as the ‘Flynn effect’, where average test scores are known to increase over time due to 
changes in a population. Thus when a test is re-standardised, a decline in mean scores can be 
expected (Gagnon & Nagle, 2000). It does not appear that the lower scores in the present study 
can be attributed to the ‘Flynn effect’. This is because the data for the standardisation of the 
BSID-II was collected in 1988 (Pearson Education, 2008), therefore it would be expected that 
mean scores in the present sample might be inflated when compared with the norming sample.  
 
Gibson and colleagues also suggested that the lower scores in their sample may have been due to 
the large number of items in the 12-month item-set for the PDI that assess a child’s ability to 
stand and walk independently (Gibson, et al., 1998). It is possible that this may account for the 
lower 12-month PDI scores observed in the present study; however, it is unlikely that this is the 
reason behind the lower PDI scores observed at 24 months. In research mentioned above (Frank, 
et al., 2002), PDI scores of cocaine-exposed and non-exposed children, assessed at six, 12 and 24 




Children who received any form of early intervention (including parent-child groups, home health 
services, and clinical services such as occupational or speech therapy), regardless of cocaine 
exposure status, showed an increase in PDI scores, whilst children not receiving any intervention 
services showed a significant decline in PDI scores across the assessment periods (Frank, et al., 
2002). While anecdotally it was found that some families in the current study had accessed 
parenting support, health, and other clinical services, children’s involvement with early 
intervention services was not formally assessed. Thus, it was not possible to examine the impact 
of this sort of intervention on developmental outcomes in the current study. 
 
Behavior Rating Scale 
Very few previous studies have examined behaviour, using the BRS, in opioid-exposed infants. In 
the present study, mean scores on the BRS did not differ significantly between the three groups of 
infants at 12 months of age. The mean score of the BM group was approximately three points 
higher than for infants in the other two groups, although this difference was not significant and 
the effect size of the difference was small. Male infants were more than three times as likely as 
female infants to obtain a behaviour score below the average range (p=.07). When infant gender, 
perceived maternal social support at four months of age, and current home environment were 
included in the analyses, male gender remained significantly associated with lower BRS scores, 
and a more optimal home environment remained significantly associated with higher BRS scores 
at 12-months of age (see Table 6.4). 
 
Consistent with the assessment at 12 months of age, behaviour scores were similar across the 
three groups of infants at 24 months of age. When perceived maternal social support at four 
months of age and current home environment were included in the analyses, 24-month home 
environment remained the only significantly predictor of 24-month behaviour score, with a more 




6.7). Contrary to the finding at 12 months, there was no effect of infant gender on behaviour at 
two years of age. There was a significant 14 point decline in mean BRS scores over the two 
assessments [t(59)=10.42, p<.0001]. This decrease in the scores may reflect normal 
developmental changes in toddler behaviour, where two year old children may have been starting 
to assert their independence and were thus becoming more difficult to assess, and less compliant 
than 12 month olds. Alternatively, the change in scores may be due to other developmental 
problems, not yet diagnosed, such as ADHD or autism, beginning to emerge. 
 
The findings of the current study are similar to those of Frank and colleagues (2002) who found no 
significant differences in Infant Behaviour Record scores (IBR, the precursor scale to the BRS) 
between cocaine-exposed infants and non-exposed infants when assessed at six and 24 months of 
age. However, contrary to results of the current study, Frank et al. found no significant decline in 
IBR scores across assessments for either group of children (Frank, et al., 2002).  
 
More recently, Messinger et al. (2004) reported that, in univariable analyses, mean 24-month BRS 
scores for opioid exposed children were significantly lower than for non-opioid exposed children. 
However, in multivariable analyses overall performance on the BRS was not associated with 
prenatal exposure to opioids. Mean BRS scores of opioid-exposed infants did not differ 
significantly from non-exposed infants at 12 or 36 months of age. As with the current study, 
Messinger et al. (2004) reported that BRS scores decreased between 12 and 24 months of age. 
However, unlike the present study, the decline in scores for the Messinger sample was not 
significant. Additionally, mean scores for each group actually significantly rose after the 24 month 
assessment, although substance exposure was not associated with this increase in scores. Similar 
to the present study, Messinger and colleagues found that higher scores on the HOME scale were 





In contrast to results found in the current research, Hans (1989) reported that methadone-
exposed infants scored significantly higher (indicating poorer functioning) on the tension, gross 
motor coordination and fine motor coordination items of the Infant Behaviour Record (IBR) than 
non-exposed infants at 24 months of age. Although it was noted that mean scores for all items 
were within the average range. When children from low SES families were examined separately, 
methadone-exposed infants from low SES backgrounds scored more poorly on the IBR items than 
non-exposed infants. The author concluded that prenatal exposure to methadone may increase 
susceptibility to the effects of a disadvantaged environment (Hans, 1989). 
 
There are a number of possible explanations for the results obtained in the present study. As 
discussed above, prenatal exposure to opioids may be associated with disturbances to selective 
neurotransmitter systems, which may in turn influence attention, memory and other cognitive 
functioning, along with motor control in exposed infants and children. Secondly, prenatal 
exposure to benzodiazepines has been shown to be associated with deviations in brain 
development and subsequent deficits in cognitive and motor performance which may not become 
evident until later infancy (Viggedal, et al., 1993). Thirdly, maternal literacy and language 
capabilities, along with cultural factors specific to this population of children, may have 
contributed to the large proportion of infants who scored below the average range on the MDI 
and PDI. Finally, it is evident from the results of the present study that the quality of the home 
environment is arguably the most important influence on a child’s cognitive, motor and 
behavioural development, over and above prenatal substance exposure. This result is consistent 
with previous research which has demonstrated the considerable effect of socioenvironmental 
factors on children’s development (Lifschitz, et al., 1985; Messinger, et al., 2004; Tong, et al., 







This chapter describes the temperament of infants at four, 12 and 24 months of age, as measured 
with the Short Temperament Scale for Infants (STSI) and the Short Temperament Scale for 
Toddlers (STST) (Prior, et al., 1989; Sanson, et al., 1987). First, temperament factor scores at four, 
12 and 24 months of age were examined. Second, relationships between potential confounding 
variables and the composite Easy/Difficult Scale (EDS) scores of the Temperament Scales were 
evaluated, and differences in EDS scores between groups were then analysed adjusting for 
significant confounding variables. Third, change in EDS scores over time was examined across the 
three groups of infants.  
 
This chapter addresses the following hypotheses:  
Hypothesis 9:  
Composite Easy/Difficult Scale (EDS) scores of infants prenatally exposed to buprenorphine will 
not differ significantly from a non-exposed control group when assessed at four, 12 and 24 
months of age.  
Hypothesis 10:  
Composite EDS scores of infants prenatally exposed to methadone will be significantly higher, 
indicating more difficult temperament, than those of infants prenatally exposed to buprenorphine 
and a non-exposed control group of infants when assessed at four, 12 and 24 months of age.  
Hypothesis 11:  
Change in composite EDS scores over time will not vary significantly between children prenatally 






Analyses were conducted according to the methods described in Chapter 2, section 2.7, and 
previously outlined in the statistical analyses section of Chapter 4.  
 
Briefly, a series of simple linear regression analyses and ANOVAs were conducted to examine the 
contribution of independent variables to the EDS scores at four, 12 and 24 months of age. 
Standard multiple regression analyses were then conducted to examine the contribution of each 
independent variable to the individual EDS scores, whilst adjusting for the effect of the other 
variables in the model. Finally, a split-plot ANOVA was undertaken to examine whether EDS 
scores changed over time, and whether change in EDS scores varied between infants in each of 
the three groups. Because the STSI and the STST differ slightly in their content and factor 
structure (Pedlow, Sanson, Prior, & Oberklaid, 1993), interpreting change in mean EDS scores 
between the four month follow-up assessment and the other two follow-up assessments, at 12 
and 24 months, may be problematic. Therefore, in order to directly compare the scores at each 
time point, the raw EDS scores were converted to z-scores for use in the split-plot ANOVA. 
 
7.1 Infant Temperament at four months of age 
Temperament scores were collected successfully from 86/87 (99%) of participating infants at the 
four month follow-up assessment. The mother of one male BM infant did not complete the Short 
Temperament Scale for Infants, as he was not in her care at the time of this assessment.   
 
Table 7.1 shows that at four months of age there were no significant differences between the 
three groups of infants for any of the temperament factor scores: Approach factor [Kruskal-Wallis: 
χ
2 (2) = 0.46, n = 86, p = .80], Rhythmicity factor [Kruskal-Wallis: χ
2 (2) = 3.67, n = 86, p = .16], 




Activity/Reactivity factor [F(2,82) = 0.54, p = .58], and Irritability factor [F(2,82) = 0.03, p = .97, 
square root transformation].  
 
At four months of age mean Composite Easy/Difficult Scale (EDS) scores did not differ significantly 
between the three groups of infants [F(2,83) = 0.16, p = .85, square root transformation, η
2 = .004] 
(Table 7.1). Overall, EDS scores for 64% of all infants fell within the ‘Average’ temperament range, 
30% of the sample (nine controls, seven BM,  ten MM) scored within the ‘Easy’ temperament 
range (≤ 1SD below the standardised mean of 2.50), while 6% (three controls, two MM) scored in 
the ‘Difficult’ temperament range (≥ 1SD above the standardised mean). There was no significant 
difference in temperament rating between the three groups of infants (Fisher’s exact test p = .21), 
and no difference between boys and girls (Fisher’s exact test p = .94). 
 
7.1.1 Relationship between four month Easy/Difficult Scale scores and potential confounding 
variables 
Lower EDS scores (indicating easier temperament) at four months of age were significantly 
associated with (1) higher maternal postnatal Global Attachment Scores (indicating better 
maternal-infant attachment) at four months of age *β = -.48, t(83) = -5.02, p < .001], (2) lower 
maternal psychological distress at four months of age *β = .41, t(84) = 4.09, p < .001, square root 
transformation], and (3) better perceived maternal social support at four months of age *β = -.27, 
t(84) = -2.52, p < .05, square root transformation].  
 
7.1.2 Four month Easy/Difficult Scale scores adjusting for potential confounding variables 
Variables entered into the model were 4-month EDS scores as the dependent variable, with 
maternal postnatal Global Attachment Score at four months, maternal psychological distress 
(GHQ Total Score) at four months, perceived maternal social support (ISSI-SF Total Score) at four 




shows that, after adjustment for other covariates, Global Attachment Score remained a significant 
predictor of infant EDS scores at four months of age (p < .001) and provided the largest unique 
contribution to the variance in the model. GHQ Total Score at four months of age also remained 
significantly associated with infant EDS scores at four months of age (p < .01), and provided the 
next largest contribution to the variance in the model. Overall, the model explained 32% of the 
variance in EDS scores at four months of age and was significant at p < .0001. After adjusting for 
covariates, ISSI-SF Total Score did not provide a significant contribution to the model. In addition, 
group was not significantly associated with EDS scores at four months of age [F(2,79) = 0.47, p 
=.62], after adjusting for covariates, indicating that prenatal exposure to buprenorphine or 
methadone did not influence infant temperament at four months of age.  
 
7.1.3 Summary of Infant Temperament at four months of age 
Easy/Difficult Scale (EDS) scores at four months of age did not differ significantly between the 
three groups of infants, after adjusting for maternal postnatal attachment, maternal psychological 
distress, and perceived maternal social support. Maternal postnatal attachment remained a 
significant predictor of EDS scores at four months of age (p < .001), with better maternal-infant 
attachment related to easier infant temperament. Lower maternal psychological distress also 
remained significantly associated with easier infant temperament at four months of age (p < .01). 
 
7.2 Infant Temperament at 12 months of age 
Temperament scores were collected from all (n = 83) participating infants at the twelve month 
follow-up assessment.  
 
Table 7.3 shows that at 12 months of age there were no significant differences across the three 
groups of infants on any of the temperament factor scores: Approach/ Adaptability factor 
[Kruskal-Wallis: χ




factor [F(2,79) = 1.46, p = .24], Cooperation/Manageability factor [F(2,80) = 0.37, p = .69], 
Distractibility factor [F(2,80) = 1.33, p = .27], and Rhythmicity factor [F(2,79) = 0.71, p = .50]. 
 
One-way ANOVA showed that, at 12 months of age, mean EDS scores were very similar across the 
three groups of infants (Table 7.3). With a small effect size of η
2 = .01, this difference did not reach 
statistical significance [F(2,80) = 0.25, p = .78, log transformation]. Overall, 77% of infants scored 
within the ‘Average’ temperament range on the 12-month EDS scores, 11% (three controls, four 
BM, two MM) scored within the ‘Easy’ temperament range (≤ 1SD below the standardised mean 
of 3.46), while 12% (four controls, four BM, two MM) scored in the ‘Difficult’ temperament range 
(≥ 1SD above the standardised mean). There was no significant difference in temperament rating 
between the three groups of infants (Fisher’s exact test p = .94), and no difference between boys 
and girls (Fisher’s exact test p = .42). 
 
7.2.1 Relationship between 12-month Easy/Difficult Scale Scores and potential confounding 
variables 
Lower EDS scores (indicating easier temperament) at 12 months of age were significantly 
associated with higher maternal postnatal attachment scores (indicating better maternal-infant 
attachment) at four months of age *β = -.32, t(80) = -3.00, p < .01]. Although there was an 
interesting suggestion of a relationship between higher 12-month EDS scores (indicating more 
difficult temperament) and 1) higher scores on the GHQ at four months of age (indicating higher 
levels of maternal psychological distress), and 2) higher scores on the Parenting Stress Index 
(suggesting higher levels of parenting stress) at 12 months of age, neither of these relationships 
reached conventional levels of statistical significance *GHQ: β = -.21, t(81) = -1.91, p = .06, inverse 





7.2.2 Twelve month Easy/Difficult Scale scores adjusting for potential confounding variables 
Variables entered into the model were 12-month EDS score as the dependent variable, with 
maternal postnatal Global Attachment Score at four months and group (control group as the 
reference) as the predictor variables. Table 7.4 shows that, after adjustment for other covariates, 
Global Attachment Score remained a significant predictor of infant EDS scores at 12 months of 
age (p < .01) and provided the largest unique contribution to the variance in the model. After 
adjusting for covariates, group status was not significantly associated with EDS scores at 12 
months of age [F(2,78)=  0.16, p = .85]. PSI Parent Domain Total score at 12 months of age and 
General Health Questionnaire (GHQ) Total score at four months were not included in the 
multivariable analyses because with limited study numbers, the use of too many covariates can be 
problematic. There was also a large amount of missing data for the PSI Parent Domain Total score 
and its inclusion in the multiple regression analysis further reduced the available sample size. 
However, when GHQ Total score at four months replaced the Global Attachment Score in the 
model, the overall results remained similar and it did not make a significant contribution to the 
model (results not shown).  
 
7.2.3 Summary of Infant Temperament at 12 months of age 
Twelve month EDS scores did not differ significantly between the three groups of infants, after 
adjusting for maternal postnatal attachment. Global Attachment Score at four months of age 
remained a significant predictor of infant EDS scores at 12 months of age (p < .01), with better 
maternal-infant attachment at four months of age associated with easier infant temperament at 





7.3 Temperament at 24 months of age  
Temperament scores were collected from 71/ 73 (97%) participating infants at the twenty-four 
month follow-up assessment. Two families (one each in the BM and MM groups) did not return a 
completed questionnaire at this assessment. 
 
Table 7.5 shows that at 24 months of age there were no significant differences between the three 
groups of infants for any of the temperament factor scores: Approach/ Adaptability factor [F(2,68) 
= 1.86, p = .16], Reactivity factor [F(2,68) = 0.15, p = .86], Persistence factor [F(2,68) = 1.57, p 
=.22], Cooperation/Manageability factor [Kruskal-Wallis: χ
2 (2) = 0.02, n = 71, p = .99], 
Distractibility factor [F(2,68) = 1.44, p = .24], and Rhythmicity factor [F(2,68) = 2.08, p = .13]. 
 
One-way ANOVA showed that, at 24 months of age, mean EDS scores did not differ significantly 
between the three groups of infants (Table 7.5) [F(2,68) = 0.21, p = .81, square root 
transformation]. At 24 months of age, EDS scores of 75% of participating infants fell within the 
‘Average’ temperament range, 6% of the sample (two controls, one each in the BM and MM 
groups) scored within the ‘Easy’ temperament range (≤ 1SD below the standardised mean of 
3.32), while 20% (eight controls, three each in the BM and MM groups) scored in the ‘Difficult’ 
temperament range (≥ 1SD above the standardised mean). There was no significant difference in 
temperament rating between the three groups of infants (Fisher’s exact test p = .75), and no 
difference between boys and girls (Fisher’s exact test p = .76). 
 
7.3.1 Relationship between 24-month Easy/Difficult Scale scores and potential confounding 
variables  
Lower EDS scores (indicating easier temperament) at 24 months of age were significantly 
associated with (1) higher maternal postnatal Global Attachment Scores (indicating better 




perceived maternal social support at four months of age *Spearman’s rho= -.33, n =71, p <.01], 
and (3) lower scores on the Parenting Stress Index (suggesting lower levels of parenting stress) at 
24 months of age *β = .35, t(59) = 2.88, p <.01]. There was an interesting suggestion of a 
relationship between higher 24-month EDS scores (indicating more difficult temperament) and 
higher scores on the GHQ (indicating higher levels of maternal psychological distress) at four 
months of age, and lower maternal educational attainment, however, neither of these 
associations reached conventional levels of statistical significance [GHQ: Spearman’s rho = .23, n = 
71, p = .06; maternal education: F(1,69) = 3.54, p = .06].  
 
7.3.2 Twenty Four month Easy/Difficult Scale scores adjusting for potential confounding variables 
Variables entered into the model were 24-month EDS score as the dependent variable (square 
transformation), with maternal postnatal Global Attachment Score at four months, perceived 
maternal social support (ISSI-SF Total Score) at four months of age, and group (control group as 
the reference) as the predictor variables. Parenting Stress Index Score at 24 months of age was 
not included in the multivariable analysis because it was significantly correlated with ISSI-SF Total 
Score at four months of age [Pearson correlation coefficient = -.67, n = 61, p < .0001] and, as there 
was a large amount of missing data, its inclusion in the multiple regression considerably reduced 
the available sample size. Table 7.6 shows that, after adjustment for other covariates, Global 
Attachment Score remained a significant predictor of infant EDS scores at 24 months of age (p < 
.05) and provided the largest unique contribution to the variance in the model. After adjusting for 
covariates, neither ISSI-SF Total Score, nor group status [F(2,65) = 0.21, p = .81] contributed 





7.3.3 Summary of Infant Temperament at 24 months of age 
Twenty-four month EDS scores did not differ significantly between the three groups of infants 
after adjusting for maternal postnatal attachment and perceived maternal social support at four 
months of age. After adjusting for covariates, better maternal postnatal attachment at four 
months of age remained a significant predictor of lower infant EDS scores (indicating easier 
temperament) at 24 months of age (p<.05). 
 
7.4 Longitudinal analyses of Easy/Difficult Scale Scores 
Figure 7.1 shows the mean EDS (raw) scores of each group at each of the three follow-up 
assessments. As mentioned earlier, the STSI and the STST differ in their content and factor 
structure (Pedlow, et al., 1993). Because of this, it is difficult to directly compare the raw EDS 
scores for the four-month assessment with the 12- and 24-month EDS scores. In order to examine 
whether there was any variation in change in temperament over the three assessments, between 
the three groups of infants, the raw EDS scores were converted to z-scores. A z-score is a 
standardised variable with a mean equal to zero, and a standard deviation equal to one (A. L. 
Edwards, 1979). To convert the raw data to z-scores, the mean of the observed EDS scores was 
taken away from the EDS score of each infant, and divided by the standard deviation of the 
observed scores. Figure 7.2 shows the mean EDS z-scores of each group at each of the three 
follow-up assessments. 
 
A split-plot ANOVA was conducted with the EDS z-scores as the dependent variable, group 
entered as the between-subjects factor, and time (4, 12 and 24 months) entered as the within-
subjects factor. Global Attachment score at four months of age was entered as a covariate. 
Preliminary checks were conducted to ensure that there was no violation of the assumptions of 





The ANOVA showed that the main effect for time was not significant [F(2,145) = 0.09, p = .91]. 
This result indicates that EDS scores did not change significantly over the three follow-up 
assessments. The ANOVA showed no significant main effect for group [F(2,82) = 0.50, p = .61], or 
Global Attachment score [F(1,82) = 0.04, p = .84]. Additionally, the time × group interaction did 
not reach statistical significance [F(4,145) = 0.27, p = .90], indicating that changes in EDS scores 
over the three follow-up assessments did not vary significantly between the three groups of 
infants. The effect sizes for all variables were small (η
2 < .01).  
 
7.4.1 Summary of temperament longitudinal analyses  
Results of the split-plot ANOVA supported the hypothesis that change in temperament scores 
over time would not vary significantly between infants prenatally exposed to buprenorphine, 
methadone or the non-exposed control group of infants. The interaction between group status 
and time was not significant, indicating that change in EDS scores over the three follow-up 
assessments did not differ significantly between the three groups of infants.  
 
7.5 Discussion 
This chapter compared the temperament of infants exposed to methadone or buprenorphine in 
pregnancy with that of a group of non-exposed infants. The key findings were that temperament, 
as measured by the Easy/Difficult Scale scores (EDS) on the Short Temperament Scale for Infants 
at four months of age, and the Short Temperament Scale for Toddlers at 12 and 24 months of age, 
did not differ significantly between infants prenatally exposed to buprenorphine, methadone, or a 
non-exposed control group. There was no change in this relationship after adjustment for 
covariates. As hypothesised, change in EDS over time did not vary significantly between the three 
groups of infants. These findings are important in terms of providing support for the ongoing use 




As described in Chapters 4 and 6, animal studies have shown that prenatal exposure to opioids 
can result in disturbance to the normal development of neurotransmitter systems in the 
developing infant. In terms of how this may affect temperament in exposed infants and children, 
research has shown that serotonin influences latent inhibition, behavioural organisation, is 
involved in the coordination of sensory responses, and is important in regulating sleep/wake 
cycles (Herlenius & Lagercrantz, 2004; Konijnenberg & Melinder, 2011). In animals, prenatal 
exposure to methadone has been shown to influence the serotonin transport system in the cortex 
and hippocampus, and increases in serotonin have been observed in the parietal cortex, 
compared with non-exposed controls (Konijnenberg & Melinder, 2011; Robinson, et al., 1997). In 
addition, opioids are known to disrupt circadian rhythms and alter the response to stress 
(Pechnick, 1993).  Previous research has suggested that opioids may act indirectly upon the 
cholinergic system, which in the CNS is responsible for regulation of memory, learning, and 
attention (Everitt & Robbins, 1997). Specifically, opioid-exposure has the effect of delaying and 
disrupting cholinergic development in the striatum (Robinson, 2000, 2002; Wu, et al., 2001), 
which is involved in the regulation of attention and inhibitory control (Herrero, et al., 2002; 
Roberts, et al., 2004). Wu and colleagues (2001) found that exposure to 9 mg/kg/day methadone 
or 1.5 mg/kg/day buprenorphine (delivered prenatally, postnatally, or both) reduced striatal 
nerve growth factor (NGF) content in 10-day-old rat pups. NGF is thought to be responsible for 
delays in cholinergic phenotype expression, which may subsequently disrupt the development of 
cholinergic neurons. These mechanisms may be responsible for behavioural difficulties, such as 
high rates of distractibility and poor inhibition, observed in some opioid-exposed human infants 
(Tempel, et al., 1995; Tiong & Olley, 1988; Wu, et al., 2001).  
 
In the current study, mean temperament factor scores for infants prenatally exposed to 
methadone, buprenorphine and a non-exposed control group, at 4, 12, and 24 months of age, 




(Oberklaid, et al., 1986; Sanson, et al., 1985). Furthermore, Easy/Difficult Scale (EDS) scores at 
each assessment were within the average range for all groups of infants. EDS scores did not differ 
significantly between the control group and the two substance-exposed groups at any of the 
three assessments. Higher maternal postnatal Global Attachment Scores at four months of age, 
indicating better maternal-infant attachment, were significantly associated with lower EDS scores, 
indicating easier temperament, at each assessment. In addition, lower GHQ Total Scores at four 
months of age, indicating lower self-reported maternal psychological distress, were significantly 
associated with easier temperament at four months of age. There were no differences in the 
proportion of infants in each of the three groups with maternal reported temperament in either 
the ‘Easy’ or ‘Difficult’ ranges at any of the three assessments. 
 
As reported in Chapter 1, only a small number of previous studies have specifically examined the 
construct of temperament in substance-exposed infants and children (van Baar, Fleury, & Ultee, 
1989; Weiss, et al., 2007). Early studies of self-regulatory behaviour have used the Brazelton 
Neonatal Behavioural Assessment Scale (NBAS), which assesses similar constructs to those 
examined in temperament scales. For example, the NBAS has shown to be moderately to strongly 
correlated with scores on the Carey Infant Temperament Questionnaire (Sostek & Anders, 1977). 
Studies using the NBAS have generally found that infants prenatally exposed to methadone 
exhibit poorer neurological functioning than non-exposed infants. Lodge and colleagues (1975) 
found that when assessed during the first week of life, infants prenatally exposed to methadone 
and/or heroin (n = 27) were significantly less alert, had significantly poorer visual orientation and 
greater levels of hypertonicity than non-exposed infants (n=10). Additionally, the opioid-exposed 
infants showed increased levels of irritability, activity and poor state lability when compared with 
the non-exposed group. The authors reported that a large proportion of the opioid-exposed 
infants required pharmacological treatment for NAS symptoms (Lodge, et al., 1975). Chasnoff et 




significantly more poorly on NBAS tasks of orientation and motor maturity, than infants in poly-
drug exposed infants (combinations of benzodiazepines, marijuana and other illicit substances, 
n=19) and a non-exposed comparison group (n=27) when assessed at two days of age. Research 
by Jeremy and Hans (1985) showed that, when assessed during the first week of life on the NBAS, 
infants prenatally exposed to methadone (n=29) had significantly higher levels of irritability, 
activity, tremulousness, hypertonicity, and significantly lower levels of motor maturity than non-
exposed infants (n=37). Additionally, the methadone-exposed infants were less ‘cuddly’, had 
higher levels of arousal, were more labile, less able to self-soothe, and displayed more hand-
sucking than the non-exposed infants (Jeremy & Hans, 1985). The authors suggested that the 
difficult behaviours displayed by the methadone-exposed infants may place them at risk of poor 
attachment relationships. Reportedly, at one month of age, the methadone-exposed group 
continued to have significantly increased muscle tone, although other behaviours did not differ 
significantly between the two groups of infants (Jeremy & Hans, 1985). Finally, van Baar et al. 
(1989) found that whilst NBAS scores of infants prenatally exposed to combinations of 
methadone, heroin and cocaine (n=28) were poorer than a non-exposed control group of infants 
(n=37), at both 40 and 44 weeks post-conception, these differences were not statistically 
significant. Follow-up at three months of age indicated that the opioid-exposed infants were 
significantly more active than their non-exposed peers. This difference was not evident at six 
months of age, and it was suggested that the early activity levels may be associated with sub-
acute symptoms of NAS (van Baar, Fleury, & Ultee, 1989).  
 
Three studies have used validated temperament questionnaires with populations of substance-
exposed children. Weiss et al. (2007) found that mothers of six month old infants prenatally 
exposed to cocaine or opiates (n = 30) rated them as significantly more distractible and intense in 
their expressiveness on the Revised Infant Temperament Questionnaire, than mothers of infants 




distractibility remained significantly associated with prenatal substance exposure. The authors 
suggested that the higher levels of distractibility observed in prenatally exposed infants may be 
associated with poor regulation of the arousal and excitatory response (Weiss, et al., 2007). Van 
Baar et al. (1989) found no significant differences in caregiver-rated temperament scores on a 
Dutch version of the Infant Behaviour Questionnaire, between nine-month old infants prenatally 
exposed to combinations of methadone, heroin and cocaine (n=28), and a non-exposed control 
group of infants (n=37). According to the authors, the substance-exposed infants had a slightly 
longer duration of orientation toward a single object, suggesting improved concentration, when 
compared with the non-exposed infants. No other differences in temperament ratings were 
reported (van Baar, Fleury, & Ultee, 1989). 
 
Quinlivan and Evans (2005) found that teenage mothers who were subject to domestic violence 
whilst pregnant (n=33) rated their six month old infants as significantly more irritable and more 
difficult, on the Short Temperament Scale for Infants, than mothers who were not subject to 
domestic violence (n=84). Additionally, after adjusting for covariates, infants whose mothers used 
illicit substances (primarily marijuana) during pregnancy were five times as likely as infants not 
exposed to an illicit substance, to be rated as having a difficult temperament, independent of 
maternal experience of domestic violence (Quinlivan & Evans, 2005). However, as only a subset of 
the overall sample reported use of illicit substances during pregnancy (N = 31), results from this 
multivariable analysis must be interpreted with caution.  
 
Only one study has examined the self-regulatory behaviour of infants prenatally exposed to 
buprenorphine (Sarfi, et al., 2009). Researchers in Norway found no differences in sleep patterns, 
amount of day or night time wakefulness, or the number of episodes of day-time distress, 
between 35 three month old infants prenatally exposed to opioid-maintenance medication 




(Sarfi, et al., 2009).  However, as results were not shown separately for infants prenatally exposed 
to buprenorphine or methadone, it is not possible to identify the specific effect of buprenorphine 
exposure on infant self-regulatory behaviour. 
 
Considered together, results for the above studies suggest that infants who are exposed to 
substances in utero have a tendency to display neurobehavioural difficulties in the early weeks of 
life, compared with non-exposed infants. It is highly likely that the poorer self-regulation 
demonstrated by substance-exposed infants is associated with NAS (Finnegan, 1990). Indeed, the 
cluster of symptoms that comprise NAS has been equated to the ‘difficult’ temperament profile 
described by Thomas and Chess (Jeremy & Bernstein, 1984). Whilst some difficulties in 
temperament, such as high levels of distractibility and irritability, may persist at least until nine 
months of age, it appears that beyond the neonatal period, differences in temperament between 
substance-exposed and non-exposed infants are not as pronounced.  
 
In the present study, mother-infant attachment, assessed at four months post-partum, remained 
significantly associated with caregiver ratings of infant temperament at each of the three follow-
up assessments. Additionally, a concurrent measure of maternal psychological distress was 
significantly associated with infant temperament ratings at four months of age, but not at later 
assessments. Previous research has shown that concurrent depression may influence mothers’ 
views of infant temperament and behaviour, with depressed mothers viewing their infants as 
more difficult to care for, and as having more behavioural problems than infants of non-
depressed mothers (Edhborg, Seimyr, Lundh, & Widstrom, 2000; Najman et al., 2000; Whiffen & 
Gotlib, 1989). However, when concurrent measures are used, it is not easy to establish the 
direction of cause-and-effect relationships between variables which are significantly associated. 
For example, it is equally possible that mother’s mental health influences infant temperament, 




determine whether maternal mental health influences infant temperament, or whether poor 
mental health colours maternal perceptions of child temperament. We attempted to address 
these issues with a prospective longitudinal design.  
 
As noted earlier, maternal psychological distress (GHQ Total score) at four months of age was 
significantly associated with caregiver ratings of child temperament at four months of age, after 
adjustment for covariates. Although there was a suggestion of a relationship between maternal 
psychological distress at four months and child temperament at 12 and 24 months, these 
univariable analyses did not reach conventional levels of statistical significance. Since maternal-
infant attachment at four months of age remained a significant predictor of temperament at 4-, 
12-, and 24-months of age, but maternal psychological distress was a significant predictor of 
temperament at only 4-months of age, this would suggest that maternal-infant attachment may 
be the more important predictor of child temperament. Given the findings of previous research, 
the possibility that maternal psychological distress mediates the apparent effect of maternal-
infant attachment on child temperament, or shows common variance with maternal-infant 
attachment, cannot be discounted. 
 
Independent observations of infant temperament by another rater may overcome this problem; 
however, examiner-rated questionnaires are limited in that they assess only situation-specific 
behaviour (Whiffen & Gotlib, 1989). In the current study, ratings of infant behaviour were 
assessed at the 12 and 24 month follow-up assessments, using the Behaviour Rating Scale (BRS) of 
the Bayley Scales of Infant Development - Second Edition (see Chapter 6).  Correlations between 
the BRS and caregiver ratings of infant temperament on the STST were small (r = .06 to -.24), with 
only the relationship between the 24-month BRS and 24-month EDS score nearing conventional 





In summary, whilst some studies indicate that prenatal exposure to opioids may influence infant 
temperament, it is possible that the presence of NAS symptoms confounds the measurement of 
underlying self-regulatory behaviour. Results of the current study suggest that assessment 
beyond the neonatal period, when the transient effects of substance exposure are less likely to 
influence outcomes, is important. Additionally, consideration must be given to the effect that 
maternal mental health may have on ratings of infant temperament. Results of the current study 
indicate that maternal-infant attachment and maternal psychological distress at four months of 
age are strong predictors of caregiver ratings of both current and future infant temperament, 
regardless of prenatal substance-exposure. These findings suggest that early psychological 
interventions, including cognitive behavioural and attachment-based therapies, designed to 
strengthen maternal mental health and support maternal-infant attachment, may enhance infant 






Conclusion and Recommendations 
Rising drug abuse is a worldwide phenomenon (Bell & Lau, 1995), with recent research pointing to 
increases in the number of people entering drug-treatment programs, as well as escalations in 
rates of drug-related harm and death (Anderson, 2006; Degenhardt, Hall, Warner-Smith, & 
Lynskey, 2004). For example, the 2010 National Drug Strategy Household Survey (NDSHS 
(Australian Institute of Health and Welfare, 2011) found that the proportion of Australians 
reporting use of illicit substances within the previous 12 months had increased from 13.4% in 
2007 to 14.7% in 2010 (Australian Institute of Health and Welfare, 2011). This is a substantial 
increase from that reported in the 1997 Australian National Survey of Mental Health and Well-
Being,  which found that 10.8% of Australians had reported recent use of an illicit substance 
(McBride, et al., 2009).  
 
Research reports that a large proportion of the drug using population are women of childbearing 
age (Laken, et al., 1997), with the 2010 NDSHS reporting that recent illicit drug use was highest 
among young people aged 18-29 years, and recent heroin use most frequently reported by 
Australians aged 30-39 years (Australian Institute of Health and Welfare, 2011). This report found 
that overall, there was a statistically significant increase in recent illicit drug use by females from 
11% in 2007 to 12.3% in 2010 (Australian Institute of Health and Welfare, 2011). 
 
Prenatal exposure to illicit opioids increases the risk of poor obstetric outcomes, growth deficits, 
and developmental problems in exposed infants and children, when compared with their non-
exposed peers (Adams, et al., 1989; Berlin, et al., 1998; Chang, et al., 1992; Kandall, et al., 1976; 




pregnant, opioid-dependent women, and while there are many benefits of methadone-
maintenance during pregnancy, its use is associated with high rates of neonatal abstinence 
syndrome (NAS). Additionally, infants who are prenatally exposed to methadone may experience 
deficits in physical growth, as well as longer term developmental and behavioural difficulties, 
compared with non- exposed infants (Australian Drug Foundation, 2005b; Bernstein, et al., 1984; 
Chang, et al., 1992; Davis & Templer, 1988; Dunlop, et al., 2003; Finnegan & Kandall, 1997; R. E. 
Johnson, Jones, et al., 2003; Lejeune, et al., 2006; Lintzeris, et al., 2006; Marcus, et al., 1984; van 
Baar, Fleury, Soepatmi, et al., 1989; van Baar, et al., 1994; Wilson, 1989).     
 
Whilst methadone appears to be an effective and acceptable treatment for opioid-dependence in 
pregnancy, buprenorphine is now increasingly being prescribed as a maintenance medication. 
This is because its partial agonist properties result in milder withdrawal effects, a longer duration 
of action, and an improved safety profile in comparison to methadone. There is a growing body of 
research to support the safety and efficacy of buprenorphine during pregnancy and the early 
neonatal period, however its use during pregnancy is still restricted in some countries, including 
Australia (Lintzeris, et al., 2006). This is because studies to date have been limited by small 
numbers, lack of comparison to existing treatments and control groups, retrospective designs, 
and short follow-up periods (Gordon, 2006; R. E. Johnson, Jones, et al., 2003; Jones, et al., 2005; 
Jones, et al., 2010; Kayemba-Kay's & Laclyde, 2003; Lacroix, et al., 2004; Lejeune, et al., 2006). 
Further, information regarding longer term developmental outcomes for children prenatally 
exposed to buprenorphine is scarce. Given the growing use of buprenorphine as a maintenance 
treatment, research examining the long term effects of prenatal exposure to buprenorphine is 
crucial (Davids & Gastpar, 2004; Lintzeris, et al., 2006; Mattick, et al., 2003).  
 
This study is the first of its kind to provide comprehensive, longitudinal data regarding the 




methadone or buprenorphine in Australia. Additionally, this is the first study to describe these 
outcomes for infants prenatally exposed to buprenorphine, beyond the neonatal period. This 
research may be useful in supporting the approval of buprenorphine as a pharmaceutical 
maintenance treatment, in addition to the use of methadone, in pregnancy in clinical settings.  
 
Of the 11 proposed hypotheses (see page 69-70), eight were supported. The results of this study 
showed that infants prenatally exposed to buprenorphine did not differ from non-exposed infants 
in their physical growth, neurological development, or temperament during the first two years of 
life. These findings add to the literature supporting the safety and efficacy of buprenorphine 
during pregnancy, the neonatal period, and early childhood. In addition, results showed that 
infants prenatally exposed to methadone fare more poorly than infants exposed to 
buprenorphine in terms of physical growth and early neurological development. It appears that 
methadone exposure in utero may continue to influence infant weight, until at least two years of 
age. Reassuringly, head circumference (HC) did not differ between the three groups of infants at 
any of the three follow-up assessments. HC is a key indicator of brain growth and cognitive 
development (García-Alix, et al., 2004; Noyola, et al., 2001), and the finding that the head growth 
of infants prenatally exposed to either methadone or buprenorphine was similar to that of non-
exposed infants is important in providing support for the continuing use of both maintenance 
treatments during pregnancy.  
 
In addition to having a pervasive influence on infant weight in early childhood, prenatal exposure 
to methadone may result in significant delays to visual maturation in early infancy. At four months 
of age, VEP latencies of infants prenatally exposed to methadone were found to be prolonged 
compared with those of both infants prenatally exposed to buprenorphine, and those of non-




caregiver-rated infant temperament at 4-, 12- and 24-months, did not differ between infants 
prenatally exposed to methadone, buprenorphine, or non-exposed controls.  
 
Results of the present study indicate that the quality of a child’s care-giving environment has a 
strong influence over their cognitive, motor and behavioural development. This finding is 
consistent with previous research which has found socio-environmental factors to be important 
predictors of children’s development (Lifschitz, et al., 1985; Messinger, et al., 2004; Tong, et al., 
2006; Wilson, 1989). Additionally, results of the current study showed that mother-infant 
attachment at four months post-partum was the most important predictor of care-giver ratings of 
infant temperament at each of the three follow-up assessments. These results are consistent with 
previous research which has shown that maternal mental health influences mother-infant 
bonding and infant temperament (Austin, Hadzi-Pavlovic, Leader, Saint, & Parker, 2005; Edhborg, 
et al., 2000; Hans, et al., 1999; Najman, et al., 2000; Whiffen & Gotlib, 1989).  
 
8.1 Study strengths and limitations  
Strengths of the study 
This is the first study to provide comprehensive data describing the longitudinal physical growth, 
neurological development, and temperament of infants and young children prenatally exposed to 
buprenorphine. This research contributes important knowledge regarding the safety and efficacy 
of buprenorphine as a maintenance treatment for pregnant women with opioid dependence. This 
is important because the number of women using illicit substances during pregnancy is high 
(Abdel-Latif, et al., 2007; Kennare, et al., 2005; Substance Abuse and Mental Health Services 
Administration, 2010). Whilst maintenance with methadone has traditionally been the first line 
treatment for pregnant women with opioid-dependence (Dunlop, et al., 2003; Farid, et al., 2008; 
Lintzeris, et al., 2006), there is evidence that increasing numbers of women are using 




2006; Gordon, 2006; R. E. Johnson, Jones, et al., 2003; Jones, et al., 2010; Lejeune, et al., 2006). 
The high incidence of NAS and poorer early developmental outcomes for methadone-exposed 
infants, along with the stigma associated with methadone use, highlights the need for additional 
maintenance pharmacotherapies for pregnant opioid-dependent women (Davis & Templer, 1988; 
Hamilton, et al., 2010; Hans, 1989; Hunt, et al., 2008; Lifschitz, et al., 1983, 1985; Soepatmi, 1994).  
 
There are several strengths of the present research. This is the first study to compare methadone 
with another active opioid treatment medication on the long-term outcomes examined. It is also 
the first study to compare the development of methadone-exposed infants with that of non-
opioid exposed comparison infants in a prospective, rigorous and well-controlled study which 
considers many of the potential confounding factors that may influence infant development. 
 
A second strength of the study was that the response (87%) and the retention (69%) rates were 
very good, particularly considering the characteristics of the study population. Previous 
longitudinal research with opioid-dependent women and their infants has been often been 
hampered by small sample sizes and poor rates of follow-up. For example, Wilson, Desmond and 
Verniaud (1973) examined the development, between the ages of three and 34 months, of 30 
infants prenatally exposed to heroin. The authors reported that only 14 of these infants were 
followed-up for 12 months or longer, and commented that lack of parental cooperation in 
attendance at follow-up appointments posed a challenge to researchers. In another early study, 
Ramer and Lodge (1975) followed the development of 34 infants prenatally exposed to 
methadone maintenance, from birth to two years of age, however, numbers at each of the six 
follow-up assessments ranged from n=4 to n=20. Lifschitz and colleagues (1983, 1985; Wilson, et 
al., 1981) recruited 125 women and their infants in a longitudinal study examining infant 
development after prenatal opioid-exposure. Whilst 95% of participants were retained at the 12 




assessment when children were a mean age of 3.4 years, 74% of the original sample were 
retained. Soepatmi (1994) reported on the longitudinal development of 168 children exposed to 
illicit drugs (mainly heroin and methadone) in pregnancy. Of the 157 children who survived 
beyond the first year of life, only 67 (43%) were followed-up longer than 12 months. One hundred 
and forty four families were approached to participate in a follow-up study between three and 12 
years later, of which 63% consented (Soepatmi, 1994). More recently, Hunt et al. (2008) examined 
the growth and cognitive development of 133 opiate-exposed infants and 103 non-exposed 
infants. Fifty nine percent of the total sample (140/236) participated in the follow-up assessment 
at 18 months of age, whilst at three years, 111 (47%) were assessed.  
 
Women who use illicit substances are at increased risk of experiencing negative life events, such 
as mental health problems, domestic violence, transience, and financial hardship (Hans, et al., 
1999; Nair, et al., 2003). All of these factors may make it difficult to engage them in longitudinal 
studies. The good response and retention rates in the present study were achieved by building 
strong relationships with participants, and with the staff from Drug and Alcohol Services South 
Australia (DASSA), the Women’s and Children’s Hospital (WCH), and Flinders Medical Centre 
(FMC). Substantial effort was required to engage and maintain contact with participating women 
and their infants. In order to maximise participation, I arranged to meet with many potential 
participants during the antenatal period, and apart from the two families who moved interstate, I 
individually conducted every follow-up assessment for each child in the study. Having a flexible 
schedule, which included contacting participants by telephone (usually mobile) or text message to 
remind them of study visits, and conducting home visits on weekends or after hours when this 
was more convenient for the families was also helpful. Whilst I visited families in their homes on 
average only yearly, I feel that this continuity and willingness to meet with the mothers and the 
children in their own environment was an important element in maintaining such high 




hours drive away from Adelaide), and many did not drive, or were unable to afford the petrol to 
travel into the city. Additionally, the provision of a small financial compensation to participants, 
along with the gift of an educational toy or book for the children at each study visit, were 
appreciated and assisted in maintaining participation. Many families commented that the children 
greatly enjoyed the gifts, and at some visits I noticed that the books provided were the only ones 
a child owned. 
 
Third, recruitment included all eligible women in the greater Adelaide area who wished to be 
maintained on buprenorphine throughout their pregnancy. Pregnant substance-dependent 
women in South Australia are usually referred to the high-risk pregnancy clinics at the Women’s 
and Children’s and Flinders Hospitals for antenatal care, thus we were able to recruit a reasonably 
high proportion of all eligible pregnant opioid-dependent women (see Chapter 3). We can be 
confident that results of the study may be generalisable to opioid-dependent women receiving 
maintenance treatment in South Australia, and their infants. The exception to this is that the 
current sample may not have been representative of indigenous opioid-dependent women 
receiving maintenance treatment in South Australia. The 2009 National Pharmacotherapy 
Statistics indicated that seven percent of pharmacotherapy clients in South Australia identified as 
being of Aboriginal and/or Torres Strait Islander (ATSI) origin (Australian Institute of Health and 
Welfare, 2010). However, in the current study, only two participating women (2.3%) reported 
their cultural background as ATSI. It is possible that some pregnant opioid-dependent indigenous 
women may have been residing in rural areas within South Australia and thus may have attended 
at regional health centres or hospitals for antenatal care. 
 
Fourth, the inclusion of a non opioid-exposed control group of infants strengthened the design of 
this study and allowed for a comparison of development in a similar population of infants. Fourth, 




useful precursor to the later testing on the Bayley Scales of Infant Development, and may have 
helped address any examiner bias present in later neurological testing. Additionally, the use of 
valid and reliable measures, along with examiner training in the administration of the Bayley 
Scales of Infant Development, further consolidated the study design. 
 
Finally, the longitudinal design of this research afforded some insight into relationships between 
prenatal exposure to opioids and later developmental outcomes. Longitudinal studies allow for 
inferences of cause and effect, and may assist in determining the predictive validity and stability 
of measures. Further, recall bias was limited due to the prospective, rather than retrospective, 
nature of data collection. Therefore, the longitudinal design of the research presented in this 
thesis was able to identify characteristics within families that were associated with better 
developmental outcomes for infants and young children.  
 
Limitations of the study 
The primary limitation of this study was that its parallel cohort design meant that participants 
were not randomly allocated to a treatment group. The incidence of opioid-dependent 
pregnancies in the Adelaide metropolitan area was not sufficient to support an adequately 
powered randomised controlled trial without an extended period of recruitment. Additionally, at 
the commencement of the longitudinal research study, research on the effects of prenatal 
exposure to buprenorphine was only just beginning to emerge and it was considered unethical to 
randomly assign women to a maintenance treatment. Consequently there may be unmeasured 
differences between the two maintenance groups that have independently influenced infant 
development. In order to try and address this issue, potential confounding variables were 
measured in detail and statistically controlled for in analyses. However, a consequence of this was 




A second important limitation was the small sample size. While the study was designed to include 
all eligible opioid-dependent women in Adelaide, and recruitment was extended over five years, 
the numbers in each group were small and almost 20% of participants were lost to attrition over 
the course of the study. This means that analyses may have been underpowered and thus the 
possibility of making a Type II error was increased. Additionally, in order to ensure that the effect 
of prenatal exposure to buprenorphine was no worse than the current gold standard treatment 
(methadone) in terms of the infant outcomes for which there was no significant difference, a non-
inferiority trial would have been appropriate. However, given the very large sample sizes required 
to conduct such trials, and the difficulty in recruiting the number of required participants, this sort 
of trial was not feasible for the current study. 
 
A third limitation was that we did not have detailed information regarding women’s substance 
use prior to study enrolment, nor was it possible to distinguish between use of licit and illicit 
forms of opioids or benzodiazepines at enrolment or during pregnancy. Self-reported substance 
use did not differ significantly between the BM and MM groups, and results of random urine drug 
screens conducted throughout pregnancy substantiated this data. A fourth limitation was that 
information about maternal mental health, socio-demographic factors and infant temperament 
was collected from only one informant. The use of multiple informants or mixed-methods, such as 
formal psychiatric assessment or inclusion of an observational component within the research 
protocol, would have strengthened the results, but was outside the scope of this study. Despite 
the strength of including a demographically similar non-opioid exposed comparison group, there 
may also be unmeasured differences (for example maternal medical or psychiatric co-morbidities) 





Another limitation of this study was the inability to blind the examiner to each infant’s group 
status. Initially this was attempted but became impossible to maintain, particularly as women in 
the control group often made their control status clear to the examiner at the first meeting. Thus, 
knowledge of the infants’ exposure status presents an additional study confounder. 
 
8.2 Implications and recommendations 
Results from this study support the use of buprenorphine as an additional pharmacological 
maintenance treatment for opioid- dependent pregnant women, and thus have important direct 
clinical implications. Although research to date has supported the short-term safety and efficacy 
of buprenorphine during pregnancy and the early neonatal period (Fischer, et al., 2006; Jones, et 
al., 2005; Kakko, et al., 2008), studies of the longer term development of children exposed to 
buprenorphine are few (Kahila, Kivitie-Kallio, et al., 2007; Kayemba-Kay's & Laclyde, 2003; Salo, et 
al., 2009; Sandtorv, et al., 2009; Sarfi, et al., 2009; Schindler, et al., 2003). All have had limitations, 
such as low participant numbers, lack of comparison with existing treatments or non-exposed 
populations, failing to account for prenatal exposure to other substances, or providing inadequate 
information concerning methodology and outcomes. Previous research indicates that 
buprenorphine may provide some advantages over methadone in terms of neonatal outcomes, 
including increased birth weight, reductions in the incidence and severity of NAS and shorter 
hospital stays for exposed infants (Fischer, et al., 2006; Jones, et al., 2005; Jones, et al., 2010). The 
information presented in this thesis is consistent with previous research and strengthens the 
argument for buprenorphine to be approved for use in pregnancy.  
 
Results showed that buprenorphine appears to confer advantages over methadone in terms of 
faster responses to VEP at four months of age, and healthy weight gain during early childhood. 
Whilst the advantages of buprenorphine did not extend to superior outcomes for infant cognitive, 




suggest that maternal use of buprenorphine in pregnancy appears to be as safe as methadone in 
terms of infant developmental outcomes. The benefits of buprenorphine, in terms of early infant 
neurodevelopment and healthy weight gain, suggest that it should be considered as a first line 
treatment for opioid dependence in pregnant women. Additionally, because there were few long 
term negative effects of methadone exposure, it would be reasonable to continue to offer it as a 
treatment option for opioid dependence during pregnancy if informed women wish to continue 
or commence maintenance with this treatment.  
 
Results from this study also highlight the importance of a child’s care-giving environment, and of 
early maternal mental health, in shaping future developmental outcomes. These findings suggest 
that there is a need to prioritise comprehensive mental health assessments for all opioid-
dependent pregnant women, with a view to identifying social and psychological needs. 
Anecdotally, some women in the current study indicated that they felt socially isolated, with 
women in the two maintenance groups reporting in questionnaires that they were less satisfied 
with their level of social interaction and support than were women in the control group. Levels of 
psychological distress and postnatal depression, measured when infants were four months of age, 
were relatively high in the current study for all three groups of mothers. Almost one third of 
participating women reported experiencing significant psychological distress, and over one 
quarter reached criteria for probable minor postnatal depression (see Chapter 3). Given these 
high rates of problems, consideration should be given to prioritising and tailoring comprehensive, 
consistent, and supportive care to all opioid-dependent women during pregnancy which 
continues into the postnatal period and beyond if necessary. Further, results from this study show 
that prenatal exposure to marijuana and benzodiazepines has ongoing detrimental effects on 
children’s neurological development. There was a high rate of other substance use reported by 
women during pregnancy in this study (see Table 3.4), with over one third of women reporting 




12% of controls reporting benzodiazepine use during pregnancy. Taken together, these results 
suggest that early substance-use screening is an important aspect of antenatal care. Pregnant 
women should be asked specifically about their use of these substances and provided with 
information and advice about management as these substances can have unrecognised health 
effects on foetal development (Fried, 1989; Tansley, et al., 1986; Viggedal, et al., 1993). 
 
Pregnancy may be an ideal time in which to engage substance-using women with appropriate 
services. Pregnancy and the impending birth may be seen as a strong motivator for some women 
in addressing their substance use issues. However, this may also be a time when social isolation 
increases as a woman distances herself from drug-using peers. Additionally, strained relationships 
with family, financial concerns, a history of abuse and trauma, or a partner’s substances use may 
all influence maternal mental health and parenting capacity (New South Wales Department of 
Health, 2006a). Holistic services are required which address the developmental and safety needs 
of children, along with the psychosocial, health, and parenting needs of substance-using women 
and their partners. Ongoing programs, including outreach or home visiting services, may be 
needed to prevent relapse into substance use, and provide extra support when traditional 
pregnancy and postnatal services cease. Early interventions, including cognitive behavioural, 
mindfulness and attachment-based therapies, designed to strengthen maternal mental health, 
support maternal-infant attachment, and increase the quality of a child’s care-giving environment, 
may enhance neurological development, behaviour,  and temperament outcomes for at-risk 
infants (Dawe & Harnett, 2007; Dawe, Harnett, Rendalls, & Staiger, 2003; Nair, et al., 2003). 
 
The present study provides new information regarding the developmental outcome of infants and 
young children prenatally exposed to buprenorphine or methadone. Results suggest that the 
physical growth, neurological development, and temperament of infants prenatally exposed to 




Additionally, maternal maintenance with buprenorphine appears to confer an advantage over 
methadone in terms of infant neural development at four months of age, and infant weight until 
at least two years of age. However, further research is needed to substantiate these findings. 
Future studies need to incorporate prospective longitudinal designs that follow exposed children 
into young adulthood if possible. Repeat testing of responses to VEP at later ages may assist in 
determining whether the difference in visual maturation, observed between the maintenance-
exposed groups at four months of age, remains in later childhood. Studies involving larger sample 
sizes and randomisation of participants to treatment groups are important in providing high 
quality evidence. The use of multiple informants (including fathers) to provide information about 
parental mental health, socio-demographic factors, infant temperament and a child’s care-giving 
environment would be an important addition to further research within this population. 
Nevertheless, the research presented in this thesis adds to the growing body of literature 
supporting the use of buprenorphine in pregnancy.   
 
Finally, despite the high level of disadvantage and multiple risk factors experienced by families 
who participated in this research, it was heartening to see the majority of women and their 
infants doing well. The majority of children were in the care of their natural mother at two years 
of age and only one had been taken into state care. Additionally, most families had stable 
accommodation. Overall, it appeared that many of the infants in the study were extremely 
resilient, with no major health, development or behavioural problems. It is a possibility that the 
women who remained in the study were highly motivated and interested in their child’s 
development. However, as a group they faced a number of hardships, and despite this they were 
able to provide a positive and nurturing environment for their children.  
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Figure 2.1 Study design, number of participants and response rate at each stage of the 
longitudinal study  
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Table 2.1 Number of participants and retention rates for each assessment in the early childhood 
phase of the study 
  Number of participants at each assessment  
Group Exposure Status  4 month  12 month  24 month 
Buprenorphine-exposed   30   28 (93)  24 (86) 
Methadone-exposed   24    22 (92)  19 (86) 
Non-exposed control  33      33 (100)  30 (91) 
Total  87    83 (95)  73 (88) 
Note. One participant = one parent-infant dyad. Percentages shown in parentheses are retention 
from the previous assessment.  3 
 
Table 2.2 Summary of data collected and measures used during each stage of the study 
  Pregnancy & Neonatal Phase  Early Childhood Phase 
  Enrolment  Delivery/Neonatal 
period 
4 months  12 months  24 months 
Infant Measures           
   Neurological Development    NAS scores  VEP  BSID-II  BSID-II 
   Psychological Development      STSI  STST  STST 




prescribed for NAS 
Growth parameters; 
sleep patterns; 








general health; BF 
status 
           
Maternal Measures           
   Obstetric History  Structured interview         
   Parent/Child Interaction      MPAS  PSI  PSI 
   Parental Psychopathology      EPDS; GHQ   GHQ  GHQ 
   Social Support       ISSI  ISSI  ISSI 
           
Environmental Measures           
   Home Environment        HOME  Inventory  HOME  Inventory 
   Maternal Drug Use  Structured interview         
           






Note. NAS=Neonatal Abstinence Syndrome; GA= Gestational Age; BF= Breast Feeding; VEP= Visual Evoked Potential; BSID-II= Bayley Scales of Infant 
Development-2
nd Edition; STSI= Short Temperament Scale for Infants; STST= Short Temperament Scale for Toddlers; EPDS= Edinburgh Postnatal Depression 






Figure 2.2 An infant and her mother photographed after a pattern-reversal VEP test. 
Note that actual testing was undertaken in a darkened room. 
Photograph used with permission.  
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Table 2.3 Sample size estimates for primary outcome variables 
















Required n to detect the 
observed difference 
with 80% power 
Neurological Development                 
VEP 48’ at 4 months  30  20  125.0  136.3    11.5  17.1  .67  36 
VEP 69’ at 4 months  30  22  121.0  135.0    14.0  23.8  .59  47 
                 
BSID-II MDI at 12 months  26  20    97.9  102.7  -4.8  8.9  .54  55 
BSID-II PDI at 12 months  26  20    92.9  88.6    4.3  8.4  .51  61 
BSID-II BRS at 12 months  25  20  123.5  120.0    3.5  8.3  .42  90 
BSID-II MDI at 24 months  24  19     89.5  95.0  -5.5  14.5  .38   111 
BSID-II PDI at 24 months  24  19     92.4  92.0    0.4  14.6  .03  >500 
BSID-II BRS at 24 months  20  17  107.5  106.2    1.3  11.4  .11  >500 
                 
Psychological Development                 
STSI EDS at 4 months  29  24       2.15  2.19    -0.04  0.5  .08  >500 
STST EDS at 12 months  28  22       3.41  3.42    -0.01  0.5  .02  >500 
STST EDS at 24 months  23  18       3.47  3.40     0.07  0.5  .14  >500 




                 
Table 2.3 continued                 
















Required n to detect the 
observed difference 
with 80% power 
Physical Development                 
Weight at 4 months  30  22     6.5  5.9   0.6  0.7  .86  23 
Length at 4 months  30  22   62.1  60.0   2.1  2.3  .91  20 
HC at 4 months  30  22  41.0  40.3   0.7  1.2  .61  44 
Weight at 12 months  27  22  10.0  9.2   0.8  1.2  .65  35 
Length at 12 months  25  22  76.3  74.6   1.7  2.9  .59  47 
HC at 12 months  27  22  46.5  46.2   0.3  1.2  .26    236 
Weight at 24 months  24  19  13.0  12.0   1.0  1.4  .71  33 
Length at 24 months  24  19  86.8  85.0   1.8  3.4  .53  57 
HC at 24 months  23  17  48.5  48.1   0.4  0.9  .47  72 
Note. VEP= Visual Evoked Potential; BSID-II= Bayley Scales of Infant Development-2
nd Edition, STSI=Short Temperament Scale for Infants, STST=Short 
Temperament Scale for Toddlers 
7 
 
Table 3.1 Maternal characteristics at enrolment 







Mother’s age, MﾱSD (years)  26.30±6.18  28.03±5.50  28.29±6.13  .37 
Gravida (% first)  33  17  21   .31 
Parity (% first)  55  47  46   .76 
Smoked in month prior to enrolment (% yes)  82  93  96   .24 
Drank alcohol in month prior to enrolment (% yes)  42  50    32   .48 
Gestation, M±SD (weeks), median (range)  23 (10-28)  15 (6-31)  18 (4-35)  .01 




Table 3.2 Differences in maternal characteristics at enrolment between study participants and 
non participants 






Mother’s age, MﾱSD (years)  27.45±5.94  25.56±6.53  .23 
Gravida (% first)  23  17  .76 
Parity (% first)  49  33  .30 
Smoked in month prior to enrolment (%)  90  94  1.00 
Drank alcohol in month prior to enrolment (%)  45  28  .20 
Gestation, M±SD (weeks)
  19.01±6.91  20.88±5.49
b  .31 
Mother’s ethnicity (% Caucasian)  94  72
c  .01 
Note. 
aData for the four BM women whose second infant was enrolled in the study are included 
in the participants column.  
b Four non-participants were unaware of their gestational age at enrolment.  
c Data missing from one woman. 
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Table 3.3 Maternal heroin use and maintenance therapy history  







Age of first heroin use (years)
a  26.00±4.24a   19.38±3.73b   17.83±2.48b  <.01 
Age first used heroin daily (years)  -  20.46±3.53  18.83±3.10    .09 
Length of consistent heroin use prior to   
beginning maintenance therapy (months)
 
-  19.37±23.22  24.37±29.39    .45 
Average daily heroin use prior to beginning 
maintenance therapy (no. times per day) 
-  2.09±1.23  2.76±1.88   .13 
Length of maintenance therapy (months), 
median (range) 
-  7.5 (0-36)  10.0 (0-120)   .33 
Note.  Where no value is reported for the control group the reported p-value is the difference between the BM and MM 
groups. Values in the same row with different subscripts differ significantly at p<0.05 using bonferroni post hoc analyses. 
Values reported as M±SD unless otherwise indicated. M±SD reported in terms of the original distributions; however 
where data has been transformed p-values reported are for the transformed distributions. 
aTwo women in the control group reported using heroin 10 years prior to enrolment in the study; data was missing for 
one woman in the BM group.   
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Table 3.4 Self reported maternal substance use (%) during pregnancy  







Tobacco   82  93  96   .24 
Alcohol   64  62  59   .96 
Heroin  -  50  42   .59 
Other opioids
a  21  32  41   .28 
Cannabis  25a  77b  71b  <.001 
Benzodiazepines  12a  40b  50b  <.01 
Amphetamines   -  38  32   .77 
Hallucinogens  0  7  0   .19 
Antidepressant prescription 
medication 
12  27  8   .21 
Positive urine screen during 
pregnancy 
b 
33b  70a  75a
  <.01 
Note. Values reported as percentages. Values in the same row with different subscripts 
differ significantly at p < .05 using Fisher’s exact tests. Where no value is reported for the 
control group the reported p-value is the difference between the BM and MM groups.  
a Seven controls reported use of opioids, and four reported use of benzodiazepines during 
pregnancy. 
bUrine drug screen results combined for opioids, benzodiazepines & cannabinoids. Three 
controls screened positive for other opioids, 8 for cannabis, and 2 for benzodiazepines.  
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Gender (% Male)  52  47  50    .93 
Gestational age at delivery (weeks)
a  38.85±1.89  38.73±1.95  38.08±1.89    .25 
Born at term (% ≥ 37 weeks gestation)  91  90  83    .70 
Birth Weight (gm)
c  3241.82±535.97a
  3055.52±511.65ab  2745.83±469.72b
  <.01 
Low Birth Weight (% < 2500gm)
 c  12a  14ab  33b    .13 
Birth Length  49.32±3.21a
  47.93±2.54ab
  46.31±2.77b
  <.001 
Birth HC  33.95±1.68a
  33.70±1.81ab
  32.68±1.28b
  .01 
Apgar 1 minute, median (range)  9 (4-9)  9 (5-10)  9 (5-9)  1.00 
Apgar 5 minutes, median (range)  9 (8-10)  9 (6-10)  9 (8-10)  .58 
         


















  12.00±3.56b  <.001 
Range of Finnegan Scores  0-12  0-18  0-21  - 
Received any pharmacological treatment for NAS (% yes)  -  47  50  .81 
Received Morphine (% yes)  -  43  50  .78 
Received Phenobarbital (% yes)  -  10  0  .25 
Note. Values reported as M±SD unless otherwise indicated. M±SD reported in terms of the original distributions; however where 
data has been transformed reported p-values are for the transformed distributions. Values in the same row with different 
subscripts differ significantly at p < .05 using Bonferroni post hoc analyses. Where no value is reported for the control group the 
reported p-value is the difference between the BM and MM groups.  
aPower 4 transformation used in analysis.  
bSquare root transformation used in analysis.
  
cData missing for one BM infant.  
dData missing for two control infants.   
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Table 3.6 Demographic characteristics of participating infants and families (N=87) 







Still breastfed (%)  48  43  38  .71 
Parent reported medical problem (%)  45  50  42  .83 
Poor sleeper (% meeting Sadeh’s criteria
a)  21  23  17  .89 
Number of children in household         
Only child  52  53  54  .95 
One other child  27  27  29   
Two other children  9  13  8   
Three or more other children  12  7  8   
         
Family Structure (% sole parent)  12  30  38  .07 
Mother’s education (% <high school)  48  53  67  .38 
  (n=29)  (n=22)  (n=14
c)   
Father’s education (% <high school)
b  55  45  79  .13 
Father not in paid employment (%)
b  21a  32ab  64b  .02 
  (n=31)  (n=28)  (n=20)
   
Household Income p/a (%≤$31,200)
d  48a  64ab  85b  .03 




         









Accommodation (% Government subsidised)
 e  15a  26ab  46b  .04 
Family moved house ≥1 time since child’s birth  15  20  21  .23 
Note. Values reported as percentages. Values in the same row with different subscripts differ significantly at p < .05 using Fisher’s 
exact tests.  
a Sadeh’s criteria for poor sleep defined as one or more of the following: a) waking >3 times per night; b) nocturnal wakefulness of >1 
hour; or c) total sleep time (including day and night sleeps) <9 hours {Sadeh, 2004 #247}. 
bFather’s education and employment status reported only for families where father lived in child’s household.  
c Parental figures for one MM family were 2 females. 
 
ddata missing for 2 control, 2 BM and 4 MM families. 
 
edata missing for 3 BM families.  
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Subscale Scores, median (range)         
     Quality of attachment   43.60 (35.10-45.00)  42.20 (37.69-45.00)  44.30 (38.20-45.00)  .10 
     Absence of Hostility   21.60 (12.60-25.00)  21.80 (16.20-25.00)  22.80 (14.90-25.00)  .16 
     Postnatal Pleasure in interaction  23.00 (16.00-25.00)  22.75 (16.00-25.00)  23.75 (20.00-25.00)  .27 
Global Attachment Score (M±SD)
b  85.84±6.74  86.56±5.17  88.64±4.28   .21 
Lowest quartile of Global scores (%)  30  30  13  .30 
Note. Higher scores indicate higher levels of attachment.  
aThe Postnatal Pleasure in Interaction and Global scores could not be calculated for one MM woman.
  
bM±SD reported in terms of the original distribution, however the reported p-value was calculated using the transformed 
(power 5) data.  
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Table 3.8 Edinburgh Postnatal Depression Scale and General Health Questionnaire scores, by group. 







Edinburgh Postnatal Depression  Scale         
EPDS Total Score (M±SD)
a  6.06±4.55  7.41±5.18  8.00±5.60  .42 
EPDS Probable Minor Depression (% ≥10)  15a  27ab  42b  .08 
EPDS Probable Major Depression (% ≥13)  12  13  29  .23 
General Health Questionnaire         
GHQ Total Score, median (range)   2.00 (0.00-17.00)  2.50 (0.00-20.00)  3.50 (0.00-21.00)  .43 
Significant Psychological Distress (% ≥6)  30  33  33  1.00 
Note. Values in the same row with different subscripts differ significantly at p=.05 using Fisher’s exact tests. Higher scores 
on the EPDS & GHQ indicate greater severity of symptoms. 
a M±SD reported in terms of the original distribution, however the reported p-value was calculated using the transformed 
(square root + 1) data.  
17 
 
Table 3.9 Interview Schedule for Social Interaction-Short Form (ISSI-SF) scores, by group  







ISSI-SF Subscales, median (range)         
Availability of Attachment  6.00 (0.00-6.00)a  5.00 (0.00-6.00)ab  5.00 (0.00-6.00)b  .08 
Adequacy of Attachment  8.00 (0.00-10.00)  6.00 (0.00-10.00)  5.78 (0.00-10.00)  .21 
Availability of Social Interaction  2.00 (0.00-6.00)  2.00 (0.00-6.00)  1.00 (0.00-6.00)  .28 
Adequacy of Social Interaction  7.00 (0.00-8.00)  5.86 (1.00-8.00)  6.00 (0.00-8.00)  .18 
ISSI-SF Total Score (M±SD)  20.18±6.63a  17.33±7.12ab  15.29±8.82b  .05 
Note. Higher scores indicate better perceived social support. Values in the same row with different subscripts differ 
significantly at p ≤ .05 using Mann-Whitney U (for comparison of median scores) or Bonferroni post hoc (for comparison of 
mean scores) analyses.   
18 
 
Table 3.10 Self-reported maternal substance use in the month prior to the four month follow-up 
assessment 







Tobacco   76  90  96   .08 
Alcohol    63a   37b   33b   .04 
Psychotropic prescription medication 
a   9  13  13   .84 
Any illicit drug use    21a   57b   75b  <.001 
    Heroin  -  17  29   .33 
    Other opioids  -  -  -  - 
    Cannabis   21  47  46   .06 
    Benzodiazepines  -  20  21   1.00 
    Amphetamines   -  17  17   1.00 
Note. Values reported as percentages. Values in the same row with different subscripts differ 
significantly at p < .05 using Fisher’s exact tests. Where no value is reported for the control group the 
reported p-value is the difference between the BM and MM groups.  
a Psychotropic prescription medication includes antidepressant and anti-psychotic drugs. 
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Table 3.11 Parenting Stress Index and HOME Inventory Total Scores, by group 
  Control  Buprenorphine   Methadone  p 
12 months   (n=33)  (n=28)  (n=22)   
PSI  Parent Domain Total Score
a  118.37±26.35  132.16±20.77  118.17±29.13  .08 
Total HOME score 
b,c  36.75±4.44  37.41±3.24  36.84±3.05  .80
 
24 months   (n=30  (n=24)  (n=19)   
PSI  Parent Domain Total Score
d  118.98±25.75  136.12±30.20  122.27±18.65  .10 
Total HOME score
e   37.98±3.48ab  36.66±3.94a  40.00±3.25b  .02 
Note. Values reported as M±SD. Values in the same row with different subscripts differ significantly at p ≤ .05 
using Bonferroni post hoc analyses. 
PSI= Parenting Stress Index (higher scores indicate greater dysfunction), HOME= Home Observation for 
Measurement of the Environment (higher scores indicate a more child-centred home environment). 
a PSI Total score could not be calculated for 1 control, 2 BM and 3 MM families. 
b Total HOME score could not be calculated for 2 MM families. 
c M±SD reported in terms of the original distribution, however the reported p-value was calculated using the 
transformed (squared) data. 
d PSI Total score could not be calculated for 4 control, 7 BM and 5 MM families. 
e Total HOME score could not be calculated for 2 control, 1 BM and 3 MM families. 
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Table 4.1 Anthropometry of infants at 4, 12 and 24 months of age 
  Control  Buprenorphine  Methadone  p  
4 months   (n=33)  (n=30)
  (n=22)
a   
Weight (kg)
b  6.67±1.00a  6.53±0.84a  5.91±0.55b  <.01 
Length (cm)
  
  62.7 (57.4-68.7)a  61.5 (57.5-68.5)ab  60.3 (56.3-63.3)b  .01 
HC (cm)
   41.4 (38.5-44.5)a  41.1 (38.0-44.1)ab  40.4 (39.2-42.2)b  .02 
12 months   (n=33)  (n=27)
c  (n=22)   
Weight (kg)  10.17±1.34a    9.95±1.13ab    9.22±1.21b  .02 
Length (cm)
d  76.8±3.3a  76.3±3.0ab  74.6±2.8b  .03 
HC (cm)  46.8±1.7  46.5±1.2  46.2±1.1  .29 
24 months  (n=30)  (n=24)  (n=19)   
Weight (kg)  13.31±1.79a  13.00±1.51ab  12.01±1.23b  .02 
Length (cm)
 e,f  87.2±4.1  86.8±3.8  85.0±3.0  .15 
HC (cm)
 g   49.3 (45.0-52.0)a  48.6 (46.5-50.5)ab  48.1 (46.9-49.3)b  .02 
Note. Values reported as M±SD or median (range). M±SD reported in terms of the original 
distributions; however where data has been transformed, reported p-values are for the 
transformed distributions. Values in the same row with different subscripts differ significantly at p 
≤ .05 using Bonferroni post hoc (for comparison of mean scores) or Mann-Whitney U (for 
comparison of median scores) analyses. 
a Data missing for two MM children. 
b Inverse square transformation.  
c Data missing for one BM child. 
d Data missing for two BM children. 
e Inverse cube transformation. 
f data missing for two MM children. 




Table 4.2 Multiple Regression Analysis for variables predicting weight (in kg) at four months 
of age (N=84) 




Birth Weight    0.73±0.21         -.42** 
Gestational age at delivery  -0.01±0.06    -.02 
Gender (male)    0.55±0.16            .34*** 
Group     
Control  0   
Buprenorphine  -0.04±0.18   -.01 
Methadone
  -0.38±0.20     .19 
Note. For the regression model as a whole, R
2=.44, F(5,78)=12.14, p<.0001. B±SE B reported 
in terms of the original distributions; however β, R
2& F values reported in terms of the 
transformed (inverse square) data.   




Table 4.3 Multiple Regression Analysis for variables predicting length (in cm) at four months 
of age (N=85)  




Birth Length    0.36±0.11        .39** 
Gestational age at delivery    0.33±0.17      .23* 
Gender (male)    1.72±0.45          .31*** 
Group     
Control  0   
Buprenorphine    0.40±0.53   .07 
Methadone
  -0.87±0.61  -.14 
Note. For the regression model as a whole, R






Table 4.4 Multiple Regression Analysis for variables predicting head circumference (in cm) at 
four months of age (N=85)  




Birth HC  0.45±0.09           .54*** 
Gestational age at delivery  -0.04±0.07  -.05 
Gender (male)  .081±0.25        .28** 
Group     
Control  0   
Buprenorphine  -0.36±0.28  -.12 
Methadone
  -0.52±0.32  -.16 
Note. For the regression model as a whole, R
2=.47, F(5,79)=13.90, p<.0001. *p<.05, ** 




Table 4.5 Multiple Regression Analysis for variables predicting weight (in kg) at 12 months of 
age (N=81)  




Birth Weight  0.64±0.25      .28* 
Gender (male)  0.74±0.25         .29** 
Group     
Control  0   
Buprenorphine  -0.11±0.30  -.04 
Methadone
  -0.62±0.33  -.22 
Note. For the regression model as a whole, R






Table 4.6 Multiple Regression Analysis for variables predicting length (in cm) at 12 months of 
age (N=80)  




Birth Length  0.37±0.15       .37* 
Gestational age at delivery  0.25±.024    .06 
Gender (male)  1.86±0.62         .28** 
Group     
Control  0   
Buprenorphine  1.00±0.90    .00 
Methadone  0.19±1.06   -.15 
Note. For the regression model as a whole, R






Table 4.7 Multiple Regression Analysis for variables predicting head circumference (in cm) at 
12 months of age (N=79)  




Birth HC  0.30±0.08          .36** 
Alcohol use (yes)
a  0.46±0.28     .16 
Gender (male)  0.96±0.28         .33** 
Group     
Control  0   
Buprenorphine
   -0.18±0.31   -.06 
Methadone
  -0.17±0.35   -.06 
Note. For the regression model as a whole, R
2=.36, F(5,73)=8.18, p<.0001. 
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in 
terms of the transformed (square) data. *p<.05, ** p<.01, ***p<.001, †p<.0001 




Table 4.8 Multiple Regression Analysis for variables predicting weight (in kg) at 24 months of 
age (N=72)  




Birth Weight  0.80±0.31       .27* 
Gender (male)  1.25±0.33            .39*** 
Group     
Control  0   
Buprenorphine  -0.09±0.39   -.07 
Methadone
  -0.85±0.43      -.24* 
Note. For the regression model as a whole, R
2=.35, F(4,67)=9.18, p<.0001. 
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in 





Table 4.9 Multiple Regression Analysis for variables predicting length (in cm) at 24 months of 
age (N=71)  




Birth Length  0.43±0.13        .36** 
Gender (male)  2.83±0.77          .37*** 
Group     
Control  0   
Buprenorphine  0.34±0.91   .04 
Methadone  -0.93±1.06  -.10 
Note. For the regression model as a whole, R
2=.33, F(4,66)=7.97, p<.0001. 




Table 4.10 Multiple Regression Analysis for variables predicting head circumference (in cm) 
at 24 months of age (N=66)  




Birth HC  0.22±0.08        .28** 
Gender (male)  1.30±0.28           .47*** 
Group     
Control  0   
Buprenorphine  -0.02±0.41  -.16 
Methadone  -0.15±0.49  -.20 
Note. For the regression model as a whole, R
2=.43, F(4,61)=11.30, p<.0001. 







































































































Table 5.1 Characteristics of participating women and infants, for VEP analyses 







Maternal variables at enrolment         
   Mother’s age, M±SD (years)  26.30±6.18  28.03±5.50  28.41±6.28  .36 
   Parity (% first)  55  47  45  .75 
   Gravida (% first)  33  20  18  .34 
   Gestational Age, M±SD (weeks)  21.45±4.41a
  16.83±7.99b
  18.23±7.86ab
  .03 
   Smoked in month prior (% yes)  82  93  95  .21 
   Alcohol in month prior (% yes)  42  50  29  .32 
         
Infant characteristics         
   Gender (% Male)  52  47  45  .89 
   Gestational age at delivery, M±SD (weeks)  38.85±1.89  38.73±1.95  38.09±1.95  .33 
   Birth Weight, M±SD (grams)  3241.82±535.97a  3055.52±511.65ab  2749.09±484.32b  <.01 














   Birth Length, M±SD (cm)  49.32±3.21a  47.93±2.54ab  46.52±2.52b  <.01 
   Birth Head Circumference, M±SD (cm)  33.95±1.68a  33.70±1.81ab  32.65±1.34b  .02 
   Age at testing, M±SD (weeks)  16.77±1.23  18.02±3.45  16.86±1.96  .09 
   Corrected age at testing , M±SD (weeks)
 a  15.62±2.33  16.76±4.20  14.95±2.02  .10 
   Received any pharmacological treatment for NAS (% yes)  -  47  50  .81 
         
Family characteristics at follow-up         
   Family Structure (% sole parent)  12  30  36  .09 
   Father Unemployed (% yes)  21a
  43ab
  63b
  .02 
   Household Income p/a (%≤$A31,200)
   48a
  68ab  83b
  .04 
   Accommodation (% Government subsidised)
   15a
  32ab
  50b
  .02 
Note. Values in the same row with different subscripts differ significantly at p < .05 using Chi
2 analyses.  
Where no value is reported for the control group, the p-value is the difference between the BM and MM groups. 




Table 5.2 VEP Latencies at four months of age, by group  
VEP viewing field  Control  Buprenorphine  Methadone  p 
         
48’ retinal arc
a  (n=33)  (n=30)  (n=20)   
  124.34±12.35  124.97±16.08  136.25±18.02  <.01 
69’ retinal arc
a  (n=33)  (n=30)  (n=22)   
  119.92±11.74  121.02±14.10  134.99±33.46  .02 
Note. M±SD reported in terms of the original distributions; p-values reported in terms of the 
transformed data (inverse square transformation).   




Table 5.3 Maternal substance use, by group, for VEP analyses 







1.  Mother’s heroin use         
Age of first heroin use, M±SD (years)
a  26.00±4.24  19.38±3.72  17.82±2.52  .10 
Age first used heroin daily, M±SD (years)  -  20.46±3.53  18.90±3.18  .12 
Length of consistent heroin use prior to 
beginning maintenance therapy, M±SD 
(months) 
-  19.37±23.22  25.67±29.67  .43 
Average daily use prior to beginning 
maintenance therapy, M±SD (no. times 
used) 
-  2.09±1.23  2.86±1.92  .10 
Length of current maintenance 
treatment, M±SD (months) 
-  9.63±8.52  17.75±25.73  .11 
2. Detailed drug use prior to conception  Not available  Not available  Not available   





Table 5.3 continued         







3. At enrolment into the study (% Yes 
within previous month) 
       
Tobacco   82  93  95  .29 
Alcohol   42  50  29  .34 
Heroin  -  34  29  .76 
Other opioids
b  3  19  19  .09 
Cannabis  22a
  66b




  .43 
Amphetamines   -
  17  14
  1.00 
Psychotropic prescription medication 
(antidepressants) 
6  21  5  .13 





Table 5.3 continued         







Opioid prescription medication  Not available  Not available  Not available   
4.During pregnancy (% Yes)         
Tobacco   82  90  95  .30 
Alcohol   64  50  55  .55 
Heroin  -  50  41  .58 
Other opioids




  <.001 
Benzodiazepines  12a




  1.00 
Psychotropic prescription medication 
(antidepressants) 
12  27  9  .21 





Table 5.3 continued         







Opioid prescription medication  Not available  Not available  Not available   
5. Positive urine drug screen during 
pregnancy (% yes)
c 
33a  70b  77b  <.01 
6. At 4 months post delivery (% Yes)         
Tobacco   79a
  90ab
  100b
  .05 
Alcohol   64a
  33b
  36ab
  .04 
Heroin  -  30  35  .76 








  1.00 
Amphetamines   -
  17
  23
  .73 
Psychotropic prescription medication 
(any) 
6  17  9  .45 




Table 5.3 Note. Values in the same row with different subscripts differ significantly at p < .05 using Fisher’s exact tests. 
Where no value is reported for the control group, the p-value is the difference between the BM and MM groups. 
aTwo women in the control group reported using heroin 10 years prior to enrolment in the study, Note continued. 
bOne control subject reported use of an opioid at enrolment, 7 controls reported use of opioids and 4 reported use of a 
benzodiazepine during pregnancy. Whether these substances were used licitly or illicitly was not reported.  
cUrine drug screen results were for opioids, benzodiazepines & cannabinoids only. Three controls screened positive for opioids, 8 for 




Table 5.4 Multiple Regression Analysis for variables predicting VEP response to 48’ checks 
(N=76)  





Corrected Age  -2.14±0.53        0.36** 
Family Income (<$31, 200)  -10.20±3.50        0.31** 
VEP equipment (2
nd)  9.86±4.42  -0.19 
Marijuana use in pregnancy (yes)  4.88±3.78     -0.23* 
Group     
Control  0   
Buprenorphine
   1.04±4.19    0.04 
Methadone  12.54±4.49     -0.30* 
Note. For the regression model as a whole, R
2=.33, F(6,69) = 5.64, p<.001.  
B±SE B reported in terms of the original distributions; β, R
2& F values reported in terms of the 
transformed data (inverse square transformation).  




Table 5.5 Multiple Regression Analysis for variables predicting VEP response to 69’ checks 
(N=77) 





Corrected Age  -2.04±0.49        0.46** 
Family Income (<$31, 200)  -5.73±3.26   0.16 
VEP equipment (2
nd)  9.89±4.12  -0.18 
Marijuana use in pregnancy (yes)  5.33±3.52     -0.25* 
Group     
Control  0   
Buprenorphine
   0.08±3.90   -0.04 
Methadone  7.75±4.13   -0.16 
Note. For the regression model as a whole, R
2=.34, F(6,70) = 5.98, p<.0001.  
B±SE B reported in terms of the original distributions; β, R
2& F values reported in terms of the 
transformed data (inverse square transformation).  *p<.05, ** p<.01.  
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Table 6.1 Index scores of the Bayley Scales of Infant Development at 12 and 24 months of age, by group 
 Bayley Scales of Infant Development  Control  Buprenorphine  Methadone  p  
12 months 
a   (n=33)  (n=27)
  (n=21)   
Mental Developmental Index, M±SD
b  100.5±9.9  97.9±10.6  102.7±7.1  .25 
Some delay (% MDI <1 SD below the mean)  6  11  0  .36 
         
Psychomotor Developmental Index, M±SD  92.6±11.7  92.9±9.8  88.6±7.0  .28 
Some delay (% PDI <1 SD below the mean)  21  11  19  .66 
         
Behavior Rating Scale Total Score, M±SD
c  120.1±7.7  123.5±7.3  120.0±9.2  .22 
Below ‘normal limits’ (% BRS ≤25 percentile)  17  12  25  .51 
         
24 months  (n=30)  (n=24)  (n=19)   
Mental Developmental Index (med, range)  97.5 (76-118)  87.0 (61-112)  98.0 (62-112)  .25 
Some delay (% MDI <1 SD below the mean)  27  42  21  .32 




Table 6.1 continued.         
  Control  Buprenorphine  Methadone  p  
24 months  (n=30)  (n=24)  (n=19)   
Psychomotor Developmental Index, M±SD  95.7±13.95  92.4±14.2  92.0±15.0  .59 
Some delay (% PDI <1 SD below the mean)  27  33  26  .83 
         
Behavior Rating Scale Total Score, M±SD
d  108.1±8.8  107.5±12.2  106.2±10.6  .84 
Below ‘normal limits’ (% BRS ≤25 percentile)  28  25  29  .96 
         
Notes: Values reported as M±SD or median (range), and percentages where indicated. M±SD reported in terms of the original 
distributions; however where data has been transformed, reported p-values are for the transformed distributions.  
a Data missing for one BM and one MM child. 
b Square transformation.  
c n for control=30, BM=25, MM=20 
d n for control=29, BM=20, MM=17 
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Table 6.2 Multiple Regression Analysis for variables predicting MDI scores at 12 months of age 
(N=80)  




ISSI-SF Total Score (4mths)    0.26±0.14  .22 
Total HOME Score (12mths)   0.74±0.28     .27* 
Group     
Control  0   
Buprenorphine  -2.42±2.35  -.12 
Methadone    3.65±2.59  .16 
Note. For the regression model as a whole, R
2=.18, F(4,75) = 4.10, p<.01.  
B±SE B reported in terms of the original distributions; β, R
2& F values reported in terms of the 
transformed data (power 2.5 transformation).  *p<.05, ** p<.01. 
 
Table 6.3 Multiple Regression Analysis for variables predicting PDI scores at 12 months of age 
(N=81)  




Birth HC  1.33±0.66       .24* 
Group     
Control  0   
Buprenorphine
   0.72±2.55     .03 
Methadone  -2.36±2.84   -.12 
Note. For the regression model as a whole, R
2=.09, F(3,77) = 2.62, p=.06.  
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in terms 
of the transformed data (square transformation). *p<.05.   
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Table 6.4 Multiple Regression Analysis for variables predicting BRS scores at 
 12 months of age (N=74)  




Infant gender (male)  -4.91±1.78        -.31** 
ISSI-SF Total Score (4mths)  -0.03±0.13   -.03 
Total HOME Score (12mths)  0.56±0.25       .26* 
Group     
Control  0   
Buprenorphine
   2.46±2.10    .14 
Methadone
  -0.88±2.31   -.05 
Note. For the regression model as a whole, R
2=.22, F(5,68) = 3.72, p<.01. 
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in  
terms of the transformed data (square root transformation).  *p<.05, ** p<.01  
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Table 6.5 Multiple Regression Analysis for variables predicting MDI scores at 24 months of 
age (N=67)  





a  -8.50±3.87   -.27* 
ISSI-SF Total Score (4mths)  0.05±0.24   .04 
Total HOME Score (24mths)  1.65±0.48       .44** 
Group     
Control  0   
Buprenorphine  -2.67±3.71  -.08 
Methadone
  -1.75±4.47  -.05 
Note. For the regression model as a whole, R
2=.30, F(5,61) = 5.21, p<.001. 
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in 
terms of the transformed data (square transformation).  *p<.05, ** p<.01, ***p<.001 




Table 6.6 Multiple Regression Analysis for variables predicting PDI scores at 24 months  
of age (N=67)  





a  -10.48±3.77        -.34** 
ISSI-SF Total Score (4mths)      0.18±0.24    .09 
Total HOME score (24mths)      1.50±0.46        .40** 
Group   
Control  0 
Buprenorphine      1.80±3.62    .06 
Methadone
     -1.33±4.36   -.04 
Note. For the regression model as a whole, R
2=.31, F(5,61) = 5.42, p<.001. 
*p<.05, ** p<.01, ***p<.001 




Table 6.7 Multiple Regression Analysis for variables predicting BRS scores at  
24 months of age (N=61)  




ISSI-SF Total Score (4mths)  0.21±0.17   .17 
Total HOME score (24mths)  0.87±0.38     .33* 
Group   
Control  0 
Buprenorphine
   2.61±3.00   .14 
Methadone
  -2.12±3.30  -.08 
Note. For the regression model as a whole, R
2=.15, F(4,56) = 2.56, p<.05. 
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in 










































































































































































Figure 6.3 Mean BRS scores for each group at 12- and 24-month follow-up assessment.  
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Table 7.1 Factor scores and Easy/Difficult Scale scores of the Short Temperament Scale for 
Infants, at 4 months of age, by group 










Factor Scores     
   
Approach 
  1.71 (1.00-3.71)  1.71 (1.00-2.71)  1.86 (1.00-3.43)  .80 
Rhythmicity 
  2.67( 1.00-4.00)  2.33 (1.67-4.00)  2.00 (1.17-3.67)  .16 
Cooperation/Manageability 
b  2.33±0.60  2.30±0.65  2.14±0.56  .48 
Activity/Reactivity   4.25±0.81  4.03±0.90  4.12±0.80  .58 
Irritability
b   2.51±0.94  2.41±0.59  2.52±1.12  .97 
Easy/Difficult Scale Score
c  2.24±0.57  2.15±0.41  2.19±0.63  .85 
Note. Higher scores reflect more difficult temperament (e.g. greater distractibility, lower 
persistence). Values reported as M±SD or median (range). M±SD reported in terms of the original 
distributions; however where data has been transformed, reported p-values are for the 
transformed distributions. 
a Data missing for one BM child 
b Power 0.4 transformation. 




Table 7.2 Multiple Regression Analysis for variables predicting Easy/Difficult Scale 
scores at four months of age (N=85) 





a  -0.04±0.01         -.43*** 
GHQ Total Score
a  0.03±0.01        .29** 
ISSI-SF Total Score
a  0.00±0.01   .03 
Group     
Control  0   
Buprenorphine  -0.07±0.12  -.06 
Methadone
  0.06±0.13   .05 
Note. For the regression model as a whole, R
2=.32, F(5,79)=7.50, p<.0001.  
*p<.05, ** p<.01, ***p<.001, †p<.0001.  
a Global attachment, GHQ and ISSI-SF scores measured at four month follow-up 
assessment.   
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Table 7.3 Factor scores and Easy/Difficult Scale scores of the Short Temperament Scale for 
Toddlers, at 12 months of age, by group 







Factor Scores     
   
Approach/ Adaptability   3.00 (2.20-4.80)  3.00 (2.00-5.25)  3.00 (2.20-4.20)  .64 
Reactivity   3.79±0.63  3.51±0.69  3.71±0.59  .23 
Persistence   2.93±0.77  2.99±0.91  2.61±0.80  .24 
Cooperation/Manageability   3.42±0.94  3.63±0.90  3.53±0.97  .69 
Distractibility   3.90±0.58  4.16±0.79  3.90±0.69  .27 
Rhythmicity   2.57±0.62  2.74±0.92  2.80±0.68  .50 
Easy/Difficult Scale Score
a  3.49±0.50  3.41±0.58  3.42±0.48  .78 
Note. Higher scores reflect more difficult temperament (e.g. greater distractibility, lower 
persistence). Values reported as median (range) or M±SD. M±SD reported in terms of the 
original distributions; however where data has been transformed, reported p-values are for the 
transformed distributions. 




Table 7.4 Multiple Regression Analysis for variables predicting Easy/Difficult Scale scores at 
12 months of age (N=82) 





a  -0.03±0.01       -.32** 
Group     
Control  0   
Buprenorphine  -0.05±0.13  -.04 
Methadone
  0.03±0.14  .03 
Note. For the regression model as a whole, R
2=.10, F(3,78)=3.05, p<.05.  
*p<.05, ** p<.01, ***p<.001, †p<.0001  
a Global attachment scores from the Maternal Postnatal Attachment Scale measured at four 
month follow-up assessment.   
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Table 7.5 Factor scores and Easy/Difficult Scale scores of the Short Temperament Scale for 
Toddlers, at 24 months of age, by group 







Factor Scores     
   
Approach/ Adaptability   3.42±0.70  3.47±0.66  3.10±0.57  .16 
Reactivity   3.80±0.64  3.75±0.61  3.87±0.82  .86 
Persistence   2.73±0.74  2.78±0.91  2.38±0.67  .22 
Cooperation/Manageability   3.20 (1.80-4.40)  3.25 (2.00-4.40)  3.10 (2.00-4.60)  .99 
Distractibility   4.08±0.59  3.91±0.70  3.77±0.58  .24 
Rhythmicity   2.61±0.73  2.84±0.59  3.04±0.84  .13 
Easy/Difficult Scale Score
a  3.48±0.49  3.47±0.44  3.40±0.56  .81 
Note. Higher scores reflect more difficult temperament (e.g. greater distractibility, lower 
persistence). †Values reported as M±SD or median (range). M±SD reported in terms of the 
original distributions; however where data has been transformed, reported p-values are for the 
transformed distributions. 




Table 7.6 Multiple Regression Analysis for variables predicting Easy/Difficult Scale scores 
at 24 months of age (N=70) 





a  -0.03±0.01    -.27* 
ISSI-SF Total Score
a  -0.01±0.01  -.20 
Group     
Control  0   
Buprenorphine  -0.07±0.13  -.08 
Methadone
  -0.08±0.15  -.06 
Note. For the regression model as a whole, R
2=.15, F(4,65)=2.86, p<.05. 
B±SE B reported in terms of the original distributions; however β, R
2& F values reported in 
terms of the transformed (squared) data.  *p<.05, ** p<.01, ***p<.001, †p<.0001  








































































































































Appendix A. Screening Questionnaire 
 
 





If all bolded boxes are ticked then the subject is eligible for the study. The “yes” box in the 
“Suitable for research study” row must then be ticked and you must sign and date below the 
survey. 
 
Subject initials:    
Are you aged between 16 and 40 years?  Yes               No 
Is your gestational age 28 weeks?  Yes               No 
Are you expecting twins?  Yes               No 
Are you participating in another research study?  Yes               No 
Do you consume more than 7 standard alcoholic 
drinks in an average week? 
Yes               No 
Are you taking any medication for HIV or epilepsy  Yes               No 
   
Suitable for research study  Yes               No 
 
 




Appendix B. Information Sheet for Maintenance Group 
Participants 
 
Study Title: Child Health and Development Study  
(Buprenorphine and methadone in pregnancy: Effects on mother, foetus/ neonate and child.) 
 
Methadone is recognised as being very beneficial in the treatment of heroin dependence, but for 
pregnant women there is a risk of Neonatal Abstinence Syndrome (NAS). The developing child 
becomes dependent on the methadone in the mother’s circulation and then experiences 
withdrawal following birth. Symptoms of NAS may be mild and include excessive crying, poor 
sleep and feeding, excessive yawning and sneezing, but may be severe with development of fever, 
diarrhoea and seizures. It is unclear why some babies suffer more severe symptoms while others 
have mild symptoms or do not develop this syndrome at all.  
 
Buprenorphine (Subutex) is now being used widely in the treatment of heroin dependence and is 
known to produce milder physical dependence and fewer withdrawal symptoms than methadone. 
However; it is has not been approved as a maintenance treatment in pregnant women. A number 
of studies have reported that babies born to women who were maintained on buprenorphine 
during pregnancy had very few symptoms of NAS or did not develop NAS at all. You should be 
aware that while existing studies suggest that buprenorphine is as safe as methadone during 
pregnancy, there have been no large-scale studies performed and therefore, the safety and 
effectiveness of this drug have not been firmly determined in this population of patients. 
Studies previously undertaken have also not directly compared the effects of buprenorphine on 
the mother and the baby with the effects of methadone. In addition, no long-term studies of 
children exposed to buprenorphine during pregnancy have been done. 
 
The first aim of this study is to determine the extent to which the NAS occurs with mothers who 
are maintained on buprenorphine during pregnancy. This study will also look at safety and 
effectiveness of buprenorphine in comparison with methadone during pregnancy. The second aim 
of the study is to assess the physical and intellectual development of children from birth up to the 
age of three years. 
 
To be eligible to take part in the project, you will need to 
a)  be between 16 and 40 years of age 
b)  have a gestational age of up to 28 weeks 
c)  be  either  requesting  an  opioid  maintenance  treatment  or  be  currently  enrolled  in  a 
methadone or buprenorphine program 
d)  cooperate with study procedures 
e)  not have major psychiatric illness 
f)  not have twin pregnancy 
 
Your eligibility to participate in this study will be confirmed by the research medical staff during 
this visit. 
 
If you are already on a methadone or buprenorphine program and eligible to enrol in the 
study, you will continue on this maintenance therapy throughout your pregnancy and 
thereafter. If you are not considered eligible to enrol in the study, you will receive standard 
clinical treatment.  
If you are currently requesting maintenance treatment and are eligible to participate in the 
study, you will be offered a choice of methadone or buprenorphine maintenance treatment. If  
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you are not eligible to enrol, you will be routinely inducted on methadone and receive 
standard clinical treatment.  
 
You will be able to continue your maintenance medication after the birth of the baby, including 
during breastfeeding. 
 
You will receive standard gynaecological and obstetrical care during your pregnancy that will not 
be affected by your participation in this study. However, if you are to be involved in this study, it 
is essential that you accurately attend all the routine pregnancy checkups. 
 
What you will need to do during your pregnancy and after the birth of your baby 
Aside from the normal medical care involved with routine pregnancy checkups, which are 
essential to attend if you are to be involved in this study, you will be required to attend 3 
additional outpatient visits, complete a number of questionnaires and supply a number of urine 
and blood samples during pregnancy (antenatally) and in the first month of the birth of the baby 
(postnatally). These requirements are outlined in the attached study timetable. 
 
In particular, you will also be asked to do the following: 
  record the exact time of taking your maintenance drug on the day you visit the outpatient 
clinic  
  complete the following questionnaires (this should take only 10 minutes for all) when 
visiting the clinic: 
1)  Short Opioid Withdrawal Scale  
2)  Visual analogue scale assessing positive effects of opioids 
3)  Use of other drugs 
4)  Adverse effects 
 
You will also be asked to complete these questionnaires once a week during the first 4 weeks 
after birth. After you have been discharged from the hospital you will be visited once a week by 
research staff who will collect the questionnaires. 
 
What additional tests you will have during your pregnancy and after the birth of your baby 
Aside from the normal medical tests that will be performed during pregnancy and after delivery, 
this study will require you to supply the following samples: 
I. Antenatal samples 
  2 (or up to 4 if you are Hep C positive) additional blood samples, of 5 ml each, will be 
taken  for  laboratory  analyses  to  assess  your  liver  and  kidney  function  and  will  be 
performed up on recruitment and once more during pregnancy. 
  4-6 random urine samples throughout your pregnancy depending on the gestational age 
at your first visit. These samples will be tested for a number of licit and illicit drugs and are 
strictly for the purposes of this study only. The results will not exclude you from the study 
or affect your medical care and will be kept confidential. We do however ask that you not 
take illicit drugs while participating in this study. 
  4-6 blood samples will be taken on the same days as your random urine samples to assess 
the concentration of your maintenance drug and other drugs if present. Blood samples 
will be 8 ml each. 
 
II. At delivery  
  1  blood  sample  (3ml)  will  be  taken  from  you  to  determine  the  concentration  of  the 
maintenance drug in your blood. 
  1 blood sample (in addition to one routine sample) will be taken from the umbilical cord 
after delivery to assess how much of the maintenance drug has crossed the placenta and 




III. Postnatal samples 
  2 samples of breast milk will be taken (on postnatal day 3 by the hospital nurses and in week 
2 post delivery by research staff at a home visit) to estimate how much of the maintenance 
drug is present in the breast milk.  
  2 blood samples will be taken at the same time as the breast milk samples [i.e. on day 3 (3 
ml)  and  in  the  second  week  post  delivery (8ml)]  to  determine  the  concentration  of  the 
maintenance drug in your blood and compare this with the concentration in the breast milk. 
You will be required to record the time of taking your maintenance medication on these 
days. 
  2 blood samples (3 ml each) will be taken once a week in weeks 3 and 4 post delivery by a 
research staff member at a home visit to determine whether there are any changes in the 
concentration of the maintenance drug as your body returns back to the pre-pregnancy 
condition 
  1 (final!) urine sample will be collected from you on one of the home visits for the purpose of 
drug use monitoring. 
 
What information we will collect from your and your baby’s case notes 
For the purpose of the study we will be collecting the following information from your Pregnancy 
Hand-Held Record: significant history factors, past pregnancies, medical examination, due date, 
laboratory tests, maintenance drug dose, scans, pregnancy problems (if any arise), pregnancy 
progress notes. Following the delivery we will collect the following information from your case 
notes: any obstetric complications during labour, baby’s condition during labour, duration of 
labour, mode of delivery, and pain management. From you baby’s case notes we will collect 
information on the baby’s condition at birth. Your baby will receive standard care and treatment 
(if necessary) prescribed by the hospital’s paediatricians. All information will be secured and kept 
confidential. This study will not influence in any way your or your baby’s routine treatment. 
 
Assessment of Neonatal Abstinence Syndrome 
One of the most important aims of this study is to assess whether your newborn baby has signs of 
opioid withdrawal, using the Neonatal Abstinence Scale. This Scale is a list of withdrawal signs 
with an accurate scoring system. It is a non-invasive, routinely administered survey performed by 
the hospital nurses, usually with the mother’s help. The baby’s condition is normally assessed 
every 4 hours (if awake) while in the hospital. In the first week of discharge from the hospital the 
scale will be administered at the hospital during your baby’s routine visit to a paediatrician. In the 
remaining weeks (until the 4
th week from the birth of your baby) this will be performed by trained 
research staff at home visits. This follow up is necessary because sometimes this syndrome 
reoccurs or presents late, between 2 and 4 weeks of age. 
 
Following up of your child 
Because methadone and other opiate drugs have the potential to cause some long-lasting effects 
on the physical and intellectual development of children, we would like to invite you to 
participate in the follow-up part of this study. This will give you the opportunity to have your child 
assessed in terms of his or her physical and intellectual functioning each year until they are 3 
years old. This part of the study will be done with one visit back to the Women’s and Children’s 
Hospital at 4 months of age and then by visits to your home by our research assistant once a year 
until your child is 3. 
 
4 Month Visit at the Hospital 
When your baby is 4 months of age we will invite you to an appointment at the Women’s and 
Children’s Hospital.   We will pay for taxis or car parking necessary for you to attend this visit.  
Because at this young age it is difficult to test children’s intellectual functioning, we can do this 
indirectly by assessing how well their vision is developing.  This is called Visual Evoked Potential  
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(VEP) testing and involves having your baby look at a series of checkerboard patterns on a 
computer screen.  Three small sensors will be attached with gel to your baby’s head in order to 
detect nerve signals.  VEP assessment takes about 20 minutes to do and is a procedure done 
frequently at the hospital.  Babies cope very well with this test.  Your baby’s length, head size and 
weight will also be measured.  At this visit we will ask you to complete a short questionnaire.  This 
questionnaire focuses on the health of your baby, the personality of your baby and sleeping 
patterns of your baby.  It will also ask about your health, your family situation and the social 
supports available to you.  We expect this visit will take no longer than 1 to 1.5 hours in total. 
 
A Visit Once a Year to your Home 
Once a year for three years you will be visited at home by one of our trained research assistants. 
During this visit your child’s development will be assessed and you will be provided with direct 
feedback about how your child is going. We will ask you again about the health of your 
baby/toddler, the personality of your baby/toddler and sleeping patterns of your baby/toddler. 
We will ask some questions about your child’s household environment and repeat some of the 
questions about your family situation and the social supports available to you. We expect this visit 
to take no longer than 1.5 to 2 hours. At the final home visit (when your child is three years of 
age) we will also ask you complete a short questionnaire about your child’s language 
development.  At this age children’s receptive and expressive language skills are rapidly 
progressing and are important for successful learning. 
 
In addition to the home visit when your child is three, you will again be invited to attend an 
appointment at the Women’s and Children’s Hospital for a follow-up assessment of your child’s 
visual development.  At this time the VEP testing will be repeated and we will weigh and 
measure your child.  We expect this visit to take no longer than 30 to 45 minutes.  We will pay 
for taxis or car parking necessary for you to attend this visit.  
 
If at any time during the follow-up part of the study your child appears to be having problems 
with their development or has any other health issues about which you are concerned we would 
be very happy to offer help or advice about services. 
 
Confidentiality 
All information that you provide in this study will be kept confidential at all times. For the purpose 
of this study you will be assigned a code instead of your name in order to prevent you from being 
identified in any way. The only exception to this is the legal requirement to pass on information 
about child abuse or neglect to CYFS (formerly FAYS).  If you wish to know what was found at the 
end of the project we will be happy to provide a summary of the results on your request. You 
won’t need to identify yourself for this purpose. In the event that we have trouble contacting you 
during the study (e.g. you change house or telephone number) we will attempt to contact you via 
the Central Register of Methadone Prescribing (DASC) in order to check whether you still wish to 
be part of the study.  We would also like to collect the name and contact details of a friend or 
relative who would know how to get in contact with you. 
 
Leaving the study 
If you decide to withdraw from this study for any reason you may do so at any time without 
having to give a reason to anyone. If you decide not to participate in this study or you withdraw, 
you may do this freely without affecting your or your or your child’s medical care at the Women’s 




Effects, side effects and inconvenience of the study procedures 
Blood samples will be collected through a needle prick that may cause temporary pain. There is 
slight risk of bruising at the site of the prick, but this risk will be reduced because we use only 
qualified people to do the procedures. The total volume of blood to be collected for the purpose 
of the study from women in the buprenorphine or methadone maintenance groups is 72-98 ml on 
11 occasions over a period of 4 - 7 months, depending on the gestational age at the time of 
enrolment. The maximum blood volume taken at one visit will be 13 ml [if both drug 
concentration (8ml, random) and liver/kidney function samples (5ml) are taken on the same 
occasion]. This is unlikely to affect your or your baby’s health. 
 
Both buprenorphine and methadone may cause a number of adverse effects.  
a.  Buprenorphine:  Like  other  opioids  it  may  cause  cardiac,  respiratory  and  central 
nervous system depression and decrease in blood pressure. It may also cause some 
increase  in  liver  enzymes.  Most  common  adverse  effects  that  develop  in  5%  of 
patients are similar to other opioids and include: constipation and opioid withdrawal 
symptoms such as abdominal pain, back pain, chills, fever, headache, upset stomach, 
insomnia, runny nose, sweating, fatigue. 
b.  Methadone: The major adverse effect of methadone is respiratory depression. Other 
reported  events  are  also  similar  to  other  opioids  and  include  nausea,  vomiting, 
constipation,  dizziness,  drowsiness,  light-headedness,  dry  mouth,  sweating  and 
confusion.  Less  common  are:  a  decrease  or  increase  in  heart  rate,  palpitations, 
blurred vision, stomach cramps or pain. 
If you have been using methadone or buprenorphine, you are already familiar with these possible 
adverse effects of these drugs. If you are new to maintenance treatment you may experience some 
of these effects. 
 
Compensation/Indemnity 
If you, as a participant of this research, suffer injury, compensation may, at the discretion of the 
researcher or sponsor of the research, be paid without litigation.  However, compensation is not 
automatic and you may have to take legal action in order to receive payment. 
 
Payment/Cost 
To compensate you for any inconvenience you experience as a result of this study you will be paid 
$350 in total for completion of the study. This will be paid in $50 instalments throughout the 
study. You will receive 2 instalments during your pregnancy, 1 instalment after the birth of your 
baby, 1 instalment when your baby is 4 months old and an instalment at each yearly visit until 
your child is 3 years old (7 instalments in total). Any additional tests involved in this study that are 
outside your routine medical checkups will be conducted at no cost to you. As a special thank you 
to your baby/child for their involvement, they will receive a small gift at each visit, beginning 
when they are 4 months of age.  We will also pay for a taxi or car-parking fees when you come 




Study timetable for maintenance subjects 
 























































Antenatal  Screening and consent form collection will occur on the first antenatal visit 
Up to 
week 11 
            X                       X 



















































     
Week 12  X  X       
Week 16  X  X       
Week 18  X  X       
Week 22    X       
Week 26    X       
Week 28  X  X       





































       
Week 32  X  X  X       
Week 34  X  X         
Week 36  X  X         
Week 37  X  X         
Week 38  X  X         
Week 39  X  X         
Week 40  X  X         
Delivery        X    X     
Postnatal   



















Week 2  X  X  X      X   X 
Week 3    X  X        X 
Week 4    X  X        X 
4 Months    X  Visit to the hospital to assess Visual Evoked Potential of your baby 
1 Year    X  Visit to your home to assess the development of your child 
2 Years    X  Visit to your home to assess the development of your child 




Questionnaires to be completed: 
Structured initial interview (first visit only) 
Clinical opioid withdrawal scale (administered by medical/research staff) 
 
Subjective opioid withdrawal scale, Visual scale of opioid effect, Other drug use/co-medication 
questionnaire (all self-report), Adverse effects questionnaire (monthly self-report) 
 
From 4 months to 3 years of age: questionnaire to assess your child’s development, your 
household environment and your current family situation. 
 
If at any time you wish to contact the project team, please ring: 
 
Pregnancy and the Neonatal Period 
  Ms Justine Whitham (Tel:              ). 
  Dr Olga Lopatko (Tel:              ). 
 
Follow-up of Your Child 
  Dr Nicola Spurrier (Tel:              ). 
  Ms Justine Whitham (Tel:              ). 
 
This study has been reviewed by the Women’s and Children’s Hospital Research Ethics 
Committee.  Should you wish to discuss the study with someone not directly involved, in 
particular in relating to matters concerning policies, your rights as a participant, or should you 
wish to make a confidential complaint, you may contact the Research Coordinator at the 
Women’s and Children’s Hospital, Ms Brenda Penny (Tel:              ).  
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Appendix C. Consent Form for Maintenance Group Participants  
 
Study Title:  Buprenorphine and methadone in pregnancy: Effects on the developing infant and 
child. 
 
1.  I   . . . . . . . . . . . . . . . . . . . . . . . . . .   (please print) hereby consent to take part in the research 
project entitled “Buprenorphine and methadone in pregnancy: Effects on the developing infant 
and child.”  I have read the Information Sheet and understood its contents.  I have had the 
nature and purpose of the research project, so far as it affects me, fully explained to my 
satisfaction by the research worker.  My consent is freely given. 
 
2.  I understand that I may not directly derive any clinical benefit from taking part in the research 
project. 
 
3.  I acknowledge that the details of the following procedures, including possible risks and or side 
effects, discomforts and inconveniences have been explained to me 
  Collection of blood and urine samples from myself 
  Visual Evoked Potential assessment of my infant at 4 months of age 
  Developmental assessments of my infant/child at 12, 24 and 36 months of age 
 
4.  I understand that while information gained during the research project may be published, I will 
not be identified and my personal results will remain confidential. 
 
5.  I understand that I may withdraw from the research project at any stage, without giving a 
reason, and that this will not affect my medical care, now or in the future. 
 
6.  I understand the statement concerning payment, which is contained in the Information Sheet. 
 
7.  I have had the opportunity to discuss taking part in the research project with a family member 
or friend. 
 
8.  I  consent  to  my  contact  details  being  accessed  from  the  Central  Register  of  Methadone 
Prescribing in the rare event that I cannot be contacted by any other means. 
 
9.  I  am  aware  that  I  should  retain  a  copy  of  this  Consent  Form,  when  completed,  and  the 
information sheet. 
 
Signed   . . . . . . . . . . . . . . . .        Date   . . . . . . . . . . . . 
 
Witness Signature   . . . . . . . . . . . . . . .      Date   . . . . . . . . . . . . 
 
        Name   . . . . . . . . . . . . . . . 
 
I   . . . . . . . . . . . . . . . . . . .   certify that I have explained the nature and procedures of the research 
project to   . . . . . . . . . . . . . . . . .   and consider that he/she understands what is involved. 
 
Signed   . . . . . . . . . . . . . . . .        Date   . . . . . . . . . . . . 
 




Appendix D. Consent Form for Infant Participation 
 
Buprenorphine and methadone in pregnancy: Effects the developing infant and child 
 
 
1.  I   . . . . . . . . . . . . . . . . . . . . . . . . . .   (please print) hereby consent for my child   . . . . . . . . . . . . . . . 
. . . . . . . . . .   (please print) to take part in the research project entitled “Buprenorphine and 
methadone in pregnancy: Effects on developing infant and child.”  I have read the Information 
Sheet on their behalf and understood its contents.  I have had the nature and purpose of the 
research project, so far as it affects my child, fully explained to my satisfaction by the research 
worker.  My consent for my child is freely given. 
 
2.  I understand that my child may not directly derive any clinical benefit from taking part in the 
research project. 
 
3.  I acknowledge that the details of the following procedures, including possible risks and or side 
effects, discomforts and inconveniences have been explained to me 
  Visual Evoked Potential assessment at 4 months of age 
  Developmental assessments at 12, 24 and 36 months of age 
 
4.  I understand that the research staff have a legal obligation to pass on information about child 
abuse or neglect to Child Youth and Family Services (formerly FAYS). 
 
5.  I understand that while information gained during the research project may be published, my 
child will not be identified and their personal results will remain confidential. 
 
6.  I understand that I may withdraw my child from the research project at any stage, without 
giving a reason, and that this will not affect their medical care, now or in the future. 
 
7.  I have had the opportunity to discuss my child taking part in the research project with a family 
member or friend. 
 




Signed   . . . . . . . . . . . . . . . .        Date   . . . . . . . . . . . . 
 
Witness Signature   . . . . . . . . . . . . . . .      Date   . . . . . . . . . . . . 
 
        Name   . . . . . . . . . . . . . . . 
 
I   . . . . . . . . . . . . . . . . . . .   certify that I have explained the nature and procedures of the research 
project to   . . . . . . . . . . . . . . . . .   and consider that he/she understands what is involved. 
 
Signed   . . . . . . . . . . . . . . . .        Date   . . . . . . . . . . . . 
 
Status in Project    . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
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Appendix E. Information Sheet for Control Group Participants 
 
Study Title: Child Health and Development Study  
(Buprenorphine and methadone in pregnancy: Effects on mother, foetus/ neonate and child.) 
 
Methadone is recognised as being very beneficial in the treatment of heroin dependence, but for 
pregnant women there is a risk of Neonatal Abstinence Syndrome (NAS). The developing child 
becomes dependent on the methadone in the mother’s circulation and then experiences 
withdrawal following birth. Symptoms of NAS may be mild and include excessive crying, poor 
sleep and feeding, excessive yawning and sneezing, but may be severe with development of fever, 
diarrhoea and seizures. It is unclear why some babies suffer more severe symptoms while others 
have mild symptoms or do not develop this syndrome at all. 
 
Buprenorphine is now being used for treatment of heroin dependence, however little is known of 
its effects during pregnancy and the effect on the unborn child. The aim of this study is to 
determine the extent to which NAS occurs, if at all, with mothers who are maintained on 
buprenorphine. It has been suggested that babies born to women who are maintained on 
buprenorphine compared to methadone will display very few symptoms of NAS or will present as 
normal healthy babies with no symptoms at all. This study will look at the safety and effectiveness 
of buprenorphine in comparison with methadone during pregnancy. We would also like to assess 
the physical and intellectual development of children up to the age of three to be absolutely sure 
that buprenorphine is a safe drug to use during pregnancy. 
 
For this project we require normal healthy control subjects who are not participating in opioid 
maintenance treatments and do not use opioids (drugs and medications like heroin, morphine 
and codeine) on a regular basis. This is a research project, and you can choose whether or not you 
would like to be involved. If you choose not to be involved, there will be no effect on your medical 
care. 
 
To be eligible to take part in the project, you will need to 
g)  be between 16 and 40 years of age 
h)  have a gestational age of up to 28 weeks 
i)  not  be  using  opioids  (drugs  and  medications  like  heroin,  morphine,  methadone  or 
codeine) on a regular basis 
j)  cooperate with study procedures 
k)  not have major psychiatric illness 
l)  not have twin pregnancy 
 
Your eligibility to participate in this study will be confirmed by the research medical staff during 
this visit. 
 
What you will need to do during your pregnancy and after the birth of your baby 
Aside from the normal medical care involved with routine pregnancy checkups, which are 
essential to attend if you are to be involved in this study, you will be required to attend 3 
additional outpatient visits, complete a questionnaire and supply a number of urine and blood 
samples during pregnancy. These requirements are outlined in the attached study timetable. 
 
In particular when visiting the clinic, you will also be asked to complete questionnaires on what 
drugs and medications you have used and how you have been feeling since your previous visit 
(this should take only 5-10 minutes).  
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What additional tests you will have during this study 
Aside from the normal medical tests that will be performed during pregnancy and after delivery 
this study will require you to supply the following samples: 
  2 (or up to 4 if you are Hepatitis C positive) additional blood samples, of 5 ml each, will be 
taken  for  laboratory  analyses  to  assess  your  liver  and  kidney  function  and  will  be 
performed upon recruitment and once more during pregnancy. 
  4-6  random  blood  and  urine  samples  throughout  your  pregnancy,  depending  on  the 
gestational age at your first visit, and one random blood and urine sample in the postnatal 
period. These samples will be tested for a number of licit and illicit drugs and are strictly 
for the purposes of this study only. The results will not exclude you from the study or 
affect your medical care and will be kept strictly confidential. We do however ask that you 
not take illicit drugs while participating in this study. Blood samples will be 5 ml each. 
Together with blood collected for your liver and kidney function tests this will add up to 
40-60 ml of blood over the 3.5-6 months period and will not affect your or your baby’s 
health. 
 
What information we will collect from your and your baby’s case notes 
For the purpose of the study we will be collecting the following information from your Pregnancy 
Hand-Held Record: significant history factors, past pregnancies, medical examination, due date, 
laboratory tests, scans, pregnancy problems (if any arise), pregnancy progress notes. Following 
the delivery we will collect the following information from your case notes: any obstetric 
complications during labour, baby’s condition during labour, duration of labour, mode of delivery, 
and pain management. From your baby’s case notes we will collect information on the baby’s 
condition at birth. Your baby will receive standard care and treatment (if necessary) prescribed by 
the hospital’s paediatricians. All information will be secured and kept confidential. This study will 
not influence in any way your or your baby’s routine treatment. 
 
Assessment of Neonatal Abstinence Syndrome 
One of the most important aims of this study is to assess whether newborn babies whose 
mothers have been on the maintenance treatment for opioid dependence develop signs and 
symptoms that are not developed by other babies. To assess this we will be using the Neonatal 
Abstinence Scale. This Scale is a list of signs that are characteristic of withdrawal with an accurate 
scoring system. It is a non-invasive, routinely administered survey performed by the hospital 
nurses, usually with the mother’s help. The baby’s condition is normally assessed every 4 hours (if 
awake) while in the hospital. Following your baby’s discharge form the hospital the scale will be 
administered by trained research staff at home visits once a week for 3 weeks. This follow up is 
necessary because sometimes this syndrome reoccurs or presents late, between 2 and 4 weeks of 
age. While this syndrome is unlikely to develop in your baby, it is important that we compare 
those babies that were born to mothers on opioid maintenance treatment with babies whose 
mothers did not use opioids during pregnancy, as some of the signs (e.g. crying) occur in normal 
babies. 
 
Follow up of your child 
Because methadone and other opiate drugs have the potential to cause some long-lasting effects 
on the physical and intellectual development of children, we would like to follow the 
development of all children to the age of three years. This will give you the opportunity to have 
your child assessed in terms of his or her physical and intellectual functioning each year until they 
are 3 years old. This part of the study will be done with one visit back to the Women’s and 
Children’s Hospital at 4 months of age and then by visits to your home by our research assistant 
once a year until your child is 3. 
 
4 Month Visit at the Hospital  
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When your baby is 4 months of age we will invite you to an appointment at the Women’s and 
Children’s Hospital.   We will pay for taxis or car parking necessary for you to attend this visit.  
Because at this young age it is difficult to test children’s intellectual functioning, we can do this 
indirectly by assessing how well their vision is developing.  This is called Visual Evoked Potential 
(VEP) testing and involves having your baby look at a series of checkerboard patterns on a 
computer screen.  Three small sensors will be attached with gel to your baby’s head in order to 
detect nerve signals.  VEP assessment takes about 20 minutes to do and is a procedure done 
frequently at the hospital.  Babies cope very well with this test.  Your baby’s length, head size and 
weight will also be measured.  At this visit we will ask you to complete a short questionnaire.  This 
questionnaire focuses on the health of your baby, the personality of your baby and sleeping 
patterns of your baby.  It will also ask about your health, your family situation and the social 
supports available to you.  We expect this visit will take no longer than 1 to 1.5 hours in total. 
 
A Visit Once a Year to your Home 
Once a year for three years you will be visited at home by one of our trained research assistants. 
During this visit your child’s development will be assessed and you will be provided with direct 
feedback about how your child is going. We will ask you again about the health of your 
baby/toddler, the personality of your baby/toddler and sleeping patterns of your baby/toddler. 
We will ask some questions about your child’s household environment and repeat some of the 
questions about your family situation and the social supports available to you. We expect this visit 
to take no longer than 1.5 to 2 hours. At the final home visit (when your child is three years of 
age) we will also ask you complete a short questionnaire about your child’s language 
development.  At this age children’s receptive and expressive language skills are rapidly 
progressing and are important for successful learning. 
 
In addition to the home visit when your child is three, you will again be invited to attend an 
appointment at the Women’s and Children’s Hospital for a follow-up assessment of your child’s 
visual development.  At this time the VEP testing will be repeated and we will weigh and measure 
your child.  We expect this visit to take no longer than 30 to 45 minutes.  We will pay for taxis or 
car parking necessary for you to attend this visit. 
If at any time during the follow-up part of the study your child appears to be having problems 
with their development or has any other health issues about which you are concerned we would 




All information that you provide in this study will be kept confidential at all times. For the purpose 
of this study you will be assigned a code instead of your name in order to prevent you from being 
identified in any way. The only exception to this is the legal requirement to pass on information 
about child abuse or neglect to CYFS (formerly FAYS).  If you wish to know what was found at the 
end of the project, we will be happy to provide a summary of the results on your request. You 
won’t need to identify yourself for this purpose. In the event that we have trouble contacting you 
during the study (e.g. you change house or telephone number) we would like to collect the name 
and contact details of a friend or relative who would know how to get in contact with you. 
 
Leaving the study 
If you decide to withdraw from this study for any reason you may do so at any time without 
having to give a reason to anyone. If you decide not to participate in this study or you withdraw, 
you may do this freely without affecting your or your or your child’s medical care at the Women’s 




Effects, side effects and inconvenience of the study procedures 
Blood samples will be collected through a needle prick that may cause temporary pain. There is 
slight risk of bruising at the site of the prick, but this risk will be reduced because we use only 
qualified people to do the procedures. 
 
The total maximum volume of blood to be collected 40-60 ml of blood on a maximum of 7 
occasions over the 3- 6 months period, depending on the gestational age at the time of 
enrolment. The maximum blood volume taken at one visit will be 10 ml [if both drug 
concentration (5ml, random) and liver/kidney function samples (5ml) are taken on the same 




If you, as a participant of this research, suffer injury, compensation may, at the discretion of the 
researcher or sponsor of the research, be paid without litigation.  However, compensation is not 
automatic and you may have to take legal action in order to receive payment. 
 
Payment/Cost 
To compensate you for any inconvenience you experience as a result of this study you will be paid 
$350 in total for completion of the study. This will be paid in $50 instalments throughout the 
study. You will receive 2 instalments during your pregnancy, 1 instalment after the birth of your 
baby, 1 instalment when your baby is 4 months old and an instalment at each yearly visit until 
your child is 3 years old (7 instalments in total). Any additional tests involved in this study that are 
outside your routine medical checkups will be conducted at no cost to you. As a special thank you 
to your baby/child for their involvement, they will receive a small gift at each follow up visit, 
beginning when they are 4 months of age.  We will also pay for a taxi or car-parking fees when 
you come for additional visits including the 4 month follow-up visit to the hospital.  
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Study timetable for control subjects 









































Antenatal  Screening and consent form collection will occur on the first antenatal visit 
Up to 
week 11 
            X                       X 




















































Week 12  X  X   
Week 16  X  X   
Week 18  X  X   
Week 22    X   
Week 26    X   
Week 28  X  X   







































   
Week 32  X  X  X   
Week 34  X  X     
Week 36  X  X     
Week 37  X  X     
Week 38  X  X     
Week 39  X  X     
Week 40  X  X     
 
               
Postnatal   
Week 1    X  X  X     X  
4-hourly until 
discharge 
Week 2    X  X    X 
Week 3    X  X    X 
Week 4    X  X    X 
4 Months    X  Visit to the hospital to assess Visual Evoked Potential of your baby 
1 Year    X  Visit to your home to assess the development of your child 
2 Years    X  Visit to your home to assess the development of your child 




Questionnaires to be completed: 
Structured initial interview (first visit only) 
Other drug use/co-medication questionnaire (self-report) 
From 4 months to 3 years of age: questionnaire to assess your child’s development, your health, 
your household environment and your current family situation. 
 
If at any time you wish to contact the project team, please ring: 
Pregnancy and the Neonatal Period 
  Ms Justine Whitham (Tel:              ). 
  Dr Olga Lopatko (Tel:              ). 
 
Follow-up of Your Child 
  Dr Nicola Spurrier (Tel:              ). 
  Ms Justine Whitham (Tel:              ). 
 
This study has been reviewed by the Women’s and Children’s Hospital Research Ethics 
Committee.  Should you wish to discuss the study with someone not directly involved, in 
particular in relating to matters concerning policies, your rights as a participant, or should you 
wish to make a confidential complaint, you may contact the Research Coordinator at the 





Appendix F. Consent Form for Control Group Participants  
 
Study Title:  Buprenorphine and methadone in pregnancy: Effects on the developing infant and 
child. 
 
1.  I   . . . . . . . . . . . . . . . . . . . . . . . . . .   (please print) hereby consent to take part in the research 
project entitled “Buprenorphine and methadone in pregnancy: Effects on the developing infant 
and child.”  I have read the Information Sheet and understood its contents.  I have had the 
nature and purpose of the research project, so far as it affects me, fully explained to my 
satisfaction by the research worker.  My consent is freely given. 
 
2.  I understand that I may not directly derive any clinical benefit from taking part in the research 
project. 
 
3.  I acknowledge that the details of the following procedures, including possible risks and or side 
effects, discomforts and inconveniences have been explained to me 
  Collection of blood and urine samples from myself 
  Visual Evoked Potential assessment of my infant at 4 months of age 
  Developmental assessments of my infant/child at 12, 24 and 36 months of age 
 
4.  I understand that while information gained during the research project may be published, I will 
not be identified and my personal results will remain confidential. 
 
5.  I understand that I may withdraw from the research project at any stage, without giving a 
reason, and that this will not affect my medical care, now or in the future. 
 
6.  I understand the statement concerning payment, which is contained in the Information Sheet. 
 
7.  I have had the opportunity to discuss taking part in the research project with a family member 
or friend. 
 




Signed   . . . . . . . . . . . . . . . .        Date   . . . . . . . . . . . . 
 
Witness Signature   . . . . . . . . . . . . . . .      Date   . . . . . . . . . . . . 
 
        Name   . . . . . . . . . . . . . . . 
 
I   . . . . . . . . . . . . . . . . . . .   certify that I have explained the nature and procedures of the research 
project to   . . . . . . . . . . . . . . . . .   and consider that he/she understands what is involved. 
 
 
Signed   . . . . . . . . . . . . . . . .        Date   . . . . . . . . . . . . 
 




Appendix G. Initial Study Assessment 
Subject initials:  Subject code: 
Date today:  CONtrol/BUPrenorphine/METhadone: 
Gestational age (weeks):  Expected date of delivery: 
Section A:  Demographics & Medical History 
 
A1  Date of Birth: 
 
A2 
Ethnicity:    Caucasian…..   A3 Post code: 
       Asian……….     
       Aboriginal…..     
       Other………..  If other, please specify: ____________________ 
 
A4 
Education: Highest level of education completed by the subject? 
    Year 10……….  TAFE/ Apprenticeship….. 
    Year 11……….  University degree……….. 
    Year 12……….  Other……………………. 
    If other, please specify: ____________________ 
 
A5 
Employment History: Usual occupation of subject over the last three years? 
    Professional…..  Skilled/Trade….  Unskilled……….. 
    Student……….  Home duties…..  Unemployed…… 




    Partner               yes           no  Living with partner            yes           no 
    Married             yes           no  Divorced/Separated           yes           no 
    No. of children  Children’s ages           1       2       3       4 
    No. of terminations  No. of miscarriages 






Medical History: List all significant medical conditions recorded at, and since, start of 
current maintenance programme (use other side of page if necessary) 
  Condition  Started (at least year)  Outcome 
(resolved/ongoing) 
A7.1 
____________________    ____________________ 
A7.2 
____________________    ____________________ 
A7.3 
____________________    ____________________ 
 
 
Section B:  Drug Use History 
 
B1 Heroin 
B1.1  Age of first heroin use................................……….    years 
B1.2  Age of first daily heroin use.......................……….    years 
B1.3  Length of consistent heroin use prior to entry……….   months 
  i.e. no interruptions greater than 1 week 
B1.4  Average monthly heroin use prior to entry...………...days per month 
B1.5  Average daily heroin use prior to entry........………...    times per day 
B1.6  Average daily heroin cost prior to entry.......……    $ per day used (= $/time x 
times/day) 
 
B2 Other Drugs     
 

























B2.1  Alcohol................. 
             
B2.2  Tobacco............... 
 
             
B2.3  Street methadone 
not prescribed for 
you 
                
B2.4  Other opiates...... 
morphine, pethidine, 
codeine, mersyndol 
                 
B2.5  Amphetamines..... 
speed 
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B2.6  Cocaine............... 
including crack 
                
B2.7  Ecstasy................ 
                
B2.8  Hallucinogens...... 
LSD, mushrooms, 
acid 
               
B2.9  Marijuana............. 
cannabis, dope 
                
B2.10  Benzodiazepines. 
Rohypnol, Valium, 
Serepax, Mogadon 
                
B2.11  Inhalants. 
Glue, nitrous, petrol 
                
 
*  i = inject; o = oral; s = smoke; n = nasal  
 
Section C:  Drug Treatment History 
 
C1 Current Treatment for Opioid Dependence 
C1.1  Currently in maintenance treatment            yes           no 
 
C1.2  Which treatment? ____________________  Number of episodes (this treatment) 
C1.3  Length of current maintenance treatment             
months 
Date started 
C1.4  Current maintenance treatment dose                        mg 
C1.5  Current stream        A                 B                C         
C2 Previous Treatment for Opioid Dependence 
C2.1  No previous opioid treatment  .......    If no previous opioid treatments, go to Question C3 
YES    NO  If YES: 
    no. of times  +  comments 
C2.2  Previous methadone maintenance        _________________ 
C2.3  Previous LAAM maintenance        _________________ 
C2.4  Previous SROM maintenance        _________________ 
C2.5  Previous buprenorphine maintenance        _________________ 
C2.6  Previous naltrexone maintenance        _________________ 
C2.7  Detox - clinic  ................................        _________________ 
C2.8  Detox - home (medically supervised)  .....        _________________  
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C2.9  Drug free counselling  ...................        _________________ 
C2.10  Therapeutic community  ................        _________________ 
C2.11  Narcotics Anonymous  .................        _________________ 
C2.12  Other: ______________  .............        _________________ 
   
C3 Other Drug Treatments 
C3.1  Have you tried any treatment for other drug use?   YES    NO   
  If YES, please give details: 
  Drug  Treatment  No. of times 
C3.3    ________________  ___________________     
C3.3    ________________  ___________________     
C3.4    ________________  ___________________     
 
 
Section D:  Criminal & Legal History 
 
D1 Criminal Activity 
  Have you ever been involved in any of the following? 
   
YES    NO  If YES 
    age at first 
    occurrence 
 
Most recent occurrence 
Month / Year 
D1.1  Dealing: Heroin .......................... .............       
D1.2  Dealing: Other drugs....................................        
D1.3  Break & Enter: Domestic (house, shed) .........        
D1.4  Break & Enter: Domestic (shop, business)..        
D1.5  Assault: Snatch & Grab       ...........................        
D1.6  Assault: Injurious  ...............................        
D1.7  Fraud  ...............................        
D1.8  Shoplifting  ...............................        
D1.9  Prostitution  ...............................        
D1.10  Armed Robbery  ...............................        




D2 Legal Pressures 
  Have any of the following ever happened to you? 
   
YES    NO  If YES 
    age at first 
    occurrence 
 
Most recent occurrence 
Month / Year 
D2.1  Police: Cautioned/Questioned  .............       
D2.2  Police: Lock-up  ....................................        
D2.3  Police: Arrested  ...................................        
D2.4  Imprisonment  .......................................        
D2.5  Community Service  .............................        
D2.6  Court Appearance  ...............................        
D2.7  Were legal pressures a reason for joining program?                        YES                  NO 
 
 




Appendix H. Modified Finnegan Scale  




                                               NOTE:   
   This appendix is included on page 78 (Volume 2)  of the print  






BUPRENORPHINE AND METHADONE 
IN PREGNANCY   
 
INFANT DATA COLLECTION INSTRUCTIONS 
  Administer the Modified Finnegan Withdrawal Scale at least every four hours from delivery. 
Scoring should encompass all signs since the last feed and be documented before the feed 
begins, preferably when the infant begins to wake. Scoring should be completed at the end of 
feed time. 
  As this chart is designed for term babies who are fed fourth hourly, adjustments must be 
made for breast feeders, demand fed infants and preterm infants. 
  Record dose of any infant medication being taken at each Finnegan scoring 
session. 
  Encourage parental involvement in noticing signs but parents are not to score 
their infants. 
  Each time baby changes wards start a new Modified Finnegan Withdrawal 
Scale sheet ensuring the ward name is written on the top of the sheet. 
 
EXTRA SCORING INFORMATION 
High-pitched cry  Score 2 if a cry is high pitched at its peak. Score 3 if a cry is high pitched 
throughout. 
Sleep  If infant wakes and settles after a nappy change or burp this is in the range of 
normal behaviour. If infant is demand breastfed see feeding. Total the time 
infant is awake and requiring attention. 
Tremors  This is a scale of increasing severity and baby should only receive one score 
from each of the two categories. Undisturbed means when baby is asleep or 
at rest in a cot. 
Increased muscle tone  Score if muscle tone is greater than the upper limit of normal. 
Excoriation  Score when it presents, increases in severity or appears in another area. 
Fever  Infants should be swaddled in a cotton sheet then covered with the same 
number of blankets as any other baby. 
Yawning and sneezing  Score if more than 3-4 times in 30 minutes. 
Nasal flaring/respiratory 
rate 
Score if present without other evidence of respiratory disease. 
Excessive sucking  Score after feeding, excessive if more than a hungry normal baby. 
Poor feeding  Accurate assessment of supply and attachment must be made. Look for signs 
of disorganisation that lead to slow feeding or taking inadequate amounts. 
Compliment with formula until supply is established if baby does not settle on 
breast milk alone.  









Modified Finnegan Score  Morphine Therapy  
0-7  0mg 
8-10  0.5mg/kg/day 4 hourly 
11-13  0.7mg/kg/day 4 hourly 




Once abstinence has been controlled (three consecutive scores less than 8) using this dosage 
regime, the following should be implemented: Please note that all doses for entire period of 
withdrawal management are calculated on birth weight and not current weight. 
 
  Maintain control for 72 hours. 
  Initiate the detoxification process by decreasing the total daily dose by 10% every 72 
hours. 
  When dosage levels reach 0.2 mg/kg/day – maintain this dose for 72 hours.  At this dose, 
consideration can be given to home management (see below). 
  Change from 4 hourly to 6 hourly dosage regime (same dose) for 72 hours prior to ceasing 
all medication. 
  When oral morphine treatment is discontinued, the NASS should continue for a further 72 
hours. 
 
Supportive  therapy  (using  a  pacifier,  swaddling,  close  wrapping,  small  frequent  feeds, 
providing close skin contact) is an important adjunct to medical therapy. 
 
If an infant is vomiting in association with morphine dosing, ensure that the infant is not 
being overfed and that the infant is being appropriately postured during and after feeding.  
Give the morphine before the feed.  If baby has a large vomit after being given morphine: 
 
1.  if vomits within 10 minutes of dose, re-dose 
2.  if vomits after 10 minutes of dose, give ½ dose 



















Name of Parent: __________________________ 
 
Name of Child: ___________________________ 
 
Date of Interview: _________________________ 
 
Name of Interviewer: ______________________ 
 
this information will be removed from  








This booklet asks about your child’s health. It also asks 
questions about yourself and your family.  Your individual 
answers will not be shared with anyone. 
 
Some questions require you to tick boxes, whilst others will ask 
you to circle a response.  Please answer each section of the 
questionnaire after reading the instructions carefully.   It is 
important that you follow the instructions, otherwise we can’t use 
the information you give us.  If you are unsure which answer to 
choose, please give the best answer you can and make a 
comment in the margin. 
 
Certain questions may look alike, but each one is different.  Some 
questions may ask about problems you or your family may not 
have.  That’s great, but it is important for us to know.  Please 
answer each question. 
 
The pages in this booklet are double-sided.  Please make sure 
you answer questions on both sides of the paper. 
 
There are no right or wrong answers; we are interested in your 
views and opinions.  All of the information you provide will be 







GROWTH AND VEP RECORD FORM 






YOUR CHILD’S MEASUREMENTS 
 
 
Height/ Length (cm)   
Weight (kg)   
Head Circumference (cm)   
 
 
VISUAL EVOKED POTENTIAL SCORES 
 
 
  VEP Latency 
File Numbers   
Trigger Used  Yes     □        No     □   
In        □          Out     □ 
Line Filter 
  Checksize 8 
 
Run 1: _______________ 
Run 2: _______________ 








Run 1: _______________ 
Run 2: _______________ 




       _______________ 
No. of runs     
Comments 
 












SLEEP AND HEALTH RECORD FORM 
 





How many hours does your child spend in sleep during the night (between 7pm and 
7am)? __________ 
 
How many hours does your child spend in sleep during the day (between 7am and 
7pm)? __________ 
 
How many times does your child wake up during the night? __________ 
 
How many hours does your child spend awake during the night (between 10pm and 
6am)? __________ 
 
How long does it take to put your child to sleep in the evening? __________ 
 
When does your child usually fall asleep for the night? __________ 
 
Do you consider your child’s sleep a problem?   
 
No     
Yes     
Unsure   
 
Has your child had any medical problems in the last 4 months?   
 
No     
Yes      
(please describe) ________________________________________ 
______________________________________________________ 
 
Has your child had any seizures/fits/convulsions in the last 4 months?   
 
No     
Yes       (please go to Question 10) 
 
Did any of these seizures/fits/convulsions occur when your child had a 
temperature?  
 
No     














What method of feeding are you using at the moment? 
 
Fully Breastfeeding  
(This means giving your baby breast milk only). 
 
Partially Breastfeeding  
(This means giving your baby breast milk and formula) 
 
Fully Bottle-feeding  
(This means giving your baby formula) 
 
 




Have you started giving your baby solids? 
 
No     









SHORT TEMPERAMENT SCALE FOR INFANTS 
 








This page in the questionnaire booklet contained the Short 
Temperament Scale for Infants. For copyright reasons it could not 






GENERAL HEALTH QUESTIONNAIRE 
 






This page in the questionnaire booklet contained the General 

























MATERNAL POSTNATAL ATTACHMENT SCALE 
Feelings About Your Baby 
 
The following questions ask about feelings you may have towards your baby 
Please place a tick in the box next to the answer that comes closest to how you feel about 
your baby. 
 
1.  When I am caring for the baby, I get feelings of annoyance or irritation 
 
very frequently          
frequently            
occasionally            
very rarely            
never              
 
2.  When I am caring for the baby I get feelings that the child is deliberately being 
difficult or trying to upset me 
 
very frequently          
frequently            
occasionally            
very rarely            
never              
 
3.  Over the last two weeks I would describe my feelings for the baby as 
 
dislike              
no strong feelings towards the baby      
slight affection           
moderate affection          
intense affection          
 
4.  Regarding my overall level of interaction with the baby 
 
I feel very guilty that I am not more involved       
I feel moderately guilty that I am not more involved      
I feel slightly guilty that I am not more involved      
I don't have any guilty feelings regarding this      
 
5.  When I interact with the baby I feel 
 
very incompetent and lacking in confidence        
moderately incompetent and lacking in confidence      
moderately competent and confident         
very competent and confident          
 
6.  When I am with the baby I feel tense and anxious 
 
very frequently          
frequently            
occasionally            






7.  When I am with the baby and other people are present I feel proud of the baby 
 
very frequently          
frequently            
occasionally            
almost never            
 
8.  I try to spend as much time as I possibly can playing with the baby 
 
this is true            
this is untrue            
 
9.  When I have to leave the baby 
 
I usually feel rather sad (or it's difficult to leave)      
I often feel rather sad (or it's difficult to leave)      
I have mixed feelings of both sadness and relief      
I often feel rather relieved (and it's easy to leave)      
I usually feel rather relieved (and it's easy to leave)     
 
10.  When I am with the baby 
 
I always get a lot of enjoyment/satisfaction        
I frequently get a lot of enjoyment/satisfaction      
I occasionally get a lot of enjoyment/satisfaction      
I very rarely get a lot of enjoyment/satisfaction      
 
11.  When I am not with the baby I find myself thinking about the baby 
 
almost all the time          
very frequently          
frequently            
occasionally            
not at all            
 
12.  When I am with the baby 
 
I usually try to prolong the time I spend with him/her      
I usually try to shorten the time I spend with him/her      
 
13.  When I have been away from the baby for awhile and I am about to be with 
him/her again, I usually feel 
 
intense pleasure at the idea        
moderate pleasure at the idea      
mild pleasure at the idea        
no feelings at all about the idea      
negative feelings about the idea      
 
 
14.  I now think of the baby as 
 
very much my own baby        
a bit like my own baby        




15.  Regarding the things that I/we have had to give up because of this baby 
 
I find that I resent it quite a lot     
I find that I resent it a moderate amount   
I find that I resent it a bit       
I don't resent it at all         
 
16.  Over the past six months I have felt that I do not have enough time for myself or to 
pursue my own interests 
 
almost all the time         
very frequently         
frequently           
occasionally           
not at all           
 
17.  Taking care of this baby is a heavy burden of responsibility.  I believe this is 
 
very much so           
somewhat so           
slightly so           
not at all           
 
18.  I trust my own judgement in deciding what the baby needs 
 
almost never           
occasionally           
most of the time         
almost all the time         
 
19.  Usually when I am with the baby 
 
I am very impatient         
I am a bit impatient         
I am moderately patient       







Source: Condon, J. T., & Corkindale, C. J. (1998). The assessment of parent-to-infant attachment: 
Development of a self-report questionnaire instrument. Journal of Reproductive and Infant 
Psychology, 16(1), 57-77.  
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EDINBURGH POSTNATAL DEPRESSION SCALE 
Your Emotional Health 
  
                                               NOTE:   
   This scale is included on pages 91-92 (Volume 2) of the print  























Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of 















This page in the questionnaire booklet contained the Interview 
Schedule for Social Interaction-Short Form. For copyright reasons 






Substance Use Checklist 
 
All questions in this questionnaire are about what has happened to you since your last visit. Any 
information you give here is completely confidential. Please answer all questions honestly and 
accurately. 
 
Buprenorphine/methadone only        Dose: 
Time of dose today   
Time of dose yesterday   
Time of dose day before yesterday   
 
Tobacco     Yes/No  In the last month  Since your last study visit 
How many cigarettes per day?     
How many mg?     
     
Heroin     Yes/No  In the last month  Since your last study visit 
Number of days used?     
Number of times used on those days?      
Cost per day on days used?     
Other opioids   Yes/No  In the last month  Since your last study visit 
Which substance (kapanol, morphine, 
pethidine, oxycodone, codeine etc)? 
   
How did you take this substance?     
Number of days used?     
Number of times used on those days?      
     
Alcohol     Yes/No  In the last month  Since your last study visit 
Number of days consumed?     
Number of drinks per day on days 
consumed? 
   
     
Marijuana     Yes/No  In the last month  Since your last study visit 
Number of days used ?     
How many cones/joints per day on days 
used? 
   
Amphetamines   Yes/No  In the last month  Since your last study visit 
Which substance (cocaine, ecstasy, 
methamphetamine etc)? 
   
How did you take this substance?     
Number of days used?     
Number of times used on those days?      
Inhalants     Yes/No  In the last month  Since your last study visit 
Which substance (petrol, glue, aerosol 
etc)? 
   
Number of days used?     
Number of times used on those days?       
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Hallucinogens   Yes/No  In the last month  Since your last study visit 
Which substance (LSD, acid, mushrooms 
etc)? 
   
Number of days used?     
Number of times used on those days?      
     
Benzodiazepines   Yes/No  In the last month  Since your last study visit 
Which substance (diazepam, 
temazepam, oxazepam, Rohypnol etc)? 
   
How did you take this substance?     
Number of days used?     
Number of times used on those days?      
Other medication  Yes/No  In the last month  Since your last study visit 
Which substance?     
How did you take this substance?     
Number of days used?     































1.  What is the sex of the child in this study? 
 
    Male           
    Female             
 
 
2.         What is the age of the child in this study? 
 
      _________   years     _________   months 
 
 
3.         What is your age? 
 
      _________   years 
 
 
4.  What are the ages of all other dependent children (18 years or younger) in your home? 
 
      ____  ____  ____  ____  ____ 
 
 
5.  Which of the following best describes your relationship to the child in this study? 
 
Natural mother   
Natural father         
Stepmother         
Stepfather     
Other  (please describe): _______________________________________ 
 
 
6.  Which of the following best describes the parents living in the child’s household? 
Two natural parents       
Mother and stepfather/defacto   
Father and stepmother/defacto   
Mother alone         
Father alone         




7.  Since your baby was born, how many times have you changed where you and 




8.  Since your baby was born have there been any changes in your living 
arrangements (eg separation from partner) for you and your baby?  
 
No     
Yes       













10.  Is the mother in the child’s household currently in paid employment? 
 
No     
Yes     
 
If yes, on what basis? 
      Casual    
      Contract   
      Permanent   
Hours per week _________ 
 
 
11.  What is the mother’s (or parental mother figure’s) highest completed level of 
schooling?   
 
  Primary school         
Some years of high school       
Year 12, Matric or equivalent    
Technical, trade or TAFE certificate   
Tertiary qualifications      
 
 




                (Please describe) 
 
 
13.  Is the father in the child’s household currently in paid employment? 
 
No     
Yes     
 
14.  What is the father’s (or parental father figure’s) highest completed level of  
schooling?   
 
  Primary school         
Some years of high school       
Year 12, Matric or equivalent    
Technical, trade or TAFE certificate   





15.  Before tax, what is your gross household income per year from all sources (eg 
wages, family payment, child maintenance etc) 
 
$0-$10,400         
$10,401-$31,200       
$31,201-$52,000       
more than $52,000       
 
 
16.  Does your family receive any pension or benefit? 
 
No     
      Yes     
Please describe: __________________________________ 
________________________________________________________________ 
 
17.  How would you describe your home at the moment? 
 
Housing trust – renting           
Housing trust – purchasing           
Renting house or unit            
Being purchased             
  Fully owned                
  Living with your parents or your partner’s parents     
  Occupying house or unit rent free         
  Caravan or Caravan Park           













Thank you very 
much for your 























Name of Parent: __________________________ 
 
Name of Child: ___________________________ 
 
Date of Interview: _________________________ 
 
Name of Interviewer: ______________________ 
 
this information will be removed from  










1. This booklet asks about your child’s health. It also asks questions 
about yourself and your family.  Your individual answers will not be 
shared with anyone. 
 
2. Some of the questions are the same or similar to the ones you 
answered when your child was 4 months old.  This is because we 
would like to measure any changes over time. 
 
3. Some questions require you to tick boxes, whilst others will ask you 
to circle a response.  Please answer each section of the 
questionnaire after reading the instructions carefully.   It is important 
that you follow the instructions, otherwise we can’t use the 
information you give us.  If you are unsure which answer to choose, 
please give the best answer you can and make a comment in the 
margin. 
 
4. Certain questions may look alike, but each one is different.  Some 
questions may ask about problems you or your family may not have.  
That’s great, but it is important for us to know.  Please answer each 
question, even if your answer is a ‘no’. 
 
5. The pages in this booklet are double-sided.  Please make sure you 
answer questions on both sides of the paper. 
 
6. There are no right or wrong answers; we are interested in your 
views and opinions.  All of the information you provide will be 








Section 1. Your Child 
 
YOUR CHILD’S MEASUREMENTS 
 
Height/ Length (cm)   
Weight (kg)   





















1.  How many hours does your child spend in sleep during the night (between 7pm and 7am)? 
__________ 
 
2.  How many hours does your child spend in sleep during the day (between 7am and 7pm)? 
__________ 
 
3.  How many times does your child wake up during the night? __________ 
 
4.  How many hours does your child spend awake during the night (between 10pm and 6am)? 
__________ 
 
5.  How long does it take to put your child to sleep in the evening? __________ 
 
6.  What time does your child usually fall asleep for the night? __________ 
 
7.  Do you consider your child’s sleep a problem?   
 
No    
Yes   
Unsure   
 
8.  Has your child had any medical problems in the last 9 months (since the 4 month visit)?   
 
No    
Yes    








9.  Has your child had any seizures/fits/convulsions in the last 9 months (since the 4 month 
visit)?   
 
No    





10. Did any of these seizures/fits/convulsions occur when your child had a temperature (ie a 
febrile convulsion)?  
 
No    
Yes    
 
11. Did any of these seizures/fits/convulsions occur when your child did not have a temperature 
(ie a febrile convulsion)?  
 
No    










1.  Are you still breastfeeding your baby/toddler? 
 
No    
Yes    
 
2.  If you have stopped breastfeeding, how old was your baby/toddler when you stopped 
breastfeeding? _______________ 
 
3.  How old was your child when you first introduced solid foods? 
 
4.  Which solid foods have you introduced to your child’s diet? (please tick those that 
apply) 
 
Red meat     
Chicken     
Fish       
Cheese             
Vegetables     
Rice cereal     
Fruits       
Yoghurt     
Egg       




















This page in the questionnaire booklet contained the Short 
Temperament Scale for Toddlers. For copyright reasons it could 














This page in the questionnaire booklet contained the Infant 
HOME Inventory. For copyright reasons it could not be 




Section 2. Your Health 
 
We would like to know if you have had any medical complaints, and how your 
health has been in general, over the past few weeks.  Please answer ALL of the 
questions on the following pages simply by circling the answer which you think 
most correctly applies to you.  Remember we want to know about present and 








This page in the questionnaire booklet contained the General 

























This page in the questionnaire booklet contained the Parent 
Domain of the Parenting Stress Index. For copyright reasons it 














This page in the questionnaire booklet contained the Interview 
Schedule for Social Interaction-Short Form. For copyright reasons 








Substance Use Checklist 
 
All questions in this questionnaire are about what has happened to you since your last visit. Any 
information you give here is completely confidential. Please answer all questions honestly and 
accurately. 
 
Buprenorphine/methadone only        Dose: 
Time of dose today   
Time of dose yesterday   
Time of dose day before yesterday   
 
Tobacco     Yes/No  In the last month  Since your last study visit 
How many cigarettes per day?     
How many mg?     
Heroin     Yes/No  In the last month  Since your last study visit 
Number of days used?     
Number of times used on those days?      
Cost per day on days used?     
Other opioids   Yes/No  In the last month  Since your last study visit 
Which substance (kapanol, morphine, 
pethidine, oxycodone, codeine etc)? 
   
How did you take this substance?     
Number of days used?     
Number of times used on those days?      
Alcohol     Yes/No  In the last month  Since your last study visit 
Number of days consumed?     
Number of drinks per day on days 
consumed? 
   
Marijuana     Yes/No  In the last month  Since your last study visit 
Number of days used?     
How many cones/joints per day on days 
used? 
   
Amphetamines   Yes/No  In the last month  Since your last study visit 
Which substance (cocaine, ecstasy, 
methamphetamine etc)? 
   
How did you take this substance?     
Number of days used?     
Number of times used on those days?      
Inhalants     Yes/No  In the last month  Since your last study visit 
Which substance (petrol, glue, aerosol 
etc)? 
   
Number of days used?     




Hallucinogens   Yes/No  In the last month  Since your last study visit 
Which substance (LSD, acid, mushrooms 
etc)? 
   
Number of days used?     
Number of times used on those days?      
Benzodiazepines   Yes/No  In the last month  Since your last study visit 
Which substance (diazepam, 
temazepam, oxazepam, Rohypnol etc)? 
   
How did you take this substance?     
Number of days used?     
Number of times used on those days?      
Other medication  Yes/No  In the last month  Since your last study visit 
Which substance?     
How did you take this substance?     
Number of days used?     































1.  What is the sex of the child in this study? 
 
    Male           
    Female             
 
 
2.         What is the age of the child in this study? 
 
      _________   years      
 
 
3.         What is your age? 
 
      _________   years 
 
 
4.  What are the ages of all other dependent children (18 years or younger) in your home? 
 
      ____  ____  ____  ____  ____ 
 
 
5.  Which of the following best describes your relationship to the child in this study? 
 
Natural mother   
Natural father         
Stepmother         
Stepfather     
Other  (please describe): _______________________________________ 
 
 
6.  Which of the following best describes the parents living in the child’s household? 
Two natural parents       
Mother and stepfather/defacto   
Father and stepmother/defacto   
Mother alone         
Father alone         






7.  Since we last saw you (when your child was 4 months old), how many times have 




8.  Since we last saw you (when your child was 4 months old) have there been any 
changes in your living arrangements (eg separation from partner) for you and your 
child?  
 
No     
Yes       












10.  Is the mother in the child’s household currently in paid employment? 
 
No     
Yes     
 
If yes, on what basis? 
      Casual   
      Contract   
      Permanent   
Hours per week _________ 
 
 
11.  What is the mother’s (or parental mother figure’s) highest completed level of 
schooling?   
 
  Primary school         
Some years of high school       
Year 12, Matric or equivalent    
Technical, trade or TAFE certificate   
Tertiary qualifications      
 
 
12.  What is the usual occupation of the father (or parental father figure) in the child’s 
household (if applicable)? 
 
_____________________________________________________________ 





13.  Is the father in the child’s household currently in paid employment? 
 
No     
Yes     
N/A     
 
14.  What is the father’s (or parental father figure’s) highest completed level of  
schooling?   
 
  Primary school         
Some years of high school       
Year 12, Matric or equivalent      
Technical, trade or TAFE certificate     
Tertiary qualifications        
  N/A             
 
15.  Before tax, what is your gross household income per year from all sources (eg 
wages, family payment, child maintenance etc) 
 
$0-$10,400         
$10,401-$31,200       
$31,201-$52,000       
more than $52,000       
 
 
16.  Does your family receive any pension or benefit? 
 
No     
      Yes     
Please describe: __________________________________ 
________________________________________________________________ 
 
17.  How would you describe your home at the moment? 
 
Housing trust – renting           
Housing trust – purchasing           
Renting house or unit            
Own house/unit - purchasing          
  Own house/unit - fully owned          
  Living with your parents or your partner’s parents     
  Occupying house or unit rent free         
  Caravan or Caravan Park           












Thank you very 
much for your 


















Dear <Parent’s name>, 
 
It is now time for the 2 year follow-up assessment in the Child Health and Development Study in 
which you and <Child’s name> are participating.  
 
Unfortunately, I have been unable to contact you by telephone.  I would be very pleased if you 
would agree to continue with this important study.      
 
During this visit I will visit you in your home or somewhere convenient for you and weigh and 
measure <Child’s name>.  I will also assess <Child’s name> on the Bayley Scales of Infant 
Development and ask you to complete a questionnaire.  The visit should take between 60 to 90 
minutes.  
 
To thank you for your time we will provide a payment of $50.  As a special thank you to <Child’s 
name> for his/her involvement, he/she will receive a small gift. 
 
Please text or telephone Justine Whitham at the Research and Evaluation Unit, Women’s and 













Child Health and Development Study 
Research and Evaluation Unit 
Women’s and Children’s Hospital  
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Appendix L. Example Report 
 
Developmental Assessment Report – 2 years 
 





Name: Child          Date of Assessment: 31/01/08   
       
Date of Birth: 14/12/06      Age at Assessment: 13 months, 17 days 
            Corrected age: 12 months, 21 days 
 
Parents: Mother and Father    Place of Testing: Child’s home 
 
Weight: 11.85kg (just above 90th percentile) 
Length: 79.0cm (75th percentile) 
Head Circumference: 48.0cm (50-98th percentile) 
 
Assessed by:  Justine Whitham 
     
This assessment is part of the Child Health and Development Study.  It is important to note 
that the results of this test represent a general indication of this child’s presentation on the 
testing day, rather than a clinical assessment. 
 
Assessment Instruments  
 
Bayley Scales of Infant Development  
The Bayley Scales of Infant Development is a standardised test that measures the 
development of children’s thinking and movement abilities, as well as their behaviour during 
the test period.  The Scales are used for children aged between 1 month and 3 years, 6 
months.  Aspects of development such as memory, simple problem solving, language abilities, 
body control, coordination, and fine motor movement are tested via observations and a series 
of simple tasks for children.  A child’s performance on these items, together with parents’ 
observations, yield estimates of the child’s current functioning, compared to other children of 
their age.  The Scales have been administered to many thousands of children to provide this 
comparative information.  Information about a child’s pattern of abilities and any areas of 
strength and weakness can be helpful in planning activities and/or any specific interventions 
necessary.  It is important to note that a child’s performance on the Bayley Scales does not 
necessarily predict how they will perform at school, or in later testing of intellectual 
functioning. 
 
Observations during Testing 
Child presented as a happy and placid child who was easy to engage and did not show any 
unusual fear of the examiner.  He demonstrated keen interest in the test items and attempted 
the majority of them with initiative and enthusiasm.  Child was generally cooperative and 
showed good attention and concentration throughout the assessment, despite obvious 
tiredness.  He was persistent when attempting the more complex activities and did not easily 
become frustrated.  Child made many attempts to interact socially with his parents and the 
examiner, smiling and giggling throughout the assessment and continuing a game of ‘peek-a-
boo’ with his father.  Child’s parents reported that his behaviour on the day of testing was 
somewhat typical of Child and that he was tired and had an ear infection at the time of  
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Summary of Scores and percentiles 
Scales  Percentile  Range 
     
Mental Scale Total Score  25-37  Within Normal Limits 
     
Motor Scale Total Score  16-25  Within Normal Limits 
     
Behaviour Scale Total Score  60  Within Normal Limits 
  
Mental Scale Total Score: This score reflects Child’s performance on tasks that require 
thinking, problem solving and memory.  Child’s score was “within normal limits” for children 
of his corrected age group and indicates that he is performing at a level that is equal to, or 
better than, 25-37% of children his age.  
 
Motor Scale Total Score:  This score reflects Child’s performance on tasks that require 
coordination, motor control and balance. Child’s score was “within normal limits”  for 
children of his corrected age group and indicates that he is performing at a level that is equal 
to, or better than, 16-25% of his peers. 
 
Behaviour Scale Total Score:  This score indicates how well Child adapted to and engaged 
with the test materials, his attention, initiative and temperament throughout the testing 
session and the appropriateness of his motor quality.  Child’s score was “within normal 
limits” expected for children of his age, indicating that Child is functioning at a level that is 
equal to or better than, 60 percent of children the same age.   
 
Summary  
Child presented as a happy and engaging child who scored ‘Within Normal Limits’ on all three 
scales of the Bayley Scales of Infant Development.  The results of this assessment indicate that 
Child is performing at an overall level that is appropriate for his age group. 
 
I would be happy to discuss the results of this assessment.  I can be contacted by telephone on                           





Child Health and Development Study 
Women’s and Children’s Hospital  
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Appendix M. Simple linear regressions for infant birth growth 
measurements, adjusting for gestational age 
 
 
Standard linear regression examining the effect of methadone exposure on birth weight (N=86)  
Variable  B±SE B (grams)  β  R
2  F 
Buprenorphine
   -156.33±93.82  -.14  0.56  34.15*** 
Methadone  -344.41±100.31       -.29**     
Gestational age (weeks)
a  186.17±21.05           .66***     
Note. Reference group is Control. *p<.05, **p<.01, ***p<.001 
a B±SE B are reported in terms of the original distribution, however all other values were 
calculated using the transformed (power 4 ) data. 
 
Standard linear regression examining the effect of methadone exposure on birth length (N=87)  
Variable  B±SE B (cm)  β  R
2  F 
Buprenorphine
   -1.27±0.53     -.20*  0.56  34.44*** 
Methadone  -2.21±0.57          -.31***     
Gestational age (weeks)
a  1.04±0.12           .64***     
Note. Reference group is Control. *p<.05, **p<.01, ***p<.001 
a B±SE B are reported in terms of the original distribution, however all other values were 




Standard linear regression examining the effect of methadone exposure on birth head 
circumference (N=86)  
Variable  B±SE B (cm)  β  R
2  F 
Buprenorphine
   -0.20±0.36    -.06  0.31  12.25*** 
Methadone  -0.94±0.39       -.25*     
Gestational age (weeks)
a  0.43±0.08           .47***     
Note. Reference group is Control. *p<.05, **p<.01, ***p<.001 
a B±SE B are reported in terms of the original distribution, however all other values were 
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Appendix O. Note regarding content of Chapter 5 
 
The content of Chapter 5 differs to that of my Master of Clinical Psychology thesis (Whitham, 
2006) which utilised a sub-set of the current study sample (N=78). Details about prenatal 
exposure to other substances and early neonatal factors (including birth measurements and 
treatment for NAS) that may contribute to VEP latency were not available at that time and were 
therefore not included in the Master’s thesis. This information has been incorporated in the 
statistical analyses in Chapter 5 of the current thesis which are of a more rigorous and 
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